|
|
Toxoplasma gondii |
| Table of Contents |
- General Information
- NCBI Taxonomy ID
- Disease
- Introduction
- Microbial Pathogenesis
- Host Ranges and Animal Models
- Vaccine Related Pathogen Genes
- dasd
- fad
- fsa
- sdfa
- BiP
(Protective antigen)
- CDPK1
(Protective antigen)
- CDPK6
(Protective antigen)
- CyP
(Protective antigen)
- GRA1
(Protective antigen)
- GRA16
(Protective antigen)
- GRA17
(Protective antigen)
- GRA2
(Protective antigen)
- GRA23
(Protective antigen)
- GRA24
(Protective antigen)
- GRA41
(Protective antigen)
- GRA5
(Protective antigen)
- GRA6
(Protective antigen)
- GRA7
(Protective antigen)
- GRA8
(Protective antigen)
- hsp70
(Protective antigen)
- ISP3
(Protective antigen)
- MIC1
(Protective antigen)
- MIC11
(Protective antigen)
- MIC13
(Protective antigen)
- MIC3
(Protective antigen)
- MIC3
(Protective antigen)
- MIC4
(Protective antigen)
- MIC6
(Protective antigen)
- MIC8
(Protective antigen)
- p30
(Protective antigen)
- PGAM2
(Protective antigen)
- PI1
(Protective antigen)
- PLP1
(Protective antigen)
- ROP16
(Protective antigen)
- ROP17
(Protective antigen)
- ROP18
(Protective antigen)
- Rop2
(Protective antigen)
- ROP2
(Protective antigen)
- Rop2
(Protective antigen)
- ROP38
(Protective antigen)
- ROP8
(Protective antigen)
- SAG1
(Protective antigen)
- SAG2
(Protective antigen)
- SAG5B
(Protective antigen)
- SAG5C
(Protective antigen)
- SOD
(Protective antigen)
- TgADF
(Protective antigen)
- TgCST2
(Protective antigen)
- TgNTPase-II
(Protective antigen)
- TgPF
(Protective antigen)
- TgRACK1
(Protective antigen)
- CDPK2
(Virmugen)
- mic2
(Virmugen)
- OMPDC
(Virmugen)
- UP
(Virmugen)
- Vaccine Related Host Genes
- Ccl2
- Ifng (Interferon gamma)
- IL-6
- Il12b
- TNF-alpha
- Vaccine Information
- CAV-2-ROP16
- CAV-2-ROP18
- CTLVECNS
- GRA7(20–28)SAPN
- ISA 201-rTgCST2
- ISP3 VLP
- Ovilis Toxovax
- PLG-rROP38-rROP18
- rBCGpMV361-TgCyP
- rCDPK6 + rROP18 + PLG
- RH-AMA1KO
- rTgADF
- rTgPGAM 2
- rTgRACK1
- rTgROP17
- T. gondii DNA vaccine encoding MIC8
- T. gondii DNA vaccine encoding multi-epitope ROP8
- T. gondii DNA vaccine pcDNA3-MIC3
- T. gondii DNA vaccine pcDNA3.1-HisGRA6
- T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2
- T. gondii DNA vaccine pcDNA3.1/MIC11
- T. gondii DNA vaccine pDREP-TgNTPase-II
- T. gondii DNA vaccine pDsRed2-GRA8
- T. gondii DNA vaccine pEGFP-C1/GRA41
- T. gondii DNA vaccine pIRESneo/MIC6/PLP1
- T. gondii DNA vaccine pIRESneo/ROP18/PLP1
- T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain)
- T. gondii DNA vaccine pSAG1-ROP2-SAG2
- T. gondii DNA vaccine pSAG5B/SAG5C
- T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL21-IL15
- T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL7-IL15
- T. gondii DNA vaccine pVAX-GRA16
- T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6
- T. gondii DNA vaccine pVAX-ROP38
- T. gondii DNA vaccine pVAX-TgGRA17
- T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23
- T. gondii DNA vaccine pVAX-TgGRA23
- T. gondii DNA vaccine pVAX-TgMIC13
- T. gondii DNA vaccine pVitro-SAG1-GRA7
- T. gondii DNA vaccine pVR1020-GRA1
- T. gondii DNA vaccine ROP8-pVAX-1
- T. gondii DNA vaccine T.g.HSP70
- T. gondii GRA17 mutant vaccine
- T. gondii irradiated sterilised tachyzoites
- T. gondii LDH1 and LDH2 mutant vaccine
- T. gondii mic2 mutant vaccine
- T. gondii OMPDC mutant vaccine
- T. gondii OMPDC/UP mutant vaccine
- T. gondii Pru strain cdpk2 mutant vaccine
- T. gondii recombinant vaccine vector rBCGpMV361-TgCyP
- T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
- TgMIC1
- TgMIC1-4
- TgMIC1-4-6
- TgMIC4
- TgMIC6
- TgPF-OML
- UV-attenuated Toxoplasma gondii with DSCG adjuvant
- References
|
| I. General Information |
| 1. NCBI Taxonomy ID: |
|
5811 |
|
2. Disease: |
| Toxoplasmosis |
|
3. Introduction |
| Toxoplasma gondii is a species of parasitic protozoa in the genus Toxoplasma. The definitive host of T. gondii is the cat, but the parasite can be carried by many warm-blooded animals (birds or mammals). Toxoplasmosis, the disease of which T. gondii is the causative agent, is usually minor and self-limiting but can have serious or even fatal effects on a fetus whose mother first contracts the disease during pregnancy or on an immunocompromised human or cat (Wiki: T. gondii). |
|
4. Microbial Pathogenesis |
| T. gondii is an intestinal coccidian of cat with man as one of the intermediate host. Humans are generally infected by ingesting oocysts released in cat faeces or by consuming meat from infected herd animals containing the long lived tissue cysts. Following ingestion, the outer wall of cysts or oocysts are disrupted by enzymatic degradation and bradyzoites and sporozoites are liberated into intestinal lumen. They rapidly invade and multiply within surrounding cells where they become tachyzoites. Thereafter, tachyzoites are disseminated via blood or lymphatic system to most of the organs of human body. At these sites, the tachyzoites infect host cells, replicate and invade the adjoining cell. In this fashion, the hallmarks of the infection develop: cell death and focal necrosis surrounded by an acute inflammatory response (Bhopale, 2003). |
|
5. Host Ranges and Animal Models |
| The life cycle of T. gondii has two phases. The sexual part of the life cycle (coccidia like) takes place only in members of the Felidae family (domestic and wild cats), which makes these animals the parasite's primary host. The asexual part of the life cycle can take place in any warm-blooded animal, like other mammals (including felines) and birds (Wiki: T. gondii). |
| II. Vaccine Related Pathogen Genes |
|
1. BiP |
-
Gene Name :
BiP
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7896014
-
NCBI Protein GI :
AAF23321
-
Other Database IDs :
CDD:331774
-
Taxonomy ID :
5811
-
Protein Name :
heat shock protein 70 precursor
-
Protein pI :
5
-
Protein Weight :
67889.46
-
Protein Length :
743
-
Protein Note :
immunoglobulin binding protein
-
Protein Sequence : Show Sequence
>AAF23321.1 heat shock protein 70 precursor [Toxoplasma gondii]
MTAAKKLSLFSLAALFCLLSVATLRPVAASDAEEGKVKDVVIGIDLGTTYSCVGVYRHGRVDIIPNDQGN
RITPSYVAFTDDDRKIGEAAKNEATINPTNTLFDVKRLIGRRFNEKEVQKDKDLLPYEIINKDGKPYIRV
MVKGEPKVLAPEEVSAMVLTKMKETAEQFLGKEVKNAVVTVPAYFNDAQRQATKDAGAIAGLNVIRIINE
PTAAAIAYGLDKKNEKTILVYDLGGGTFDVSVLVIDNGVFEVLATSGDTHLGGEDFDQRVMDHFIKLVKK
KYDKDLRTDKRGLQKLRREVERAKRALSSQHQAKVEVENLMEGVDFSETLTRAKFEELNSDLFQKTLKPV
KQVLEDADLQKSQVDEIVLVGGSTRIPKIQQLIKDFFNGKEPNRGINPDEAVAYGAAVQAGILSGEGAQD
MVLLDVTPLTLGIETAGGVMAKIINKNTVIPTKKTQTFSTYSDNQSAVLIQVYEGERPMTKHNHLLGKFE
LTGIPPAPRGVPQIEVTFDVDRNGILSVSAVDKGTGKSEKITITNDKGRLTPEEIERMISEAEKFAEEDK
KVKERVDARNALEGYLHSMKTTVEDKDKLADKIEEDDKKTILDKVTEAQEWLNTNPDADAEETRDKLKDV
EAVCNPIISKVYGQSGGPGAGGAAGGADDDDYGGHDEL
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
(Czarnewski et al., 2017)
|
|
2. CDPK1 |
-
Gene Name :
CDPK1
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7896758
-
NCBI Protein GI :
1084942668
-
Locus Tag :
TGME49_301440
-
Genbank Accession :
CM002038
-
Protein Accession :
XP_018637931
-
Taxonomy ID :
508771
-
Chromosome No :
IV
-
Gene Starting Position :
2477279
-
Gene Ending Position :
2488278
-
Gene Strand (Orientation) :
+
-
Protein pI :
6.39
-
Protein Weight :
61848.68
-
Protein Length :
582
-
DNA Sequence : Show Sequence
>NC_031471.1:2477279-2488278 Toxoplasma gondii ME49 chromosome IV, whole genome shotgun sequence
ACGGTATCTGGTCGACGCAGCTTCCACAGATGGCGTGAAGACGTGGTTAGCATGGGGAAGCAAAATCCCA
GACAAAGCGTCTGTGCTTCTTTACTTTCTCTGTATTTCTCAGCAACGACAGTCGTTGGAAAGCAGCTGCG
CGTCTGGATCCAGTGTGGCTTGTGTCTTCATAAGTCTCGTACAAGAGGCATCTAGTAGCCAGCTCGTCGC
TTCCAGCCCCCCAATCGTTTCTTCAGTGGCCCCGCACTACCAGTTTCCCCCTGAAGTGTGCTTGTAGCTG
GGAAACGCAATACTGTCGAACGGTTTCCATCTCTAACGCCTGAATGCGTCTCACTCCCAAAAGCGCAAAA
CAGGTCAATCCTGTTCGGGAATGCCTTTCGTGAAACAGCGATGTCGAGGGGTGGTGAGTGAAGACCGCTC
CCACGAAAAGAAAACAAAGCCACTCCCTCAGCCCCACAAAAAAGCGCTTTCCTCCACTATACCCTATTCG
TATCACTGTCTCCCTGTATGTGTGCAAGGTCCCTCTAGAAACAACGAACATTGGACCGTTTTCATGCGTT
TGTGCTATTTCTCCACGGGTGTGCGTAGGCATTTGCTGGGCCTCTCTGCTAACGAAAATATGTCTTCTCG
GTTTTGCCTTTCCGCACAACTTCTAATGTGCTTTCTGGTGGTTTATGAAGGCTGTGACCCCTAATTGGAA
GAGCGATCACGGAACGGTGCGTGTTGCCTCGACTGCTTGATGGGGTTTCCTCGTGCCCGTCCTCTTTTGA
CCCGCTGAAATTACCTCGAAGCTCGGCAGGCAAAACAGCGCATTCTCTTGATCACGTGTCTCCTCTCTGT
CCTCAGACATCCGAAACGAGTGCAGCAGACGAGAGATGACTATATGACGCGGGCGTCGATAAGATTGGCC
GACTGAAAATTGAGGCGACAGGCGTTAGTCGCACCTCAACCGGACGTCCTCCTGCTTTCCTTCTCCTAAA
AAATGATGTTGGACATTAACGCCAGAACACATCGAAGCGTCTTGTAGTGTTCCTGACAGTTCAGGGATTA
CTGGGTGCGTATACCAGCGTGACCTAATCATACGCGCATGTGGCCTATGCACATGAACCTCGACGACTCG
TTGTTCTTTTGAGAGCTTCCGCCTTGCAGAGAAGCAGGGGCAGCTGTACGGAAAAAGGTTTTCTTTTCTC
CAGTTGCGTTCCCCCACGTCTTCTTTGAAGCCGGCCGTGCACATGCGGACGCTGTGTGGCGTCCAGAGGC
CCAGAGACCACAGAGAGCTTCTAGCCAGTTGGTTTCCTCGTCAGATTTGTCTATGGTATCTCGTGGACCG
CAGCGGTAAAATTCTACGGGAAAGGCTCCTTCTATTTAGAATCCGTGGTCCTCTACAGACCTACTGTGTC
GCGTGACACTGTCGGTCTTGTTTTCTTTGTTGTCATTCTCTCTCGACGTGTTCAGAGCTCCAACCCCCGT
TTCGAATTTCGTGAATTCGGCTCCGTTACAGGGAGAAATTGTGTTTCGTCGACGGTGACCTTGTGAGAGC
TGTTCGATTCCCTCTTCGCAACTGTTCCACGTCCTCGATTTGACCGGCAAGAACCTATCTTGGCCTTCAG
CCCAACGGCTCTTTTACATATTCGAGAAACACCTGCATATACACATCACTGTTTACAGTTAGGCGCACAC
ATCGACGCGACAACGCTGTCGTACCTATATATGCGCGTGTGCATACTTACGTAAATTATGTGTACGAGGG
TGTGTGTCGTTTCCCTACCTTCCGTTTCCTCGTTGCTGCTATCGCTATTTTGCCCAATAAACGCGTCGAT
CCGCAGCGGAGGCCTGGAATTGCGTTCTGGAGATTGGAAACAGGTGCTTCGCCGCTGTGACTTTAAAGGC
GAGGCACACTTTGGCTGGTTTTTCTGTGTGTGATCGGCCGCTTTGACGAGCTCCCCCGCTCGCATCAAAA
ATCGACGACGATCTGCGAGTTGACTGGACGAGGCGTGCTAGGGTTCCTCCCTCTCTTTACGCTGGCTCCT
TGTGGCTGGCTGTTTCTCATTTCCCCGAGGGAGAGCCAGAGCGCTTTAAGGTAGCAACGTGGGTTTTTTG
TGGCCAGATTGACATTTTTTTCTTGCGGCAGAAGGCATTTCACAGTGGTGAAGTTGGATTGCAGTTCCTC
CCCTTTCTTCAACGGCGCTCCGTGGCATCGCTAGATCCAGAGTCGCTCTTTAACTCGCGCAGCAACTGAG
CTCTCGACGTCGGCCTGCTAGCAGCCACACCCGTCGTTGGTGAAAAAACGAGTTCCACCCGGCGGGCGAC
GACAGGGGCGGCGAGCGCACGAAGGCGCTCTGTTCTTGCATTTTCTACTGCTCTTGTGGTCCGATTTTGC
AAACGCCGCCTGCCTTCCTCTCTAGTCTTTTCTCCGCGTTCTCTGAAAACGCAACGGAAAAGCACGTCGA
TACCGGGAGAGCGCGAGTGGGCCAGAGAGCGCTTGCCATCTACAGTGTGGCGCGGAGCTGGTAAGGAGCG
AACAGCACACAGCCAAGCTTGCACCGCTCGGACGTTTTTCTTCGCTTCTGCCACCCAGGCGTTTTCGTGC
GTCCACTTCCAGCGAAAACGGAGTTCACCCTCGAAGGCTTAACCAGACGTTGGGAAAAAAAGTTATCGGC
GTAGTTCTCCACACAGGCCGTGCGGGGGTCCTCAAGCGTCCGAGCCGACGCGCACGGCTTCTCTCCGCAA
TCGCTTTTCTGGTATCTTCTCTAGAGACGCCAGCTGGTCAAGTATTCTCTGTACTAAGCAGACGAAGGAG
GCCTTCCTCTTCGCCTGCAACCTTCAGAGAACTCGCGCGCGAACGTGTTCGCCAGCGAGGAGCTGCGAAA
CGGAAGGGGGAAAACCCACCCTGCTACGCTTCGTTTCCCGAGAGTCGCGTGCTCCCTGGGGAAACAGAAC
ACCCAGGGGTCTGTTTTTCCGGCTCTGTGACAACGCCGCCTTTGGACGACCCTTTTTTCGCGACAGCACA
CCCTGCAACGGTCGCGCACGGTTGTGAGAGCCTTGCAGCACGACAAACTCGCCGCCGAGTCAACAGCCTC
TCGACAAGGTCAGAGCAGTGGCTCTTGAATTCGTGCTTCCTGTGCGATCACGGATTGCGTTGCTCTTTTG
AGACTTTTTAACGCCGTCGTGGACCTCTTTGTTTCGAGCTCTTCTGCGTTGTCCGCTCGAAGGAACGCGT
CCGAGTTGGAATGGTCTCTATACTCGTACGTCTCTGTTTCTCGACCTTTTTCGATTTGCAGATACGGTGC
GTTCCACGTATTTCGAAATCCTCATCTCTCCCCGCCCACTGCGCACGTTCATCTTTGACGTCTTGCTGGA
GATATTTTTTGTAGGCCCCGTGTATAAGTTAACGTCCTTTGCGAGACCGCTGTCTGTGCTGCCGCGTTTC
CCGGCCGCGGGCCTTCTTCTCTTTGTCTCTGAACAAGACGCAGTCAAGACTTTTACAAGTTCGGAAAACA
ACGCCCTCCGAGAGTCCTTCTGCGCTCTCTCCTCCCGCGCCTCCTTGTGCAGACCTAGACGCGGCACACC
TCTGCGTGGACTTCGACACATTCTCGTGTGCATGCATGCAAGTGCCGTCGAGGCTTTGTTGTTTGTTGGA
GAAACAGCTTTTCTATCGAACGCGAGAAAATGGGGCAGCAGGAAAGCACTCTTGGGGGTGCGGCCGGGGA
GCCTCGCTCGCGCGGTCATGCGGCGGGGACCAGCGGTGGACCAGGAGACCATCTCCACGCGACGCCCGGG
ATGTTCGTTCAGCATTCGACTGCGATCTTCTCCGACCGGTAAGATTTTCGAGTTCCCCGCCCAGGCGTTG
CGGTCGCTGTCTCTCCTCCTGTCTCGCATGCATGTCGCTGGTCTGTCCGCTTCGTCTTCGTGGTCGTCCG
TTCCGGGCAAGATGTCGCGCGTTCGCGCAAGCCAGCCGCCTTGGCGCCTCTGTGTGCGTCGTTTGTGTTT
TTTCATGAAGCATCGTGGTGCTTCTGTCTTGTGCGGCTCCTTTGCCGGTCGCTTGAGACGACTCCACATC
GTTTCTTAGACAGTGGACGCTCTTTTTTCTGAAATGCTGCATCACCCCGCAGTCACCGTGTTCGTGTGTA
TACAGAAGTGTATAAAGTTCGAACACATTTGAATAGACTGACAGATTGGCAGTGGAACGGACAAGGATGT
CGCTGCGCATCTGCAGTGGGAATCCTGGTGCGCCGCTGGTGTGTACTCGAAGAATCTGGAGAGGTCTGCA
GAGCGGTATCGATGTGTGTCTGTCGTCTTCCGTGGAGTCAGAGAGGTCTGCAGGGACCTGTCCCTGCGCA
TTCATCGCCCATGTTTACCTGCCTGTTCACATTGTCTTCTGCATCTACATATCTGTGTTTCCTCTGAACA
TGTCTGTCCACGCGCGTCTTCATACGTCGAGACTGAGCGACCTGCATCCCTGCGTTTCGCGCTTTTTCGC
GTACGTGGGCTGCTCCGGGTCCTGCGGCCCCAGCTGTTCGCGTTTTTTCCGTTCGGGTGTCTTTCCGACA
GGTAGATCTCAGAATCGGTGCCCAGCTTGCTTGCGCCTTCTCGGAAGCCGAAGTATTTGTGTGTCGACTT
GTCGTTCTGTGTCCGCGTGCGGTTCAGGTACAAGGGACAGCGGGTGTTGGGGAAGGGGTCTTTTGGTGAG
GTGATTCTGTGCAAAGACAAGATCACCGGTCAGGAGTGTGCGGTGAAGGTCATTAGCAAGCGCCAAGTGA
AGCAGAAGACGGACAAGGAGTCTCTGCTTCGCGAGGTGCAGTTGCTGAAGCAGCTGGACCACCCCAACAT
CATGAAGCTGTATGAATTCTTCGAGGACAAAGGCTACTTCTACCTCGTCGGCGAAGTGTACACGGGAGGC
GAGTTGTTCGACGAGATCATTTCCCGCAAGCGCTTCAGCGAAGTCGATGCGGCGCGGATCATCCGCCAAG
TCCTCAGCGGCATCACGTACATGCACAAAAATAAAATCGTACATCGGGACCTCAAACCGGAAAACCTGCT
CCTGGAAAGCAAAAGCAAGGACGCGAACATCCGCATCATCGACTTTGGCCTCAGCACTCACTTCGAAGCG
AGCAAGAAGATGAAGGACAAAATCGGAACGTAAGGAGACCGTTCACACTCTCGTCGATTCCGACGAAGGA
AAATGCCTTTGGCTTTTCGCTTTCGCTTCCAGTGTCGCTCTTCTCTTACGTAAAACGAAGGGACTCCCTC
GTGACCTTGTCTGCCCTTCTTTCCTCCTGCCGCATGCGCTCGGCAGTTCCCTTCACTACGCGTCTCCTCA
GGTGTTCGCGTCATCTGTTGCTCTGCGTTTGAAGGGTGGAACAGGATGCCCTTGGCGCCGCGGGTGCTTG
CGTGGAACTCGAGAGAGACGACGGAAAGGCCTCAACGGACTTTCCATGTCGCGCCGTGCTTTTGTATCTG
GAGAGCCGCTGCCTCCAGCTCCTTGCAGCCACTGTCTGTCTTAGAAACAAAGGACCCTCTGTTCTGTGAT
TCGTTTCCCCTCCTCCGTGGGGGAGACACATTGGTGAAAAGCTACAGAGGGGGAACCTCAAAAGGGAAAG
AAGTCAAACTGGAAACACGAAAACAGAAATACGGGCCCTCGCTTCAAACGCCTCTGGTTCGTTTGCATGC
TCTCCGCCACGGTTCCTGTCCGCGTCAGCGCTCCTAGCTATACGCTGGGGACATCTGCAGAAGGTTTCCT
ATCGAACCTCGGTTTTGTAACCTTTGTCCATCGCCGTGCGTCCATTGTATGGTGCTCTCTGCTTCTCCCG
GTTCTCCAAAGTCCACGGAGTTCCCTTGCCTTGTTTGTGTGGCTTCTCAGTGCATACTACATCGCACCCG
AGGTCCTCCACGGCACTTACGACGAGAAATGCGACGTATGGTCGACCGGTGTTATTCTCTACATCCTTCT
TTCCGGTGAGTCTGTACCGCGCAGTGCTTTCCCGGTCTCTCCTCGCTCTTCAAGTTCTTTTTGCTCTTCA
AGTTCGTTTTGCTCTCCAGGTCTCCCGGTGTACCTGCAGAAAAGAGAGATAAAATCTTGTGTTGCTTTCT
ATGTGGGGATGCAGAGGGATGCATGTGCACTCATATATCTGGGAACGCAGGATGCCAGAGCAGGCGCATT
TTTCCCCGACGAGAAGCCAAGTGCGTTTTCAAAAGGTTGCTGTCTACACAGTTCTCGAGAGACTGCGCGG
GGCATGGACCTCTCGACGTCCGCCCTGTTGTTCTGCCTCTTCCCAGTTTCGCAGTGTGTGTCTTTTGTTT
CATCTCGTGCTCTGTCCTCATCTCTCTTCGCCTCACTCGCTGGCTCTCAGGATGCCCACCCTTCAATGGA
GCAAACGAGTACGACATCCTGAAGAAGGTTGAGAAAGGTAGGCTGTGTGTTCTCCGACGTTGTTTTTCTG
GACCGTCGGGCTCTTGCGTTTTTGTTTCGTCTCCAACTCGCCTCCTCAGGTTCTCTGGCCGCTCTCTCTG
TTTTATTGCTTCCCTCGTCTTCGGTGGGTCTTTCCCTCGATCCCCGTCTGCCTGTGTCACTTCAGTGGTG
CGGCTGCGGGTGAAGGTGCATCCGGGTGCCTCGGTGCTCGTGGATCCTTGGTTGTGAAGCAAAGTGTGTG
TGTCAACAAGCCGACGCAGTCTGTGTGTCGCGAGCCCGCATGGGTTCGCCTCTCTAAAACGAATTCACCT
TGTAGACAGAGATTCCTGCGGACGCCGAATGAGGCAGCGACGAAAGCCGCATCGTGCCTAGATGATAAGT
GACCGGGGAGCGTCTGTTCCATGCCGTCTGTCGACGGATGTGCGCGTTTCACCGTGAATACGGGGCGAAG
CCTGGAAATCCTGAAAATGTTGAAGAAGCACAGCTGTCTTCCGATGAAGAGATACATAAAGGGAGAGAGA
GGTGACAAGATAGCTGACGAAAAAGGTAGAGAGAGAGAGATACGCGGGGCCTTGCTTTCGCGGTCCAGCG
CCGTGAGTTACTGGGGACAGGCTTGGTTCATGCGCGCCGCCCTCGCTTCTTCTGTCTCGCGTTCCTCCAG
GCAAGTACACCTTTGAACTGCCTCAGTGGAAGAAAGTGTCAGAGAGCGCAAAAGATTTGATTCGCAAAAT
GCTGACCTACGTCCCCAGCATGAGAATCAGCGCGCGAGATGCTCTGGACCACGAGTGGATCCAGACCTAC
ACGAAGGAGCAGATCAGCGTGGACGTTCCGTCTCTGGACAACGCCATTCTCAACATCCGGTGAGATTCCC
CTCGCGTCTGTCTCTTGGTTCCTCCTCCTTTTTTTGTTTTTCGTCGCGCCGCCCCGGTGTTTCTCCGCCC
CCCGACGACACGCAGCCGAGCAGCGGCGTCACAGAGAGGGCGTCTCTGGTTCAGCGGTCGTCGAGAAACC
GAGTGCATCCCAGTCTCTCTCTTTGTCTGTGGGCGCGGCGACGCTTCGAGGGGAAGTGCCAAGAAGCGAA
CCGTCTCTTCCGCTTCGCGAGGCACACGACTGCAGCGAAAGACACCTCGTAGCACCTCCTCTCTCCGAAG
TCGCATGCAGAAAGGATCCTGTCACAGAGAGGGGACTTCTGGCCGGACGAGGGTGCTTCCGACCAAAAAA
AACAGAGGCGCCCTTCCGCGTCTCTCGGGGTAGCCGCTGCCTGCATGGATCTGTGTGTGTTCGTTGTGGA
TGTTCCTCGCGGCCTTCTCTCAGACAGTTCCAAGGCACTCAGAAGCTCGCGCAAGCTGCGCTGCTCTACA
TGGGCTCGAAACTGACAAGCCAAGACGAAACGAAGGAACTGACGGCCATCTTCCATAAGATGGACAAGAA
TGGAGACGGGCAACTGGACCGTGCAGAGCTCATCGAAGGGTACAAGGAGTTGATGCGGATGAAGGGCCAA
GATGCGAGCATGCTCGACGCGAGCGCTGTTGAACACGAAGTTGACCAGGTCTTGGACGCAGTCGACTTCG
ACAAAAACGGCTACATCGAGTACTCTGGTGAGAACGCATTCCCTTCTCCAAAAGCGGCTCTGTATCCATC
TCGGTACAAACACACATACCTACATACATACACATCCATGTACATATACGTCCTTATATATATATATATA
TGTATATATATGTATATTTCTGTGGAGCACGGTGTAGAGGGAGCGATATGGATGCGGAGATCCATTTTCG
GTCAGAAGTGAAGATGCAGGGAAAGGTACATATCTAAGGGGGACATGGGGGCGGGTGTGGGGTGGGGGGT
ATGGTCGGGAGAAACGTCGGTAGGTGTATCTGCGACACTCGTGTATGGTCTGTACGAGGAGCTTGTTTCT
TGTCCGGCGGACAAAACATTTTTGTGGAGGAAACAGATGGACATGTTTCTGACACTCTGTAGCCACTCGA
CTCGCTCCCGATTTGGCCGCTCACTCGTTCGCTTTTTCATCTCAACTGTTTTCCAGAGTTCGTCACCGTG
GCGATGGACAGAAAGACGCTGCTTTCGCGAGAACGCCTGGAGCGCGCCTTCCGGATGTTTGACTCCGACA
ACTCAGGAAAGATTTCTTCCACTGAGCTGGCCACCGTGAGTATTTCAAGGTCTCTTTTTCTTCTCGCGTA
GTTGCCGTTGGCGCGCGAACCTCGACTTTTTCCAAGAATTGCGCGTGTCTCCAGGATTTCGTTCCCCCTC
AACAGAATCTTTGTTTCCGAATTTGTCTGTGTGTTTCTCCCTCGTCGCCCCGTCTCCACTGCCTCCTTCT
CCACATGCGGCAGCGCTTCCACGAAACTCGCGGAAACGGCGTGTAGCGTTTTCTGTGTTTTTGTCGGAGG
GAAGAAGTTTTGTCTCGAGTGCGTGCAGCGCTGAGTCGCCGTTTTTTCGTCCGGTTTCTGGGTGTCTGTT
TCTCAGATCTTTGGCGTCTCCGACGTGGACAGCGAAACATGGAAGAGCGTGCTGTCTGAGGTCGACAAGA
ATAACGACGGCGAAGTCGACTTTGACGAGTTTCAACAGATGCTCTTGAAGCTCTGCGGAAACTAAAAGCT
TGCACTCTCCCTGTGCGTGACGTCTATTCTCCCCCAGACTCCCGTGCACCCCTCTCTTTTGCCGTAAATC
CTGCGGTGGCCCTCTCCGACTTCACAGCCCAAGACGAGAAAGCTGCAGAATCGGGTGCCAGCTTCAGAGG
GGAGCGAACAGAGAGCAGAGAGACGCGGAAGCTGTCCTGGCGGGAGGCTCCTTCTTCTTCACGGACCCGT
TGTGGGACGTGCACTCTTTTGAGTGTGGGGTTCTGAGCAAGTTGTCTCGGGATCATCGGTGCTCTTGGCG
TCAATAACGCATTTCCATTTTCGCTCTTCCTCTCGGCGTCAATCACGCTTTTTCGTTTTCTCTCTACTTC
TCTTCAAAGAGAGACCTAGCCTAAGCCAAAAAAAGGGGGAGGCAGTTGTCAGCCGGTGATCCTCACGCGT
TCGAGCCACTGTGTGTGCATGTAATAATGTATTTGTTTACTTACGCATGCATCTTTGTCTCGCCGAGACT
CCGGACGGATTTGAGGAGCAGACGAGCTCGACAACGCGCGCGCATGGAGAACGCGTCCGAGCCGTCTGCC
CACAGACCTCGTCCTGCCCCTGGCTGCGCGAGTGCACGAAGAGACCGAGTTCCGTTTTTCGCGCTGCGCT
GCAGAGGGAACGTCGAAATTCGATGTGCGAGTTCGACTCGAGCCTGCGGCGAGGCGAAACGCTTCATTTC
AGCGATCTGTTCGTCGAAGCCACCATTCCCGTGCGTGGGCATGTATGCCCTGTCCATGTTCCTGCGCATC
CTTCCCTCCGAATGTCCGCATCCTTCGACTGCCTCCACATACGCCGATCTGTGTTTGTACACTTCATTTC
CAGCCGATTTGTTTCGCTTTTCTCGGGGCTCGTGAGACGTGCTCTGCACAGAAGAAAGAGGAAGCACGAC
ATGACACAGGCTGTCGCTTGGTCTCGTACGCTCGCTTGAACTTTTTTTCGCGCGGTTCCCGTTGTTGGGT
GTGTTTCTCTGGCGCCATTCGCACAGAAGAGAAAGCAAAAAAACCAGCAGAGGACTCACTGTTCGCGCCG
CTGTCGCAGTCACTTGAGGGGGGAGGGGGGGCGTTCACCACCTACTGCAAGGCACCTCGGTCCCGGCTAC
GCGTCTTCGTTGACTGTCGTAGCGCGCGAAGGATTTCCGGGTGCCTCGCGAGAGATGAGGCAGAGAAGAC
GCCTGGAAACTCGCAAAAGAGGTATCGAGAGAGAGCGGAAGCATTCGTCTCGTGAGAATAATTTGTGTTC
TTTTGAAAGAAGGACGAAGCGAAGGCCGCAGCGATATAGACTCACATCCTCTGCGGCGTTTCTTCGCAAA
TGGAGAGTGTGGGGCCTCCTAGGTGTGCCTCAGGTGTTGACTCGAAGCGCAGAGGCCATCCCTTCCTCGC
GCTGCCATCTCGTCGCTCGTTTTTCGGAGACTCGCGACGCGTTGGCTTTTTCTGCGAGACTTTTGTGTCG
TTCCAGGAAACTGAGATGAGCGCGGGCAGACGCTCACGACGCTCAGGGTACAAGTGCGTGTCAGTTGTCT
CATTTTGCTTCGTGTGGAGAGCATTGTGTTTCACGCCTCTTGTTCAACGTTTCGCCGGCCGTGTAAACAC
CGACTGTCTTCAGAGAGATTCGGTCCACCGGACAAGTACACCAAAACCTGATAAACGACACAAGACGCCG
TCAGCCTCGCGCGTCGCGTTCAGGCCCGACGCCTGTGTAGACTGAGAAGCAGCAGACGAACTTTGCGCGT
TTTCCGCACCAGGTTTTATGTGTCTCTCTTCGCGCATAATCGATGACCATCCTCACGGAAGACACAGAAC
CCAGCATTCTTAAGGAAACAGCTCAGACAGGGCTGCTAGTCTGCTGATACATACGGGAAGCATGCAATTC
TAGGAGACGATGAGTTCGTCACTCTTCGTCCTGCTGTTTACAGCGTGATGAGACATGAGCTTCTCCGACG
GTGGTCTTTC
-
Protein Sequence : Show Sequence
>XP_018637931.1 calcium-dependent protein kinase CDPK1 [Toxoplasma gondii ME49]
MGQQESTLGGAAGEPRSRGHAAGTSGGPGDHLHATPGMFVQHSTAIFSDRYKGQRVLGKGSFGEVILCKD
KITGQECAVKVISKRQVKQKTDKESLLREVQLLKQLDHPNIMKLYEFFEDKGYFYLVGEVYTGGELFDEI
ISRKRFSEVDAARIIRQVLSGITYMHKNKIVHRDLKPENLLLESKSKDANIRIIDFGLSTHFEASKKMKD
KIGTAYYIAPEVLHGTYDEKCDVWSTGVILYILLSGESVPRSAFPVSPRSSSSFCSSSSFCSPGLPVYLQ
KREIKSCVAFYVGMQRDACALIYLGTQDARAGAFFPDEKPRCPPFNGANEYDILKKVEKGKYTFELPQWK
KVSESAKDLIRKMLTYVPSMRISARDALDHEWIQTYTKEQISVDVPSLDNAILNIRQFQGTQKLAQAALL
YMGSKLTSQDETKELTAIFHKMDKNGDGQLDRAELIEGYKELMRMKGQDASMLDASAVEHEVDQVLDAVD
FDKNGYIEYSEFVTVAMDRKTLLSRERLERAFRMFDSDNSGKISSTELATIFGVSDVDSETWKSVLSEVD
KNNDGEVDFDEFQQMLLKLCGN
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL21-IL15
,
T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL7-IL15
|
|
3. CDPK2 |
-
Gene Name :
CDPK2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7895412
-
NCBI Protein GI :
237833849
-
Locus Tag :
TGME49_225490
-
Genbank Accession :
KE138836
-
Protein Accession :
XP_002366222
-
Taxonomy ID :
508771
-
Chromosome No :
X
-
Gene Starting Position :
2207265
-
Gene Ending Position :
2214583
-
Gene Strand (Orientation) :
+
-
Protein pI :
6.76
-
Protein Weight :
74568.34
-
Protein Length :
711
-
DNA Sequence : Show Sequence
>NC_031478.1:2207265-2214583 Toxoplasma gondii ME49 chromosome X, whole genome shotgun sequence
CGGCCAGTTTCCTGCTAACCCTGAATCACGGTATAGTTCGCACCAGTTGGAGCAGCACTTAAAACCCTTA
CTCGAGAAGAGGAGTAGTGGCGCCGATATTTATCACTGGTTTAAAGCGATTCGGGACGATCTACCTTTGA
CGCAGCATTCGGGGCTAATGGTCTGTGCTCTGTGTACCTGGACATCTATGTGGTTTATGTTGACATGACT
GTTCAACTAAGGTGGAACTCTGAGATATTTAGGCTGTGTCAGTCTCTGAAGTTCCGGATGTTTGCACAAA
GTCGTTTCAGAAATCTAGCGCAGCGATCAGATTTTGCGACGGGTGTGTCAAGACAGCTTAACCGAGTGAT
CTGGCGTGCCTACCCTCGATCCCACGGTGGTGTTTCGTTTCTTGAAAACCCGCCAGACAAAGTCTTCCAG
ACGCTGTGTGCCTAACGGCCATTCGTAGGCGAGTACAAAAGAGTAAAAGAGGACGTACTACTACGGTGCT
TGGCGAATTGGGTATCGCGGGCGTTTTAATGGGACCTGCCTTTGTCTTCGACGGGGAGCTAGCTATTGAG
CACCATGAAGTAGCAGAGCCCTGTGCGAGCTCGGACGAGGAAAACGTGATTCTAACGCTCTTAAGGGTGA
GAATTACACATGCTGCTCTACCACATTGGAGTTGTGACAGGCTGAAGCACTCGTGTTTTGTCGCCACGTA
CACCTCGGCGAGTGCATGCGTGCAAAAAAAGCGGGCTTTCTATAACACACAGGGGGTCGAAAAGGTCACG
TATATCTGCCATTCCCAAACTACAAATGGAAGACTATATCATAGCTCCAGATGAATACGGCTGATAACGC
GCACGAGAAGGTTTTTCGAGACCTGCTTCTCTTAAGACAGTGTAAGTGCCTGACTCTAGCGACGGCGCAT
TCTTTTGCGCCGCCTGTGCTGGTTCGAGGTTCGCCACTTTTCCGGTGGTGGGTCGCCGCCAGGATGCCGC
CACTCACGGTTTTCTTTTATGCTCGGGAGCAGGCACTTGGAAGCTTCACCGCAAGCTCGTCAGAACTGTT
TGGTTGGAGAAAAGCGGCAGCAATCGTACAGCGTCTCGTCCTTATGTTCACAGAAAAACCATAGGCAGGC
AGGAAGCTTAGTTTTGTTCAGTATGGTTGGTTGCCTTGCCTGGCGGAACGAACTCGGTTGTTTGTGGTGG
TGTATTTTTCTTTCTGGGCAATGTTCGACATTGCCGAAACGCGGATATTTCATGTTTTCTCGTCATCTGA
GCACTGCGTCGTTTAAATAACCCAATATCTATCCCGTCTTTTTCTCGCAGAAAGGGAGCATCTTGTCCCT
CCGACACCGCTGAACGGAAAGCGTCCTCGCGAAACGGGTGCAGGGACCACGCCATCGGATACTTTTCGTT
CCTCTGCCGTAAACGTCTGCTTTTTGTTTCATTATCATACTTTTTTGCGTGAGGTTTCTAAATAGCGTAC
ACTGGATCGTGTCTGGGGCAGGAAATCAGTCAAAAAGTGTTCCTTCCATCGGGAGCTGGTGCGCGTCGCG
TTTGTCTGTTGAGTGTTAACGCGTTTTGCTTGAAAAAGCTGCCCCTTCCGGCCTGCGGGCTAGGTTCGAA
AAAACAGCCGATGCTTATGAACTCTTTCTAAATTCAGAGATTCCGTGTTGAGGGCGCGGTAACGGAACAG
TTCTCCGCTGCAATTCGGCGTGAGTCCGTCGGCCACCGATGGAATATGTGAAAGTAGAAGCGAACGCCTT
TCCTCGTTGTAAGAGTCCACTGGTCGGACAAGGATTTTTTATGGTCTCTCAGATGCAGACACAACGTCGT
TTTTCTTATTCTCTCAGTCCGGTGGCAGGTGCTGCCATGATGGACCCCACTTGCGCTGACCTCCAGCTAA
ACGCGAGGGTAACACGGATCTTTCACACCATATTGTCCTGCCGGGAATTTTTGTACCGTCTGTCTTTCTG
AAGAGGCCCCGTTTTTTTTTCTGTGTTGACCGAGGGTCCGAGTCTGCGGTGCACTGAGTTGCGCCTCGCC
GTTCGCCGCAGCCTTCCAGCTCTCGCCTCTTTTCTTCTTCGTCCGCCGCGTTTGTTGTCTCGTTTCTGCG
GAATTTGTGCGTGAGACAGTAACTTTCTAGATTCGTATTTTGGTTTCCAAGCCGAAGCCAAATGGCACTG
CGTTGTCTGGCGGCTTTCGGATATTCCCTCATCGCCAAAACCGTTTTTCTTCCACCTCCTCTAATCCTTT
CGATTTAACTCTTCTGTAGAGATGCCGCTCAAGACTTCCTGGCATTGTTCGTGCAACGCCACCTTTCCAG
GTGACTTGCTCATGGTTGTTGCTAACCACGATCGCGTGGGCAACTGGAATCCTCAGAACTCGGTGGTTCT
TTCGACAGACGCATCCTCTTTCCCGACATGGCGCTCTGGCGAGGTCTGCTTCGACGAGCAGCAGCCCGTC
CGGCTCGAGTACAAGCTGATTATTCGCCGCGCCTCAGGAGAAATTTACTGGGAGCCGATTCCCACCAACC
GCGTAGTCACGCTGACTGCGAATACGTCCTCAGTCATCGAAAACGTTTGGGGTTCGCTGGCCACTTGCTC
CATCACCTTCTTCCCGCTGCAGCCGATTCCGTCCCCGTCCTTCTACAAGCACGCAGAAAGGACGAAGAAA
GAGGCCAGTTCCGTCCATCTGCACTCCGCCTCCATTTCCGACGACTCCGGGTCCGACACTGGGACATGTT
CACAGGTCGACGAATCGCGAACGCAACGCAACGTCCGCGGACAGCCTGCCTCCGTGGGGACGGGGAAGGC
CACAGCCGCCGAGAGAGGCGGCAAAGGATACGTCATGCCGCATCACCAGTGCAGCACCAGCCAGAGACGC
CACTCCATCAGTACGCAAGCTGCGGACGAAGCGGCCGGCGGAGGGAATCGCGTTTCCTTCAAACGCTCCG
CCTTCATTTTGGCCAACACTGGTCCCATCACAAACTACTACACAGTCTCAAAGACAATTGGTACGTTGTT
CGCTGATCTGAAAAGAAAGCTGCACAACGTGCCGGCTTCGTCGTGGTAACTTCCGGTTCGAACGTGGCGA
CGCGGCTGTATGTACACCCGCCTTTTTTCTGCTTCCAAGGCGCCGAAAGGCTGAAAGTGTTAGGACGTGT
GGTGTAAGATTGCTGCGCAGCCGCGCCAAGACTTTTGGCTGGGAAGGGGGTGCATGCCGCTGTCGTATGT
TTTTCGGTATATGCCCCGGTGTTCACGTCTGCCTTACCTGAATAAGAAGTTGCGTGTCGTGTGAGAAGTT
CGTCGCGTTTGTGGGAACTGCAGAGTCTGAGATCACACCAGAACCGAAGGGTTTGGAAAAGGTGAAAGAC
TTAGAAACTCTAGAAGAAACACGGAGACACAAGTGGTGACGGATCTTAGCCCAGCGGTCTTGTCGATCTT
TCTGCGTTTTTCCGAGCAGGGCGTGGCACATGGGGAGAAGTGAAGCTGGTCATTGACAACGGGACCGGAG
CGCGTCGCGCGGCGAAGAAGATTCCCAAGTGTTACGTTGAAGACGCCGACCGTTTTCGTCAGGAAATCGA
GATCATGAAGAGCCTCGACCACCCAAACATTGTGCGACTCTACGAGACTTTCGAGGATATGACGGACTTC
TACCTGGTGATGGAGTACTGCACTGGGGGCGAGCTCTTTGATCGCTTGGTTCACCAGGGTGTCTTCACAG
AGGCTCTGGCCTGCCGCATCATGCGGCAGATTCTCGCAGCTGTTGCTTATTGCCATGCCCACCGCGTCGC
CCACCGAGACCTGAAGCCGGAGAACTTCCTGTTTTTGCATGACAACCCCGAATCTCCCATCAAGCTCATC
GACTTCGGCCTCGCCGCTCGTTTCAAGTCTGGACAGCCCATGAGGACGAGAGCCGGGACGCCTTACTATG
TATCGCCGCAGGTACAGAGCACAGACAAGAAGTCAAATCTCCCTCTGTGTTTTCTCCAGGCTAGGCGACG
ATTAAATTTCACTCGCCCGATGCTGCCATGCTTGTAATCTAGGGTCTTCGTTAACTCGACACATGTTCGT
TGTGTTTCTCCATTCTGCCCATATATTTATATACGTAAGCTGTTTTTGCCGATGTGTAAGACCGTACATC
TTTCGTGTCTTTTAATCAAGCGTATGTGTACTCTGCGGCGTTTGCCGATTGAAATACGGTTCCGCGCTGG
CCTGGTATCTAGTTCTCTCTCCACCTTGCACACGGTACGTCGCCAGTCCTCTATGGGGATGCGTTTGCTG
TGCCCGCTTTTCCTGGCTCTTCATAAAGGCTTGGACTTCACACAAAGAACGCATTTCACATAACCAAAAA
GAATTCGGAAACTGCTCTGCTCTGTGTGCGCCTGCAGGTGTTGGAGGGACGGTATGGCCCAGAGTGCGAC
GTCTGGTCCGCCGGAGTCATGATGTACATTCTGCTTTGTGGGTATCCTCCGTTCAATGCGCCGTCGGACA
GGGCGATTATGAACAAAGTGCGTGCGGGACATTACACCTTCCCAGACAGCGAATGGAGTCGAGTGTCACT
ACAGGCCAAGGATCTCATCTCGCGTCTTCTTGATCGCCATCCGCGCACTCGAATCAGTGCCGAGCAAGCG
CTCCGACACGCCTGGTTCGCCATGCATGCTCCGGGAGACCATTTTGAGCCTCTAGGTGAGACACGAAGTC
TTTTCCGAGGAATATATGTCAGGCGGAAGAACCCTCGAAAGATAACTCTCACACACATGCTTATCTTTCT
GCGTAGAGATATGTATAGGTGGCTTGTCTTTCTGAGTTGTGGCATCTCGAGTGTAGCCACTGGCGGCGAA
GGTGGGTCATCCGATTTTTTGGATCGTCAGTTACGCGGGTTGTCCGCGTGTAGAGCGGCATGCGTTTTTT
CAAAAGCAGGTGACGAGAAACTCTTGTTTGTTTCCACCTCCGCAGGCTTGGACATTTTGAGCAAATTTCG
GCGATTCCAGGGCTTGAGTCGACTGAAGAAGCTGGCTCTGACGGTTATTGCACAGCATTTGGAGGACTCG
GAAATCGAGGGTCTCAAGAACTTGTTCACTCAGCTCGACACCGAGGGTGACGGTGTCCTGACAGTGGAGG
AAATTCGCAAGGGCATCGAGCGGAGCGGCGTCCACTTACCTCCGGACATGGTCCTCGAAGATGTCTTGAG
GGAAGTGGACACCGCCGGCACTGGAAGCATTGATTACACAGAGTTCATTGCAGCTTGCCTCCACCAGTCC
CACTACATCCGAGAGGAGGCGTGTCGAGCTGCTTTCCGCGTGCTAGATATCAATGGAGACGGCCTCGTCA
GGTGAGTTTTCAGGCGTATTTCACCAGTCAGCTTCACGCCGGCAGAGAAAGGGTGTTGATGCAGCTTCCA
TGTTTCGATTGCAGACGCCAGAACATGTGTGTCAGTTTCTATCTGTGAGCAGGGGCTGCTCCCCGGCTTT
TTCGAGAGACGCGCCGTCGCGTTCTACCGCTTCTTTTGAACAGTGAAAAAGGGCATCTGCTGTATAGACG
CAATCGTGTCAGATCGGATATTGATGCACAAGCGTCCCCAGAAAGCACAACTGATCTAGACAGAGACCGC
ACATTGCCCTTACCATTCGTCTTTTCTTGTGGAGGTCACAGCCAGCTGCGTTGACATGCATGCGGGTTCC
GCCCTTTTTTTGCGTGTGTGCAGTGCTCAAGAACTGCGCCAGGTGTTCCACATGGCTGGTGATTTGGAGA
CAGACGCGGCGGCGGAGTTGCTGGAGGCAGACGCGGATGGTGACGGGCACATAACTTTCGATGAGTTTTG
CGGACTCATGCGGAAGGTGCCGTCGCTCGCCTTGGTCACGGAGCACACAGTGTCGATGATGCGGCGAACG
TGTTCGCGCACAAACATCAGCGAAGCCAGTCTGACGCCTCGCGCTACGGGGTAAATCGCAGAAGCGAACA
CAAATGGAAAGACAGGAAAACGACTTTTTCTGTAGTGGGGAAACCCGGCGAACGTTCCGCTGGAATGTGC
CAGGGACGGGCCATGAGATGCCGGTCAACACCGGGCGAGGCCTGTCGTTGGAACGGACTGCGATGTTCTC
GGCGTGGGCGTCCGACAGTGTCAACAGGCTCTACAACGCGCAGAAAAAAAATTCCCGCACGTGTTCCATA
GACAAACCGTCCTTCGGGCGGGAGATTTGCTTTTTCGGGAGATTGCGACGGAAGTGGGTTTTGTTTAGGT
CGCAGTGGGGACAGTCTGCTGGTTCTGCGAGTAGATATTGGTGTATCGACGGTACTTCAGACACTGCCGT
CACTAATCACGTTCGGTCTCTGGGAGATGCAAGGGAAATTCTTTTTCATTTTGGGGTTTACGTCGCGTGC
ACGCGTTGTGACTGAGAAATGCGCGCATGTGGTCGAAAGCGCCGCATGCGACAGTTCAGCAAACTGCGTG
CAAGGAACTGATAACGTATCGTACTTTGTGCAAGACAATCTCCGTTAATATGTGGCGACTTCCGAGTTCG
TGTGAAGTTCCCAAATTGAGAGCAGGCTCTTTGGTGGGTCACCCGATGTGCACCGGAGACAGACCCGTCT
GTCACTCGATGGTACAGTGGGATTGAGTTTTCTGCGTTGTCTTCGTTTCGTGATCTCATCTGCGGGGGAA
ACAGACGGCTCAGTCCTTCTGGTCCCGAAAACTCGACTAGAGGTTGGGTGCGGGCTGCACAACCGCAAAC
TCCGGAAGGTGGAAACATGTCGCACCGAAAGGTGCTGGTTTGAAGGGCTGTATTGAGATGGGCGACGACG
CGGGAGATGAGTTTCAGCGATCTATCGTTTTTTCCACCAAATATATGTGGTCTGCCGTCCAGGTTTAGTT
CTTCTTTGAGTATATGCGATTTTGCGTCACTGGCTGCGGGCCAGGGATCAGGTCCATGTCGGTTCAAAGG
TACCGCGCTGGCGTCTCGGCGGGCTTACTGTTCTACATCGCGTGATAGAGAGTGGATTTCAGAGGGCAAG
GAGGGCGCTTTCTGGCGCGTCCTCTTTAGAAAGACTCTGTTTTCGCGGCGAAAATGCAGTCTATGAGAAA
CGAACGACCGACTGTGTAGTAGCACGCAAAGGGACGACCGCAACGATATGCGTATTTCGGTGGTTGCCGG
CTTCTTTGCTTTGTTCTTGCCTGAGAAATGAGGACAGAAAATGTAACGAAGGGCTTTTTTTTATACAGAT
ACCGTAAAATCGATTCATGAACAAGATGTGGAATCGTACCCTCTCGTTTTGTACAATTCGTGCCCGAAAC
ATATATTTCACAGAGACTTTGGCTGTCAATCAAACCTGC
-
Protein Sequence : Show Sequence
>XP_002366222.1 calcium-dependent protein kinase CDPK2 [Toxoplasma gondii ME49]
MPLKTSWHCSCNATFPGDLLMVVANHDRVGNWNPQNSVVLSTDASSFPTWRSGEVCFDEQQPVRLEYKLI
IRRASGEIYWEPIPTNRVVTLTANTSSVIENVWGSLATCSITFFPLQPIPSPSFYKHAERTKKEASSVHL
HSASISDDSGSDTGTCSQVDESRTQRNVRGQPASVGTGKATAAERGGKGYVMPHHQCSTSQRRHSISTQA
ADEAAGGGNRVSFKRSAFILANTGPITNYYTVSKTIGRGTWGEVKLVIDNGTGARRAAKKIPKCYVEDAD
RFRQEIEIMKSLDHPNIVRLYETFEDMTDFYLVMEYCTGGELFDRLVHQGVFTEALACRIMRQILAAVAY
CHAHRVAHRDLKPENFLFLHDNPESPIKLIDFGLAARFKSGQPMRTRAGTPYYVSPQVLEGRYGPECDVW
SAGVMMYILLCGYPPFNAPSDRAIMNKVRAGHYTFPDSEWSRVSLQAKDLISRLLDRHPRTRISAEQALR
HAWFAMHAPGDHFEPLGLDILSKFRRFQGLSRLKKLALTVIAQHLEDSEIEGLKNLFTQLDTEGDGVLTV
EEIRKGIERSGVHLPPDMVLEDVLREVDTAGTGSIDYTEFIAACLHQSHYIREEACRAAFRVLDINGDGL
VSAQELRQVFHMAGDLETDAAAELLEADADGDGHITFDEFCGLMRKVPSLALVTEHTVSMMRRTCSRTNI
SEASLTPRATG
-
Molecule Role :
Virmugen
|
|
4. CDPK6 |
-
Gene Name :
CDPK6
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7893531
-
NCBI Protein GI :
1085164115
-
Locus Tag :
TGME49_218720
-
Genbank Accession :
KE138840
-
Protein Accession :
XP_002370646
-
Taxonomy ID :
508771
-
Chromosome No :
XII
-
Gene Starting Position :
1352526
-
Gene Ending Position :
1363776
-
Gene Strand (Orientation) :
+
-
Protein pI :
9.09
-
Protein Weight :
152891.46
-
Protein Length :
1477
-
DNA Sequence : Show Sequence
>NC_031480.1:1352526-1363776 Toxoplasma gondii ME49 chromosome XII, whole genome shotgun sequence
CATGCATAGTGCTGGTATATCGAGTGCGTGGATTGGGGGCCGTTTCATCTCCGCAGGCCGAAGGCTGTAT
TTCGGCGAGCCATCCACCGCGCTGTTCTTTCTCTCAAAATTTGACATTTGCTCTCCACGACCCGCCAGTT
CTTTGCGTGGAGGGTGGCCCGAATTAACATTTACAGGGTGTGCTTCCTCCTGTACAAGTTCGTGTTTCCC
AGCTGTTGCGCGGGTATCAGTGTCTCGTCACACACCAGGAGTCCGCGCGACGTCTCTGGCTCTTCCTATC
TCGTCGCCTCCCCGGTTCGCGTCGCCTCGCTCTCTGTCGCGTTCTCTGCATCCACTTTCTTCCACCTTTT
CCCCTTTTCCTGTCGACCCCTCCAACACGCTTGCCCTTTCTCTTCCACACACAGATTCGACTCTTTCTCT
ATCCCGCGCCTCGGGACTTCCTTCTGCCTCCGTGCTTTCTGCTTCTCTCACCGCCGCCGCTTCTTGTCTG
GTCTCTCCGCTAGGCTCTCTTTGTCGGGCCTCTGGCGGTGCGCTCGACAGAGGGGAGGTAGGCGAGAAGA
GGGAGCGCGGAGACACGGGAGGAGACAGCGAGGACGCTTCTGCCTCAGGGGGACAGTCGCCTTCGACCTC
AGCGAAGGCCAAACAGGCCTCACGCTTCAAGGGAGTCGGAGTCGCGAGCGGAGACAGAGAACGACCGATT
CGCAAGGGACGCAGAGACAGCGTCGGTGGAAAGAATCGAGAGGACGGACACACAGAAGAGGGGGCTGGCA
AGACCAGGAAGCCACAGGGAAAAGAGCAGAAGGCTTCCACAGAGGCTTGGGATCTCAGGGAACTCATTCT
TTTCGGTCGTCGTCCGGAACGCACCCACACGAGAAGAGAGACAGGGAAAAGTCGAGCCACTCTCAGCAGT
GCGCTACACAGGAAGCGCGGTGGATCGAAGCTCGGGTTGACGCTTGCGTCCGAAGAAGCGGCGGGAAAGG
CAGCACAGCATCCAAGGTCCGACACGAAGACATGCTGGAAAGAAAGAGACGAGACAGTCTGTTCTTCGAC
TCGAGGTCTACTGCCCGGAACTGTTAACATCCCGTCTTGCCAAGAGAAGACTCCTCTCGATTTGTACCGC
TCTACTCCTCCTTCTCCTTCGCATTCTCACGCCTTCGCTTCATCGCCGACCGGAGTGGCTCTGGCTTCGT
TTTTCGGGAGTTTTCCACTCAACTCCTCACGACCTTTCTACGAGTTTTTGTGGTGTGCGCCGGCACCTGG
CGAGCCGCCTCGAACGTACGTGCCAGAGGGGCTGGAAGACTGGGATTTCCGAAACTTGAAGCTGGATCGG
CCGCTGCTCCACAAGCCTGGACCATTCTTCGATTCGTCCGCTTTCTTTTGGCATTTCCTCCTGCGTGACC
TAGTCGCTGCTGCTCGACGGCCTTCCCCCCCGTTTCTTCCGCCTCCGCGTCGCTACATTTTCTATCCCCT
CCCCGAGTCCTCCTATCCTTCTTCCTCTCCTTCTCCTTCGTCTTCTCCTTCTTCGTCTCCTGCTGCTTCT
CCGTCTTCTTCTTCTCCTTCTTCTCCTTCTCCTCTTCCTTCTTGTGTGGGAGAGGGTGTTGCGTCAGGTT
CGCCGGTGTCTGCGAGCCGGACCGTTCCGGTTGCGAGCGTTTATCCTAGAGAGGCAGATCTCGTAGGCGT
CGCGCCTATGTCTCCTTCTCCGGTTGCCGACGGAGGCCGCGAGGGACTGGCAGCTCCGTCCTCTTCTCCA
CACTCTCAGGGAACGACGCGCCAGTCTCCCTGGAGTTGCCCCAGACGCCCGCTAGGCGTCGAATCTCGCG
TTTCTTCTCCTGTGTTGACGCATGCACTTTTACCAGGCAACCCACCGCCTTCGCCGTACAACGTCAACGG
CAGATACCTCCCCTCTGCTCCTCCACGGTTTCGCGACTCTCTGCTTCCTCCAGGTCCTCGTCAGCAGGCG
CAAGGTGAAGCCTGTGCTTCCCCTCAGTCTCGGGTCTCTGCTGTCGAGCCTCGGGGGTCTGCACCTGCTT
CTTTGCTCCAACAGGAGACTGTCTCCTTTGCGTGCCTCCCGAGCCCTGCACCGTGTCCGAAGTGTCTCTC
TTTGTCTCCACGCCCTGTCAGCTGCCCCTCTTCCTCGAGCTCCACTTCTTCCTCGTCTTCGTCTTCTTCT
CGCAGAGGCCGGCTCCCTCTGTCTGCAAGTGAGTCTCCCGTTGTCACGGCCGCGTCGAGCAGCGAGAGGT
CGGACTCCCGCAAGTCTTCAGGGAAACCGCACTACTACATTCCTCTCCCTCCTCTTCCGCAGTCTTCTGT
CCCCACGGCTCTCCCTTCTTCGACGAGAGAGAATTCTCAGTATCCTGTCTCGCCCACGGAGTCTTCTGCC
TCGACTCCAAGAGGCAAGTCTGAACCGAGCGAAATCTCTTCTTCTTCGCCTCGCGGCCAGACGCCTCGCC
TCAGAGTTGCTCAGCCCCCAGACTCTGCTCCTCACGCTGCAACGCTCCCCAGGTCCGCTCCACAGCTCTT
CGTCTCTTCTGTTCCTCCAACGCCTCTGACCGCTTCGCCGGTGCATGCACCCATTTTTGGCACAATGAAC
CGCGTGTCGATGAAGCGCGACGGACCGCCTTGGCAGCAGGCAGGCGCGATGAAAGCGGAGGATCCGCATG
GAAGCCGCCAGCGAGGGCGAGGCCCCGAGCGCGAAAAGACACACCGGCATCCCATCGCAGGACCGCCTCC
AGAGCTGATTCGAGCGAAGCTTCACAAGGTGATGGACGATCCTGCGAACTTCCGAAAAAGCGCGAGAGCC
TCTTTCAAGTAGGTCCACGCATCGTTGGTCTCTTGGTCACGCGAGGAGCGAGAGGGCCATCGTTACGCAG
TTTTCGCGCTACCGTACGGCTTGTGCAGAAGTGAAGAGAGCATGAGATGCGAGAGAGAAAGGGCAGATGC
TCTCTGCGTGACGCTGCTCGGAGCTTCGCTCATTCCGAAGAGAGAAAGGGAATGCGCGAAGGAGAACACA
AAGAGTGCGAAAGATAGGCGTATGAAGAAATTTAGACGTTCGACATTGGAAATTCGATGTTGCTCTAAAC
ACAGTCAGTGTATTGGAAGTGGGCTTCGACCCTCAAGTCTTCTTTGCGACGTCGAGAGAGCACCTTGTAG
CTGTGGGCTCATTTCTCTATTCACTTTTTTAAAATTGTCTCTGATTTGTCTGCTTCTCTCCACCCAACCG
CCTTTGTTCCCTTAATACCTGATGTTCACCTGGTTCCTTTTCTACAACACATATCCCCTTCGTTTTCGTT
TTTTCTCAGGCAATTCGACCGCGATGGCGACGGCTTGCTGGCATTCGAAGATCTGCGCCTGTTGATAGCG
CGTCTGTGTCGGAACCTGCAACTGCCTCCCGTGGACGACGAGGTTTTGCGAGTCATTTTTCGTGCCTTTG
ACTCTGAAAAAAAGGACAAACTTGATGTGGCAGACTTCTCTCGGCTGTACTGGGAGCTCTTGGGAAGAAT
TCGAGACAAATTCTACCCGGTCAAAAAGATGCTCGTTCGACGCTCGGTCTTTGTCGGCAGACGAAACTTG
GGCGAATCCAAGAAAACGATCGATGGTGAGAAGAGAAGCTGGACGCAGGGGTCTTGGATGGAAGCGCCTG
ACACACCTGGCATCATGCCAGAAAATACAGTCTTTCACCACTGGGTAATAGACCAGGAAGTGCCATTTTT
CAACGTCGCAACGCCGAGAAAGGACCTTCGTCCAGCACCGCACAATAGCGTGGAAATCACCGTTAAGTCG
CTGGTGCGATGGTATCTTCGTTCACGGAAACAACACAGAAGAAAAGGAGTTACTAGATGCTTAGTCCGAC
GGCATAAACCAGGGTAAAATGTACGAGATGAGCAACACAGTGAGATGCATCTTGCGAGGAGAAAATCTCT
CAAATGAGCACGAGGAGCTCAAGTCGCAGTCAACAGTCATGCGCTCTCCATGTCGAGTTTCGTTGTCGCA
GTTGCTTTTTTCCGGTGGAGTGCATCCGCTTTTCACTCCTCCTATGTGCATCTAGAGATCTTCTGGATAA
GTCCAGTTGGAGAACATCGTTTTGGTGCAATGTCTTCGACGCAGACCTCTTCATCTTCAAAAGGAAACTC
GGGTCCGGCGCATTCGGGGATGTCCACCTTGTTGAGGAAAGGAGGTGCGTTCAACCACACTTGCATTTCG
CGCTTCTAAAGCCATATACAACTACCTAGGCATATATATATATATATATATATATATATATGTATTTATT
TATGTATAGATGCTTATTGGTGCATCTGTATTTGTTCAACATATACGCAAGTGATTGTTTCAATGCCAAT
CACCTTAGCAACGTAATGGTGTAGCATTGTTCATGTGTATGTATAGTTATGTATGTAAATCACGCGCACC
TGCATACGGATCTACAATTACTTACATATATATATATATATAATGTATTTTTGTTTTTTTACAGACGTGT
GCATTTGTGTAGGCCTAACCTGATGTAGGCGTCTTATCTGTGTCGACCTAAATAGCGTCGTATATTGTAT
ATATGCATGTATGTATGTATATACATATATAAATGTATGGTGTGGTAATGCGTGCATTTGTGTGTAAATG
TGTTTGCATGCTGGTTCGTTTTCAGTAGTGGTCTGGAGCGTGTAATCAAAACCATCAACAAGGACAGAAG
CCAAGTGCCGATGGAGCAGATCGAGGCCGAGATTGAAGTTCTGAAGAGTCTCGACCATCCGAACATCATC
AAAATCTTTGAAGTTTTCGAAGACTACCACAATATGTACATCGTCATGGAGTAAGCGGCCGCTCACGGTC
CAGGAAGTAACGGAACAAACGTTGAGAAATGGCCTTCGCCATTCACGGCTCACGCCAGAATTTACACACC
AATGTGACTCTCGGGATCCTCTCGCGTTCAGCGCATTTCAGTGAGCATGTGCATATATATATATATATAT
ATATATATATATATGCATACATATGTAATTGGGTGTAATGCACGCATAATGTGTGTGGCTAAAAAGGGGA
TGCGACATGGTGGACAGTGGACTGGTCATGAAAACTAGGATAGTGTCACTCTTTGAATTCGTGTAGTGCT
TTTGTTTTTCTTCTTCAGAACCTGCGAGGGAGGAGAATTGCTTGAGCGCATTGTCTCTGCACAAGCGCGA
GGCAAAGCTCTCAGCGAAGGCTACGTGAGTGCAGGAACGTTGACAAGCTTACGCGCCTCACGTCTCCATG
CATGCGGTCTTACACGCTCGCTACCGAACATATATATGCATATACACAATCTAAATATATGCATGTCCTT
GGTTCTATAAACGCGTATAGTTTCTGGGGGGCTGCCATGCAACTATGAAACGTAGTCTTTGCTCATTCAT
CCACGCAGGCACCTTTTCAAACGAAGATGCGTCTCGCCGCCCATCGATATCAATAAACATATGTAGCCAT
GAAAGTTCAAATGTCACTCCGTATCCCTAGATAGAAGTAGGTAGGTAGGCATAGATGGAAGGCGATAAAT
ACATTGGCTGATACATACAGATGTGCAGAGACAGACTGCTCCCGAGTGTGTGTTCATGCCGCTCTAGTGC
TTGATTTCGTCGTCCGTCTCTTCTCAAGTCTCGTAATTGGTTTCATTTTTTTTATTTCAGGTTGCTGAGT
TGATGAAGCAAATGATGAACGCGCTCGCCTACTTCCATTCCCAACATGTTGTTCACAAGTACGCGTTTTC
TTTCCTTGCCATGAGTTGTCAGTTCTCTCCATCGCGTGAGAGACACGTTCGAGTTTCCTGTCGTTTTCTC
GACCTCGTCGGATTCGTCTGGTGGATTTCCACCTGCCATGGTCCATGTGCATACCTGTCACTGTCTATCC
TCCTCTCTTCACAACCATCTGTGCGTTCAGAATTCCTTTTCGAATCTGTTCACACAGCTTTCTGTATCTC
TGTAGATGTGTAACGGCATCTGTAAACGCAGGGCCTTTATTATCTTCGATAGAGGTCGACATAGGCGACC
ATCAACTGTGTCGCGGAGGAAGCGTCTGAGTATCAGAGCAGTGCATCTGCGACTTTCGTTTTCTTTTCGT
TTTTTCCTTTCCCGGTCTGTATCTCCTGATCTGTCTATTTTTCTCCTTTCTCTCTTCTTTCGCGTCTGTT
ATCTCTCTCTTGCTTGTTCTCGCTCTTCTCTCTCTTTTGCAGCCTGCTCCTTCTGGATCTCCCTTTGCTT
CTTCCTGTTCTCTCTTTCTCTTCTCTTTCACTCGGTCTCTCTATTGCTCGCTTGCGGCAAACAGATGTTT
GCTTGAAGTGCCTGTGAGTGTGGGGGTGACAGGCCGTGGTTTCGCCTGTGCGATTGCAGGCCTGCAAATT
TGCTTGTCCAGTTCACTGGAGCTTCGCGATTCGTTTGGGTTCAAAGGCGTTCGCCGTTCCATCTGCATGT
CGCGTTTCTGCCTCAGAGACCTCAAGCCGGAAAACATTCTCTTTCAAGACACTTCGCCTCACTCTCCGAT
TAAAATTATCGACTTCGGTACGCCATCTTTGTCTTTGTCTTTTCAAAGGAAACGCCGTGGGTGGAAGTTT
CTTCTTTGAGGAAACTGAAACCCACACCCATGAAAATGTGCATTTCCACTACACATTTGTCTGCATCCGC
AGCAAGTCGATACCTTGGCCACCTGCGTACATATTCAAACATGTAATTGTAGTCTGTATCTGTATGAATC
CATATATTTACCTGAAGCCGTAGGTATGTTTGGAGACGTATATCCGTAGGTAGATGAAGATATATATAAA
TATATATATGCATGGACAGAACAGGCATGTATATCTGTCTGCCGCTGTACAAATGAAGCGGCATATGCTG
CACATGAACAATATATATATATATATATATATATATATCCCTATATATATCTCTGCATGTGTGTTTATGT
ACAGAACATATCTCTACATGTACATACATAGAAAATACTGCACTACGGATCGTTGTAGATCTCGTCATGC
TCGTAACGCTGCTCGTATGCACACTCGAGTATGTACGTCTCTGTGCAGCTTTGTTAGATCTGCATAAACC
TGTACATGATTGACTGCATATTTATACCGAATTGTACATTAGTTGTTGATGATGCATATGTGTATATGTA
CAGGGTACCGCGGCGACTGTTTCGCCGTTGATTTCGTTTGTGTCTTTCGAATGAGCGTTGAGTTGCCCTT
TCGTTTTTGTGTTCATTCTCTTTTTTGTAGGTCTCGCAGAACTTTTCAAGAGCGACGAACACAGCACTAA
TGCGGCTGGCACTGCCTTATACATGGCACCGGAAGTCTTCAAGCGAGATGTAACTTTCAAATGCGACATC
TGGTCTGCAGGTGAGACGCTTGTGTTTTTCGTCTCTTCGTTTTCCTCTCTGCTGCTTCTTTTGGTCTGTT
TGTTTGTTTCGTGTGCTCTGTCTTCTTCGCCGTTCCTTCCGGTGTGTTTCGCTTCGTCTTGTCTCTGTTC
TGCTCCTTTTCTCTTCTTTGCCGTTCTGCTTTCTTCTCCTCGTCGGTTGCTTTCTCTTCTGTCTCTGCTG
TCGGATTCTCGAGGTTTGTTTCTTGTGTGCGCTTTCGCGCGCTTCGTAAACCGGTGTCTTCGTTGAGTGT
CAGACAGACCGAGACCTGGCAGGCTCTGGGTGCGTCGTTCCATCTCTCGCCTTTGGTTTCGTCTTTCGCA
TATTGTTTTCCTTCGATATATGCGTTGGATGTGCTTGCTTTCTCCCTAGAGAAAAAGATGCATTTCACAT
TGGGTTTCCTCCCGACAACTTCGGACGTCCTGTGCGCTCCTCCATTCTCTGTCTCTCTGTGTCGATTTGC
CTCATTTCCTTTGCCTTTCTTCCAGGAGTGGTGATGTACTTCCTTCTCACTGGCTGCCTGCCGTTCACTG
GGACGAGCCTGGAAGAAGTGCAGCAGAAAGCGACGTACAGTAAGCTGCTCAGGAACAACGTCGTCGCTCT
GTCCAAAAGGAAAGGGTGTTGACTGATCTCTGCATGCGGCTGCTCGCGTCTCCTCTCAGTCTCTCGACCT
CCGCGTCCATCTGGCAGCGCTCGATCCGCGAGTTCCTGTTTAACGCAGACACACACAAGACAGATGCAAC
TGTGTTGACTGGGGATCGCATGGCCTGCGCAACGGTGTGTGCCTTTCCAGCTCTCTCGTTCTCTCTGGGC
CGCCGCGGTCAGGAGAGAGTTCCTCTGCAGAGCGGGAACTCAGTACTCAGAGGGGGGTGGGTGTTCAGGC
GTCTCTGCTGAATGGCGTCGAAGGATTCTTTCGATGGCTCGAAACCGACTGACGCGGTCACAGAAAGGAA
GAACTCCTCGCAGCGGGAGAGAGCCGTGCAAGAGCCGCAGAGGAGCGAGGAAGAGAAGCGGCGGAAAGAA
GAGATGGCCCGAAGGGTGCCGAGAGATCCAACAAGAGAGTATACCTGCTGGGTTTCGCGAAGCGCGGAAC
ATGAAACGCGAAGAAGGAGAAGAGAAGGAAAGACGCACTCTGAGCTCTTATGAAGTTTCTTGCCGCCGTC
CATGCGCCGCGCTCTGTGTGCGCCTTGTGTCTTGTGCAGAAGAGCCGAACTACGCAGTGGAGTGTCGCCC
GTTGACGCCGCAGGCTGTTGATCTGCTCAAGCAAATGCTGACGAAAGATCCCGAGCGAAGACCCTCGGCA
GCACAAGTTCTTCACCACGAATGGTTCAAACAGGCCAACACAGCAGCTCTGCCCATCTCGCCCATCATCT
GCGAAAACATGAAGGTGAGGCAAATGGAGTCGAACCCGCAGCTTGACGGTGGTTCAAGCGCCACGATGGA
CCTGCGCGCATGCAAAGCAACTCAAAGCGAATGGCCTCGCTGCGCGCGCGTTCTTCTCCAACCGGGGTGC
TTCGAAGTTCTTAAACCGCAAAAGGCGAAAACAAGGACACCCCCATTCATGCATAGGCATCGAGACAAAT
GCCTGTCTACAAAAACAGTTATGGAGGTCTTTCTGTTTCGCTTGTAGGGTGATGGGTCCTTCTCACAGGG
TGGTCCACATACTTTCCATGAAACGCTCAAAACACAGGGACACAGCAGAGGACTGCAGAGCTGTTGTACT
TTCGAAAGACATTCTGTGTAATCGCATCTGGAAAGGCATAAACATCTAGATACCCAGATCTACAGATACA
CCAACACAGGTGTCTACATATATATATATATATATATATATATATGCTGCACAGAGTTGTGCGCGTGCTG
CTGTCCATGTTCAACTTTTGTGTGAGAAATTTGTTTCAGCTTTTAGAGATTGTGGGTCATGCGAATTTTG
AGGAAGTTCTAAATTACGGGTCAAGAACTCGTATTTGTCCAGTACATTTTTTTCGCAACTTTTAAGAATT
GGCGTACCGTCCACGTTTCGGTTTTTCGTTCTTTTTCCACTGGCTTTCAGCGATACATGCGGCAGAGTCA
CTTGAAGAACGCTCTGGTGAATTTAATGGCACACCAGCTGAATGTGACGGGCCAGCAGATTCGCCACATT
AATCAGATTTTCCGACAACTTGACAAGAACGGCGATGGACTCCTTTCTCATCAGGAACTCACAGAAGGTG
CGACAGTAAAAATGATTCGTTTTCTCTTCGTCTTCTCCCCTTCGAGTTAAAGACGACGCCCGTCAGCCTT
CGCGTCGCATCTACATTATAAACATATGCATGCATTTACGTTGAATATCGTGAAGAATCGTTGGGATCTA
AGGGCATAGAGATCCATGTAAACACCGACACACATATCCGTGTCTACACCTGAGAAAAGATACAGGAGGA
GAAGCCCTCTCTCCATACACTCATACACATATAATATATATATATATATATATGTATATGTATATATATG
TATATGTATATATATGTATATATATATATATATGCGTACAAAGGTGTCAGCATGCGTTTTGGCGTGTGCT
TTGTTTTTGTAGGGTTGGCGGAGGCGGGCGTTCCGCAGTGGGACATCAACCGTATTCTTCAATCGATCGA
CGTAGACGACTCTGGCAACGTTTCCTACACAGAATTTCTCGCTGCATGCTACTGTTGGCAAGAGACAGAG
CTGAACGTTGTCTGGACAGCCTTTCAAAAGATCGACAAAGTAGGCCTTGCCTGAAGCTTGCGTTCGCGCT
GTGTCACGGCTCGTATATCCAACTGCGAGCAAAAAAAGGGCAAAGGGAAGCCGGCACTCCCTCTGTTTCG
AGGCGAGGCGCAATAGTGGGCTTTTCGCTTTCACCCTGTCGGCGAAAACGCCTCACCGGAGTTTCTGTTT
TTTCATGTTGTTCAATCGCTTGGGGTTGCTGTGTCCGTCGCCCCTGCGTCTCGCCTCTCGAGTCTCCTGC
AGGGACGTTCCTCTGTTTCTGTGGCGTTTCCCCGTTCCCTCGCATTTTGGTTCAGCGTTTCATGGTGCAG
GCGTGGGTGCAAATCGAAGGAAATTTTCGCGCTTCACGCATTTAACTTTCAGGAGGCTGCTGAGTTTCGA
GGACTTCCCTCTCGTTTCTCCACCCGGCTGACGGATTTTTTGTGCTGGCTTCTCTCGCGTCCAAGCATTC
GTGCTTTCCTTCGTCTTCCCCTACCTCCTTCTCTCCTCTGTGCATTGCAGATTGTGGTTCTTGTCCTTCG
TTTGGTATGCTTTCCAGGATGGAGATGGGCGGATTTCTGTTCGAGAATTTTGCGACTTGGTGCTCGGCCG
CGACAACAAGCTCATCCCCGAGGAAGAGTTGCGAGCGATGGTGGCGCAGATGGACAGAGACGGCGACGGC
CAGGTGAGAAAAGGTTTCCGCAGTTCCTGCCGGGTGAGGAAAATTGCTCAAACCCACAGCGCATCGACTT
CTCAACGCAGAGGGGCTGTCGGGGACGCACGATGAGAGAGCAGTGGAAGACTAAATAGGCAAGGCGTTGT
GAAAAGAAAAACGAAGAAAGACAACGATTTGCTAAGCTTCTGCGGCGTCATTTGCCTGTCTGTCTCGGAC
TCGAACATCCGCCTGAACCGTGTGTGGCGTCTCCTTTTTCTCGTTTTCCGAGTTGCTGAAGAAAACGCAA
CGGCCTGGTGTCTTCTCCGTTCTTCTTTGCAGATCGACTGGGACGAGTTCGTCGCGTATATGCGCCACGA
CTAAACGCATTTCAAGATTCGAGCCTTTTTCCTTTCGCCGCTCTCGTCGGAGCTTCCTTCGGCATGCCTG
GCACTGCGGGTCGCTCTGCCCATGCCAGCCCCCCTCACGCGGAACTTGGTT
-
Protein Sequence : Show Sequence
>XP_002370646.2 calcium-dependent protein kinase CDPK6 [Toxoplasma gondii ME49]
MHSAGISSAWIGGRFISAGRRLYFGEPSTALFFLSKFDICSPRPASSLRGGWPELTFTGCASSCTSSCFP
AVARVSVSRHTPGVRATSLALPISSPPRFASPRSLSRSLHPLSSTFSPFPVDPSNTLALSLPHTDSTLSL
SRASGLPSASVLSASLTAAASCLVSPLGSLCRASGGALDRGEVGEKRERGDTGGDSEDASASGGQSPSTS
AKAKQASRFKGVGVASGDRERPIRKGRRDSVGGKNREDGHTEEGAGKTRKPQGKEQKASTEAWDLRELIL
FGRRPERTHTRRETGKSRATLSSALHRKRGGSKLGLTLASEEAAGKAAQHPRSDTKTCWKERDETVCSST
RGLLPGTVNIPSCQEKTPLDLYRSTPPSPSHSHAFASSPTGVALASFFGSFPLNSSRPFYEFLWCAPAPG
EPPRTYVPEGLEDWDFRNLKLDRPLLHKPGPFFDSSAFFWHFLLRDLVAAARRPSPPFLPPPRRYIFYPL
PESSYPSSSPSPSSSPSSSPAASPSSSSPSSPSPLPSCVGEGVASGSPVSASRTVPVASVYPREADLVGV
APMSPSPVADGGREGLAAPSSSPHSQGTTRQSPWSCPRRPLGVESRVSSPVLTHALLPGNPPPSPYNVNG
RYLPSAPPRFRDSLLPPGPRQQAQGEACASPQSRVSAVEPRGSAPASLLQQETVSFACLPSPAPCPKCLS
LSPRPVSCPSSSSSTSSSSSSSSRRGRLPLSASESPVVTAASSSERSDSRKSSGKPHYYIPLPPLPQSSV
PTALPSSTRENSQYPVSPTESSASTPRGKSEPSEISSSSPRGQTPRLRVAQPPDSAPHAATLPRSAPQLF
VSSVPPTPLTASPVHAPIFGTMNRVSMKRDGPPWQQAGAMKAEDPHGSRQRGRGPEREKTHRHPIAGPPP
ELIRAKLHKVMDDPANFRKSARASFKQFDRDGDGLLAFEDLRLLIARLCRNLQLPPVDDEVLRVIFRAFD
SEKKDKLDVADFSRLYWELLGRIRDKFYPVKKMLVRRSVFVGRRNLGESKKTIDDLFIFKRKLGSGAFGD
VHLVEERSSGLERVIKTINKDRSQVPMEQIEAEIEVLKSLDHPNIIKIFEVFEDYHNMYIVMETCEGGEL
LERIVSAQARGKALSEGYVAELMKQMMNALAYFHSQHVVHKDLKPENILFQDTSPHSPIKIIDFGLAELF
KSDEHSTNAAGTALYMAPEVFKRDVTFKCDIWSAGVVMYFLLTGCLPFTGTSLEEVQQKATYKEPNYAVE
CRPLTPQAVDLLKQMLTKDPERRPSAAQVLHHEWFKQANTAALPISPIICENMKRYMRQSHLKNALVNLM
AHQLNVTGQQIRHINQIFRQLDKNGDGLLSHQELTEGLAEAGVPQWDINRILQSIDVDDSGNVSYTEFLA
ACYCWQETELNVVWTAFQKIDKDGDGRISVREFCDLVLGRDNKLIPEEELRAMVAQMDRDGDGQIDWDEF
VAYMRHD
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
rCDPK6 + rROP18 + PLG
|
|
5. CyP |
-
Gene Name :
CyP
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7895236
-
NCBI Protein GI :
237841307
-
Locus Tag :
TGME49_221210
-
Genbank Accession :
CM002036
-
Protein Accession :
XP_002369951
-
Taxonomy ID :
508771
-
Chromosome No :
II
-
Gene Starting Position :
135473
-
Gene Ending Position :
137826
-
Gene Strand (Orientation) :
+
-
Protein pI :
6.52
-
Protein Weight :
18413.56
-
Protein Length :
179
-
DNA Sequence : Show Sequence
>NC_031469.1:135473-137826 Toxoplasma gondii ME49 chromosome II, whole genome shotgun sequence
CTGACTACATTCATGCTCGCTTGATTTGCCCTGCTAGAAAAGAAGCGGTTTCTGCTGCCGACGGCGATGT
GCTCTTTGGTGGCGGCACTGCACCAGTCAGCGGGTCCCGTTCCTGTCTCTGCGCTTTTCCCTCCCCCCCC
TCCCCCCCAGGAGGCACATGGGAGGTTCGCGACGGAGGAGAGTCGAAGAGAAAGGGGTCGTTTTGGGCCT
GACACTTTTCGTCACCTTCCCGAGATCTTTTTCTGAAACGAGTTGTGTTTGCGATCTTTTTGGTGACGGC
TCTAGACGACCTTGAAAATGAAGCTCGTGGTGAGTCAGCGACAGTTTCCAAACACCGGGAAACCTAGTCG
CGGCGGTCTAGGCTGTTTTCGGCGTCATCCTTCCGTGCGGCACCTGAGACACAAAGAGCCGGGGAAGAAA
GAGGGGATGCCTGCGTGCGCATACTAAGGCGGAAAAACTCTCCAGAGGGGCGTTTCATTTCGACGGACGG
AGAGGCGAGGGACTAGCCAGCTGCGAACCTAACCTCGTGTGTCTTCAAATGTCCATGTGTGCAGAACGCG
GAGAGCGAAAACTTAGTTTGAGTGCATCGGAAGGCCGTCTCGTTTTCTGGACGGCGTTGAGACAGACAAA
GTTGGGTTTTTCGCTGTCTCACCAAGTCATTCCGTGACAATTTGTGTCCCTGCGTTGCAGCTGCTTTTCC
TCGCTCTTGCGGTGTCTGGCGCCGTGGCAGAAAATGCCGGAGTCAGAAAGGTAAGCCATCCCAAACACAG
TGAACGTGCGGGTTTTATCCAGGCTACGCGGCGTTTCTCCGTTCACTTTCTGAGGTCTTCTGCACAGATA
CGAAGGGATAGAAGGCTCCGGAAAACGACGTCGGGAAAAAGTGCACGTTGCTGGGTGTGTGTGTGTGTGT
GTTTTCTAGGCGTACATGGATATCGACATCGACGGTGAACATGCCGGGCGCATTATCTTGGAGCTCCGTG
AGGACATCGCTCCCAAAACTGTCAAGAACTTCATTGGCCTTTTCGACAAGTACAAGGGCAGCGTTTTCCA
CCGTATCATCCCCGACTTCATGATCCAGGTAAAACGTCCCTCCAGTCCGAATCGACGTGTGTCGCATTTC
CGATGTTCGATGACATCGCAGCGGTCTCTCTCAAATCGTACAAGAATGGTATTTTCGAACGTCTGACGCG
GATCCGGTTCCTGCCCACACGACGCTCGGCAGGCGACCACCGCATGGACCCACACTTGCCTTGTAGCCGA
TGGACTGTGACAAGATCGACGTGGAAATCATCCACGCTTGGTGAGGGTGCAGAGAGCAGTTGCTTCTTTG
AGCAAGTGTGGCCATTCTGTCGGATGTTTTCAAACGCTGGAAATCGGTGATTCTCAACTGAAACGACCCT
ACTGACGGAGAAAAGGGTGTCCGGGCTGGAACACATCGTGGTGTGCCGTCAGACGAGGAAGATCGCCAGT
GTCCTCGTGTACACGACTTTGTTGTCTTCGTGTCAAACTTGTCATTTCCCCGTCCACTAAAATGCCTCAG
GGAGGAGATTTCGAGAACCACAACGGCACTGGAGGACACAGCATCTACGGCCGAAGATTTGACGACGAAA
ACTTTGATTTGAAGCACGAGCGAGGCGTCATCTCTATGGCGAACGCCGGTAAGGGTCATTGCTCCAGCCT
GCAGAGTCATGTACTCTCAAGGTGAATACGCGTAGTTTTTAGATCCTGTACGGCCAGCAAGCTTGGAATG
CCGGTGGATCTCAATTTCTTCCGTCGACCCGGCGTCGACACATGGCACCACACTTCCCCACTCGCGCCAC
GGAGAGCAATTCTGCGGCCACAGAGAACCGGAGTTTCGCAGAACTGCAAGACTGGAGTTTCTGAAGTGTC
GTGGGCAGATGCGTGCAGAAAGTCGCATTACACAGAGGCCTGGGTGAGGCGTTGATACAAACGTTTGCCG
CGTCCCTCTTCTGTGGGTGCAGGTCCGAACACCAATGGCAGCCAATTTTTCATCACCACCGTGAAGACAG
AGTGGCTCGACGGCAGACACGTTGTTTTCGGGAAGATCACAACTGAGTCGTGGCCTACCGTCCAGGCTAT
TGAGGCTCTCGGCGGCAGCGGCGGCCGCCCGTCTAAGGTCGCGAAGATCACGGACATTGGTTTGTTGGAG
TAAATCGAGAAGATCCTGTGTACATCTGGATGCACGTGTCGTTTCCCCTGATATCTATTCGTGTGAGGCA
AGTGTGCCCTCTTCCCGACGAAAGTGGGGAGTCCACACCACTGAACGTTTTTTTAAACATTTCTAAATAC
TAGACTCTGTCGACTCATTCTTTCTGCTAAGAACGCTGAGCACA
-
Protein Sequence : Show Sequence
>XP_002369951.1 cyclophilin [Toxoplasma gondii ME49]
MKLVLLFLALAVSGAVAENAGVRKAYMDIDIDGEHAGRIILELREDIAPKTVKNFIGLFDKYKGSVFHRI
IPDFMIQGGDFENHNGTGGHSIYGRRFDDENFDLKHERGVISMANAGPNTNGSQFFITTVKTEWLDGRHV
VFGKITTESWPTVQAIEALGGSGGRPSKVAKITDIGLLE
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
rBCGpMV361-TgCyP
|
|
6. dasd |
-
Gene Name :
dasd
-
Molecule Role Annotation :
Oral immunization of mice with ZJ111/pcDNA3-SAG1 elicited specific humoral responses and stimulated proliferation of splenocytes (P<0.05). Mice immunized with ZJ111/pcDNA3-SAG1 displayed significant protection against an intraperitoneally challenge with 500 tachyzoite forms of T. gondii RH strain. Vaccination at 107 and 108 CFU per mice provided a 20% and 10% survival rate comparing 100% mortality of the non-immunized mice, exhibiting longer living time and better survival rate (Qu et al., 2008).
|
|
7. fad |
|
|
8. fsa |
|
|
9. GRA1 |
-
Gene Name :
GRA1
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7896994
-
NCBI Protein GI :
301750620
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
P24 granule antigen
-
Protein pI :
3.92
-
Protein Weight :
18678.03
-
Protein Length :
246
-
Protein Sequence : Show Sequence
>ADK88943.1 P24 granule antigen [Toxoplasma gondii]
MVRVSAIVGAAASVFVCLSAGAYAAEGGDNQSSAVSDRASLFGLLSGGTGQGLGIGESVDLEMMGNTYRV
ERPTGNPDLLKIAIKASDGSYSEVGNVNVEEVIDTMKSMQRDEDIFLRALNKGETVEEAIEDVAQAEGLN
SEQTLQLEDAVSAVASVVQDEMKVIDDVQQLEKDKQQLKDDIGFLTGERE
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pVR1020-GRA1
|
|
10. GRA16 |
-
Gene Name :
GRA16
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7896580
-
NCBI Protein GI :
237840711
-
Locus Tag :
TGME49_208830
-
Genbank Accession :
CM002035
-
Protein Accession :
XP_002369653
-
Taxonomy ID :
508771
-
Chromosome No :
Ib
-
Gene Starting Position :
888007
-
Gene Ending Position :
891282
-
Gene Strand (Orientation) :
-
-
Protein pI :
10.58
-
Protein Weight :
52190.66
-
Protein Length :
505
-
DNA Sequence : Show Sequence
>NC_031468.1:888007-891282 Toxoplasma gondii ME49 chromosome Ib, whole genome shotgun sequence
CGCGTCGTGTTCTCTGAAACTCACAGAAGCCCCCACCCAAGGATCCGTGCTGACAACCATGGCAGAAAAA
TACTGGTATAATCTGCATGCTGCCGGTTACATAACCTGAAGCGTCTGGTCATTACAGCCCGCGTAGTAGC
GCGATACAGGACACATTTTGAATTAAAGGGAATGCAGTTGCTAGCTTCCCTGGTGAACGTTGTTTAATGA
CACTGGCCCGCGGCAACGCATGAATTAAAGCCTGCGGCATTCAGACGAAGGGCCTACGCCTGCCCCCTCC
CGAAACAAATAAGTCAACTATCTTGCATTCTCGGTCAACCAAAGTTGCAAGAAGAAACAACATGCACCAC
ATCTACTGTCATGTGGCGTGCTACTCACTACCCATTAACGCGGAGTAGTTGTTGGCGGCACTGCCTCACA
TTTGCAGTGGCCTCGCTTAATCTGCACGAACACGCCGAGACGACATGTCCGCACTGTCGGCTCAGTATGA
CTCGCCTTCAGTCTGCCAGCACGTGGGTACCGTCCGAGAGAGGCGTGTCACCTCCTTCTGGTTAGTCACA
TCTGATCATTTTTCCGCTTCGCGCGTGAACAGTCAAAATCATCTTCGTCGTCGGGTTTCCGCTTCCCCCC
CGAAGGACCAAGACCTCCCGAAGCACCTGGAACTGAAGTGCTGGGACCCTGTACAGCAGCTGCACCTGAG
CTGGTACTACCCTGCATACCATGTGAAATTGAAGTGCTAGAGTCGTCCACAGTCGCTGCTTCGGAAGACG
TCTGACGAGCCATCAGTGCTCTGTCCATGCTTTCGACGACTGGCAAGACCTTCTCAAGTTTCTTCATCAT
GATACTATTTAACAAAACGACCCTCAGGGGGGTGGCATGTACCCTCCCCTTCTCCGTCAGCTCCCGGTTC
TTGTTTTTTACTAAATCCAGCGTGTCCTTCAGTGAATGACTATCATCCTTCAGAAAAAGAGGAGCGTTCT
GTACGAGACGAGACGGACTTCGCTTTGAACACTTTCTACGTCCGCTGTCCTGCCCTTCGTCGGAAGAGGG
CCGTCGCGGATATGACGCGGCGGGGGATGTCTGGTTGACGGAAGCGTTGCCCTCACTGGCTCGTGTTGCT
TCGTCTTCCGACGATTTACTAGTGCCGTCAGTACCACTTGCGGGTTCTGTAGTTCGCGTGGTGTGGGAAG
CCTGCAGAGCTCTTTGTCGTCCCTGCAACACGATCTGCAAAATTCCTAGAGCCCATTCCTGGGCCATGTC
GTTCATGAGGAGCTTTCTGAGCGAGGGGCTCTTTGATGACATTAAGAGTTTTTGTTTCTTGCTCCTCGTC
AGATTCACAAATTGAAGTAAGTCAAATTTCCTATCTCGTACGTAAAGAGGGGCAAGCTTTTTACCAATCC
CTCCAAAGCCGGTAAGGCCGGGCGAAGCAGTTGTCTCACTCGTTGTTACATAGAGCCAATCCCGTGATGT
TCCTTCGAGTGGATCCGAATCCCATGAGCTCTCCAAAGATTTCATTGTTTGTCCCATTGTCCTTGGGCGC
ATTGCCAGAGACTGCGCCCCATGCGATATTCCTGATCGTTCCCCTGTCGATGAAAGCCTGTTCCCCTGCA
AGCCATCTCCATCTGTTTGTGAATATTGAGGCCTGGTTCTACGAAGCTTCAAGGTGCCTTCGACTTCACC
TGGCCTCCTCCAAATTGTACCTCGGATCGCCTCCGACGCCACAACACCACTCCGTATTCGCGGAGCGGCA
ACACGCCCACCTGTTGCACCAAAACCGCCCAGACTGCCAGGAGAAGTCGTCCTGGAACCTTGAGCAGAAT
CTGAGTCACGATCTGATTTGTTTGTTTTTCGCAAGCGCTTTCTAGGAGGTTCCTCAGCAAGTCGCCGACT
GACTAATCCGTCAGGTGGAATCACCCAAGGAGACGTCGTGTACTGAAAATCCTCTTTCCCTTCGTTCCAC
TCAATCCCGGCGACGAACCGGTGAATACCAGAGACATTTTCTAAAGCTAAAACGAGAGCTCCAACTTCGA
AGAGCCTGCAGGCAAGCCGTATCCCTGAGTGGTTTCGATACATGACGGTATCCGCACAAAGTCTACCACG
ATTCCTGCTGGTGAATTCACACTTGCGAATTCACTCAAAGTATCTGCACAGTGCTGCTGTGCCTCAGTAG
GCATCCGATCATCGGTTTAAGCCTCGGCCGACACGGCAGCTCGGAGACTATTCACAGTAGGCCGAGCAGT
CGCACACAGGTATAAAGATGGAGGCACCAAAGTGTAAGGAACACGTCTCAGAAAGCTTTGACCGACGCGC
TGCGAGCTCCGATTCCTTCTGACACAAAAGCCAGCCGCTAAGACAACACAGAAACACGGATTGGATGTCC
TCGCTCAGACAAGCAATGACAATGGATCTGCCGGAAGCCGAACAAACTCCCAGGAAAAGTGAGTTCGTTC
GGATGCCCCACGCGTTCCTTTGAATTGCTTTACGGCGCCACGAGAAATAGGCGTGCCAAACAAAGTCGAC
ACAGACCAACAAGCCCGCTGAACGGCGATCCGAGCCCCGGCCTTATTAGTGACGAATAAAACAGCCAACT
GGTTCAGAGTGCGAACCCGGCAAACAGATGAATACGCTCCTCTGTCACCGTCCGTCTTGTAACAGAAGAA
ATGGGAATAAGAATGAAACCTTAAAACTGTGACCACCTTGAAAGGGCCCTGTGGGGCCTGTGAAGAAGCA
CCTGTTCTGCGGCCGTCGCAAAAAACAACACCACACCGTGTGGGGTTCTTAGCGGGAGCTTATGTAGTTA
GTTCCGAAGCACAATCGGCGAACGGCTAACTATCAGTCGACGAAGCGCGCAAGAAGTTGGCTTGGTCCAC
GAGGATGGAGTCAAGTCATTTGTAAAGCGTGAGCTGCGGCACTGAAAAGCATTTTACACGTTTGTTGTCA
GAACGCGGCATTAACGCCGCGCCGGCATACCAGCAGTGTCAGACCTGAAAAGTAGCAGAACGATTGCCAG
ATAGCCCGTGCAAGGGTTGACCGTTGATTCATGCGTCGCTGTTGATTTGTCTGTCTGGAACAGGAACATA
TGTGTACTCTAAACATCTGTTTATCGATACGGGTTGTAAAGTGCCATCGTCGGTACCGCAGTCGTGATCC
TTTTAGAGACGCCCAGGTTCCCACCACTTGACACCGAAAGGCCAAGCCACAAGGTTGGTTCCATTAAATC
ACCTGTACAAGCATAAATAGTTCAGATGAGTTCCGTATTCTGAATGCAATGAACGG
-
Protein Sequence : Show Sequence
>XP_002369653.1 hypothetical protein TGME49_208830 [Toxoplasma gondii ME49]
MYRNHSGIRLACRLFEVGALVLALENVSGIHRFVAGIEWNEGKEDFQYTTSPWVIPPDGLVSRRLAEEPP
RKRLRKTNKSDRDSDSAQGSRTTSPGSLGGFGATGGRVAAPRIRSGVVASEAIRGTIWRRPGEVEGTLKL
RRTRPQYSQTDGDGLQGNRLSSTGERSGISHGAQSLAMRPRTMGQTMKSLESSWDSDPLEGTSRDWLYVT
TSETTASPGLTGFGGIGKKLAPLYVRDRKFDLLQFVNLTRSKKQKLLMSSKSPSLRKLLMNDMAQEWALG
ILQIVLQGRQRALQASHTTRTTEPASGTDGTSKSSEDEATRASEGNASVNQTSPAASYPRRPSSDEGQDS
GRRKCSKRSPSRLVQNAPLFLKDDSHSLKDTLDLVKNKNRELTEKGRVHATPLRVVLLNSIMMKKLEKVL
PVVESMDRALMARQTSSEAATVDDSSTSISHGMQGSTSSGAAAVQGPSTSVPGASGGLGPSGGKRKPDDE
DDFDCSRAKRKNDQM
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pVAX-GRA16
|
|
11. GRA17 |
-
Gene Name :
GRA17
-
NCBI Protein GI :
EPR58489.1
-
Taxonomy ID :
507601
-
Gene Strand (Orientation) :
?
-
Protein Name :
dense-granule antigen DG32
-
Protein pI :
9.86
-
Protein Weight :
32466.37
-
Protein Length :
369
-
Protein Note :
encoded by transcript TGGT1_222170 (Gold et al., 2015)
-
Protein Sequence : Show Sequence
>EPR58489.1 dense-granule antigen DG32 [Toxoplasma gondii GT1]
MKSGSCPFTFSPTLSHPLEIAWRARPLQWPEIERQPEPAAPCGALYPASRVLSFSPTMRAIRSVVGLPVM
GAAVFLGLLSGELPNSSVLPVPEVASTPFLLSVAADGDGGKNYAEVAKVEALTNMISTPIELFVKDVWQQ
LFHKSGKPVWENMLFKFGSMIRHRAAHKATLVIMWELRHFLYGTAKVNPSAWKKLETKFESYLREWWMTV
PEDPWAALHAGAWKSLLKLYNEDLEPLLRGSPKLKDLESILFDSKLATIRRWTDEAHIEVMKGRTSNMVP
RLEALSAKMAVKQKAMQGKQ
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pVAX-TgGRA17
,
T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23
,
T. gondii GRA17 mutant vaccine
|
|
12. GRA2 |
-
Gene Name :
GRA2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7897424
-
NCBI Protein GI :
EPT27242
-
Taxonomy ID :
508771
-
Protein Name :
dense granule protein GRA2
-
Protein pI :
9.71
-
Protein Weight :
18298.13
-
Protein Length :
253
-
Protein Note :
encoded by transcript TGME49_227620;
Signal peptide predicted by SignalP 2.0 HMM (probability 0.997) with cleavage site probability 0.917 at residue 23;
GO_component: GO:0020003 - symbiont-containing vacuole;ev_code=EXP;
GO_component: GO:0045177 - apical part of cell;ev_code=EXP
-
Protein Sequence : Show Sequence
>EPT27242.1 dense granule protein GRA2 [Toxoplasma gondii ME49]
MFAVKHCLLVVAVGALVNVSVRAAEFSGVVNQGPVDVPFSGKPLDERAVGGKGEHTPPLPDERQQEPEEP
VSQRASRVAEQLFRKFLKFAENVGQHSEKAFKKAKVVAEKGFTAAKTHTVRGFKVAKEAAGRGMVTVGKK
LANVESDRSTTTTQAPDSPNGLAETQAPVEPQQRAAHVPVPDFSQ
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
(Ching et al., 2017)
|
|
13. GRA23 |
-
Gene Name :
GRA23
-
NCBI Protein GI :
EPR58349.1
-
Taxonomy ID :
507601
-
Gene Strand (Orientation) :
?
-
Protein Name :
dense granule protein DG32
-
Protein pI :
10.03
-
Protein Weight :
23280.19
-
Protein Length :
287
-
Protein Note :
encoded by transcript TGGT1_297880 (Gold et al., 2015);
Signal peptide predicted by SignalP 2.0 HMM (probability 1.000) with cleavage site probability 0.976 at residue 30;
Predicted trans-membrane domain (TMHMM2.0):12-35
-
Protein Sequence : Show Sequence
>EPR58349.1 dense granule protein DG32 [Toxoplasma gondii GT1]
MAARAGSSGVSRRFLFVLFTVLAGSSFVSADDAFIDNVKKGVGEHIGGTPVDLVLNDLYPLIVKQGLGGV
LGKIMYKVKGIMYYRLADGVADVVMSELEFYLFGEKGANQSSFKELRKLYEAYMRKFFAESPEDPVDALT
TGVWKGLLQLFTEKLQDAFRGSPKGQKMADLLFDSNLTLVKSWTDAAHLQIMQLSSSSARANALRLLRAK
QKKPLARKN
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23
,
T. gondii DNA vaccine pVAX-TgGRA23
|
|
14. GRA24 |
-
Gene Name :
GRA24
-
NCBI Protein GI :
EPR64168.1
-
Other Database IDs :
CDD:223021
-
Taxonomy ID :
507601
-
Gene Strand (Orientation) :
?
-
Protein Name :
hypothetical protein
-
Protein pI :
10.73
-
Protein Weight :
54986.26
-
Protein Length :
621
-
Protein Note :
large tegument protein UL36; Provisional
-
Protein Sequence : Show Sequence
>EPR64168.1 hypothetical protein TGGT1_230180 [Toxoplasma gondii GT1]
MLQMARYTVNICAVSICSLVLVVALSVDILPTPDWKDRMKMGGTESGPFVLQVCASDPLLHAPKERESGS
DSTRGYHGGSSSGGSSSRQGTTVRSDAGPSSQSSQSSASTSAKTSEKHQQGPAFLTSVFRKGETPALHWV
PYGTLEGAKWHPGQQKSKRRSSATTSRQQGASHSGNPGQLPAPRGGLQPTTTLSGTAGQPRTDSTDEGAA
ATSVIPNRSGDPQPVPYLIHPVGFLSGDYNSLGMSGLVPSVYTTTSVQHMVGQPGTIIPLVLLPGKQEPE
GLVSTGTLSDSVVYEPFGVVNLGTEMPNQGSTSQSGAVASRKRPAGGASGPDKRRRVEPAGLTESRLRPE
PSLSSLTEKGSTAFSTRPPSSRSVLEGLTQETIEMLLDTPSYPISSVVSSPPPARKSSTSSSQHLEGRLS
QSRGSTRTRPPFNPWSTKTGLLERRGVSELPPLYIPRPLASGYRNPADSRKHSTVIPQTTPPARKSSTSS
SQHLEGRLSQSRGSTRTRPPFNPWSTKTGLLERRGVSELPPLRIVKPPTKGN
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6
|
|
15. GRA41 |
-
Gene Name :
GRA41
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Protein GI :
CEL76947.1
-
Taxonomy ID :
432359
-
Gene Strand (Orientation) :
?
-
Protein Name :
hypothetical protein
-
Protein pI :
4.9
-
Protein Weight :
19562.58
-
Protein Length :
259
-
Protein Note :
original entry in database:TGVEG_chrX;
new assembly:TransferStrain.TGVEG_chrIa.final_12_41033529-48599468
-
Protein Sequence : Show Sequence
>CEL76947.1 TPA: hypothetical protein BN1205_060360 [Toxoplasma gondii VEG]
MARKRATYLLACIALPAINVLLFGDCIPSHQLSITSTEPPGRNASVHSALPADVTEQDEDETSVEEDVLA
PGSYGSLRYHLSDMDTTFRWPSERHRTSALMRDTIPGLLLVAALVLMSRRARPEEEEGMVAQLRILNQGD
VAPAVAGGQVQERAESPPPAYSDWKPRKTSLLSKLHLPE
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pEGFP-C1/GRA41
|
|
16. GRA5 |
-
Gene Name :
GRA5
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7898187
-
NCBI Protein GI :
EPT31025
-
Taxonomy ID :
508771
-
Protein Name :
dense granule protein GRA5
-
Protein pI :
5.01
-
Protein Weight :
12026.38
-
Protein Length :
187
-
Protein Note :
encoded by transcript TGME49_286450;
Signal peptide predicted by SignalP 2.0 HMM (probability 0.923) with cleavage site probability 0.441 at residue 26;
Predicted trans-membrane domain (TMHMM2.0):6-26:70-93;
GO_component: GO:0020003 - symbiont-containing vacuole;ev_code=EXP;
GO_component: GO:0045177 - apical part of cell;ev_code=EXP
-
Protein Sequence : Show Sequence
>EPT31025.1 dense granule protein GRA5 [Toxoplasma gondii ME49]
MASVKRVVVAVMIVNVLALIFVGVAGSTRDTGSGGDDSEGAWGGEQQQVQQHGQSEDRSLFERGRAAVTG
HPVRTAVGLAAAVVAVVSLLRLLRRRRRRAIQEESKESATAEEEEVAEEE
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
(Ching et al., 2017)
|
|
17. GRA6 |
-
Gene Name :
GRA6
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7895853
-
NCBI Protein GI :
237845283
-
Locus Tag :
TGME49_275440
-
Genbank Accession :
CM002045
-
Protein Accession :
XP_002371939
-
Taxonomy ID :
508771
-
Chromosome No :
X
-
Gene Starting Position :
7270767
-
Gene Ending Position :
7274201
-
Gene Strand (Orientation) :
-
-
Protein pI :
4.96
-
Protein Weight :
21225.33
-
Protein Length :
224
-
DNA Sequence : Show Sequence
>NC_031478.1:7270767-7274201 Toxoplasma gondii ME49 chromosome X, whole genome shotgun sequence
CGCATGTTAAACTGGGTACCAGCTGTAAATACGAATGTCCTTATACCTAGGATACCAGCTTGTTAGTCAA
ACCGTTTCACCGTTCTTCGAAAGGGAGCGGAGCGCTCTAGACCGGGGATTTCGTTGGGGATGAGGGAAGT
CGTCAGGCCGTTAGCATCAACACCGCTTTGGACACTATCAACGGAGTGTTCTCTAAACGGCACGAGGCAA
AAACACTTGTTACAGTAAACGAAGACATCTGAAATTTATACGCGCAGTCGAGCTCACAGTGTATACTGGT
CTCCATTGCGTCATCGGCTGCGGGACGTCTCTGGCCACAGCTCTAGTTTCGATAGTCACAGACAAGGTTG
AAAGAGTCCAACCCGTAGACGATACTCCCCAGAAAAAGCTTGTAAGAACGCCGGTCTCAACAGGTCAATA
ACACGCCCTACGATGGTACTGATCATACGAGCAATTGAGTTGTAGCAGTTGTCTCTTGCTGTTAACCTTC
ACACCTCTGTAACTCACACACACCTGTATCAACGTCCACACGGACGCTTTCACGGGTACACTCTTCCCGA
AGGTGGCTTTCCTTTTGTTGTCTCTGCTAGATAGTTCATTCTAGAGACCATCTGCGTGCATGCGATGCGA
ATGCTCAAAGTGTTTATAGGAACGGCCTCGGCCATACATCCAGGGTTCATTTCTTTGTCCTTTATACGTT
GCCTTCTGGAAGGGGATTTCCATACACTGGAAAACGTAGATGATCTCCTGACATGGGACTCCTCTACTAT
ATTTTGTGTTGCAATTAATAGCACCGTCTGCACTCTTCTGTAGGGGCTGGTAGCTCAACGCATGTAGGTG
TCGCTGTTTTGCAGTCTCTGTACACTCGCGCTGTTCTGCCTACCCATTACCAGTCGCTACAACTTCTGAA
TCGCTTGCCCGGCCCAAACCCACGAAAACGTGAAACCTGCTAGTTTCGCTGGCATGTGCACGTGCAATTC
AACATCGTATTCAGCCCACGCATGATACGTTTCCATAATTTTTCGCGCTTGTGTGGAGTTTTGAAAGACG
AAATCGCGACACGGCATACACACGACGCAAAACACAAAACACGTGAAAACTTTGACAAATCGCGGCAGCT
TCGGCGCAGCGGCTCTGCCTCATCGACGGGTCGGTGTATGATCCGGCCCCTGTTTTACACTCATTCGTTC
TCGTGTGTGCGACTCTTTTCGCTTCACACTTTAAGCATCTTCCCCGACTGAAACGTCACGCTTGCAGGTG
ATGCCGGCGGTGTCGGAGGCATTATCGTATTCCTACTTATGTTTCATCTCTTCGACGTTTCACTGGAATC
GCTGCCACAGACTTTACGAAAACTTTGCTTTTTATTTCAGTCCGGTAGTACCACGTCACAACTGCCAGAT
GGTAACTCGACAGATTCGGCTTCACCGTTCTTTGGAAGATTCTCCTGAGCGTTACAGCCCTGCGATCGCC
GACGTACACTACCTCAGGTGTAAAAGACGCAAACCATTCATCGCGACCCGTCCACACATGTCGACCTGTC
CACGTCCCAAGTCTGTAAGGAGCGCAGTTCGTACAGATTCCTACGTTCTTCTCCACGTCGGACAGTGCCG
CTCTCCCGGTCGTTGCATGGCATCGACTACAAGACACAGAGTGCCCCAGTGGCGCATAGACCCCCTGTTT
TCATCTTTAAAAATCAAACTCATTCACACTTCCCGGGTGCAACGGGCGCCTGTCATCCTCGCCTCCTTCA
CCTCTGCCTTCATTCCCACCGTTCCCAGCATTATTGCCTGCATCATTTCCACCACCACCCCCAGATGGTT
CTTGGGGAGAGCGTCGTCCAGTCCTTCGAAGAAAGAAAGCGGTAAGCATTGCCACAGATACTGCCAACAC
CACAGCACCAATGAGTCTGTGGCGTTTCTGTGTTCGTTTGCTAGGCACCTTCGCTTGTGGTTCTTGAACA
GAGGAGTAACGTCGTCTTGTGCCCTGTTCTTCGATTCTTTCCTCGAGCGACGGGCCACGCGCCTCCGACT
TCCCCTCATTCGCCAGCGCGGGAAAAGGGTCAACGTCGCCCTCCGCCGCATCGGAGGTTGTATCATCTTC
AGCTAACGAGTCGCCTTGGCCACCGCCCATCGCCGAAGAGTTGACATAGTCTTCAGTGGTCCCCACTGCT
TCTTGCTGTCCACCGCTCGAACCGGTTTCCGAAGGGGTCTGCCTAACACCACCGCTGTCTGCTGCGACAG
CGACTCCACCCAACGAATTGACGAGTACACCCATGAAGACTACAAAGACCACAGCAACTGTGGAGACAGT
TAAAGGACAGAAGTTACGCTTCTGCCTCAGATAGATGCCACCGTGTGCCATTTCGCCGACACTCCCAAGA
AAAAAAGGTAGTCGCCAACAAGCACGCTACGTGGCACCACGAAGCTGTTTTCCTGCTGTTTCAAAAAAGC
GACCCAGGTCACCTGCTCGGAAACACAAATCTTTTGCGGCCAAAATGTCTAAATAAAGCAGCCTGCAATG
CACAGCAAAACACGCTGTAGACACTTCGTTTTGTTTGCCGTCAGCATTCGACGACGCAAATATTCTACTA
ATGGGGAAGAGTCAGCCAGTGGGCATTTGCTGAGACGCGCGAGACTCGTGTTTCGTACAGGTCCGGCCGT
TCCTGCTCCGCGTCGCAGCCGGTGGAACAAGATGAGAAGCATCCTCAGCGACGAAAGCCAACGCCCTCCG
GTGGTGATCAGCTCGTCGCACCACGTTCACCTAGACCAGTCCGACGTATTCGTGATACGGTCAACCGGTC
GCCGCAAGGGTTCAACTAGGAAAAAGTGTACGTGTCTGTTGCTAGGTTGTGGTGACGGGGAAAACTTGAA
TGCGGCCTATCAACGCAGCCACAACTTGGGAGGCGTCAACAATCCTCTTTCGAAATTTAGCCACAAGACA
CCAGAAAGTCGCTTCTATAAGCTGCAGCATACGCAGTCTCCACGATCCCGCGTTGGCGGGAGAGACACGC
TATCCTAAACAGTTTGTGCGGGTAACGCGTAGCAGCGAAACCAATGTGAAGGGCGGCTGTCTGGTGACAA
CGTTACACCCGCTGCTCCCCCTTCCCCTCCGGATTGCCGTGCAGATACGCAGCGAACTGCATGTAGGACA
TTCGGGCTGAGGCATTTCCTCTGTGTATTCAGTCGTTCTTGATCGGGGAGTCAATAAGTCGGAGCAGGTT
AGCCTCGCGCGTCGGAACTTGTATGCATTTGCGTAAAGTGACTCAGCAAGACAGCACAACGTTCCAGTGT
GTTTAAATACCAAGGAAACCAGCCAGCAAAAGCGAGTGTGAGTGCGTTCATCAGCAGCCGTTTCGGTTGG
TCGCCTTTTGACAACATCGGCGGCGTATTGTCTCCACCCTTCTTTTTCCCCGTGCCCAGTGTGGTGTCAT
CGGAG
-
Protein Sequence : Show Sequence
>XP_002371939.1 dense granule protein GRA6 [Toxoplasma gondii ME49]
MAHGGIYLRQKRNFCPLTVSTVAVVFVVFMGVLVNSLGGVAVAADSGGVRQTPSETGSSGGQQEAVGTTE
DYVNSSAMGGGQGDSLAEDDTTSDAAEGDVDPFPALANEGKSEARGPSLEERIEEQGTRRRYSSVQEPQA
KVPSKRTQKRHRLIGAVVLAVSVAMLTAFFLRRTGRRSPQEPSGGGGGNDAGNNAGNGGNEGRGEGGEDD
RRPLHPGSVNEFDF
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pcDNA3.1-HisGRA6
|
|
18. GRA7 |
-
Gene Name :
GRA7
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7894037
-
NCBI Protein GI :
237836631
-
Locus Tag :
TGME49_203310
-
Genbank Accession :
CM002041
-
Protein Accession :
XP_002367613
-
Taxonomy ID :
508771
-
Chromosome No :
VIIa
-
Gene Starting Position :
2602298
-
Gene Ending Position :
2607509
-
Gene Strand (Orientation) :
+
-
Protein pI :
5.06
-
Protein Weight :
24529.52
-
Protein Length :
236
-
DNA Sequence : Show Sequence
>NC_031474.1:2602298-2607509 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
CCGGTAAACATGCCAATATTTGGGTGGCGCGCGGGGATCGACGCAGCAATTGAAACCGTGCTTCCGGAAT
TAGTGGGAAACAATCGTGTGCACTTATAGCAACGCACTTTAAAAACCTTCGCCAGCTGTGGAACTACGCT
TCCAACCGGGGAGAACGCGTTGTCACTGTTGTTCCTCCCGGTGCAGGCTGCCCATGGCCTCTTGGGGTGG
CACTAAGTAAAGTCTCATTTCTTCTCGCGTTCGCCTCCCGGCTCATGTCGATAGAACACTTACGTGTCTG
TGCTTAGTAGTGGAGGGGTGACGGGAGGTGACACACGCGGAGGAGTAACGGAAAGGCAGCTATCACTGAA
GCCACAACTGATTATGGAGTTGACCGGGGAAACCCGGTCCCCATGTCTTTCCATGACCCGACTACAGCCA
CACAGACATATACCTTTATGCGAAAGACAGTCGACTGTTTCGTGGGTGTTAAAAACCGTTAAAGGTGATG
TTGAGAAAGATTCGGTCTTCCGCGTCGCTGTCAGGTGGGTCGAACAACCTCATTGATTTAACTCGAAAAG
GAAGCATTAACAAAGTCCGCTTGACTCATATGAAGAAACGGAGAAACACTGCAGCATTTCAACGCTTGTG
CTATCTTAAACGTTCCTGAATGCACCCTATTTGTTCCTCTTCTTGCTTACTACAGTGTCATCGAGATCCA
TATTCTATCCTTCTTGCGTTACTTCCCTCTGCCTTCTACCTTTCCTGTATTTCTTTCGATTTGTTTTCTA
TTCCTTCCGACACTTCCCACCTTATTGCCTCTCTTTACTACTCGTGGTTCTCCCCTGTGAGGTTCGTGCA
TCCAGAACCTTCTGTCCTCCGCTGGCGGTCGTCGACCGTTTTTACACCACACGCTCCACTGTCATATTTC
CTTCGGTCTCGCTTCATTACCCTTCTCCCTGCGAATTTGAACCCTTAACTCCCTCTGCTCTGTTTTTTCT
GCACTGCACCGCCAGCCTTTCGCTCTTGTCATAGTTGCAGTTGCTTGAGAGGCAGTTCCCATCCGGGAAC
ACCCCGCCCCCTCCCAAGGCGAGACATGACAGCTGCATTATGCCATCCTCTGGTGTAGGAGATTCACAAA
AAGTTCAGGAAAACAGTGTTTCCGAACAACGGTTCGTCCCCGCTGCACTGGCCGGCACACTTCCACTCCG
CCCTTACCCTGCTCCGCTTGTAGCTCGGCTGGGCTACGACTGAGGACAGGGCTCGCGACATCGATCTCTA
TTGAACAACTTCTGAGTAACTAATTGCACATCCTGGAGGGTTGCATTTCTCTTTATCCGCCGTCTTTCCA
AGTGGCCAAAGTCGGCGTTTCCCCTCCCCCTACGCCCCTCGTTTTTTTCACACCCTTGGCCTGTCTTGAC
GGTGTCACTCGACGCGTTGAGAACGGCAGTGTCAAAGTGCTACGCGATCGGTAGAATTTCGGACAGTGAA
CCATTTATACGGAAGCAAAGAATGAAGTCAACCATGTATAATATCTTAAAAGCAGTTGGGTAGGTCGAAG
CCACCCCACCTGGAGTTGTGTCCCGTTCGCGCCTGCAGAAACCCACGAGCCCGACAGGCGTGGCTGAAAA
TCCTCAGCCACGGGCAAACTGGCTGCACCGAGTAGAGCGCGGTTCCATCGTCAGCGACGAGGTTCGACGT
TGAGACGCCGAGATCCCTTGGCCTTTCGGGCACTCGACAGGGTGGTTTGAAGTGGAATCTCGGAACGAGG
AGACGCGCGTCTCTAGAGAGACCCGCGCCACCGCCCGTGACGAACCACGAACCGCGGCGAACGGCGAGCT
CACCGGGTTTTCAGAGACGCGCGAGATCCCTGATTTCGTTTACCATTGACGCCCGCCGCCGTCGACGTCT
TTGGAACGTGTTTCACGTTTGAGTTGCACTGTTACTTTCTTCGGATTACATTCTTCCACTAAAAGCTGGT
TTTGTCCAGTATCCATTCGTCGCTACCGTTGCGCAGTCACGTTGAATTTTGCAGCGGCAAAACATCTTGT
GTAAAATTCGAGTTTTGTTGATGATTGAAGTACCCTGTATTGGGGCTTGCTAACGTTTTGTATTAAAAGG
GTTTACTGCGGCGTCTCATTTCCAAAATGGCCCGACACGCAATTTTTTTCGCGCTTTGTGTTTTAGGCCT
GGTGGCGGCGGCTTTGCCCCAGTTCGCTACCGCGGCCACCGCGTCAGATGACGAACTGATGAGTCGAATC
CGAAATTCTGACTTTTTCGATGGTCAAGCACCCGTTGACAGTCTCAGACCGACGAACGCCGGTGTCGACT
CGAAAGGGACCGACGATCACCTCACCACCAGCATGGATAAGGCATCTGTAGAGAGTCAGCTTCCGAGAAG
AGAGCCATTGGAGACGGAGCCAGATGAACAAGAAGAAGTTCATTTCAGGAAGCGAGGCGTCCGTTCCGAC
GCTGAAGTGACTGACGACAACATCTACGAGGAGCACACTGATCGTAAAGTGGTTCCGAGGAAGTCGGAGG
GCAAGCGAAGCTTCAAAGACTTGCTGAAGAAGCTCGCGCTGCCGGCTGTTGGTATGGGTGCATCGTATTT
TGCCGCTGATAGAATTCTGCCGGAACTAACAGAGCAGCAACAGACAGGCGAAGAACCCCTAACCACCGGC
CAGAATGTGAGCACTGTGTTAGGCTTCGCAGCGCTTGCTGCTGCCGCAGCGTTCCTTGGCATGGGTCTCA
CGAGGACGTACCGACATTTTTCCCCACGCAAAAACAGATCACGGCAGCCTGCACTCGAGCAAGAGGTGCC
TGAATCAGGCAAAGATGGGGAGGATGCCCGCCAGTAGGATATGGGGGCTAATAAAAGTGAGTAGGAGCTC
GAGGACAGTGTCCCGAACGCGCCTGAGAGGCAGACAGACACAGAAGAGTGAAGAAAAACAACATGGTATT
ACGTGCGGTGAGTGTTTGCTGTCACGTGTTTTTTGCGCCACAAAGACAGCTTGTGTTGTATGCATGGGAT
CGACAGTTCATGGACGGCGCTACCCAGAGAGGCGGCATTTGCGTACACCGTGGGTCGTCATGAGTACCGG
GACATCGTGTTCGTGTTTATTTGTTCATGTCGAAGTGCACTAAGACACGAGACGAAAGGGTGGTTCCGTC
CCTGGCAGCATCACGTAGTGGTTTCTTTGTCGAGAACAGCGGCAGTCCGAGGCCACTTGAGACAGGATGT
TTGAGTGTATACAGACAACGCGGTCACAGCATGAGGCAAAGCTGTCTAAGCAGCCATTTGCGCGAGCGAA
GTCATCCATGCCGACTGTGTGAGCCTCTTTAGTTACTTTGAATGAGACAGAAACTAAGGCTCGCAGCAGG
TCTGAATATTGCGAATAATCTACTTTTAAAACCCGGGGGAGCCTAGTCGTTGGGCGCGTGGTGCTGAGGA
GGTTGGAAAAGGACCCGTATGCAGGTAGCTGGTATTTCTTGCAGGGTGAAGGATTCTCCATCTGTTTTGA
GGCAGTCCAACGTTGGTTGCTTCAAAACAGACGAAAACACGCATGATCGTTCCTTGCAGTGTCAGCGGGA
GTGTTTACCTCTGGTGGATCCTACCAGAGTGGTGTATCGTGTCGTGGCGGGAAAGTCAGAAACGGAAGTG
GACGGTAGATGAAGTTGTAGTAGCGAATGATGTGAGGCCGCCTTTTGAAGCAGGAACTTTCCTGCCGCGT
CCACTTCTTGCTAGGTGGCAGTAGAGAGCACTCGATCTCGGAACAGAGACGCACGTTTGCGCGCTGCAAT
CCAGCTGACACATTCGAGAATACATTGCTGAGGCTGGATTCACTACAAAAGACGCATTCTTTTGCTATGC
TAATTTAGTACTTGCGTTTCTTGCTCTACTGAGATTCGATGTTCCGTCATTAGCCTTTACGAACAGGACG
ACACAAGCCGTCGTGAAAGGACTTTCGCGCAAGCACCTGCCGCTCACAGGAACCGTCTTCACCTCCGACA
TTGCTTGAGACTGCTGCCAGCGCCCCTCCGAGCACGGCTACTATCTCTATTTCTTCTTGGTCAGTGCGAC
TGCTGGTACATGTGTCAGAGTATTCGAATGCTGCTCCTTCCGAAGGGACCAGCGCAGCCATTGGCGGACC
GTTTTCTACGCATAGTATGGGTGGATAATCCAGAACTGTTCCTCGCGCTCGTTTTATGCGCGTTACCGCT
TCTCGTCTTCAACTCCTATCAAACACCATCGACTTAAGACGCATGTGCGACGAACGCCTGTGCTGTTCAC
TCTCTACCTGCTGGACTCTGTGCCCCCTATGGTGCTCGTGTTGAGTGGGCGCAGGCACAGTCTCGCTCTC
CGGCCTAGGCAGCCTTCGTTGTGATGCGCGGTGTCAACTTTCGAAAGGTGGTAACGCGTTTCTTCTGACA
TCTACCGTGGCTGCTAGACAAAAAATGTAGGGGGAACCGACCCGGAAGTAAGGAAAATTGCCTTGTCCGA
AGGAGAGACACAAGTCACCTGCCTCTTCCCGCGCCGCCTTTTTTTCGCTGGCCGCGCGACGGACGAACAG
CATTGCTCTTTCGTTGTCGAGCCGGTGGTCTGTCGAGACCCGTTGTGTTTTGCAGCCTCGGGTGTGCATA
TCTGTGGTGCATCGCCGCTTGCTTCTATCCCGAGAGCAGCCAAGCTAGCGCGCTGAGGAACCGAGAAAAG
ATGCGTTTTGCGGAGGGGAGAGCGACGAAACCTCGACACGGAGAGGTCCTTTTCTGGTTTGTGAAGCGGG
TTCTATGTCTCTCATTTCCGTTGTGTCTTCCAAAAGTGGGCAGAGACTTTCTCTTCAAGTTGTGTAGGCA
AAAGACTCCCTCAACCGTAGCCGTGTTTCTCCTTCACCATCGAGTCCGTCGTGCTCCTTGGTCACCACGC
CACTTGCCCGGCGCGTTCAGCAGACTCCGGGTTGGAGGTTCTTTTAAACTCGGTAAAGTAGATGCAGCAA
TGCTTGGACCGGCCGCTTTTCTTTTTCTCTTCATCCCTTTTCAAGCAGTGTGTTCCTCGCAACGCACCCT
TGTGTTTTATTCAAAAATCCTCTTCGCGTAGCCGCACTCCGACCAGATCGTCGGTGTCTTGCATGCGCCG
CAACGGTCCTTCCATATGGTGCCTGCGACGTTCCAGCAAATTTTCCTTCCTTCTCGACGTAGTTCCCGTT
CTCCCTCTCGCTGTCGATAGACAGGTCTCTTT
-
Protein Sequence : Show Sequence
>XP_002367613.1 dense granule protein GRA7 [Toxoplasma gondii ME49]
MARHAIFFALCVLGLVAAALPQFATAATASDDELMSRIRNSDFFDGQAPVDSLRPTNAGVDSKGTDDHLT
TSMDKASVESQLPRREPLETEPDEQEEVHFRKRGVRSDAEVTDDNIYEEHTDRKVVPRKSEGKRSFKDLL
KKLALPAVGMGASYFAADRILPELTEQQQTGEEPLTTGQNVSTVLGFAALAAAAAFLGMGLTRTYRHFSP
RKNRSRQPALEQEVPESGKDGEDARQ
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
GRA7(20–28)SAPN
,
T. gondii DNA vaccine pVitro-SAG1-GRA7
|
|
19. GRA8 |
-
Gene Name :
GRA8
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7894224
-
NCBI Protein GI :
237840457
-
Locus Tag :
TGME49_254720
-
Genbank Accession :
CM002037
-
Protein Accession :
XP_002369526
-
Taxonomy ID :
508771
-
Chromosome No :
III
-
Gene Starting Position :
1904183
-
Gene Ending Position :
1905992
-
Gene Strand (Orientation) :
+
-
Protein pI :
10.87
-
Protein Weight :
26346.49
-
Protein Length :
269
-
DNA Sequence : Show Sequence
>NC_031470.1:1904183-1905992 Toxoplasma gondii ME49 chromosome III, whole genome shotgun sequence
CTTGCTCCGAGTTGACCTTGTTTTCAGCAGTGCCGTGTTTGTCTCATATCTGACACAGCAGATTCAGTGT
TAACAGTTGACAGAATCTGTGGGTTTTTATGGAGACGCGGACTACGTACAATAACGACACTGTCGCTGTT
TTGCGACACACGTGCTATGGAGCAGGATTTCGTGACACAGACACCAACGCCTCAAAACGTTTCAGAGACG
CGGACGCGAACGTCTCGAGGGATACCTCGTGTGATTCGATCTCCACCAGAAATATCCATTCTCCCTTTAG
CGACACTCAGGTTTGAGCAGTTGCATACGCTCATGGTCGCTTCTGCGACTTAAATTGTTGTTTGCAGCCC
GCAGCTCTTCAAGTTCTTTTCTTCGACAGTTTCCGCGCTGTAGTAAGATGGCTTTACCATTGCGTGTTTC
GGCCACGGTGTTCGTGGTCTTCGCTGTCTTTGGTGTAGCTCGCGCCATGAACGGTCCTTTGAGTTATCAT
CCAAGCAGTTACGGAGCGTCGTATCCGAATCCGAGTAATCCTCTGCATGGAATGCCCAAGCCAGAGAACC
CGGTGAGACCGCCTCCTCCCGGTTTCCATCCAAGCGTTATTCCCAATCCCCCGTACCCGCTGGGCACTCC
AGCGGGCATGCCACAGCCAGAGGTTCCGCCACTTCAGCATCCCCCGCCAACGGGTTCCCCTCCCGCGGCA
GCTCCCCAGCCTCCATATCCAGTGGGTACTCCAGGAATGCCACAGCCAGAGATACCGCCTGTTCATCGGC
CGCCGCCTCCGGGTTTCCGTCCCGAAGTGGCTCCCGTGCCCCCGTATCCAGTGGGCACTCCAACGGGCAT
GCCCCAGCCGGAGATACCGGCAGTTCACCATCCGTTCCCCTACGTTACGACAACCACGACAGCTGCTCCT
CGTGTGCTGGTTTATAAGATTCCCTATGGAGGCGCTGCGCCCCCCCGTGCTCCTCCAGTGCCACCCCGTA
TGGGCCCGAGTGATATCAGCACTCACGTGCGGGGTGCAATCCGGCGTCAACCCGCTACCGCCACCACAAC
CACTACTACCCGCAATGTACTACTCAGGACAGCGATACTGGCTGCAGCGGCAGCAACCTTGATAGCCCTG
TTCAGACAAAGACCTTTGTTCACGGAGGGGGTACGGATGTTTCCAGATTTCCAATACAGATTCACCGTCC
AAACGACGCAGAATTAAATTTCCGGTTTACGAATTCAGAAGTCACTTATACAGTGGGTACACGACCTTCG
TGTCGTCCACACCTTGTTTCCGTTCCGGTCACAGGTTGTGTCTACAAACGAACACGGTGGTATGTGCTGT
AGACTCAGGGGTGGGAGGAGCGCTGTAGGGCCTTCTGGAGAGCTCTCAATGTGCGCTCTCCGCTTATATT
CGTGCAGCGTTATCCTCGTGAGGAGCGTCGATTGTGTCGTGCCCAGTGTCGCCGGACTCGAATCAGAAAC
CTGCTCTGTAGTAGCTCGTGCTAACGTCCTGAGAAACGCTGTATTGGACATTTTGAAACCTCAAAGAAAT
AAGCGCCACAAAAGAGCGTGAAAAGTGGAGAGGACATTGCAGTCCGGGATCGTCAGAGCATGCTGCATGC
GAACAGCGGCGCAAACCTCGCGGTTACTTCCGAGTTTCGTCTTTGCCGGTCATGCTGTAAGACTGGTTCT
GCATCACCGGGATGGACTTTCTCCCACCGGCTAAGGTTGAAGATAAAAACTGGCTCGGCAGAACAGAGTA
GATCGGCACAGAAGTCTTCCTTTCTATCATGTGCACAGTGGGACAGCACCCGCGAGCCAG
-
Protein Sequence : Show Sequence
>XP_002369526.1 dense granule protein GRA8 [Toxoplasma gondii ME49]
MALPLRVSATVFVVFAVFGVARAMNGPLSYHPSSYGASYPNPSNPLHGMPKPENPVRPPPPGFHPSVIPN
PPYPLGTPAGMPQPEVPPLQHPPPTGSPPAAAPQPPYPVGTPGMPQPEIPPVHRPPPPGFRPEVAPVPPY
PVGTPTGMPQPEIPAVHHPFPYVTTTTTAAPRVLVYKIPYGGAAPPRAPPVPPRMGPSDISTHVRGAIRR
QPATATTTTTTRNVLLRTAILAAAAATLIALFRQRPLFTEGVRMFPDFQYRFTVQTTQN
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pDsRed2-GRA8
|
|
20. hsp70 |
-
Gene Name :
hsp70
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7895357
-
NCBI Protein GI :
12248795
-
Other Database IDs :
CDD:240227
CDD:212675
CDD:295646
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein pI :
5.38
-
Protein Weight :
69239.84
-
Protein Length :
723
-
Protein Note :
heat shock 70 kDa protein; Provisional
-
Protein Sequence : Show Sequence
>BAB20284.1 hsp70 [Toxoplasma gondii]
MGSSHHHHHHSSGLVPRGSHMLEMADSPAVGIDLGTTYSCVGVWKNDAVEIIANDQGNRTTPSYVAFTDT
ERLVGDAAKNQVARNPENTIFDAKRLIGRKFDDPSVQSDMKHWPFKVIAGPGDKPLIEVTYQGEKKTFHP
EEVSAMVLGKMKEIAEAYLGKEVKEAVITVLAYFNDSQRQATKDAGTIAGLSVLRIINEPTAAAIAYGLD
KKGCGEMNVLIFDMGGGTFDVSLLTIEDGIFEVKATAGDTHLGGEDFDNRLVDFCVQDFKRKNRGKDIST
NSRALRRLRTQCERTKRTLSSSIQATIEIDSLFEGIDYSVSISRARFEELCMDYFRNSLLPVEKVLKDSG
IDKRSVSEVVLVGGSTRIPKIQQLITDFFNGKEPCRSINPDEAVAYGAAVQAAILKGVTSSQVQDLLLLD
VALLSLGLETAGGVMTKLIERNTTIPTKKSQTFTTYADNQPGVLIQVYEGERAMTKDNNLLGKFHLDGIP
PAPRGVPQIEVTFDIDANGIMNVTAQDKSTGKSNQITITNDKGRLSASEIDRMVQEAEKYKAEDEQNKHR
VEAKNGLENYCYHMRQTLDDEKLKDKISSEDRDTANKAIQEALDWLDKNQLAEKEEFEAKQKEVESVCTP
IITKLYQAGAAAGGMPGGMGGMPGGMGGMPGGMGGMPGGMGSGC
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine T.g.HSP70
|
|
21. ISP3 |
-
Gene Name :
ISP3
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7897539
-
NCBI Protein GI :
1085146070
-
Locus Tag :
TGME49_316540
-
Genbank Accession :
CM002046
-
Protein Accession :
XP_018635288
-
Taxonomy ID :
508771
-
Chromosome No :
XI
-
Gene Starting Position :
5390204
-
Gene Ending Position :
5394071
-
Gene Strand (Orientation) :
-
-
Protein pI :
4.87
-
Protein Weight :
17596.07
-
Protein Length :
164
-
DNA Sequence : Show Sequence
>NC_031479.1:5390204-5394071 Toxoplasma gondii ME49 chromosome XI, whole genome shotgun sequence
CTGATTCCACCCCCTCCGACGCAGCACATTATCGCCGTGAGGCAACCGATGTGCAATACGCGTTCGGCGA
CCCGTCGAGAAGCAATGTTTTACTGTAACGGTCTTAAAAACACCATCACAGCTCCTGTTTCACCGAGATT
CGCGTATTTTTCGGGAACCAGAGATACAACATACTCAGGGTGGGCGGGACAACACAGCAGCCTAACCACT
TAAGTACGCACACGTACTAAAGGTTGCTCTTGGAGGCGGAGCAATGCTTCCATCTTAAGGGGTGAGCGTC
GCCACTTCCCACTGGCAACCATTTCTTTAGTGCAAGTATCGCTGTTGCAAGGTGCTTTTGGCTTCCCGCC
CAGACGACGAAAAGGGAACTCCTCTCCATCACCCGATCCCCGCCCCCTGTTCTCCACTTTGTTGAACATT
TGCGGTAGGGGTTCCACGGCAATATAGACGTCAAAATTTTGTTGTGCACACTGGAGGCGCGAGGAAAAGC
CAACAACTAATACACGAGCATGTTGAACGTCACAGCCCTCCACCCCCTGTCTCCTCAAGTACCATTCCTT
ATACGCCTGGCAAACTGACTGGCACTCCTCCTACGCATCCACCTAGTGAGTGGTTAGTCGTCTTCGCGAA
ACAGCAAAGATCGGAAAAATCCTATATGACATGAACCCATTTGTAAAAAACGTTTCATCAGAGCGAAATA
AAGAAAGGCGATCTACTCCTGACACGTGAGGCGAAAGTCAGACGGAATGGGGTAGGAACGACTATTCTCG
CAAGAGGCATGGGGAATAACGACTCCGCGCAGAAAACAGCTGCAATGCAAAAACTGTTAACAGCGTGCAA
ACGGTTCGCTCGAGGGTTGTTCCTCAGCATGTCGCATGCCAACGTCGATCATGGGTGTTAGCGAGTGTGT
GATTCACCTCATCTTAGTTTCTGTCGTTGCTTGCTGAAGACTTGTTTGACTCCTGATTCTTCTTGATTTC
GTCGTCCAGGAAAGACACAAAACACTGCGCGTCCGTGATGTCTTTAAAAGAAAACGCGATGGCTCGTCCA
GAGCTCGCGAGGCGGAAGCCCACGACACAGGGGTTTCGCAGCATTTTGCTATCTGCGCATTCGGAACTGC
GAGGATCCGAGCCATATAGGACGGCTGCAATGTCATCGAGCTGGATGGGTCTTACTTTCTGATTGAAGGT
GAGATTCATGAAGTTTTTCGGTCGGTCGATTTTCAAGTTACACTCAATTCGGTGACCATCAGGAAAAAGC
ACTTCCATCGTGTCTCCAGCCTCATAACGATTCATCCAGTTGTCAAACGCCTCCTTGGATACCTGAATTG
GCTTGCGACTCCTCACTTCCCCCTCTCGACCGATCTCGAGGTCAGCAGTAGAGTCACTGTCGAAACCGCA
GCACGCCGTGTTCCCCATCCTGGTAGAAGTAAGTGCACGGAACAAGGCCTCGAAATAAGGTGTCCGGAGA
CAGCAAGAGACGTGTGCTTCCGCTCACGTGGATAATCCGGGGATGAAAAAGGATAGCTAGGAGGATAGTG
TTCAAGATGTCGCAAGGGTAGCGCTGCGGCTAAAGGACAACCGCAGATGCCTGTCGAGTTGAGGAAACAG
ATCGGAGCTTCGTCCCGGTGAGGGTGGTGTGACGCGTACAGACAAGAGCAACTTCTACGGGTGCCTGCTG
TACTCGGACAGAACACAAATTCCTGTTTTCGATGCATTCAAGGGTCGCAATCCTGGCAGCGGCTCCAGAA
AGTACACCGAGGCGGCACGGACGTCAAAGCGAGACCCCCCCAGCGGTAAACGAGCGAGTCGACTAGCGCT
GTTGCGCGCGCAAATGATGCGAACCTTCGAAAGGCGGGAAAAGACGGGTCAATTCATCGGGACTGCACAG
AACACAAAGTAACGCGTGATACCTTGCAAAATGCGCCGCAGACTCGGCGTTGCATAGAAAAAGGCAAGAG
ACACTTGAAGTGGGCAACGACAGCAAAGTATCTGTTTGGAGAATCAAGACGCGGAAGCGAACGCGCGACG
CCACACAGCCGGTTCTCTACCCTGAAAAGTCAGAGAAAGGAGACAGGCAAAAACGCTGGGTGGCCTGGTC
TTGGTATAAAAGCAAGCAACTCTTCACTACATGGCACAGAGGTAGCTCGACAAGGAGCGAAGACGCGCTG
CACAAAGTGGACGACTCTGCGGGGCTGCGCTTGTCACGGGGTTGCAACGTTGGACGACCAGCACGACTGC
TGGAACCGCGCGCGCATGCCGCTAGAAAATTTGACGGGACGATCAAGGGCGTCTGAAGCGTTGTTGCCAA
TGACGAGCCAAACGTTGTAAAATTGGGTTATTACTATGCACGTCCATGGACATTCTGAGTCTTCAAAGTG
TCAACGTGTGGAAATTAGTTGGAGGAAGCGGATCTGACTCTCGTGTCAGCAGGCGGGTGCCCGGTCATCC
CAACAAAAACAGCGAAATCCGTGCAGACTTGGTTGACTTCGAAAGTGCGATGTTACGCCAAAGAGCTGAA
ACACCCAGGTTTCCTTCAGTTAGTGGACCTATCGAGTGTCAATTAACCCACTAACGAGATACAAAAGTAT
TCCGAGGTAAGTCTGCAGATGCAATAGCTTTTTTCAGCGGCGAAATTTTACGGCCGCTGGCGCAACGATG
CCTGATCTTACCACGCCAGAAGTTAACGCGACTGCAGTGAAGAAAAACAAGAGGGTCTGTACTTACAACT
AATCCAGACAGAAGCCAGCAAGCAGATTTTTTCGCTGAAAACCGCAGACACAGGGCACTCAGCTGGCGAC
GTCTTGAAAAGTCAACCGCTGCGATGACAGCAGTACGCCGCTAACCAGCCAGCGTTGAACGGGAGCCAGT
GTACGAGCAGTCAAGCCACACATTTTCATGCTTATCTCACGGTACTGTTGTCGCCTTGCTTCACATCCCT
CTGTCTGCGTTTCGATATGTTTCACTCATCTGGATACGTCTAGCAAATCAACAGTTCCTCCCTTTCAATT
AGAAAGAAGCAGACACCCCGAGTTGAGAGGTGAAGCTGGCACACGCATTCAAAGCTAAAAAGATCAGTAT
CTTCTCTGCCGTACACAGAAGACCAAAGCTTTCCAGTTTATTAAAGTGGCAAGGTATCATTTCATGGCAC
TGTTCTCCGTGTGCCGCCAGGGAAACAGGGCAGTCTCTTCAATGTAGTAGCGTGGGTTAGGGATGCCAAC
GTGGAATGGGGCTTGGCTCAGTCAGCCGATGACCTGATGAAAGCGTTCTTCTGCGCGAACTTGTTTACAT
GCGTGGCCCCCTAGTTGATTAAGGAGGGCTTTTGCAGCCGGTGCGAAAGAAGATCTTGAATATCGCCTCT
AGGCGCGGCCTGCGCGTCCAAAAATGGGATGAGCAATCGCTTCTCAAAAGGTCACGAACACTCGTTTCAT
AAATCGTTTCATCCGGGAAACCTGGACTTCTTTTGCGCGATTGCGACAGTTGATCTTCTATTCTGGGGAA
TTTTTGTGAAATGTCGAGTGAGAGTGGCCGTAACGCAGCAATCGGCCCGCTGACTCTAGGTATGTCAAGC
CAGAGAGCAGGCGGCGAGACAGCAAGAAGACTGATGCTTTCATCAGTACGATGAGGTGAATCTGCTACCG
CCAAAATCGTTTTCTGTGATTCAACGGCGAGTCCGGGAAAGGTGTCTATGACGAAACTTGATTCGTTGCA
AACTCACTCCTCCAGGCTCCCTACGTATTGTCCTCGGCTAACTACGGTTGCAGTGACCACTGGTCCGACC
ACCTGTTTGATCTACCCTACCTTTCAGGCTGCTCACCTAGCGCGGCATTTAGAATGAGCAAATCTCAGTG
ACCAGATACTGCCGACAT
-
Protein Sequence : Show Sequence
>XP_018635288.1 IMC sub-compartment protein ISP3 [Toxoplasma gondii ME49]
MGNTACCGFDSDSTADLEIGREGEVRSRKPIQVSKEAFDNWMNRYEAGDTMEVLFPDGHRIECNLKIDRP
KNFMNLTFNQKVRPIQLDDIAAVLYGSDPRSSECADSKMLRNPCVVGFRLASSGRAIAFSFKDITDAQCF
VSFLDDEIKKNQESNKSSASNDRN
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
ISP3 VLP
|
|
22. MIC1 |
-
Gene Name :
MIC1
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7896467
-
NCBI Protein GI :
237838467
-
Locus Tag :
TGME49_291890
-
Genbank Accession :
CM002044
-
Protein Accession :
XP_002368531
-
Taxonomy ID :
508771
-
Chromosome No :
IX
-
Gene Starting Position :
4393560
-
Gene Ending Position :
4398559
-
Gene Strand (Orientation) :
-
-
Protein pI :
4.94
-
Protein Weight :
45255.12
-
Protein Length :
456
-
DNA Sequence : Show Sequence
>NC_031477.1:4393560-4398559 Toxoplasma gondii ME49 chromosome IX, whole genome shotgun sequence
TGCAGTTATTTATTGCCTTCTACCAGAAGTCCCATGTTGCAGATCTCTCCAAAAATGTGATCGCGGCATC
TCGTATCAAATAACTTTTACATAGAGATGTTGTTGTACCACCAAGCTTGAGCTTGACCCGGCTATAGAAT
TTACCTGCATTGAACAGCCCGTTTACTACTCACGAAACACTATCTCCAACTATTCACATAGCGAGTAACT
CCTGATTCGCCCGGTGGGGAGAAGCAATTTGACGACTAAACAGGACATGACTATCGCCGACAAGCATTAA
CGCCTTCCGTCGGTCCTCTGCGTAGTGTGGCGCTTTGTGGTTGAAGCGAGACAACTCGTTTTGAATGTTG
TAGAGCCGACTGACCGTATAATACACTTGTATTTTGCAGCGTCACCAAACGAGTGGGATGATCTCTCGTC
ACTTGCTGCGTTCGCGCCCGTACGTGAGATGCGTGGACGTATGACAATACGTATAAAACTGACAGGATTA
CACCATAATACATTTTGATTCACTACTCAAGAAACATCTGACCGCGTAACAAGAATTCGGGCAACATGCT
GCATTAAAGAGATAAGCAAGAACCTCAGAAAGTAGATTCAATACAAGGCCCCGAAATACGGTGGGACGGC
ATGCAACAGAAACACTGAGGGCGGAATCTCGAGAAAGCCACAGTTCCCCGTATGAAGTTATATCCGTATG
TCATAGTCATTACACCTGCAAGAACTCCAACTCTACAAGAACCAGGACGCATATAGGTGTAATAGTGACG
CATCTTCCACTGTTCAGGAACGATCTGTATCTCACAAACTTCATCCTGATTTTGCCGAGATTGTCCCGTT
CCTCCACAAGCATGCTCCAAAGAGTACTATAAATCAAGCAGAGACGGCCGTAGGACTCTCGCCAAGCGTC
GTCACCACGAGCGTCGCTCCACTACCCACTCCTTGGAAACTAACCTCTTCACTTGAGCTGCATCCAGAAT
CTTCGACCACGTAAGCAGCTGATCCTAAAGCAGCATTGAGCCTGGTGTAGTCGAGGACAACAGCGAGACG
GCCTTTGTGTCCCAGACCTATCGTAAGCACTGCGGGTCCTGCTGGCTCTTCCACTTCTACCACATCGAAC
GCCGAATTTGAGCCCGTCTGAAACTTCAAAAATCCATCAAGGAAATTCGCGACGAGTGAATGACACGAGC
CTACAGCAACATCCAGTTTAGTGGAGATAAACGTGAGCGTTAGTTGCTGCCCCTCTTCGAGCGTCGCTTT
CGTGCTGTCACCATGGATCTCGGTTTTCGGCGTCTTCTCGGGAGATGTTGATTTCTCAGGCAGGTCTATG
TTACCACCCTTCGTTGGATGGTCCGGCTGAGCTTCTCCTCCAGGCGACTGTTCCTTACCGCCACCTCTCT
CGTCCGAACGATCGGCGGGCTGTTGCATCTCAGGCGGTTGTGACGGTGGCCCACCACCAGTTCGTGAAAT
CTGGCCACTTTCATCTAAACACACCGGGGGATTCTCATCCTTCGGTAGGCAGACTTCAACTTCAGAACAT
GGGCTGTCGACGGATCCGATTGCCTGGCGAATTCCTTCCTCTTCTGTATAATGCCGCTTGTCTAGTTCTG
TCGACGTCCCTGCAGGTAACGGGGTGCCGGCAAGAAAACGGGGAACGGATGAGCCATCGGTGGAAACTGG
TAAAAGATGACTTCGATGGAAAAACATGACCAGAACCACCCCGTTCTCCCCACAGACCGCACTACTCTTG
TCCTGGCTTGATCATCAAGAAAAAAATTGACAACATCTGTGGTGTCGAGCATGACAGCGGTAAGGACGCA
AAATGAGAGGTTGCAGCCGCAACTTGTGGCGCTGTTTTTGCTTTCCCTGCATTTCCAACTTACCTCGTCG
TCCTCCAGGGCAGTACCACGTTGTTCCGCAGTTGCTCGCACACTCAGCATAAACCGAGTACAGCAAGCTG
GCCTAAACAGTATTGACGACAGCAAACAATGCCAACCTAACATTCCTTCCATGTTCCTCCAGTCTCTGCA
AAGAAAAGCTTAGAATGGATGTGTACACTGTTATCTGTTGTACCGCTGTGAAAAAATAATTAAAGAAAAC
ATACACGCCACTAGATTTCTGCAGCTCGTTTCGAGCGTCTGCCCATTAACTGGAAAAAACGGGAATGAAC
TGCGGTAAATAACCCCTCTTCACCTTTCGTGGTGTTGCTTTGCCTCGCAGTTATGGACGGCATATCAGGC
TTCCCTTTTCCACAAGATACAAAGTTTTCTGTCCCCAACAAGATGCATACGCTGAGAAGGCGATGGTCTG
AATACTGATGTACGGGTGCACTCTAACAGGTTCTTCCTCACCTTCTCGTAACACCTCCACGCAACCTCGA
CATTGTTTCCGAAGCCCTTCGACCTCCTCGCAATGGTCCCTGGAAATTTGTCGTTACAGTACTTGTTGGC
AGATGCTTGATAAGGACTGCAGAACCGTTGTACTCCTTCTTCGACCAATTTGGACAGTATCTCATGGCGC
GTTGCGTGATTACTGTTTTGCCGGTGTACGCCGCCAGGACACGGTATCGTGTGGCCACAGTCGTCCACGC
AATTAACACCGTTGTTTTCTTGATTGCTCTCCAGCAAAGAGGCTGTATCAAAGCATCTCCATTCAAGTGT
ATTTTGATGAGTAATGCCCACGGCGTTTCGAGCTACTATCCGGCTAGAGGGCACACACATTTTACGAAGT
CCGCCTTGGCAGAGTTCTGCAGCAATCTCTTGGCAGCGTTGGTCAAGCATCTGTTGTATATAACGTCCCG
ATGCCGGCGAATGAGAATGCGACGCTGAAAAAACACCGACAGAATCGAGAGAGCCAGTTCACGTGTCGTC
GCTGCAATTTCACCGCACGTGAAACGTCCAGTTTCAGCCACAGTAAACTCAGATAGAAGCCTTGAAAAAA
GAGGACGACTGAGTGCGCTCGTACCATTCAAAGCGAGCCAATGGCTTGCGTTCCCTTGTCCAGCTGACTA
CTACTACGGGCAAATCTTGTACATCACGACAGCTGTGTGCATTGATCCAAAAAATCGTGCACCCATCAGT
CCTTGGTCTACACCCCCGATATCCAAGAACAAGAGCGATGTTAGCGAACGAACTGGAAACGTACCTTCTC
CATATGCTTCTGGCCCAACGCCAAATAACACCGGCAATAGAACGGTGAGAAACAACGCCTGGCCCATCTT
TGCAAATCCGTTCTAGGTCAACTACAGAATCGAGGCACGTGTACACAGCTGCATCAACAGATCAGCAGCC
ATGTGAGACGAAACCAACACACAAAAACGCACTCCTGCAAGCTAGCTGACAGGAAAATAACTAAATTTTC
TACAGCTTTCAGCCGGTGCGACGTCTAGCAACACGAGAACCGCGTCGCACCAATAAGGAACGTAACATCG
AAGTGCGAGTAGAAGGAGCCAGGCGACTGGAACACCCGCGTCGGCGTTCCATGCCGGACGTTACTGTTAC
TTCGGATGTCGCACTAGAGACGCCACAGGAAACGGTAGCGACGCGGCACCCGCTTTCAGGTTGACGTGTA
GAAGGCTCTGAAAAATGTTGAAAACGCATGTGTACTAGGTTATTTTCGCCGACTTCCGGTGGCTCCTCCA
CTTGGTTGGTTCACTCACTGTAGTGCACTGTAAGTAAGTTTCGAGATCAGGTGAGGTGGAACGGGACCGT
CTCGATTGTCAAATCCTACAGTACTTAGAACAGTGATTTTTCAGATACTACTGCACGCAGTCGTCTACCA
GACTCCGATTCTTTATAGCGCGCATTAGTAAACGGTGTTTTGGTAGCCGTAAAGATGTGCAGTGACGGAA
GAAAACGTCATTTCCACGGATGACGTGAGGTAGAGCAGTTCCGACACTAGATGGGGACACTCCCGGTAAA
CAGTATCACAGGTCGCCGCAAACCGTGCACCTTCTCTCTTTTAAGCTGTGACCTTTACTCGGATTCAAAT
TAATTGTCTTCGTTTTCTCAAAAAACCCGAAGCTGCACCACCGGAAAACACTTTGAACGAAGGTACCCCT
TTTTCTTTCTGTGAATACGGTTTCGGGGATTTTTCGACCCACCGTTCAAGGGCGGACAATTACTGAGCAG
CACCGACACGGCCTCCTTTTTTAGTCACCATGTATCAGAGAAAAAGTGACTGAAGGTACAGCTGGTGAGC
ACCACTACATTCCGATACAAAGGGGTGAATGAGACGGCGTGGCAAAATTGACTGTCTTTTATCTCCTGCT
CTGTATTGCTTTCGTTTAGTAATCCCCGTCTTCCACTGAACGATCAGTCTGTACTCCGGTGGTTGACACG
CTAATATGTGACGCTGGCTGCTTACTAGAAATCGCGTGTTCTTCAGTGAAATGACCTGAAACTTTTCATT
AGGAGTCTGCTTTCATCGTTACGCGTTCTAGCGAGTGAGCCTGCACAACGTCCACATAGTGCAGGTGTGG
AGGTGGTTCAGTACGCGCCAGCAGTACACATGCGAAAAACCATCGGAAATATTATCAGAAACCGGTATCA
CTGACTCCCTGTCGCATCTGTGACCATCTGACTGTTCTGCCGTAATCAAAGGCGGTGAAATTTGATGTCT
CACTTCAAAAACAACGACGCCAGGACAGAAACACCACCACAGGCACACAGTACATTTTGAGAGGGGACAC
CTTTTTTGCCAAGAAGACCGAGGCGAAGTTCCGAGAACAGAAATGCTCACTATCTGTGCGCGCTTATCCT
AAATGAGTTCACGACATCTATAAATTCAGATCGTTTCGACGAATATTAAGCTCCCTAAGCAAGCAGAATC
TGCCTTAACGCTTATCGTAGGCCTTCTGACAATCGATAAACGCTGGTCACAACAACACGATCATCTACAA
CTATTGCGCTCTAAATTGAAATGGTCAAGTGCCTTTACTTCACGGAGGTTGTGATCACAATTCCAAGAGA
TTCTCACGTGTTCCTTGACATTAAATGGCG
-
Protein Sequence : Show Sequence
>XP_002368531.1 microneme protein MIC1 [Toxoplasma gondii ME49]
MGQALFLTVLLPVLFGVGPEAYGEASHSHSPASGRYIQQMLDQRCQEIAAELCQGGLRKMCVPSSRIVAR
NAVGITHQNTLEWRCFDTASLLESNQENNGVNCVDDCGHTIPCPGGVHRQNSNHATRHEILSKLVEEGVQ
RFCSPYQASANKYCNDKFPGTIARRSKGFGNNVEVAWRCYEKASLLYSVYAECASNCGTTWYCPGGRRGT
STELDKRHYTEEEGIRQAIGSVDSPCSEVEVCLPKDENPPVCLDESGQISRTGGGPPSQPPEMQQPADRS
DERGGGKEQSPGGEAQPDHPTKGGNIDLPEKSTSPEKTPKTEIHGDSTKATLEEGQQLTLTFISTKLDVA
VGSCHSLVANFLDGFLKFQTGSNSAFDVVEVEEPAGPAVLTIGLGHKGRLAVVLDYTRLNAALGSAAYVV
EDSGCSSSEEVSFQGVGSGATLVVTTLGESPTAVSA
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
TgMIC1
,
TgMIC1-4
,
TgMIC1-4-6
|
|
23. MIC11 |
-
Gene Name :
MIC11
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7901413
-
NCBI Protein GI :
1084997115
-
Locus Tag :
TGME49_204530
-
Genbank Accession :
CM002041
-
Protein Accession :
XP_018637299
-
Taxonomy ID :
508771
-
Chromosome No :
VIIa
-
Gene Starting Position :
1730525
-
Gene Ending Position :
1733662
-
Gene Strand (Orientation) :
-
-
Protein pI :
4.83
-
Protein Weight :
20349.6
-
Protein Length :
204
-
DNA Sequence : Show Sequence
>NC_031474.1:1730525-1733662 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
AACGAAGCCGCTTTGAAGCAGTACAGAATGTATGGCGTCGATGAACACTCAATGGTGCAGACCGAACAAA
AAATACTACAGTCCGTAGAAAGACAACGACAAACAGGAAAACACACGCCCCTGCCGATGCCAGGAACATA
CGATGGGTCATCCAGTTCGAGCGAAGCATCAGACTGTGATGACGACACGGTTACGACCACTTTAAACTCC
GATACAGCTGCCTTGTCTTCTGGCGGCCAGGCGAGCCGCGGCACAGTTGCCATTGAAAGGTAAAGCGAAG
CTGGCTGACACCTCTACATGGCTGGACGTCAGCAACCGCCAGATCTACTCGCCCGGTGCTCGCGGGTCCT
GCGTCCCACTTTATCTTTGTTATATACTCGTCAAGCCTACCAGACTTCAAGGAGCTTTGGTCTGTCGACG
ATAACGACTTTCGTTGAGCGTATCACGACTTGAAAACGTTGTCCAGGTTCATCAACTTCCATTCCCTTGA
CTTTTGAAGTGACAAGTTGGTATCTGGCAGTGAACACATGCTACGTGCCTGCGACCCTCTTGTACTTCAA
GACTGATTAGACGATGATTTACCAGTGTTCCCATAATTGGAATTGGATACAATTTCGCTTAAGGGAGTGC
AATGCACTGGTTTAAAGAACACTGTGGTGCGGCGGTAAGCTCATGCCTCACCAGTGAGCTTAAGATGCTT
TAAATTGTTTCCGCTTCAACCAGTCAATTAAGCAGCAAATGGGATAATGCTGTGGCGCCCAGAATTCCTT
TTCAAGACCAGAACTACAGCCCACAATGTTATCAAAACTCGGTATACCAGTCACTATCGCAACTTTACCT
TTCGGTAGAAAAAAGAGAGGTGACTCAAAAACATGTCAGCAGTGGAAACTCCCACTCAGCGTCTTCATTT
GTTGTGCGCCTCTCAATGTGATTGATGAGCAAACGCAACATAGGCACAGGCTCCACCATACGCAAAAAAC
ACGGAAAGCGCCGAGAGAGGAGTGGCTCTTACGCGTCCTGGAGCTTCTCCTCTGCGTGTTCACACGCCTG
TCTAAAGACGTCTATAGCTACCTCCTTAATTTTCGGCAGCATTGGCCTTATTCCGTCGACAAGTGCAGCT
TTCATAGGTTCAACAAAGGTCTTGAGCGCTCCCTTCGCAAGAGTCTTCAACGTATCTACGAACTTTCTCT
CTTGAAGAAAACCGTGAGGCCTGATAGAAGCTTCACTCGTCTTCGGGGAATCCAAGAAGCTGAAATCTGT
CGACCACATCACGAGCACCACACAGTTTCGAAGTACTCTTTACAAATCAAAGCGTCACGCATTAAATATC
TTGTCTTTGGATCTGACCTCTTCACTCACCTGACTCATCGTCAACGGCCTCTTCCTTGTCGAGACGACCC
TCGCCACGTTCTTCGGCCTCGTGGATTTTTCGCGCTGCAAGATCCGCAAGCTCCTCGCATGTTTGTTGAA
CCTCTCCTTTCACTGCAACAAGTATTTCCTTCAAGGCACTCCTGAAGGCGCCTCTCACGATAGATGCGGC
GCTTTTGTCATCTTCAGTAGTTTCTACTAAGGAGAATACTGCAGAAAACGCAGGCGTAGTTATTCACAAA
AAACACAACTGTCTTATGTTGATAAGTCTTGAAAATGTCGGCACAAAATGCATTATCTATCGTCCATGTG
GTGCTTACCTGTCTCTGACACTTGGTTCAACAGGTCAGCACGGGCCGTCTCCGATCCGAATCTTACTGGG
ACGACCACGCCCTCGGAGACTCCTGGAAAAAAAAAAGCAGAAGCAACCCAAAGAAGTGGTGCAGAGTCCA
AATATGACGTGATTCACCCTGGCTCTCTTTATAAGAAAAACTGTCAGCCTACCAATGCGAACGAATTCGC
CTTACCATTAACGAACTTAAAAAGCCCCAAAAGGGTGATAGAGACGACTGAAAGCTTCTTGAGCTGCATT
TTTTAATCGAATTATTTTGACCTGGTGTTTCAATGTCTGCAAACCACAAGCCCACACGATGCATACGTTT
GACGGAACACGTCAAAGAAAACGTGCTCAAAACAGTTGACTACCCCAGTTTGCGTGAGCAGTCCATGTTC
TTAGCCCCACTAATAATGGAGCATCGACTTCGGTCTGGCAACCAGAGACGCCCTTGTGCGCTGTCTGAGA
AACAACCTAAAATCTCACCTAACAATACGTCGCAAGGGGAATCACGCGGCCTGGGCCAGGAAGGAATAAT
GAGTTACAAACGATGTAGAAAACACAAGTTTATGCTAGACAAAAAACCGTACGAAAAGGAGATAACGACT
GCGTTTGTGCCACGTTGCCCATGAGATCATCGAAAGCTTCAAGTTTAACTGACACGAACTCTCTCGACAG
ACGTCTCGAAAAAAGGAAAACATAATATGATAGATAAATGGAAGTGTTTGTGTTTTAGTTTGTGTCGGGG
TCCAAGCGAAAGAAACTTCGATGTTACATCAAAGACCACGTCGAGCTGTACGTGCGGTGCTCGATGGCTT
GAAAGCCGAGACTGGCCGCGGGTTTCCTACCGTGTGTGTCGCAAGCAACTCGAACCTGGTCGTAAAAATG
AGACGCGGGTTCCTTGGCAAATACAGGCATGCATCCGGCTGAAAAAGACGCCGTTCGCAGTTTCGGTACG
TGAGTAGGACTCGGTTGAGCGTCGCGAACTAGCGAAAGAAACCCGCTATTGACCCCGCTGTAGTTCTAGA
GGGGTGGACTTCAATGCCCCCTTCTATATTATTATGCGAAATACGGTGGCAGTGAAGGCTCGCTTTTTGC
ATTTGGTGATTCAAGTTTTGCGAAACGGAAGAAAAAGGCGAGTGTTCAGCACCTCGAGCACATCTCAAGA
TAGCTGACTGCATCCCTTATAGAATGACTAACAATAGGTGCCACTGGAGCCACCGTTACTGGCAGTCTTT
TCAAAACGTAGGGCAAATGTTCTTAAATAATATATACAGCGGAAGTCACTTCCTTCTCATCGCCGGACTT
CTGGAGCATTCCAGTAGTTCTGTAATGTGTAACTGCCAGCGACACAGTCCGGGAAAGGTGTTCATGTCAC
GATAATCTTCAGTGGCACACTTAGCCCGCGACTATAGACACTCGCACTGCACCGAATA
-
Protein Sequence : Show Sequence
>XP_018637299.1 microneme protein MIC11 [Toxoplasma gondii ME49]
MQLKKLSVVSITLLGLFKFVNGVSEGVVVPVRFGSETARADLLNQVSETVFSLVETTEDDKSAASIVRGA
FRSALKEILVAVKGEVQQTCEELADLAARKIHEAEERGEGRLDKEEAVDDESDFSFLDSPKTSEASIRPH
GFLQERKFVDTLKTLAKGALKTFVEPMKAALVDGIRPMLPKIKEVAIDVFRQACEHAEEKLQDA
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pcDNA3.1/MIC11
|
|
24. MIC13 |
-
Gene Name :
MIC13
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7899621
-
NCBI Protein GI :
380449403
-
Other Database IDs :
CDD:287526
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
microneme protein 13
-
Protein pI :
6.48
-
Protein Weight :
49684.02
-
Protein Length :
529
-
Protein Note :
Sialic-acid binding micronemal adhesive repeat; pfam10564
-
Protein Sequence : Show Sequence
>AFD54637.1 microneme protein 13 [Toxoplasma gondii]
MVGVFQLCLLTCLLCLLKGSDAIQLRQHRNGLGVEQSFVSEETDIVGGRISSLQAELDSYCHNRYKQLCD
GGNKNFCDKTGVARYGTGIQSQQTAEWRCYFAEVLKPSGRKVQCVDDCGNYFPCLGVVDPNDTFHATAHN
QILNFIKDGVEKHCSPFQMAGNNYCQGVLADTVARKDTGTASQKAKAWRCYKKDSLTYEARSICVDNCGG
EIECPGGRSETSGELLSQHSTREKELLKVIESQSAPCRDSCVATPINPPICADTESLLQSTKRSRAQRFI
DDACQKLFNCHCKKDKKFCTTVVARKDRGRAGSQNDAEWRCYSLEELDFQKTNPSCIDECGNELPCQGAV
PEESTHHITWTKLPSKIDEATQKFCTERQRAANDYCASEFADSLARYGPGAGDQTSQFRCIKKAAMRADA
EGKCADSCKGTETCGGCRSRLDGPLSVNDVLNAHEGISEAMKSASTEC
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pVAX-TgMIC13
|
|
25. mic2 |
-
Gene Name :
mic2
-
NCBI Protein GI :
1923217
-
3D structure: PDB ID :
2XGG
-
Other Database IDs :
CDD:29244
CDD:154951
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
micronemal protein MIC2
-
Protein Length :
769
-
Protein Note :
Micronemal proteins: The Toxoplasma lytic cycle begins when the parasite actively invades a target cell. In association with invasion, T. gondii sequentially discharges three sets of secretory organelles beginning with the micronemes, which contain...; cd01471
-
Protein Sequence : Show Sequence
>gi|1923217|gb|AAB63303.1| micronemal protein MIC2 [Toxoplasma gondii]
MRLQREAVFGLMFACGMWMWPSEVAGGGWSIVDALRKRYDTSRGGDANGVDTSGVEDVIQSDSAIGAAEG
CTNQLDICFLIDSSGSIGIQNFRLVKQFLHTFLMVLPIGPEEVNNAVVTYSTDVHLQWDLQSPNAVDKQL
AAHAVLEMPYKKGSTNTSDGLKACKQILFTGSRPGREHVPKLVIGMTDGESDSDFRTVRAAKEIRELGGI
VTVLAVGHYVKHSECRSMCGCSGTSDDDSPCPLYLRADWGQLATAIKPMLKEVCKTLPQDAICSDWSAWS
PCSVSCGDGSQIRTRTEVSAPQPGTPTCPDCPAPMGRTCVEQGGLEEIRECSAGVCAVDAGCGVWGEWSA
WSASCGNATRKRERTRYNDPPPQGAGRRCENQDPPVLQEQTEEATLAPCITIPPTPPEWAAWSDCTVTCG
GGNRHRVRNALPPGLGSQNGESDESLVSKLWPGTDLRQEEACNTSPCPINATCGQFEEWSTCSVSCGGGL
KTRSRNPWNEDQQHGGLSCEQQHPGGRTETVTCNPQACPVDERPGEWAEWGECSVTCGDGVRERRRGKSL
VEAKFGGRTIDQQNEALPEDLKIKNVEYEPCSYPACGASCTYVWSDWNKCVCPMGYQARHAAVKFDYRNK
PCDLPTFETKACSCGETNPVPSEGTTPGAPGATGPEQPNQRPLPEGSDENETPTNEEGEQSKKESGSGIA
GAIAGGVIGGLILLGAAGGASYHYYLSSSVGSPSAEIEYEADDGATKVVMEEEKETLVPVDDDSDMWME
-
Molecule Role :
Virmugen
-
Molecule Role Annotation :
A mic2 mutant is attenuated in mice and induces protection from challenge with wild type T. gondii (Huynh and Carruthers, 2006).
- Related Vaccine(s):
T. gondii mic2 mutant vaccine
|
|
26. MIC3 |
-
Gene Name :
MIC3
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
VO ID :
VO_0011174
-
NCBI Gene ID :
7901253
-
NCBI Protein GI :
1085201908
-
Locus Tag :
TGME49_325800
-
Genbank Accession :
KE139555
-
Protein Accession :
XP_002369833
-
Taxonomy ID :
508771
-
Chromosome No :
Unknown
-
Gene Starting Position :
8
-
Gene Ending Position :
917
-
Gene Strand (Orientation) :
-
-
Protein pI :
6.46
-
Protein Weight :
26732.05
-
Protein Length :
269
-
DNA Sequence : Show Sequence
>NW_017383630.1:8-917 Toxoplasma gondii ME49 unplaced genomic scaffold asmbl.1555, whole genome shotgun sequence
CTCACGTGAGTACCCTGGTGGGGCACTCGCAGGTGTAGCCATTCTCATGCGAGGCGTCATCAATACATCT
ACCAGGGCTGCAGTTCTCCCTGAAGGCATGACATCCAGTCCTCTTGCATCCTTGTCCCCCTTCCGGGAGG
TTCACTAGAGTTTCGCCGTCGCCGCAGGTGCATGTGTAGCTGACTGAATCGACGACGATGCACGTCCCGT
TGGGTCCGCACTTCGCGTTCCCTCTTTTTGAACAAGGATCCTCGGAGCAAGTCAACCCAGTGCCGACGAA
GCCGTCTTTGCACTTGCAGTGCACACCCCCACCCGCGTCCAAGTTTTCGACGCATTCTGCGTTTTTGTCG
CACCGATGGCCCTGCTTTTCACAGCTGCAGTCTCCTCCATAGCTTTTGTCAGGATGGTAGATGAGCGAAC
TGCTGCAAAAAATCCAGTTGCTGGAGCAGAATTCTCCGCAGCCGCCGGGGCCGCACATGGTCTTGCTGCA
GCAAGCGCTCTTGGGGCAACTGGCCCCGATGAAGTACCCGTTGTCAGTGTGCAACTGACGGTTTCGACAT
GGCTTGCCTTCACTCGAGATAGCACAGAGTTGCGTCTCCTGCTTGCTGGGGGATTGCACAGACGAGTGAG
TCTCAGTCACCGCGAAAGACGGAGCAAGACTCTCAGAGACGACTTCGCGGCTCGGCACAACTTTGTCAAA
GCTGCCCAGCTGCACAGACTTCTGAATCGGCAAAGCCTCCGCTGGGGTGCACATCCACACGGCCCCACTG
AAGGTGAGCGCGTGCAACAGCGCGGACGTCCCGCCTCGCATTTTTACCAGTGTTGGACAAGGAAGTTACA
CACAGAGTAAGGCGCGCAAACGCGCTGCACTGCCCACAGAAATGCACAGAAACGCACTCTCGACGAGCTG
-
Protein Sequence : Show Sequence
>XP_002369833.2 EGF family domain-containing protein [Toxoplasma gondii ME49]
MRGGTSALLHALTFSGAVWMCTPAEALPIQKSVQLGSFDKVVPSREVVSESLAPSFAVTETHSSVQSPSK
QETQLCAISSEGKPCRNRQLHTDNGYFIGASCPKSACCSKTMCGPGGCGEFCSSNWIFCSSSLIYHPDKS
YGGDCSCEKQGHRCDKNAECVENLDAGGGVHCKCKDGFVGTGLTCSEDPCSKRGNAKCGPNGTCIVVDSV
SYTCTCGDGETLVNLPEGGQGCKRTGCHAFRENCSPGRCIDDASHENGYTCECPTRVLT
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
Protective experiments of DNA vaccine pcDNA3-MIC3 (pMIC3i) in Kumming mice showed that the vaccine could significantly prolong the survival time of the mice challenged by virulent RH strains of T. gondii (Xiang et al., 2009).
- Related Vaccine(s):
T. gondii DNA vaccine pcDNA3-MIC3
|
|
27. MIC3 |
-
Gene Name :
MIC3
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii strain RH(ERP)
-
NCBI Nucleotide GI :
5931753
-
NCBI Protein GI :
5931754
-
Protein Accession :
CAB56644.1
-
Other Database IDs :
CDD:304395
CDD:283826
InterPro: IPR000742
InterPro: IPR006210
UniProtKB/TrEMBL: Q9GRG4
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
MIC3 microneme protein
-
Protein pI :
6.42
-
Protein Weight :
36421.86
-
Protein Length :
421
-
Protein Note :
Calcium-binding EGF-like domain, present in a large number of membrane-bound and extracellular (mostly animal) proteins. Many of these proteins require calcium for their biological function and calcium-binding sites have been found to be located at the...; cl21504
-
DNA Sequence : Show Sequence
>gi|5931753|emb|AJ132530.1| Toxoplasma gondii MIC3 gene
CCGCTGTCCCGCCTGGTCAACAAGTATCACACCCTCGTCCCCGCCATTGGCACGGAGCTCGATGAGCTGC
AGTGTCGCTTTTAGGGGAGTCGTGCAATCACGCCGCAACACAGGCGTGATTCGATCTTCAATTGCTAGGT
AACCACTCGTGCTTGGTAGCTCTGCAATGGCTCGAGCGACGGGGGTGATGCAACATGCTGCTAAAAACTC
GACAGACGTGTCACCGGAACCCACCTAAATAGGAGACCACGGGTCTCTGGTGTGTCGCGTCGCATTCTCG
CGTCGCATTCTCGCGTCGCAATGACCGGCCAGTTGCTCGACGTCGCCAGCCGGGACTGAAGAGCGTTCAT
CGAGTCAGCAGCATTGCGTCCCCTTGCTCGGTGAAAAAAGACTCTCTGGTCGAGTCTAGCTCGTGTCACT
TCTGTTTCTAACCTCCTTCGTTCACCGGTACACCTCCGATGTGACTTTTGGTACACTTGCCCTGTCGCAC
GACGCACGCTGTCACTCAACTTGCTGCTAGCGCAATCGATAGGTTCCCTCGAACCAGCCATCACACACAC
ACCTTTTCCGGGAAGACGTTTGCGGGCGGTGGGTCGCAGCTCGTCGAGAGTGCGTTTCTGTGCATTTCTG
TGGGCAGTGCAGCGCGTTTGCGCGCCTTACTCTGTGTGTAACTTCCTTGTCCAACACTGGTAAAAATGCG
AGGCGGGACGTCCGCGCTGTTGCACGCGCTCACCTTCAGTGGGGCCGTGTGGATGTGCACCCCAGCGGAG
GCTTTGCCGATTCAGAAGTCTGTGCAGCTGGGCAGCTTTGACAAAGTTGTGCCGAGCCGCGAAGTCGTCT
CTGAGAGTCTTGCTCCGTCTTTCGCGGTGACTGAGACTCACTCGTCTGTGCAATCCCCCAGCAAGCAGGA
GACGCAACTCTGTGCTATCTCGAGTGAAGGCAAGCCATGTCGAAACCGTCAGTTGCACACTGACAACGGG
TACTTCATCGGGGCCAGTTGCCCCAAGAGCGCTTGCTGCAGCAAGACCATGTGCGGCCCCGGCGGCTGCG
GAGAATTCTGCTCCAGCAACTGGATTTTTTGCAGCAGTTCGCTCATCTACCATCCTGACAAAAGCTATGG
AGGAGACTGCAGCTGTGAAAAGCAGGGCCATCGGTGCGACAAAAACGCAGAATGCGTCGAAAACTTGGAC
GCGGGTGGGGGTGTGCACTGCAAGTGCAAAGACGGCTTCGTCGGCACTGGGTTGACTTGCTCCGAGGATC
CTTGTTCAAAAAGAGGGAACGCGAAGTGCGGACCCAACGGGACGTGCATCGTCGTCGATTCAGTCAGCTA
CACATGCACCTGCGGCGACGGCGAAACTCTAGTGAACCTCCCGGAAGGGGGACAAGGATGCAAGAGGACT
GGATGTCATGCCTTCAGGGAGAACTGCAGCCCTGGTAGATGTATTGATGACGCCTCGCATGAGAATGGCT
ACACCTGCGAGTGCCCCACAGGGTACTCACGTGAGGTGACTTCCAAGGCGGAGGAGTCGTGTGTGGAAGG
AGTCGAAGTCACGCTGGCTGAGAAATGCGAGAAGGAATTCGGCATCAGCGCGTCATCCTGCAAATGCGAT
AACGGATACTCCGGATCTGCTTCCGCAACCTCCCACCATGGGAAAGGAGAATCGGGATCCGAGGGGAGCT
TGAGTGAAAAAATGAATATTGTCTTCAAGTGCCCCAGTGGCTACCATCCAAGATACCATGCCCACACCGT
GACGTGTGAGAAAATTAAGCAGTGAGCTGGAGTCTGTCCTTTACTTTAGCATTGGAGAATGCGCCCATTC
GCAGCTGTCCGTGCATGCAATCATCGCCGTCTGTATAAAACCGACACAAACTGACCTTTATGTAACTGTA
CAGCTTTGCCCTTGACGGGGCCGGCAACCACGACACGACTACGTATGTCGCAAGACGAAGGTACCCAGCG
AGTCTCTGAGAGCGGAGATCAGCGCAAAGACAAGATGCAGAGTTTGACTCGAGAAACAATAGTAACACGA
AGTAAAAAGTCTCCACACTAAGCCAAGGATTGAGAATATTTCGATTTGTGCCGCTGGCAATAGTGGCCTT
GGCTAGAAAGAAGTTCTGCAACGAAGCGATCGGCTCACACGCGGATACACAGATGGGTTTGTACCGAGAA
CGTTAGGTTTGTGAACCGAGTTCAGGTAAAACAAAGTAGATTGTGTGCCTTTACGCAGACAGCGAGGGAA
AACATAG
-
Protein Sequence : Show Sequence
>CAB56644.1 MIC3 microneme protein [Toxoplasma gondii]
MRGGTSALLHALTFSGAVWMCTPAEALPIQKSVQLGSFDKVVPSREVVSESLAPSFAVTETHSSVQSPSK
QETQLCAISSEGKPCRNRQLHTDNGYFIGASCPKSACCSKTMCGPGGCGEFCSSNWIFCSSSLIYHPDKS
YGGDCSCEKQGHRCDKNAECVENLDAGGGVHCKCKDGFVGTGLTCSEDPCSKRGNAKCGPNGTCIVVDSV
SYTCTCGDGETLVNLPEGGQGCKRTGCHAFRENCSPGRCIDDASHENGYTCECPTGYSREVTSKAEESCV
EGVEVTLAEKCEKEFGISASSCKCDNGYSGSASATSHHGKGESGSEGSLSEKMNIVFKCPSGYHPRYHAH
TVTCEKIKQ
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain)
|
|
28. MIC4 |
-
Gene Name :
MIC4
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7896295
-
NCBI Protein GI :
237840617
-
Locus Tag :
TGME49_208030
-
Genbank Accession :
CM002035
-
Protein Accession :
XP_002369606
-
Taxonomy ID :
508771
-
Chromosome No :
Ib
-
Gene Starting Position :
531350
-
Gene Ending Position :
534470
-
Gene Strand (Orientation) :
+
-
Protein pI :
4.84
-
Protein Weight :
58654.56
-
Protein Length :
580
-
DNA Sequence : Show Sequence
>NC_031468.1:531350-534470 Toxoplasma gondii ME49 chromosome Ib, whole genome shotgun sequence
ATTTTCTGTGCATCTGTGCTGCAAAACGGGCCTCTGTGCATTATTTCCCCACCAACAATTGCCGCGTCGA
TCCGGGTCCCGCTCAAGCTCTGCAGAACTAGGCTCTCGATATAGATCAGTACAATCATTCGCTTCTGACA
ATCGCATCGACTGAGCGACGCGTTGATCGTCGACTGTCGTGCGTCGCATTCGGGCATCTCGAACCGGTGT
TGATTCCCTGTGTCATTATTTCACTTCCGTCCTTCTCTCGTGGCGATCTATAATACGCGTGTGTTGTTGC
GTGCATTGCTTGTGTTGTTGTGGATGTGTTTTCTTTTGTGACCGCTCACGAACACCCCACGCAAAATGAG
AGCGTCGCTCCCGGTTCACCTCGTTGTGTGCACGCAGCTAAGTGCCGTTTGGTTTGGAGTGGCTAAAGCC
CATGGTGGACACCGACTGGAACCGCATGTTCCCGGATTCCTGCAAGGCTTCACTGATATCACGCCTGCAG
GTGATGACGTTAGTGCCAACGTAACAAGTTCGGAGCCTGCAAAACTTGATCTCTCTTGTGTGCACTCTGA
CAATAAGGGATCAAGGGCTCCCACAATAGGCGAGCCAGTGCCAGATGTGTCCCTGGAACAATGTGCTGCG
CAATGCAAGGCTGTTGATGGCTGCACACATTTCACTTATAATGACGATTCGAAGATGTGCCATGTGAAGG
AGGGAAAACCCGATTTATACGATCTCACAGGAGGCAAAACAGCATCGCGCAGTTGCGATAGATCATGCTT
CGAACAACACGTATCGTATGAGGGAGCTCCTGACGTGATGACAGCGATGGTCACGAGCCAGTCAGCGGAC
TGTCAGGCTGCGTGTGCGGCTGACCCGAGCTGCGAGATCTTCACTTATAACGAACACGACCAGAAATGTA
CTTTCAAAGGAAGGGGGTTTTCTGCGTTTAAGGAACGAGGGGTGTTGGGTGTGACTTCCGGGCCGAAACA
GTTCTGCGATGAAGGCGGTAAATTAACTCAAGAGGAGATGGAAGATCAGATCAGTGGCTGCATTCAATTG
AGTGACGTTGGATCAATGACTGCTGACCTGGAGGAGCCTATGGAGGCTGATTCTGTTGGCGCTTGTATGG
AACGGTGCCGCTGTGATGGAAGATGCACGCACTTCACGTTCAACGATAATACTCGGATGTGCTACCTCAA
AGGTGACAAGATGCAGTTGTACTCATCTCCAGGTGACAGAACCGGCCCAAAGAGCTGCGATTCAAGCTGC
TTCTCGAACGGGGTTTCTTACGTCGATGATCCGGCGACAGATGTTGAGACCGTATTCGAAATTTCACACC
CAATTTATTGTCAAGTAATCTGCGCCGCAAATCCGTTGTGTACAGTGTTTCAGTGGTATGCCTCCGAGGC
AAAGTGCGTCGTCAAGAGAAAGGGGTTTTACAAACACAGAAAAACAGGTGTCACGGGAGTCACAGTGGGC
CCTCGGGAGTTCTGCGATTTTGGCGGTAGCATCCGCGACCGAGAAGAGGCAGACGCCGTTGGATCAGACG
ATGGCCTCAACGCGGAAGCAACTATGGCAAATTCTCCTGATTTTCACGACGAAGTAGAATGCGTCCACAC
GGGCAACATTGGGTCAAAAGCACAAACCATTGGAGAAGTGAAACGCGCAAGTAGTTTGAGTGAGTGCAGA
GCCAGATGCCAAGCGGAGAAAGAATGCAGCCACTACACTTACAATGTAAAATCCGGTTTGTGTTATCCAA
AAAGAGGAAAGCCTCAATTTTATAAGTATCTTGGCGACATGACGGGATCCAGAACATGTGATACAAGTTG
CCTTAGGAGGGGAGTCGATTACTCACAGGGCCCTGAAGTAGGAAAGCCTTGGTATTCTACGCTGCCGACA
GACTGCCAAGTTGCATGCGACGCTGAGGATGCTTGCCTGGTGTTCACCTGGGATTCGGCGACGTCACGAT
GCTACCTCATCGGCTCAGGTTTCTCGGCACATCGACGGAACGACGTGGATGGCGTGGTATCTGGACCCTA
TACTTTCTGTGACAATGGCGAAAACCTTCAGGTGCTTGAAGCGAAAGACACAGAATGACCCAGGAGGGTG
CCAGATACTTTGTGTGACTGCGACATGCAGTCATGTACTCAAAGTGTTGTACATGGACAGGAGGACTTTT
TTTTTAAGTCATTGCAGAGGTGCGTTTTCGGAGCAGCACTATAACTGCGTCAGCGACTAAGCACGCCACG
TAGCTGAATGAAACGCAGCCACCTTCGTGTATGTATGCTTCGTTTTTTGTCGCTGTGCAGTTTTGAATCA
TTTCCCTTATGGGACATTTCTGAAAAATGCTCCCCGTTCGCTTGTAGCACTATGAGAGGGGCCGAAGACT
GCAATGGAGGTAGCGCTGCGTTGAAAAGACGAGGCGCTACATTTCGCGTAGCGACAAGGCCGTGTAGAGT
TTTGCTTTTCGCGAGACACTGCTCTGAGTGTCATATGCATCAAATGCAGTGGTAGCACACAGAGGTGAGA
AGAATGATCACCTGCGGGGGAATGGCTTTGCTAAACAACAAGGTCGCTGTGTGACTTTACACAACGAAAC
TACTGTGGTGAGTGCTCAGTTGAGTGAAAAGAAATGCCGCGTTATCGTGAGTTCTGGTTCGGTGGACTTT
GCCACCGTAGTAAAACTCAACCTGTAACGGAATGCCCAGTTTTACTGCTCTCTTTAAAGGGCGTCCACGT
TCTCTATATTCAAGCTGTTTACCCACCTGCGTTTCGGTGCATCGCGCGTGCCACATCAAAAATCCAGGTA
ACGGTGCGGGACCTATGCTACACTTTATATCTCTCAGAAAGCATACACCCACTGATTATGGACAACGCTG
TGGTCGCGTTGTACCACAATGCAGGAATACTCAGTTCACCTTGCAAGTGTTCTGGTGTTCATTGCGTGTC
AGAAGTACACGAAAAGAGACTTCTTTGGCCTCCAAGTGATACGTAACCGCGGCAGTCATGAACAGAGTCA
CTCGTGCTTCTGAAACGCACGTCTTCTGTACAGAGACAGATGCAGTGTGCATACAGGAAGCCCCTCGATT
GTTGCCGTAGCAGGTAGCCAGTAGAAGAAACAAAGACACGG
-
Protein Sequence : Show Sequence
>XP_002369606.1 microneme protein MIC4 [Toxoplasma gondii ME49]
MRASLPVHLVVCTQLSAVWFGVAKAHGGHRLEPHVPGFLQGFTDITPAGDDVSANVTSSEPAKLDLSCVH
SDNKGSRAPTIGEPVPDVSLEQCAAQCKAVDGCTHFTYNDDSKMCHVKEGKPDLYDLTGGKTASRSCDRS
CFEQHVSYEGAPDVMTAMVTSQSADCQAACAADPSCEIFTYNEHDQKCTFKGRGFSAFKERGVLGVTSGP
KQFCDEGGKLTQEEMEDQISGCIQLSDVGSMTADLEEPMEADSVGACMERCRCDGRCTHFTFNDNTRMCY
LKGDKMQLYSSPGDRTGPKSCDSSCFSNGVSYVDDPATDVETVFEISHPIYCQVICAANPLCTVFQWYAS
EAKCVVKRKGFYKHRKTGVTGVTVGPREFCDFGGSIRDREEADAVGSDDGLNAEATMANSPDFHDEVECV
HTGNIGSKAQTIGEVKRASSLSECRARCQAEKECSHYTYNVKSGLCYPKRGKPQFYKYLGDMTGSRTCDT
SCLRRGVDYSQGPEVGKPWYSTLPTDCQVACDAEDACLVFTWDSATSRCYLIGSGFSAHRRNDVDGVVSG
PYTFCDNGENLQVLEAKDTE
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
TgMIC1-4
,
TgMIC1-4-6
,
TgMIC4
|
|
29. MIC6 |
-
Gene Name :
MIC6
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
29768960
-
NCBI Protein GI :
1085164641
-
Locus Tag :
TGME49_218520
-
Genbank Accession :
CM002047
-
Protein Accession :
XP_018634830
-
Taxonomy ID :
508771
-
Chromosome No :
XII
-
Gene Starting Position :
1477418
-
Gene Ending Position :
1482971
-
Gene Strand (Orientation) :
-
-
Protein pI :
4.34
-
Protein Weight :
34882.04
-
Protein Length :
349
-
DNA Sequence : Show Sequence
>NC_031480.1:1477418-1482971 Toxoplasma gondii ME49 chromosome XII, whole genome shotgun sequence
AGCAAGCGTTAGGTCGAGCAAATTGCTCTTTGCCGCCCCAAATCTGTTATACTGAATGAACTAGGTTCCT
GCTACTGGACCAGCGGGTGCCACTTGCGGAATCCCGGGTCCCGACGGTCGAATGTGTACTGACACTTCAG
GTGCTCACCGAGTTGTGTTTCCGACTGTTTTCTGCGCTAGCGACGGAAGTTGGTGAACCGCACGTCGTCA
TTGATACTATCGAGGTGTTTCATGGCTACCTAAATAAGTTGTCTCGCCTCGCTAAAGAGCAAGGTAGTCT
ATGCTAATGGTGATATCCTCGCATCAACCGTCCCAGACTGCTACATTCCACCATCACTTCAGGGTGTTTA
AGCACTCATTCACAAGCATGCTGTTCAAAGTCGGTTGGACCGGTCTTCTCTAGAGCGGAGGTACGCCGCC
GCTGTACGTATGCCGACCTCATAAGAAAGCCTGGGAGCAAAGATCCGGTATGCGGCGTGCACGTGGAATT
ACCGTTATTGCCACATGACGCGGGAAAATTGCAACGCGGCAGTGAAGCAGAAGTCTCCAGAGTCCTATCG
GGGTTACACTGATGCCTTGCGTTTGGGGACAGACAGTAAAGCCACTCTTCCGTGACACCAGATAGTTCCA
GCGAACCCTACAAGCCAAATGACAAGAAACAGGGATCACCCCCATCACCTGTGGGCTCCTCTAAATACCC
ACTGATGGCTTAGGGTAATATCAAGTGCAAACGCATCGCTATACGTTAAAAACAACTCGCGCACAGAACA
AGAGGACAGTTCTCGGTGTCTGCTAAATTCCCTGCATTTCACTGCATTCATTTGACTAAACGGAAAACGA
CCAAACAGTCAACACACAGATGATATGAAGGTGCGCATTACGCAACAGATCACCTAAAAAACGACGCAGC
ATAGTTTCTCTGGGAGCTGATGGTTTCCGTCGGCGATGAGGTGTCTCTAAAACATCAGTCCATCTCATTT
GGGATGAGTGCACAGAAGCCGGCCTCGACACAGCAGTTCTTTGTCGGCAGGGGAAGTCAACAGGAACTAT
TATCATACATGTGTTTTGATTCGGGGGTGACAGAAGACCGAGCACAATGTCCGCGCTTAAAAGAAGCGGT
GCTCACTACTCGCGTCACCTCTCGCATTGCAGCTGATCTGCCAGCGACACCCTACATTGTGAAGTCTCAG
CCGAGAACGTGTTAATCCCATGTTTTGCTATCCAAATCAACGAGGACTTCGACTTCACTGGCCTCTGCAG
CCTCGATACCCCTCTCGTATTCTATCTCCTCCCCTCCACCGCTCCCACTCTTTCTCATGTATGCAACACC
CGCTCCGGCAGCGCTCAGAAGTAACAGGCCTCCAATAACTCCCCCAGCGATCGCACCAGCATGTCCACTT
CCTTCCTCTCTCTCCTTTCCTTGTTCCTCGCTCTCGGTACTGTCGCTACCAGAACCACCTCGGCTCTGCT
GACTGTCCGGGGTGCTTCCTTCCGGTTCCTGGCTTTCCTCAAGTGGTGTTCTTCTTTCCTGATCTCTCCC
CGGTTCTGTTGAGTCGCTTTCAGGCTCACGACTTTCACCTTCATCTTCCCTCTGGCGTTTCGATGGTTCT
GAGTCCACAGGATGACCTCCCTTGCCAAATTCGAAGGGAGGCTTCCTATAATGGGGAGGCACACGCTTGC
AGGTGATATGGGCACTGGCGTCGATTGTCGCTATAAAGTTTTCCTTGCATACACATAGTCGACCTGCCGT
CCCTGTTAGTCGGCGGCAACTCTGTACTGCATCTGGCGGCCCACACCCGTTTTCCTCACAGCCGCTTTCC
TGTCTTACAATACATGTCACGTTTCCTGTCCCGTCGAGAGATATTCTGTAGCCTTGATTACAGCGGCAAA
TGTAACCACTGTTTGTCTCGTTGCAGGTGCCGGCTGCCTCAGGTCCACAAGGGTTTGAGCTGCAAGCTGC
AGGCTTTTCCGACAGCTGTACAAAATTAGCCATGGGTACACCTGAGGGCATCATGCACGTGACCTGGTCA
TTTTCAACGCCCAGAACGTAGCCTGGTTCGCACCTGCAATCATATCCAGATGGTGTGTTTATGCACGTAC
CAGCTGCGGTGCCACCGCATGGATTCCCAGAGCAGTTGTCTGCAATCTCTCCATTCCCAGGAAGAAAGGC
AAAAAACGGGGAGCCGTTCTTCAGCCACAGTAACGATTCGGCCGCCACAACGGCCGCAGCACAGCACCGG
AAGAGCCTCATAGCAGAGACGCGCGGCAGGAAGCTTACTGGAATGTGCTCATCCAATCGAAAAAAAACAC
ATCATATATCAAAGCACAGTCGATGTCATCACGATCCCAAACGCCCACAGATGTCGAATCTCACCCTCCT
CTTGCAGCGAAGTACACAACTCAAAAAAATACGAGACCGACGACAACAGAGTACACTTCGTGCTCCCACG
AAGGTCGTGGTGGAGCTACAGTCCTCTTCAGATACGCCGTCGCATCACTGAGCATCGACACACCTCTGCC
TGTTGCAGGATCGGATCGACTGCCGCGTCGCTGACACACACTAGCGCGTTACTCCTCTCGCCGTCACACA
GAGAATTGTTGTATGGAGCTACGGAACGACCATGCAGGCTCGAATCTAGCGACACCTGGACTGTGCTTCT
TGTTGCAGCGTTTTGGGTTGCCCAGTAATCCTCCTTTAGGTGGTTACCGGAAGAGGTCCGTGACGGAAGA
TTGGGCATTGTGCGCAGCATGGCGGGAAAGCTTCGGTAACATCAGTGGCAATGCTTTTGCCTTGATGACG
CGGAAGGAAACATCTAAAGCAGACGAAACCCGTTTAATGGTAGCGGAGCTTGCGGTGCGCGTTTTCGTGG
CGGAATACTGCATCGTGCCGGTGGCAGTTCAACAGGAGCGTCTGGTGGCGGAACTGGAAAGTCGGCAAAT
CTCAAAAGAACCATTCTTAAAAAAAAGCCGTAAGGCATCAAAGTCTAATAGGACTCGGAGAAAGCCGGCA
AAACCAGACGGCGTCGTGCCATCTGGCAGGCATTTTAAACGGAAACAAAGGATGCTTACAGGACTCTGAT
GGTGGTTAAAGACCACAGTGGAGTCACTGACGAATCACGCAGCGTGTATTCACGTGATGAGGAAAGATTT
GTCAGAGGCTCAACTTGTGCGCTACCGAATGGTTGTCCAGTAGTGTTTTCTATGGAAAACAATGAATGCC
TCTCATGTCGCGCGATGTACGTACACCGGAAGTGGGCAAGTAGTTTTGGATCGGCTGCGAAAGATCATTG
GTGAATCCGCCCTACAGCTTCGTGAGACAGTCCGAGTGGTTATGTGCTGTGTCGTTTCACAAAATGACAC
GTATCAAGTTTATTGTAGGAGTGTGCTCCGGACTGGTTGCTAGTTCTAGTATGTCGGCTTTTGGCATGCT
TGACCCAGCAGCGCTACATGGAGATGCCATCGAGGGAACAAGAGATATCAGTTTGAGAGCAAAAACGATG
CTAAACTTCGCTGACAGAATATATGATAAATGCTTCAGTGTGCCAAACGCACTTTGCCTTGGTATGGCGC
TACTGAAGCAACACTGAAGACCAGCTTTAACACTGCATCCTAATCCAGGAGGAACGTCTCAAATTATAAC
TGCGAATGCAGTCCCGGAAGGTCTCAGCGCTTGGTTCACATTCGACGAGATCTACCCAGTTGACCAAACT
GGAAACGGCAATCACATGCACAGGGCACCCCGGTCTGGGCCACCTCATAACGGTACAGAAGGAAGATATT
CTGTTGAAATGCCAGAGACCACGAGACGTTTCGCGTACAGGGAAGGGCGCGAGCGCCGCTTTTGTCAATG
GTAAGAGTAGCAGCAAATCGTGGCCACCGCAACCAAAGCACCTACGATATGCTAGGAGCGAGCGGGACCA
TACGGTCAAGCTCCACTTTGGAGTCCAGCGAGTTTACAGTGTAGGGACGCAGTCAAGAATTAACCCTGCT
GCCATTTCCCCCTTCAATGGTCCCGTCGCCACAGGGCCTTCTGGATGTACCTTTTGGGCGACTCGACCGG
CTACTTTCGTAATATCATATCGAAAGGGTGCGTGTGTTACTGGGGAAAATTCCTAGGTCCTCGGTGATAA
TAATATTCGTTACAGGACTGATGCCAGCCAAACGCCCACCATACTGCTGTACCCGAAAACAAGGAAACTT
TCAATCCGCGTGACGACAACGGACAGCACCTCGGAGGGGATTCCCTCTCTTGGCGCTCTCCCGCTGAGGA
GGTGGACTCACATTGCAGGTACCCTCCTTCGGTTAGGGATTGAAGACACCAACATGCAGAAATGCATACG
GTTCAGTCACTGCCAGTGAAAGCAGATTGAAACTGTTCGTCAATGTGAGCGACTCAAACATGCAATCACT
CAGACGTAATGTCACTGTTTTCGTGTAGGGTGTCAAGGATAACGAAATTGTCAGTATCTAATGTTCTTTC
GTGCTTTCGTTTCTGAACACTGACCGGTTTTGGTCGCATTCCAGGCACTACGTGGGGTGGTCGTTTCAAA
CAGCGGAGATATTGTCGTTGGATCTACCATGGAGAACTCCGGATTCGAGGTACAGATGCTGCAGTTCGTG
GCGTCAGAAAAATCGGTGCATAATTAACGTCTCAGGGATACATTGACGAGTTGCGATTCTACAGACGTGC
CCTTCCTGTGAGTGGATAGTGTCTATTCGTGAGGTCCTTTGCAACGCAAGAAACGCTCTGCTCAGGAGGG
AGAAGTCGCCAGCCTAACCGCAGGTGGACTCACAGGAATTGCCGATACAGAGTTCGTTTTCCAAGGTGCG
TGCACTTTTGATGCTCATTAAGTGATGTCATGGATGCCTCGATTTCCTTTGCAGGCTGCGCAGGCTGTAC
ATTTGAGATGGCACTACACTTCAATATCTGCGGCGAGCCCGCTGCCCATCTTTGCTCTCTTCGAGAGCTC
TACCAGGGTGCAATCCACATCGCCAGAGTGAATGGTGAGGTCACGTAAATAGATGCGGATGACTGACACG
TACATCACTAGCTACTTCTGCCAGGTCTGCTCGCTGGTGGTCAAGATATATGGCACAGTGAGATGTCATC
CAGCGATGTCGCTGCTGGAGAAAAACGTTTGGCCCTGTGCTGTCGGGTGCCTGGATTGCCAGCTCCTCCG
CAGAGGTTGGTGGCGTCTGTTGCGTGACCCCACACAAGCTAACAGTGACGGAGGTGTTCTGAATGACAAT
TCAGTTGAGATAACTCTCCCTGCTAACGTAGAAAATAGCTGCAGTTGTAGCTTGAACCACGTATCAACCA
CTGCATGCGTTGACATTGGGCCGAGGGCACTAAGTCGTTGCCACTCTCAGTGACACAGAAACCCATGTTA
CATACTCGAGACAAAATGCCCAAACTCGTTTATCATTTCATTTGTCGAGTGAACCTGGACGACGTGCAGA
TGTGCGAAGTGACATGTACCCTTGATAGACCAACACAACACACACGAGACAGACGAGGCGTGCGACCATA
GCGAGAATGCACGGTTTGACCGGA
-
Protein Sequence : Show Sequence
>XP_018634830.1 microneme protein MIC6 [Toxoplasma gondii ME49]
MRLFRCCAAAVVAAESLLWLKNGSPFFAFLPGNGEIADNCSGNPCGGTAAGTCINTPSGYDCRCEPGYVL
GVENDQVTCMMPSGVPMANFVQLSEKPAACSSNPCGPEAAGTCNETNSGYICRCNQGYRISLDGTGNVTC
IVRQESGCEENGCGPPDAVQSCRRLTGTAGRLCVCKENFIATIDASAHITCKRVPPHYRKPPFEFGKGGH
PVDSEPSKRQREDEGESREPESDSTEPGRDQERRTPLEESQEPEGSTPDSQQSRGGSGSDSTESEEQGKE
REEGSGHAGAIAGGVIGGLLLLSAAGAGVAYMRKSGSGGGEEIEYERGIEAAEASEVEVLVDLDSKTWD
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pIRESneo/MIC6/PLP1
,
T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6
,
TgMIC1-4-6
,
TgMIC6
|
|
30. MIC8 |
-
Gene Name :
MIC8
-
NCBI Gene ID :
7899500
-
NCBI Nucleotide GI :
13346486
-
NCBI Protein GI :
13346487
-
Protein Accession :
AAK19757.1
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
microneme protein 8
-
Protein pI :
5.13
-
Protein Weight :
71329.71
-
Protein Length :
747
-
DNA Sequence : Show Sequence
>gi|13346486|gb|AF353165.1| Toxoplasma gondii microneme protein 8 (MIC8) gene, complete cds
ATGAAGGCCAATCGAATATGGTGTTTTTTTGCGTGGCGTATGGTTGTGCGGGCCTCATTTCTGAAAGAGA
TGGACAGCATTTTCGTTTCTGCTATCCGACAGAATGTACAGCATACTCATTCTGCCCTTCTCGCCAAACT
GAAGGAACCCCCAGATCCAGATGATGAGAACTCTTGGCTTTGTCGAATATCAAAAAAATATGACGCATGC
GGTAGCAGGGAATATTCCGATAAGGGCCTCAAAGGGACGTACTGTCCCGAGGATTTTTGCTGTAGCAAGA
CGGCATGTTTTTACGGTTCATGTGGGAGTTGGTGCCACGACAACTGGGCTCTGTGCAGCTCATCTATAAT
CTACCACGACGAGTACAGTTACGGGAAATGCAACTGTAAACGGTTTCAAGAAAACTGTGATGTGAATGCA
ATTTGTGTGCATGCGAACAGAGAGGATGGCGGTGCGTATTGTCAGTGCAAGGAAGGATATTGGGGTGATG
GTAAATCGTGCAAGATTGACTTCTGCCAACTGCAGCCCTGTGGTGCAGGGACCTGCACCAGGACGGATGA
AGGATACAAGTGTGATTGCCCAGAAACTCACAAGCTTATTGTCGTTGAAGACAAAGAGACGTGCAAGGCA
AAACCGGACTTTTGCGCGGAAGAGCCTTGCGGACCACCCTCTATGGTTGAAAATTGCGTGAACACCGATG
ACAGCTACGAATGTGTTTGCAAACAGGGGTATGAAGTGAGGAACGGTCGGTGCGAAGAAATTGACTTATG
CGCGGACAAGCCATGTGGGCCAGATGAGGGTGTGCATGAGTGTGTAACAGAGAGGCAACCGAAATTAAGG
TACAGATGCACGTGCAAGGCAGGATTCGATTTGACCACCTTGCCTGATGGTGTTTCCCAGAAGTGCCTGA
AGAACTTCTGTTACGAGGAGCCCTGCGGCACCCGGGACCTAGTTGAAAGCTGTAAGTCAAAGGCATATGG
ATACTCGTGTTTGTGTGCGGCAGGTGCCATGGTTCAAGTGATTAACGGAAAAGAAAAGTGCATCAAGGCG
GACTTGTGCCGCAATGATCCGTGTGGTCCAGAGACAGCAGTGATTCAATGTTACTCTCATGGCACCAGCT
ATAGGTGTTTGTGCAAAGCAGGCTACACTGAAGTTTTTGTTAACGGGAAGAGTTCATGTCAAAAGGGCGA
CCCATGCACTCTGAACATGTGTGGCGGTAACGAAGCGGTCCAGGAGTGCACAACTGATGGCACGGCGTAC
GGGTGTACCTGCAAGCCAGGCTATTCGATAGCCATTAAGCATGGTCAGAAGTTTTGCAACCCTGAAGAGG
AGTGTGCTTCTCATTGTGGCTCGGCAGCTGCAGTGAAAAGCTGTGAAATACTTGACTCTGGCGGATACCA
GTGTACATGCAATCCAGGATACGTCATGAGATACAGCGACTATGTAAAAGGATGCGTCGAGGGAAATCAG
TGTTCTCTCAATCCTTGTGGGGAGCAGGAAGCCGTGCAAAGGTGCATTCCTGAAGGTGACACGTATGATT
GCGAGTGCAATCCGGGGTTCGTCAAAAGAGTCTTGCCGGATGGGAATTTCATTTGCGCCGATCCAGCGAG
CTGTGTAGGGAATCCCTGTGGTAGCTCAGATGCGGTCGATGCGTGCATTGCCGGGACTAGCACGTATACA
TGCAGGTGTAAGGACGGATACACACCTCAGTCAATTGGGTCAAAGTTGCAGTGTTTACCAGAAAGCACTG
ATCAGACAGATTTCGATTCCAAACACAAACCAGAGGACAACAAAGGTCGATATTCGAAAGGAACAATTGC
ATTGGTGGTTGTGGGGTGTGTAGCCTTGTTGGGTATTATAGCCGGAGGAATTTCTTACGCCAGAAACAGA
GGAGGTGAGCGCGATGATGAAGACTTGGCACCACCACCTCGTTCCACACGAGAACGGAGGCTCTCATCAA
TGGGCGAAGGTTTTGAGAATGCCTCATGGGCATCTTCTGTAAGTATGATTCCTAGTGCACCTGCTCCGCC
ACCTTCGGGCGGTATCTGGTCCTAA
-
Protein Sequence : Show Sequence
>AAK19757.1 microneme protein 8 [Toxoplasma gondii]
MKANRIWCFFAWRMVVRASFLKEMDSIFVSAIRQNVQHTHSALLAKLKEPPDPDDENSWLCRISKKYDAC
GSREYSDKGLKGTYCPEDFCCSKTACFYGSCGSWCHDNWALCSSSIIYHDEYSYGKCNCKRFQENCDVNA
ICVHANREDGGAYCQCKEGYWGDGKSCKIDFCQLQPCGAGTCTRTDEGYKCDCPETHKLIVVEDKETCKA
KPDFCAEEPCGPPSMVENCVNTDDSYECVCKQGYEVRNGRCEEIDLCADKPCGPDEGVHECVTERQPKLR
YRCTCKAGFDLTTLPDGVSQKCLKNFCYEEPCGTRDLVESCKSKAYGYSCLCAAGAMVQVINGKEKCIKA
DLCRNDPCGPETAVIQCYSHGTSYRCLCKAGYTEVFVNGKSSCQKGDPCTLNMCGGNEAVQECTTDGTAY
GCTCKPGYSIAIKHGQKFCNPEEECASHCGSAAAVKSCEILDSGGYQCTCNPGYVMRYSDYVKGCVEGNQ
CSLNPCGEQEAVQRCIPEGDTYDCECNPGFVKRVLPDGNFICADPASCVGNPCGSSDAVDACIAGTSTYT
CRCKDGYTPQSIGSKLQCLPESTDQTDFDSKHKPEDNKGRYSKGTIALVVVGCVALLGIIAGGISYARNR
GGERDDEDLAPPPRSTRERRLSSMGEGFENASWASSVSMIPSAPAPPPSGGIWS
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
The gene sequence encoding MIC8 was inserted into the eukaryotic expression vector pVAX I, and the pVAX-MIC8 expression plasmid was constructed, and the plasmid diluted with PBS to 100 mg/100 microl was injected into the Kunming mice muscularly. Levels of IgG antibody, gamma-interferon (IFN-gamma), interleukin-2 (IL-2), interleukin-4, and interleukin-10 were detected. The mice were challenged with tachyzoites of the virulent T. gondii RH strain at the 14th day after the last immunization to observe the survival time. The high level of IFN-gamma, IL-2, and IgG antibody indicated that mice vaccinated with recombinant pVAX-MIC8 plasmid could elicit strong cellular and humoral immune responses and showed a significantly increased survival time (10.3 +/- 0.9 days) compared with control mice which died within 5 days of challenge infection (Liu et al., 2010).
- Related Vaccine(s):
T. gondii DNA vaccine encoding MIC8
|
|
31. OMPDC |
-
Gene Name :
OMPDC
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7899615
-
NCBI Protein GI :
237831731
-
Locus Tag :
TGME49_059690
-
Genbank Accession :
DS984728
-
Protein Accession :
XP_002365163
-
Taxonomy ID :
508771
-
Gene Starting Position :
2298541
-
Gene Ending Position :
2301456
-
Gene Strand (Orientation) :
+
-
Protein pI :
4.79
-
Protein Weight :
31611.79
-
Protein Length :
320
-
DNA Sequence : Show Sequence
>gi|212659390:2298541-2301456 Toxoplasma gondii ME49 scf_1112359874900, whole genome shotgun sequence
GATGCCGGCAGACGCGCTGCGTGAGAAGCCGGTTGTCCAGGCTGCTGTGAATACCTCGGAAGGGTGCAAG
AACTTCTTCAAGACATTGGATGCAAGGATCGAAGCGGTAGATTCCTTGCTCACAGTCGGCCTTGATCCGC
ACATCGCGGACCTCCCGTCGCCAGCCACAGCTGAGCGTGCCTTTGTATTTTGTGAACGCATCATCAGGGA
AACTCTTCCTTTTACGTGTTGTTACAAACCGAACAGCGCGTTTTTTGAGGCATTTGGTCCCCCGGGTTTG
CAGGTACGTATTTCAATGTGAGGATGGAGCATGGTTGTCATGGCCAGATATACTTTAGCCCGACAACGTT
ACCAGGCATTTGGAGTACCTCCAACTCCTCAGTTGCAAAGATACACTGCACATGCTCGTGTAGTACCGCT
GAGAGACAGAACCACTTGAAACGTCATCTTTCATTAGTATGAAGCGGTTGTCCGAAGTTCGGCCATCATT
CTGGAATCTATCAGTCCTATGTTTCCTCACTGCCTAGGTACTGTTTTCCTGTTTGTGTATATCCCGAAAA
ACTGTATTGAAAGCAAGCAGTGGGGATAGCGGTGAAGCAGGGGGTTGGTGAAGCGGTTTCGGAGGGGACA
GGGAAATACCTTCAATTTTTGAAAGGCGCAGTTCCCTGTTCCTTCGCAGTCACCACGGACAGACTAGAGA
TATGTCTGTTCTGTACGCGCCTTACCAAGACCCGAACCGCGTACAGGGTGCAAACCTTTCGCGCCATAAT
CGAATGCCGCTTGTCGCCACGTGTAGGCACTCGAGAGAGTCTGCGCGCTGATTCCCGACGATGTTCCTAT
TCTTCTAGACGCCAAAAGAGGGGACATAGGATCGACGGCGCAAGCCTACGCATCTTCGGCTTTTGACGCG
TTCAAGGTATGGAACTTCGAGCCCTAAGAGGTTGAAGAGAGTACGTAGAACCATGTTTATTTCATTAACA
TCGAGTCGGTTCTGTATACATACGCGTGCTGCTGCAGTGAATGTATTACAAGATATCTCGTATGCATGCG
CCCGACGAGAATATCGCCAATATCATAGCCTTATGACGTGCGCGATTCGTCTGGTGGCAAATCTGCGGTC
TACAAGTGATCTATTGTCAGCGCATGGCAGTAACGATCTCATCCATTTATGCGGGTGACGCATTACATCG
TGTCTTTTGTCAAAAATGTGCTGCTTGATGTCGCGCAGGCGGACGGTGTCACCGTCAACGCCTACATGGG
CAGAGAAGCAGTTCGACCGTTTCTGTCGTATCGAAACAAAGGCGTATTTGTACTTGTGAAGACGTCGAAT
CAATCGTCCAACGAGTTTCAGACCCTGCCAGTGAGGGTGGAGTCAAGCTCCGACACTCAGGATGTCCCGC
TGTATGTACAGATGGCCAGAGTTTGCAACGAACTTGCCCAAGGTGAGAGTGGGTCCGTCAGCTTCGTTAG
ACCAGCTTCTCTTCCGTTGTATTTGTCTTTTGTGAGCGACCCGTGTCGCCAGAGCTTCATGCTTAGCTAC
ACCGCTCGGCAGAACTGGCATCTCTCTCGCTCCAGGAGTGTGATCCGCGTTTCCAGTTTTTGGTTGATAA
GTCGCACCCCAGAGGAGAAAAATCCTCAGCACCTGCCATACAGATTCAACGGAGTCTCAGGCAGCTTTTT
ACTCCGAGCCCGCACTTGCCCGACCTGCCATTTTCGTTTACACAGAGCCACTTTCTGCGGGGCGGTGGCG
ACAAAAACCGCGAGCTTTGTAGTAAATGAAACCACGTCGTGAGAAGTAGTCCAGTTCTCCCTTCGAACAC
TACGTTGCCTGCTACATATCTGTGCCTCATCGTCGAGTGCCGCTGTCCGTGTCTTGCTCCACTTTGTCAA
TCCGAACTCAGAATGCGTTTCTGAGGAAGACTCTCCATCCACGACTGGACATGGCCTCCGTCATAATGCG
TCGGGCGGTGGTGTCGGACTCGTAGTAGGAGCAACAGATATAGAAGCTCTTCGCGAGGTGCGAAAGGCAT
GCCCGGACCTTTATATTCTTGCTCCCGGAGTCGGTGCCCAAGGAGCGGACCTCGAGAGGGCCTTGAGTGC
CGGTAAGCATGGAGCTGGGTCTCAGTTGAGAGCGAAGTTACACAATTGAATCTGACATTGAGGTTGATTT
GATTGTCGCTTGAGGCGCCTGTGACCCTAATGATCCCGAAACGCAGGAACCATAGAAGCAACGGAGGGAG
ACGGAACCTTGCTGTTTTAGGTCATTGTGCGCTAAACGTGGTTTCTGGTACACCGTGCAAGATCGTATAC
TCACGGGTATGATCGCAGTGAAAATGCTCCTAAGAGCGAAGAAATAAGGTACCACATTTTCAACACCTCT
ACGGTTTTTCCTGTTACTTGGGACTCGTTGCTCTGCCAGGTCTCTGCAAGGACGGCAAAGGGATGCTTAT
TCCCGTCTCTCGTGGCATATCACGAGCGGAGGTAAGGGCAGGTTGTCTTGACACTTGTAGCCCGTAGTTT
TTGAAAATCCAGCACACCGCATAGAACCTTGGTGACAGAGATGCGTGCGTCACTCGAACGAATATTCCGA
TGACGGCGAAGTTGACTGAAGTATTTCTGTTTTCAGCAGTATATTTTTCAGCGTTTGTATGGCCCCAGGA
TGGATGCAAAACCAACCGACTGCGCCCTTCGCTCAGATGTGCGGAATCCACCGGATCCATGCAATAGAAA
ATAGATTTCAGATGACACGGATTTGAGATGAAATCACCCGTTCATAGTACAGCTGTTTGCGTCCACTTTG
TCCGTCCTCCCTGTTCCGTTCCCTTCATTGCAGAATTTAGCTGCCCAAGCTAACGCATACAGAGAACAGA
TCAATGAAGTCAGAAGAGGCATTGTCCAGCAGTACGAGGAAAGCTG
-
Protein Sequence : Show Sequence
>gi|237831731|ref|XP_002365163.1| orotidine-monophosphate-decarboxylase, putative [Toxoplasma gondii ME49]
MPADALREKPVVQAAVNTSEGCKNFFKTLDARIEAVDSLLTVGLDPHIADLPSPATAERAFVFCERIIRE
TLPFTCCYKPNSAFFEAFGPPGLQALERVCALIPDDVPILLDAKRGDIGSTAQAYASSAFDAFKADGVTV
NAYMGREAVRPFLSYRNKGVFVLVKTSNQSSNEFQTLPVRVESSSDTQDVPLYVQMARVCNELAQECVSE
EDSPSTTGHGLRHNASGGGVGLVVGATDIEALREVRKACPDLYILAPGVGAQGADLERALSAGLCKDGKG
MLIPVSRGISRAENLAAQANAYREQINEVRRGIVQQYEES
-
Molecule Role :
Virmugen
-
Molecule Role Annotation :
An OMPDC mutant, alone or in combination with an UP mutation, is attenuated in mice and induces significant protection from challenge with wild type T. gondii (Fox and Bzik, 2010).
- Related Vaccine(s):
T. gondii OMPDC mutant vaccine
,
T. gondii OMPDC/UP mutant vaccine
|
|
32. p30 |
-
Gene Name :
p30
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Nucleotide GI :
894214
-
NCBI Protein GI :
894215
-
Protein Accession :
AAB33440.1
-
Other Database IDs :
CDD:332018
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
p30 antigen
-
Protein pI :
8.08
-
Protein Weight :
32194.82
-
Protein Length :
386
-
Protein Note :
SRS domain; cl27197
-
DNA Sequence : Show Sequence
>gi|894214|gb|S76248.1| p30=p30 antigen [Toxoplasma gondii, RH, Genomic, 1634 nt]
CGCGTGTTCTAACCACAAACCTTGAGACGCGTGTTCCAACCACGCACCCTGACACGCGTGTTCCAACCAC
GCACCCTGAGACGCGTGTTCTAACCACGCACCCTGAGACGCGTGTTCTAACCACGCACCCTGAGACGCGT
GTTCTGCCGCACAATGTGCACCTGTAGGAAGCTGTAGTCACTGCTGATTCTCACTGTTCTCGGCAAGGGC
CGACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGTTGTGCAGCTTTCCGTTCTTCTCGGTTGTGTCACA
TGTGTCATTGTCGTGTAAACACACGGTTGTATGTCGGTTTCGCTGCACCACTTCATTATTTCTTCTGGTT
TTTTGACGAGTATGTTTCCGAAGGCAGTGAGACGCGCCGTCACGGCAGGGGTGTTTGCCGCGCCCACACT
GATGTCGTTCTTGCGATGTGGCGTTATGGCATCGGATCCCCCTCTTGTTGCCAATCAAGTTGTCACCTGC
CCAGATAAAAAATCGACAGCCGCGGTCATTCTCACACCGACGGAGAACCACTTCACTCTCAAGTGCCCTA
AAACAGCGCTCACAGAGCCTCCCACTCTTGCGTACTCACCCAACAGGCAAATCTGCCCAGCGGGTACTAC
AAGTAGCTGTACATCAAAGGCTGTAACATTGAGCTCCTTGATTCCTGAAGCAGAAGATAGCTGGTGGACG
GGGGATTCTGCTAGTCTCGACACGGCAGGCATCAAACTCACAGTTCCAATCGAGAAGTTCCCCGTGACAA
CGCAGACGTTTGTGGTCGGTTGCATCAAGGGAGACGACGCACAGAGTTGTATGGTCACGGTGACAGTACA
AGCCAGAGCCTCATCGGTCGTCAATAATGTCGCAAGGTGCTCCTACGGTGCAGACAGCACTCTTGGTCCT
GTCAAGTTGTCTGCGGAAGGACCCACTACAATGACCCTCGTGTGCGGGAAAGATGGAGTCAAAGTTCCTC
AAGACAACAATCAGTACTGTTCCGGGACGACGCTGACTGGTTGCAACGAGAAATCGTTCAAAGATATTTT
GCCAAAATTAACTGAGAACCCGTGGCAGGGTAACGCTTCGAGTGATAAGGGTGCCACGCTAACGATCAAG
AAGGAAGCATTTCCAGCCGAGTCAAAAAGCGTCATTATTGGATGCACAGGGGGATCGCCTGAGAAGCATC
ACTGTACCGTGAAACTGGAGTTTGCCGGGGCTGCAGGGTCAGCAAAATCGGCTGCGGGAACAGCCAGTCA
CGTTTCCATTTTTGCCATGGTGATCGGACTTATTGGCTCTATCGCAGCTTGTGTCGCGTGAGTGATCACC
GTTGTGCTCACTTCTCAAATCGACAAAGGAAACACACTTCGTGCAGCATGTGCCCCATTATAAAGAAACT
GAGTTGTTCCGCTGTGGCTTGCAGGTGTCACATCCACAAAAACCGGCCGACTCTAAATAGGAGTGTTTCG
CAGCAAGCAGCGAAAGTTTATGACTGGGTCCGAATCTCTGAACGGATGTGTGGCGGACCTGGCTGATGTT
GATCGCCGTCGACACACGCGCCACATGGGTCAATACACAAGACAGCTATCAGTTGTTTTAGTCGAACCGG
TTAACACAATTCTTGCCCCCCCGA
-
Protein Sequence : Show Sequence
>AAB33440.1 p30 antigen [Toxoplasma gondii]
MSVSLHHFIISSGFLTSMFPKAVRRAVTAGVFAAPTLMSFLRCGVMASDPPLVANQVVTCPDKKSTAAVI
LTPTENHFTLKCPKTALTEPPTLAYSPNRQICPAGTTSSCTSKAVTLSSLIPEAEDSWWTGDSASLDTAG
IKLTVPIEKFPVTTQTFVVGCIKGDDAQSCMVTVTVQARASSVVNNVARCSYGADSTLGPVKLSAEGPTT
MTLVCGKDGVKVPQDNNQYCSGTTLTGCNEKSFKDILPKLTENPWQGNASSDKGATLTIKKEAFPAESKS
VIIGCTGGSPEKHHCTVKLEFAGAAGSAKSAAGTASHVSIFAMVIGLIGSIAACVA
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2
,
T. gondii DNA vaccine pSAG1-ROP2-SAG2
|
|
33. PGAM2 |
-
Gene Name :
PGAM2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7898971
-
NCBI Protein GI :
1084907167
-
Locus Tag :
TGME49_297060
-
Genbank Accession :
CM002036
-
Protein Accession :
XP_002371136
-
Taxonomy ID :
508771
-
Chromosome No :
II
-
Gene Starting Position :
1510430
-
Gene Ending Position :
1514514
-
Gene Strand (Orientation) :
-
-
Protein pI :
8.41
-
Protein Weight :
35579.75
-
Protein Length :
339
-
DNA Sequence : Show Sequence
>NC_031469.1:1510430-1514514 Toxoplasma gondii ME49 chromosome II, whole genome shotgun sequence
ATAACCTGACAAAACTTTTACGGTGAAGGGGTTTGTGTTATTGTCGGGCAAAGCGGGTTTCTTAAGTACC
CGACTAGGCCGCACGCCCGAACGAATTACGAATACCACAACAGATGGGCACCACTCGCGTTTCAGTCACG
TGACTAGCCCCAAACCTGATCGATGTGTGAGAATGTGCATGCGGCTTTCTTATGACGGGGCTGTTTACTT
GGCCTTTCCTTGGTTGGCGACAGCCTCCATCTTTGCCTTCAATTCCGCCTCGTCCAGGAGATAGTAGTGT
CTCACTGGCTGCAGGTCTTCATCGAGTTCGTAAACAAGCGGTACGCCTGTGGGGATGTTCAGCTCGAGAA
CAGCTTCATCGCTCATCTTATCGAGGTGCTTAACGAGACCCCGAAGAGAGTTACCGTGGGCTACAAAGTA
AAAAAAGACAGCGACAGAAAAAGCGGACCATTACAAAACACAAATCAGAGCAATGGGCCAGGGGTCAGGC
AGTTCTGAAGTGCGAAAGCACAAGACATTTACGTAGATATTCCGACGTAATGAAGGCAACTAAGCGGCAA
CTGAAGGCGGAAACTAGTAGAGCAAACAACGCTCGGAAAATGACTTCCACAGATGCTAAACGAAAGTTTT
CTGCCTCCGCTTCTAACGGGCTGCTCCATCTGGCAGACTTCCGTTACCCTATCATAAAGAAGACAGACAT
TGTTACCTAATTCGGATATGTATCATTTCTAGCCTAGTGCCTTGCAGGAAGCGGAAAGAATGCAGACTCG
GAATGAGCCTTACCAGCAACAAGAACCCTCTTGCCTTCCATGATGGACGGGGCGATGTGGTCGAACCAGA
ACGGCAGGACTGCAGTACAGAGAGCAAGATAAATACGAAGAAACATCTCGAGTCCTGTTGTATAAGCTGG
GGCTGAGACGAGGCAGTGACACGTAACGGAAATCTGAATGCACCGGCAACATGAGCTGTAGCTTGCTACC
TTAAAGCGGAAGCCAATACCGCAAGAACACGCCCGAGAGAACTGAACAGGTACACATTGTTTACCTCGCT
CGACGGTGTCCTTGAGACACTCTGTCAGGGGCAAGGCCTCATTGGGGACCATCTTGTAGACGGCGTCATT
GCCAGGCCATCTGCATAAGAGCGCACGACAAACTTGTTACTCATAAATGCACCAACAGCACGAATTATCA
ACACGGATTAACAAAGTCGCCCCACTCGCCCCGCGCCGAGTAAACCGAGGCAGAAAACACTCGTAGCCTA
GTAAGATGAAGAGGTGTGTCGACACGACCAAAAGACGCACAGATCGGTCGCCAAGCGGCACAGAACCAAG
GAAACGGAAAATCCCTCACTACACAAATGCAATAGGGATCGATACCGGCAGGAAGTATAAAGGGACACGA
CCAGTTACAAGAGAGAGGATCTGTCATGGCATGCTCAACAACGTAGAGGACCGCACATCCGTTTGGGTTG
TCTAAAACTGTGTCAAGCAAAGTGTGGCACGAGCTACAACATACGGAATCAACATGAATGCAACTATTGA
GAAATTTCCACGCTTGACGCGGCCGTAAGGTACGCGAGGGATAACAGGTCAGATAATATTCGGAGTTCTA
ATCCTCGGATTGTATCAGCACCTGCGTGTTGACTCATTACTCCCTTACTGGAAAACAATCGGTTAGGAAC
GGTATTTCCCCGTCAGATGTAATACGTGAGCTGGGATAAGAACGTCTGGAGACAGTTGACGCACTAGAGA
CGAAAGTTCGCTACATGCCCAAACTTGTTACATGGAAGCAATTTCCGGTTACCTTACCTCTTGTCAGACT
TCTCCAGAGGGGGGGGAGGGATGTCATAGGAGCGACGCCAAATCTTGACTTGCTCATCTCCGTGCTTGGC
TGCGGTCTCAGCCTTGTTGAGGCCCTGGAGGGCGCCGTAGTGACGCTCGTTCAGTCTGTAAATTGCACCA
CAAAGGAACATAGTTCAAAAACATGGAATCCTTGGAAATGAACGTTATCTGCACCCGCGTGTGTGTGACT
CTGTGCATCCATTTGTCTGGTTATGCATAAAACCTTGTTTGCACCGGTGCTAAATGCCGCCTGTCTCGTT
GAGAAAGTGAGTACTCTGGCGAGACAGACAGTCGTTTAGAGAGGTAGACGCACAGCTTACCTCCATGAGC
TCTTCACAGGGATGTGGCACATATCAGTCCCTTTCAGGACGGTCCAGCAGGTGACGACGGCTCTGCACAC
CCACACCAGCAAGAAAAAAGGCACGCATGGCTATTTTCCGACAGGAGGCGGATTTCCAAAAGGCGGCTCA
GCGAAATGAGGCCGTGTATTGTAAACAAAATGGACTAAAATTTGAATGCCTTTGTTTTTTCTTACAAGAC
GCTTTTGATATGACAAAACATTCCTCTAGGGTCACCATGCATCGCAAACTGGTGTATATATACCTGCACA
ACGTAAGTGTGCGAACATATTGGATCTGGTCTTGGAAAGACGATCTGAGAGTCCACTGAGAAACCTGCCC
ACGCGTGAAAAACGCAACGGCACAAACTCTCTCAAGTTCCCCTTCGACAGAATCCTTCCACAAAAAACTG
GGTCCCTCGTCGGCGCGACAAAGTAGTAAAATTTTGGGCTACCAGAGGGTAGTACGGAACTGCAACCACA
AGCACCCCTCGCATTCACTTGAGCAAAAGCCGACATCTTCCGGCAAAGGAAAGAACACCTATACCGGTGA
ATTTCCGTGATCTGCTTACATACACCGGCTGTGAAAACACGGGGCGTCCGCTACGACACATGGCAATGCC
GCGTCAGCCGTTCCTCTGCCTTACCTCTGAAGCACGGAAGTGTAGGCGACGTCAAACTCGAAACCCTTTT
CCTTGAGAGCCTTTGCAGCTTCCCTGTTACAGAAGAAAACCCAGATCAACAGCAATCGTGAACGTGGGAA
ATTTTGCGGTGAAGAGGAACACGGCAACAAAACACCCGCGAACACAGGTCACAGAGATATCAAACGGCAC
CCATAGAAAACACAGATCCGTACTTCAGTTACCAGTGTTATTCTTGTGGAAAAGAGGAGCGGAAAAAAGG
CAACTACACGCAACTCCAGTTGCGATATACTAGGGGGACAGAAGATATAAAAGAGGAGGATTACATCCTC
TTGCACGCCGCCTAGGAACATACGGGGAGAAGTTTGCGTTCGCCGATTCACGAGGTCCGGTTGGTTTGCT
TCTCCTTCTACCTACCCCGCTATCGTAGCTGCACCAGCTACCTGTCACCAGACAAACTAATCCAAGAGAC
TTACACGGCCTCTTGCTCGCCGACAGGGGACAACGGCACATCGGTCCAGCCGGTGAACCTGTTCTCCTTG
TTCCACGTCGATTCGCCTGGAAAGGGAGAACACACACAAATGCTTGCATTCTCACGTACAACTTCGCTCC
AGAATGAGTAAGCTGCCGGTGAACAATAGCAGAGTCCCTCGTGCTTCCTACCGCGCTCCCCATTAACTGT
CTTTCCCGTGGCAGACACTGCAGTCCCGTATCGTCGACAGTTCCCTGAGCCACGGGGTTGCCATTTTGGT
GCTGCCACAGCTCGAACTCGAGAGGCACATAACGGGTGAAGTCGACATCTTCCACGGAGAAATAAACTTT
TTTTGACACTGTAATGGTAGCGTGTCACTATTGGAAGAGAAAAACAGCGTTCTTCCAGTGGAAATCAAGG
GGACGACGCAGACGGCCGCTCGTCTACAGAGAAGCACCGCAACTACCACTCTTGTGCAAATAGTGTGGCG
CGTACCGTGGCGGATGAGGACAAGAGTGTACTTTGCTTTTGCCATATTGCCGAAAAAACGACGAAAAGTT
GAAGCAGGAAACATGTAATGTACGTTGCCGTGAGAAAAAGAAAGATCTGAAGACAAAAAAGGCGACGTCA
GAACTGGGGAGAGATGACAGGATGCGCCACACAAATGCCGGTGCCGGGTTCTCCCCTGTTTGGGGGTGTG
CGGGGGTAGTGTGTGCCCGGAACAAACTCCAGCACATTGCCTGCTTCTTTCACAGCATGTCCGGCGTGTA
GGGTCGCAAGAAGATGGCCACCCCA
-
Protein Sequence : Show Sequence
>XP_002371136.2 phosphoglycerate mutase PGMII [Toxoplasma gondii ME49]
MGWPSSCDPTRRTCCERSRQCAGVCSGHTLPPHTPKQGRTRHRHLCGASCHLSPVLTSPFLSSDLSFSHG
NVHYMFPASTFRRFFGNMAKAKYTLVLIRHGESTWNKENRFTGWTDVPLSPVGEQEAVEAAKALKEKGFE
FDVAYTSVLQRAVVTCWTVLKGTDMCHIPVKSSWRLNERHYGALQGLNKAETAAKHGDEQVKIWRRSYDI
PPPPLEKSDKRWPGNDAVYKMVPNEALPLTECLKDTVERVLPFWFDHIAPSIMEGKRVLVAAHGNSLRGL
VKHLDKMSDEAVLELNIPTGVPLVYELDEDLQPVRHYYLLDEAELKAKMEAVANQGKAK
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
rTgPGAM 2
|
|
34. PI1 |
-
Gene Name :
PI1
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7901030
-
NCBI Protein GI :
ADJ17341
-
Other Database IDs :
CDD:238052
-
Taxonomy ID :
5811
-
Protein Name :
serine protease inhibitor 1 isoform beta
-
Protein pI :
4.61
-
Protein Weight :
30858.24
-
Protein Length :
373
-
Protein Note :
Kazal type serine protease inhibitors and follistatin-like domains. Kazal inhibitors inhibit serine proteases, such as, trypsin, chyomotrypsin, avian ovomucoids, and elastases. The inhibitory domain has one reactive site peptide bond, which serves the...; cd00104
-
Protein Sequence : Show Sequence
>ADJ17341.1 serine protease inhibitor 1 isoform beta [Toxoplasma gondii]
MGKNPLLFLAGVLVCSFSVAVFASPETKVCSCPRNLELNCGGDHVTYANHCIRECHGVGLLHDGPCADQE
DQGSSVNEPSEVADTTEQPSITPSGEEDRPPKDAPKERKRLRGCACTRELRLNCGVDGVTYSNHCVRKCE
RVKLLHEGPCRGGPGRTLFSQQDDESENDALEEEEQRLQSCPCPLNLMLNCGVDGVTYDNHCLRRCRRVE
LKHEGPCEADEQKQLPVQHGDNEIDVPERRIEDLKDCACPLILTPNCGTDRKTYPNNCVRECAGVKLLHE
GPCEGDTEEIWDDQ
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
(Picchio et al., 2018)
|
|
35. PLP1 |
-
Gene Name :
PLP1
-
NCBI Gene ID :
7894496
-
NCBI Protein GI :
EPT30053.1
-
Other Database IDs :
CDD:240433
-
Taxonomy ID :
508771
-
Gene Strand (Orientation) :
?
-
Protein Name :
perforin-like protein PLP1
-
Protein pI :
6.18
-
Protein Weight :
118563.51
-
Protein Length :
1243
-
Protein Note :
membrane-attack complex/perforin (MACPF) Superfamily; Provisional
-
Protein Sequence : Show Sequence
>EPT30053.1 perforin-like protein PLP1 [Toxoplasma gondii ME49]
MFVVDLSLSGNMRSLTHGKSIHRSSIVVVTHCSHRLSLSPLNRPALFPSHSDRYTVPWRCRPSSWRLWIT
FVCLSTLHMFGLSSAVKRDGEVPTANLRASLSPDSSKENAMLLSAIGGIGPTESRLQHIPFSTTRYLPIR
SHVLQSTVERIESPEALNEVPTKVERNEFTEKGDKTEQVLTAQADHKSLLEGRSESTSTAPDDDFDFLFE
DDTPKKPKSRVNKGTSSDETSPGDRSSGEGSSDSDSLLSVVHRTKGNATQANKNQTRITHPKSKAQHQKK
VTKKQGIPGSDSLGTSSADFDFDIDSSSNTQADDSQRQSLGDSSALDLFGSDTGDTGDIFGFSNSSSDGG
NAAANDGGLFSSSGMGPTGASDETSANPLGSILGGVLNPFAQQQSITPMTDKADEWSKENMKAFEEKMPK
KMRDDGSPDSWYKQAVPQESVADLNRMRENRRIAEENRAAAPLSAVYTKATKTVPAINYLGAGYDHVRGN
PVGDPSSMGDPGIRPPVLRFTYAQNEDGVSNDLTVLQPLGGYVRQYVACRQSETISELSNLSDYQNELSV
DASLQGGDPIGLNSFSASTGYRDFAKEVSKKDTRTYMLKNYCMRYEAGVAQSNHFKWNVTIAFAAGVSQL
PDVFDAHNPECACSAEQWRQDQNAEACTKTNVPIWISFIEQFGTHFLVRLFAGGKMTYQVTAKRSEVEKM
RNMGIDVKTQLKMQLGGVSGGAGQGTSSKKNQSSSEYQMNVQKETLVIGGRPPGNVSDPAALAAWADTVE
ELPMPVKFEVQPLYHLLPVEKQEAFKQAVTFYSKSVGLTPQDLSALTGVTRNLPKQLTQATQVAWSGPPP
GFAKCPEGQVVILGFAMHLNFKEPGTDNFRIISCPPGREKCDGVGTASSETDEGRIYILCGEEPINEIQQ
VVAESPAHAGASVLEASCPDETVVVGGFGISVRGGSDGLDSFSIESCTTGQTICTKAPTRGSEKNFLWMM
CVDKQYPGLRELVNVAELGSHGNANKRAVNSDGNVDVKCPANSSIVLGYVMEAHTNLQFVRDKFLQCPEN
ASECKMTGKGVDHGMLWLFDRHALFGWIICKTVNEPAMHVATDVGKAKGNGKKRKGKKGKNKTNAPNEVE
EGQQLGADSPSQVSVPADADSGPTSKTMSSLKLAPVKLLDL
-
Molecule Role :
Protective antigen
|
|
36. ROP16 |
-
Gene Name :
ROP16
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7894782
-
NCBI Protein GI :
237832151
-
Locus Tag :
TGME49_262730
-
Genbank Accession :
CM002042
-
Protein Accession :
XP_002365373
-
Taxonomy ID :
508771
-
Chromosome No :
VIIb
-
Gene Starting Position :
1053319
-
Gene Ending Position :
1056332
-
Gene Strand (Orientation) :
-
-
Protein pI :
9.07
-
Protein Weight :
71254.93
-
Protein Length :
707
-
DNA Sequence : Show Sequence
>NC_031475.1:1053319-1056332 Toxoplasma gondii ME49 chromosome VIIb, whole genome shotgun sequence
AAATGAACACGAGCTGTTTCCCATGTCTCTTAAGGTGTGCGTCAATTTTTATAAGGGCCGCCCGCAGGTA
TCGGGACCAACTTACACTTCACCTTGTGCTTCATATGAATTCATTTAGCGGACACTACAAATATATACTG
GCAACTTTCCACACCTTTTCGGAGTCTCTTACGCCGTATAGGCGCAAGTACAATTGTCCGCTTCTTGGCG
TTGGTCGTCGTCAACTTCTAGACGTTCCACGTCAACTAACGGCATTGATTCAACAAAGATTCCAAGTCCC
AAAACAATTCATGGGCGCATAGTCAAGTGCTGTACAATTATGGAGTCTATTTGAGGGCCACCGTACCAGA
TGGTGAAATTCACCTTACATAAGATGTCAATGTACTGTAATCGTGACAGGAACATGCGCCGTACATTTTC
CAAACGCATAATACACGCGACCGCATGCAGTAACCTTTCAACCGTTTGGCAATAGAAGGACGAAGAAAGC
GTGGCCGTTTCGTTGCGATATGTCAACGGGACCTAGCTTCCTACTCAGGGATAACTCAAAAGCGGTAACA
TCCTCGGCCCAAGCATCTTGCTACCCCTAGCCTCTCAACCAGTTCCATAAGAAGAGGAAGGAAACACAAC
CTCTTCACACACGAATTCAAGAACTGTACCGGACTAGAAAGGTAGCACAATATCAAAATAACCCTTTCCC
GCCGAAACGTGGCACAGCGACCAAGGCTTCGTACTCAAAATCGGAGGCCTTCTTAGTTGCGGATGAAACC
GTGCCTTCTTTGATTTTCATCCGTGCGTCGCCTTCGAGATCGGTTGATAGACCGTTTCATGAACATGCTG
AAAACCATATACGCGCACAAAAAAATGGTGTTAAGGTGGGAACCTTACACCCTACATCCGATGTGAAGAA
AGTTCGGTAGTTGGAATCCTAGTGAGATGAGAAGTAACTCCAGGGGCTTGCCGAAAGAAGGTGTAACTGC
TGACGAATTTCGGGAGTTCAGGGCGCTCTTCAGGATTTGGATTTAGAAATTGAGCAACAATTCCCATCAC
TGCTGGATCAGATTCGTTACAATCCTTGGCAGAGAAATCTGAGAGGCGAAGGCGCGAAAGGTGTTCAACT
CTCGACCAGAGTGAACTCGGCAGATTCGAAAGGCTGTAAGGAAGTCGGTTGAAGCAGACGAACTCGAAGA
TTGCCAACCCTAAGGCCCACACATCGAGAGCGCCACGCTTCAGACATGTCTGCTGCGACGTGTGCTGTGA
TTTCGCAAGTTCAGGAGCCCACAAACGCAGGTAATATTTATCTTCCTCGCTTACACAGCTGTCAACAGGC
CGCACACTGCCCATGTCAAGCATATGCCCAAAGCCGTGGACATCGATCATCATGTTGTTCAATTTAACAT
CTCCATGCGCGAATCCAAGTTCGTGAAGCTTGGCCAATGCAATAATTGCTTCCCTTGCCACAGCTCGCTG
GAAGAGAAATGGTGGTTGCGACTGGACTAGACTGTTCGATGGGGAGCCATCAATTAATGGCAGCAGCATG
ACTTCTTTAGACACGACAACGAGTCGAGAACCTCGACGTACCACGGTTGCTTTGTTCTCAGGAAGCGTTA
AAGTCATTTGGCACAATGGTAGACCGTATTGCTCCGCAGTCTCTGTAAGTGTGAGCCCTTTAGCCACCAG
CTTATCCCGAACATCCAACTCCTGTCGAATTGTCTTTACCAACTCCGCCCTAGCTGAGGAAATTTCCGCC
TCCAGTTCTGCTGACGTGGCATCAGCATTCGGGACGATCTGGCTGTACGGCACCTTCGCTGCATACAACG
TCCCATCGTCTAAGCTGGCCTTGATGACAGCCCCGAAATGTCCACTGCCGAGGTGCCCACGATTGTATAG
AGCGATCGGCACTCCGTTGGCATTTATCATCATGACACGCTCATTTGGAGGGAACACTTCGTCAACAGCT
GACTCCACCGCTCCTGGAGGTTGCTTTCTCTTCCGCTTACGGGTAGCAACCCTCTGTTCTGAGAGGACCG
CCTCTTGCAGAACAGCCCGCATTGCCTCATAGTCCGGAACCGCTACGAGAAGCTGTGCGGCAGCTGCTTT
CAGCTGCTGAACTTCTTCCAGACCCTCTTCTGAAAGTCGAACGCGCCGGATGCGTTCTGAACGTTTCACA
TGAGGAGTTTGTACTGCTACATAACTAGAAACACTGGAGGCAAGCTGCGAGGCGCCGCTATCCGCTGGAT
TTTCGGTCGACATCGCAATCTGTCTTTGAGGGGATCCCCGACGCTCTTGTGCCGGAGACTGTATTCCTGA
ATCCAATGTAGCGCTCTGAACAGGGAAAAGAGGATTTTCTTGACCAAGCGACGCAGGCGTTGGCACCGCC
TTTCCTGACAATGCACTCGAGCTTGCGCCACTGACGTATCGCTTTGGCGAGGACGCAAGACTGCTCGCTG
CGCCATACTGTTCTTGTGGCTCTTGAAATTCGGTAACGACCACCCCAGATAGAGATGGCTTTCGTTGTGT
CAATGGTTGCGGCGGAGAACTCCATGGCGTAAATATTGACTCTGTTGGAAACCATCCTCCCGGTCCGCTG
CTGCGTGGTGGAAGATGCGAGGGTGAAAGCTGGGTTTGGTAGCCCCTTAGCGAGGCTGAGCTAGTCGCCG
GATAAGCAGATTGGGGGGAAGGACTCCTCCGCTCCTCTCTAGCACCCGCGCTGCCACCGGTGCGTCCCTG
CCCCTGAGTCGAGCCACCAGCACCGAGACCTACTTCAGCCGCCGCTTGTTCAGGTTGTAGTGTGGATTGA
GAAGGTTGCCCTGCCGCAGGAGACCCTCCCCGGTTTCTATGCTTGCTACCTGGATTCGAAAGAGTAGAAT
CTGGAGAGGGGAGTGTGGCAATCTGGCGCTTCGCTGCTTCACTTGCTTTTTGCGCTTCCTCAAACGACAT
GTATCGTGCAGTTGCGCAGCGTGTACAAAACAACAGTGCAAGAGCAAAAGCAAGCCCTTTCGTGGTCACT
TTCA
-
Protein Sequence : Show Sequence
>XP_002365373.1 rhoptry protein ROP16 [Toxoplasma gondii ME49]
MKVTTKGLAFALALLFCTRCATARYMSFEEAQKASEAAKRQIATLPSPDSTLSNPGSKHRNRGGSPAAGQ
PSQSTLQPEQAAAEVGLGAGGSTQGQGRTGGSAGAREERRSPSPQSAYPATSSASLRGYQTQLSPSHLPP
RSSGPGGWFPTESIFTPWSSPPQPLTQRKPSLSGVVVTEFQEPQEQYGAASSLASSPKRYVSGASSSALS
GKAVPTPASLGQENPLFPVQSATLDSGIQSPAQERRGSPQRQIAMSTENPADSGASQLASSVSSYVAVQT
PHVKRSERIRRVRLSEEGLEEVQQLKAAAAQLLVAVPDYEAMRAVLQEAVLSEQRVATRKRKRKQPPGAV
ESAVDEVFPPNERVMMINANGVPIALYNRGHLGSGHFGAVIKASLDDGTLYAAKVPYSQIVPNADATSAE
LEAEISSARAELVKTIRQELDVRDKLVAKGLTLTETAEQYGLPLCQMTLTLPENKATVVRRGSRLVVVSK
EVMLLPLIDGSPSNSLVQSQPPFLFQRAVAREAIIALAKLHELGFAHGDVKLNNMMIDVHGFGHMLDMGS
VRPVDSCVSEEDKYYLRLWAPELAKSQHTSQQTCLKRGALDVWALGLAIFEFVCFNRLPYSLSNLPSSLW
SRVEHLSRLRLSDFSAKDCNESDPAVMGIVAQFLNPNPEERPELPKFVSSYTFFRQAPGVTSHLTRIPTT
ELSSHRM
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
CAV-2-ROP16
|
|
37. ROP17 |
-
Gene Name :
ROP17
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7896648
-
NCBI Protein GI :
237831549
-
Locus Tag :
TGME49_258580
-
Genbank Accession :
CM002042
-
Protein Accession :
XP_002365072
-
Taxonomy ID :
508771
-
Chromosome No :
VIIb
-
Gene Starting Position :
3321441
-
Gene Ending Position :
3324437
-
Gene Strand (Orientation) :
-
-
Protein pI :
9.81
-
Protein Weight :
64820.37
-
Protein Length :
608
-
DNA Sequence : Show Sequence
>NC_031475.1:3321441-3324437 Toxoplasma gondii ME49 chromosome VIIb, whole genome shotgun sequence
GTAAGTCCGCGAAGCTGGTTGCTGGATTGCGATTGTACTTTTAGCAATGCATGAAGGCATTCGCTAGGAT
AAATGAAAGGACTAGAAGAATGTGTTCATAAGCTCCATAGGATACAAAATGGCAAACCAACAACTTCTGT
CGCAGTTTCAATCGCCGTTTCAAGAGCAGAAGCGTGAAATAGTGACAGGGATCGAGTGGTACATGTGGCG
TAGTCTACAGGGGCATGTCCACGTGAATGCATGAGCGGATCAGAAATCTGAAGGCGGCCGCTTCCATGAT
GCCTTGCAACCTTCGCGGTTCTAGGGAGCAGTTTCAAAGCAAAAAAAAAAGATTTGTCTTCGCATGTGAC
TTTAAACATCCGCAGCATATGGGCACAAGGATCCACGGAAAGAGTTACAATGTTGTCACCTCGAGTGTTC
GCTGGAGATCACGGATATATGGAGCATCCGTCCATGGAAGCAATAGAACGAATGGCGACCCCCAATCCAG
ATGCCTCTTCTTTCTGCGATGCCTGACTTCGCTCTTTTCGCTGTCGGACTTCGCTCTACCGTTTGCGGCA
GTTTGTCGTTGATGGACAGGCATTTAGACTGCTTTGGCGAGGGTTCCACTCCTACCACAAGTGACGGCAG
TACCTCACTATGTCACACCGACCGTCCTTTCTTGTTGCATTGACCGCATCAGATTACTCCTTCTGTAATA
AAGCCGCCTCCTCGGTACTGACTGGTTCACTTTCGGAAGCCGTATCCGATGCCGGGGATGGTCCTTTCCA
GTTGAGTAACGAGAACTGCTCCAGCGCCTGTTGTGGAGATAGTCGAACACCAGGTGTTTTGCGTAGAAAT
CCCACTATCATCTCGCGGAACTGTTCTGGAATGTCGTGGCAACTGGCGAAGTCAAGAGACGACGCAGAAG
ACCTGATTACAATTCCAGCCACCTGCAGTGCGGTGGCGTCCAGAGTCATTCCGAAGGGGAAGTTACCACA
CCACAAACGATACAAGGATATTCCTAGCATCCACGAGTCTATCTGAGGCGTGTATGGAATAGCATTCCGC
AAGCGAGTGATCATACAGGTCGCTATTTCTGGAGACATGTAAATCACTGTTACCACAGGTGGATAGCGTC
TCTCATTCGTACGAAGAATTTGAGTGAAGTCAGAAAGTAGAAGCAATCCCGATTTATCAACAAGAAAATT
TTGCAGTTTCACATCGCCATGAACAAGTTCAAACGCGTGGAATCTTGCAAGTAGTTTGACCATTTGAATC
GTACAGCTCATACGAATGTTGTAAGCGTTTGTTCTGTCCATGTCTGCAAGTAAAACAACAGCTTCTTCTA
AGTCTCCTTGCGCCTTCGGAAATAGGGCGCAAACACTGTATATACGCAAATGGTTCCGCACATCCTGGAA
TTCGGGCTTTCCTAAAACTCTGAGCTTTAGAAGTGGCACCATAAACCGGAGTTCCGAGTACATGCGCGCA
GGCGTCCATTCGGGGGGGAAGTACTTCATGACTCCAAATTCATCCTCGATCAGGTCAGATATTTTATCCC
CTACCTCATTGTTCATCACCCGTTGAACAAATATCTTCAGCGCGAATGGTTGCCCTGTGGTGGGATGTTC
AACATGGTACACAAGACCAAAGCCGCCACCACCAAGGAAGCCACGTTTTTTTAACAAGATGTATCGGCCA
CCCGGACTACTGATAAACCACGTATTTTCGGCGGAGTTTATCAGGTATGTCCCGACCGCTTGTTGGGCTT
CAGTGGGGTTTTTCTCCGTGAGTGCTTTCTCGCGAAGGCCAGCTTCCATGCGCTCCGCCACCAGTGCGAC
AGAAGCCTGCCCCGGCTCGTTGCCTATCAAAGGCGGAACTACCGGTGGGAGGCCCTGGTCCCAAAACCGT
AGCCTCCGCAGCTGGGGCATCAAGTGCCCAACGAACAAATCCCCGATTTTTCGTCGTACTCGCCTACCCC
ACCCGCCCACGGCGCCTCTGGCCGATCTCCAGAGTCGTCTCACATTCTGTTTTATTCTTGAGCGCAGTCC
GGCCCGTGCCCGTTGTCTATGAAGCTGTGATCTTCTTCTGAAGGTATACTCATCAAAAGCACGCTGATCG
AAAAAGGAAACTGGTTCTTCATGATACGAATGAACACTGCGCCCCCTACGTTCCTGAACACCTAAAACGG
GTGACAACCTCCCATCACGGTAATAGGGTCTTTCGATCAGAGAATGACTGGCAGGTCTTCGTCGGTTCTC
GCTACCTAGTGTTGTCCTGCCGTTCACCAACGTATAGGAATTGTTCCAGGAAGCGTCTCCATGGTCTTCC
CAGAAGTCGTCCTCGCGGTCGTTGAAGTTCAACCTTGATATGCGTTTTGTAAGGCGGGTCGCCAGAGGCT
GGGCACGTTCCGCCGACGCCACCAACTCTCCAAACACATCATTGCTCGTTGGTGACCGTAAAAGAAGGGC
AGAGCTCTCGCGAATGACGCCAGAGATCGTTATTATCACAAAGCACAACACCAACTCCATGGCGAGTCAC
GGACGAAGCTTCAACTGACAGCGGCGGGCTGTCTTGCGACTAGCTGTCTGCAGGAGCGAAACGACAGCGT
ATGGCATCTATGCCACTCAGACGTGAAGCCAAAATGTTATTTCAAAACAGTAACAACCGACAGCGACATC
ATGTAAATATTCGACCGCACAAAAACAAAACTATGTTGTGAACTCCTCCTTCTACCCTGATTTTGACCTC
GATCGTTACGCCCAACTTGTACCGGTGAGGAATCTACACGCGCTCTCTTGCCACGAATGGGGCCAGCATC
CGGAAGGACACCGATTCTCAGGGGGTCGTTTTAGATGCATGAACACGAACAACAGAACTATCAACATCAC
CGTCTGGTCACACAAGGTCTGGCTGAAACAATACGCCGAAGTAAACACACAAAATCCCGACAGAATGCAT
TTGTAGTCCTAGCTCACCACGAACGCAGTGCCGCCGGTTTCAACAGACTGGTGCAGC
-
Protein Sequence : Show Sequence
>XP_002365072.1 rhoptry protein ROP17 [Toxoplasma gondii ME49]
MELVLCFVIITISGVIRESSALLLRSPTSNDVFGELVASAERAQPLATRLTKRISRLNFNDREDDFWEDH
GDASWNNSYTLVNGRTTLGSENRRRPASHSLIERPYYRDGRLSPVLGVQERRGRSVHSYHEEPVSFFDQR
AFDEYTFRRRSQLHRQRARAGLRSRIKQNVRRLWRSARGAVGGWGRRVRRKIGDLFVGHLMPQLRRLRFW
DQGLPPVVPPLIGNEPGQASVALVAERMEAGLREKALTEKNPTEAQQAVGTYLINSAENTWFISSPGGRY
ILLKKRGFLGGGGFGLVYHVEHPTTGQPFALKIFVQRVMNNEVGDKISDLIEDEFGVMKYFPPEWTPARM
YSELRFMVPLLKLRVLGKPEFQDVRNHLRIYSVCALFPKAQGDLEEAVVLLADMDRTNAYNIRMSCTIQM
VKLLARFHAFELVHGDVKLQNFLVDKSGLLLLSDFTQILRTNERRYPPVVTVIYMSPEIATCMITRLRNA
IPYTPQIDSWMLGISLYRLWCGNFPFGMTLDATALQVAGIVIRSSASSLDFASCHDIPEQFREMIVGFLR
KTPGVRLSPQQALEQFSLLNWKGPSPASDTASESEPVSTEEAALLQKE
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
rTgROP17
|
|
38. ROP18 |
-
Gene Name :
ROP18
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7894509
-
NCBI Protein GI :
237836919
-
Locus Tag :
TGME49_205250
-
Genbank Accession :
CM002041
-
Protein Accession :
XP_002367757
-
Taxonomy ID :
508771
-
Chromosome No :
VIIa
-
Gene Starting Position :
1513496
-
Gene Ending Position :
1516224
-
Gene Strand (Orientation) :
-
-
Protein pI :
8.97
-
Protein Weight :
58597.2
-
Protein Length :
554
-
DNA Sequence : Show Sequence
>NC_031474.1:1513496-1516224 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
TGTACTAATACCTGGTTAACAAGGGTGTTATCCATTTCCTGTGCAGAGTCGATACGAACAACATGGGAGG
CACAGCTGGACCTTTTATTATAATATGCATTAAGTAGAAACCGTCTCTGTAACACAACCAGCTCTCCAGA
ATCGGATCAGCCGAATCGAACGAACAAACACAAATATCTTGTTGCCCCGGTACAACTCTTACATCGAGAC
AGATAATGTTGTCATCTATTTAATCTAGGCAACGCCAGATGGATAGCGAACACGTTTGCCCTGCCCCTCT
CTCAATTGATCGGCAAAAACATCTTCCTACAGGAATAATGGCATATCAATTTGCGCAACACTTGTGCCCC
ATTTCTGGACGAATGCTATTTCTATTCGGGACTAACTGCGCGTTTCCCGATTGACATTTTGAGACCTCGT
TCTCTTCCTGTAGATATCTTATCCCAGCACAACGGAATAGGCTAACAGACTAAAGGCGTATAAGGCGCAT
TAATGCTCTGAGAGAACCGCCTGATTTCAGTCCTGTATTCAAGACTGTTTCATGATAGGGTGGGATCGTC
GCCGCGTCGGAGACGAAGGAATATCCCCACTGTGTAGCAATCTGCCACGTTCTATCAAGACTTATACATG
CGCCGTGCTCATGAGGATGATCCTGGAAGCGTTCAACCAACACACTTCGTACACCGTATTTCACTGTGAA
GCCAACATCAACAACAATTTGATGCAAAATTACCCGTCTCCCTGCTTTCCCGGAACTACCGGCGTACACC
TTTGCCCAGTGAACAAGCGAGAAGCAGCAACACAGATATGCAAGTAATCCATGTAGAGAATCTGTCTGTT
TTAATTCGCTTATGACGCCTGCTTCGCCAATGTGGCAATAATGCCATCCGTCGAGAGGCGTTCGGTCGGC
GGTAGGGCGGCACCGCCACGTTCCCCTCTTCATTTTGAGTCTTTTATTCTGTGTGGAGATGTTCCTGCTG
TTCGAAGTTTTGCGCGGCGCGTTTTACTACTGAATCCATCTCGTTAAACGCTGCGGTCTCCAAGGCTTGT
AGCGGGAGCATCCGTTTCTGAGGCTCTCGATTCAAGAGGTTTCGGATGAGGTCTTGAACCAGCTCAGGCG
TGGAAGGACAATCTGCGAAGTGTAAGTAGTCCCAGATGCCGTCGGCCGGAGTTGGACGTTCCTTGCACCA
GATGCAGTACAAAGTTATACCGAGTTGCCACGCGTCAGTGGTGAATGTATAGGTGATGTCTGTAGTCTGA
AACGGTCGCTCCGGAGGCTCGTAACCGGGAGTACCTATCGCGGGTCCAACCGAATTATTGATTCTATACG
TTCCGAAGTCGCCGAGAAACAGGCGACCGTCTTTCAAGAGGAGGAAATTCGCCGGTTTGATATCCGTATG
CACAATTCCCTGAGCTTGAACATTGGCCACTAGTCTGATTGCCTGACTGGATAGGTACATTCGAACGACC
AGGCCTAATTCACTGTTATTGACAGACGCATCTCCAAATACCCATGAAATGACTTTGCTCATGTCCGTTT
CTGCCCGCATCATGAGAAGAAAATAGTTTGGTACCCACCGAGTCGTCAAACCAATCACGACCTCTGTGGA
TGCTGGCTGTCCCTCTAACATCACAACATCACTAGGAACCATGAATCTACAGCGTTCCTGGGCATCCTTC
GCCGTCTTGGCTAGACTAAAGTTCCTGTAGCAGAACGACTCCCTCTGCAAGTCACGCATAGTCTCATCGG
TGGGCTCCTTTTCTGACATGAAAACCTTAACAGCCAACTCTTCATTCGTCTCCACGTCTGTAGCCTCATA
TACAGTGGCGAATCCACCAGAGCCAAGGGGTGCACCTCTCACCAGCGTCCGGGTTTCACCGGTAGTCACA
GAAACAAATCTTTCTGGAACGTCCGGAGGCCAGGCAGCGACAGTCAGAATTCTATCCAGTCGTTCACTAT
TTCCTAGCGCTTGAGGCTGCCCGATTTGTTCTTGCATGTGCGCCAGGATGCGTTTGCCGATGACGCATCC
AGAATCCGCCTTCTCAAAAAACAATTCAGATCGCCGTCTTTGTGCCCGCAAACTTCGCAGTCGGTTACGC
CCTTGAGAAAAGTACCTCGGGATTCCGCGTGTGAAGAACGATTTCGCTTTACGCCAAAGTTGAGCAAGCC
TCTGTCGTACGGACAGACGGGGTCTCGAGGAGCTATCAGCTGCGGAACCCGAGACTTCACCATCTCTTTC
TCTCCGTCTCAAGAGATTCAGAAGCCTCTGAAAAATCGTGCGCCGTTGGTTTGTTTCTTGCGCATTTACC
CGGTGTTGAGCCCTTTCCTCCAGCAATGAAACGTCTCGAGTGCTTTCTGTCGCTCCTGCTAAATATTTGT
AGTGGCCAACTGTAGCAGGCCACCGCTTGTCAGCAACGTGCTGTTGCGAATCCAAACTTGTCGGTTTGGA
GTCGAGTTTTGAAGGATCAAGTGTGATTCCGGTCCCATCCTGGACTTGGAAGAGCAGGAAGACAAGCGCT
ACATTTAACACCGCAAGACAGGCTGTCTTCGGGAGAAGAGTCGCTAAACCCATTCGGACGACGGTACGCG
TAAGAGGTGGCCGCTGTACCGAAAACATCACAACTTTCACACAAACTGGACTGGGGTGAGTACAAAACTG
TAAAATATGGTATTGCTTTGTCAACGGCTGTATCAATCTGTCGAAGACACGGACAGGTTTTTGGAAGAA
-
Protein Sequence : Show Sequence
>XP_002367757.1 rhoptry protein ROP18 [Toxoplasma gondii ME49]
MFSVQRPPLTRTVVRMGLATLLPKTACLAVLNVALVFLLFQVQDGTGITLDPSKLDSKPTSLDSQQHVAD
KRWPATVGHYKYLAGATESTRDVSLLEERAQHRVNAQETNQRRTIFQRLLNLLRRRERDGEVSGSAADSS
SRPRLSVRQRLAQLWRKAKSFFTRGIPRYFSQGRNRLRSLRAQRRRSELFFEKADSGCVIGKRILAHMQE
QIGQPQALGNSERLDRILTVAAWPPDVPERFVSVTTGETRTLVRGAPLGSGGFATVYEATDVETNEELAV
KVFMSEKEPTDETMRDLQRESFCYRNFSLAKTAKDAQERCRFMVPSDVVMLEGQPASTEVVIGLTTRWVP
NYFLLMMRAETDMSKVISWVFGDASVNNSELGLVVRMYLSSQAIRLVANVQAQGIVHTDIKPANFLLLKD
GRLFLGDFGTYRINNSVGPAIGTPGYEPPERPFQTTDITYTFTTDAWQLGITLYCIWCKERPTPADGIWD
YLHFADCPSTPELVQDLIRNLLNREPQKRMLPLQALETAAFNEMDSVVKRAAQNFEQQEHLHTE
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
CAV-2-ROP18
,
PLG-rROP38-rROP18
,
rCDPK6 + rROP18 + PLG
,
T. gondii DNA vaccine pIRESneo/ROP18/PLP1
|
|
39. Rop2 |
-
Gene Name :
Rop2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
VO ID :
VO_0011340
-
NCBI Protein GI :
115299638
-
3D structure: PDB ID :
2W1Z
-
Other Database IDs :
CDD:291215
CDD:304357
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
Rop2 protein
-
Protein pI :
9.64
-
Protein Weight :
28699.38
-
Protein Length :
316
-
Protein Note :
Kinase-like; pfam14531
-
Protein Sequence : Show Sequence
>ABI93795.1 Rop2 protein, partial [Toxoplasma gondii]
LRLLRGIKNQKQAKVHLRFIFPFDLVKDPKKRKMIRVRLDERDMWVLSRFFLYPRMQSNLQMLGDVLLSH
SSTHKSLVHHARLQLTLQLIRLLASLHHYGLVHADFQVSNILLDQRGGVFLTGFEHLVRDGASAVSPIGR
GFAPPETTAERMLPFGQHHPTLMTFAFDTWTLGLAIYWIWCADLPNTDDAALGGSEWIFRSCKNIPQPVR
ALLEGFLRYPKEDRLLPLQAMETPEYEQLRTELSAVLPLYQTDGEPA
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
A study to examine the immunostimulatory properties of Leishmania infantum Hsp83 (83) to elicit humoral and cellular response against the Toxoplasma gondii Rop2 protein in an adjuvant-free vaccination system was conducted. Mice immunized with fusion Rop2-83 elicited a stronger humoral and cellular response in comparison to mice immunized with Rop2 alone, or a mix of LiHsp83 and Rop2. The fusion protein induced a Th1 type response, with predominance of specific IgG2a/IgG2c isotype and IFN-gamma secretions, whereas Rop2 alone or mixed with LiHsp83 produced a Th1/Th2 mixed response. Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups (Echeverria et al., 2006).
- Related Vaccine(s):
T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2
,
T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
|
|
40. ROP2 |
-
Gene Name :
ROP2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii RH
-
NCBI Protein GI :
563627
-
Other Database IDs :
CDD:291215
CDD:287472
CDD:304357
GOA:Q27007
InterPro: IPR000719
InterPro: IPR011009
InterPro: IPR016815
PDB: 2W1Z
UniProtKB/TrEMBL: Q27007
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
ROP 2
-
Protein pI :
8.19
-
Protein Weight :
61058.83
-
Protein Length :
609
-
Protein Note :
Kinase-like; pfam14531
-
Protein Sequence : Show Sequence
>CAA85377.1 ROP 2 [Toxoplasma gondii]
MENCASVRSSSCLIWLAAAFFVSALGHVQQGAGVVRPRHWQNSEAAVSVRPPGGASPRHFHSPIEPVAFI
DGEHVEDKHGGSWLEQEAAEEVTPLLNSHTETPTQSPSAFRRLLRRLRFWRRGRTGGSDGGGEPPQTPRP
SLPTRLFQHLRRAAAAIPAAASRFFRRFRRVQEPVFPPDEFPEDVDTNPMYFRGTDPGDVVIEELFNRIP
ETSVWNENERVLSNANHLVSTALWRNEQSFRVESELGERPRTLVRGPVLRDDGSYICLEATDQETGEPLE
VHVPYFTERPPSNAIKQLSEQVLRLRLLRGIKNQRQAKAYLRFIFPIDLVKDPKKRKMIRVRLDERDMWV
LSRFFLYPRMQSNLHILGDVLLSHSSTHKSLVHHARLQLTLQLIRLAASLQHYGLVHADFQVRNILLDQR
GGVFLTGFEHLVRDGASAVSPIGRGFAPPETTAERMLPYRQHHPTLMTFPFDTWTLGLAIYWIWCADLPN
TEDAELGGIEWIYRRCKNIPQPVRALLEGFLRYSKEDRLLPLQAMETSEYEQLRTELSAVLPLYQTDGEP
A
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pSAG1-ROP2-SAG2
|
|
41. Rop2 |
-
Gene Name :
Rop2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Protein GI :
ABI93795
-
Other Database IDs :
CDD:291215
CDD:304357
-
Taxonomy ID :
5811
-
Protein Name :
Rop2 protein
-
Protein pI :
9.64
-
Protein Weight :
28699.38
-
Protein Length :
316
-
Protein Note :
Kinase-like; pfam14531
-
Protein Sequence : Show Sequence
>ABI93795.1 Rop2 protein, partial [Toxoplasma gondii]
LRLLRGIKNQKQAKVHLRFIFPFDLVKDPKKRKMIRVRLDERDMWVLSRFFLYPRMQSNLQMLGDVLLSH
SSTHKSLVHHARLQLTLQLIRLLASLHHYGLVHADFQVSNILLDQRGGVFLTGFEHLVRDGASAVSPIGR
GFAPPETTAERMLPFGQHHPTLMTFAFDTWTLGLAIYWIWCADLPNTDDAALGGSEWIFRSCKNIPQPVR
ALLEGFLRYPKEDRLLPLQAMETPEYEQLRTELSAVLPLYQTDGEPA
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
(Picchio et al., 2018)
|
|
42. ROP38 |
-
Gene Name :
ROP38
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7898368
-
NCBI Protein GI :
1085190577
-
Locus Tag :
TGME49_242110
-
Genbank Accession :
KE138867
-
Protein Accession :
XP_002366751
-
Taxonomy ID :
508771
-
Chromosome No :
Unknown
-
Gene Starting Position :
2132
-
Gene Ending Position :
4703
-
Gene Strand (Orientation) :
+
-
Protein pI :
8.61
-
Protein Weight :
55203.27
-
Protein Length :
541
-
DNA Sequence : Show Sequence
>NW_017382942.1:2132-4703 Toxoplasma gondii ME49 unplaced genomic scaffold asmbl.24, whole genome shotgun sequence
GATGAAAAATACTCTGTTGTCACCTGTTGGTTTCTTTACCGCTCTCGCTGTACTTATAGAATGCCACCTG
AGTGACCGGTGTGTTGCTCATCATGGCAGCAGCACTGATGGATCAGGCCTACGGCCCCCTCAAGAGGTCG
ACTCGGCACCACGAACGCCGTCGATCGCTGTTAAAGAGCTTGCCACGTTTCCTGGAGATGACATTCAGAC
GTCATCTCAAGAATTGCCCGGCTATGAACTTTGGACCAGGGAACAATCAGGGGCATCTGTGCGTGTTGGG
TTTCCGCAGAACGCCGAAAGTTTTCTGACACAAAGAGAAGCGAGAGACGAAATCGCGAATGCTCACGAGC
TCGTCGCTGTAACTCCAGAAGGCGATGCGTGGAATCACAGTGGTGTTGTCCCCGAGGAGCAGACTGTCAC
GCCTGCTTCAGGTAGCTTCATTCAGAGGCAAGCCGCGCATGCACCGCCTTCGACTCGATTGACGCCCGTG
GACCGCCGTGGCAGGTCACACACAGTGTCAGCTGTCAGACGGCGGGTGACCGTGGAAGACGTTATGCGAC
CGGACCAATCGGCAGCCATGCATGCAGTGTTGTCAGCATTTGGAGGAGGCCTGGTTCTGAAGGCTAAGAA
CAAATGGGGTAGAACACGTTACACGCTACAGGGACCCGCAACATTCTTAGGAATGGGAGCCGAGGGCATT
GTTGTACGTCTAAATCAGGTGAAAAGCGACCGGGAAAGATCGGTGACACCGGTGGCAGTCAAGCTGTGCC
TCATTCGTGCAGCAGTGTTCTCGGGGCTGACATGGTGGAGAAAACGAAGGACCAGAACAGAACTAATGAA
ACTGTTTCTGTCGAACGAGAATTCTGTGAAGCGTGCTCTACCAGATTTGGACCCGGCCGAAATGCTAGAG
CACGGTCTCGTCGTTCCACATCATGCTGAGCTTGTTTCCGGTATGCCCACGTGGTTTGCCGCGGGCGACT
CATTTTTTGTATTACCCGTTGTTTCTGTGTCTCCTCTTTTTACTTGCGACCTCGAAACGGTCGTGCAAAA
CCCGTTGACCTTTTGGGCGAAGATGTACATTACCCGCCAGTTGCTAAAGAGTATTGCGTGGATGCATCAA
AAAGGCATTTCTCATAATGACTTGAAGCTTGAGAATGTCCTGCTCAGTGCAGACGGAAGGGTTGCCATCG
GCGATTTTGGTTTTTCAAGCCCCTTCGGGGCTTCGTTGCCCATCAGGGGCACTCATCTATACATGGACCC
CGACAGCTCAGAAGCATTTTTTGAACAACGAGAGAACGAAATCACTCCCCACAGAGATGCATGGGCGACT
GGAGTCCTTCTTTTCTATCTGTGGTGTGGCGTGTTTCCATTCGGGTTACAGAATGTCGCTAACGCGGGTC
CGCCACAGGTGATGAGGGTCACAGTCATGCATGCAAGGACTACCAGGCCGCCGCCCAACTTCCGGCTGTG
TCGGCGCATCCCGCGTGAGGTTCGGAACCTCGTTACCGGATTTCTGCAGTGGAACGAGGAAGCTCGGCGT
CTCCCCAGCGATGTTGCCGACGCGTTCCTTGCCGCTACGGACGACGGTGGTAGAGAGGCGCGTCGGATAA
GAACGCATCAATTTTGAGATCAGCGCCGGCTGAATGCATGCCTAAGAGTTGGAGCTCCCAGGCATGGCGG
AAGTGTCTCCACCAGACAAGCAACGAGCAAGATGGTGTCGCACACTAGACATCGTCGGCTGCGAAGGCGA
CAGTGCAAATGGCGGGCTTGCGTGGCCGTGTGTGGAATGCAGAGATGTGCTCTGCACCTGATGAACATGA
TTGTCCGTACTCCATATCGCGTGCTGATTGTACCATTCGATGTGCATGGCGAGTGAGGGAAAGTGGGATG
CTTCTGGAAATACTGTGAACAGCAGGAAACAGAGCGGTGGGGACGCCAAGACACCGATACATGAGCTTTT
ATGCTTTTACAGATGTGCCTCACAAAATCAGTTTTATTGCCTTCTTTTGGAGGAATCCCGTGGGGCATGG
GCATCGTCATGTTCACGGTGTAAAAGGTTGACTTCACCGTGTAAGTGTGCGCGGCTGTGCTCAGTGAGAA
ATGAAGATGCTCGCGTGAAACTCTATGGCAGTCCACCTAATGAGGCGTCTCTTGCAGTAACGCTTACAGG
CCGACAATTCAAGCAGGCAATGGACCAAGTAGACACGGCTCGTCAGACGTACGTAGATAACTGCTGAAGG
AGAAGTAACCCATGATTGTCATCGCTCGAGAGAAAATAGTGGTTGTACGTTTATGTGACTGCTTGTGGCA
GAACCCACAAGGGAATGCAGAAATGAATACGCAGGTCAAATTGATGATATATTTATCTGCCTCCTGACCT
CCTATACAGCTACCCTGTCAGCTCAAGGACACTTCTCTAGTCTCCTGCCGACTGGCGTGTTCAGGAAGTT
CACTAACGTTAGGCGGACGTGCTGCAACCATTCAATTGTTTGTCTCGCGCGTTCCCCTCTTCCGTTCTCG
CCTCCCTGCCACTGCGTTCTTTCGTGTGACGCACACTTTGTCGATTACAATG
-
Protein Sequence : Show Sequence
>XP_002366751.2 rhoptry kinase family protein ROP38 [Toxoplasma gondii ME49]
MKNTLLSPVGFFTALAVLIECHLSDRCVAHHGSSTDGSGLRPPQEVDSAPRTPSIAVKELATFPGDDIQT
SSQELPGYELWTREQSGASVRVGFPQNAESFLTQREARDEIANAHELVAVTPEGDAWNHSGVVPEEQTVT
PASGSFIQRQAAHAPPSTRLTPVDRRGRSHTVSAVRRRVTVEDVMRPDQSAAMHAVLSAFGGGLVLKAKN
KWGRTRYTLQGPATFLGMGAEGIVVRLNQVKSDRERSVTPVAVKLCLIRAAVFSGLTWWRKRRTRTELMK
LFLSNENSVKRALPDLDPAEMLEHGLVVPHHAELVSGMPTWFAAGDSFFVLPVVSVSPLFTCDLETVVQN
PLTFWAKMYITRQLLKSIAWMHQKGISHNDLKLENVLLSADGRVAIGDFGFSSPFGASLPIRGTHLYMDP
DSSEAFFEQRENEITPHRDAWATGVLLFYLWCGVFPFGLQNVANAGPPQVMRVTVMHARTTRPPPNFRLC
RRIPREVRNLVTGFLQWNEEARRLPSDVADAFLAATDDGGREARRIRTHQF
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
PLG-rROP38-rROP18
,
T. gondii DNA vaccine pVAX-ROP38
|
|
43. ROP8 |
-
Gene Name :
ROP8
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7897075
-
NCBI Nucleotide GI :
2293518
-
NCBI Protein GI :
2293519
-
Protein Accession :
AAC47797.1
-
Other Database IDs :
CDD:291215
CDD:304357
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
ROP8
-
Protein pI :
9.42
-
Protein Weight :
61810.69
-
Protein Length :
622
-
Protein Note :
Kinase-like; pfam14531
-
DNA Sequence : Show Sequence
>gi|2293518|gb|AF011377.1| Toxoplasma gondii rhoptry antigen ROP8 gene, complete cds
GAATTCGCTAGTCTCAGGTCGAGTCGCCGGGGCGTCAGGAGACAAGCACCGGCGCCCCGCGCGCCAACTG
TCCGTCCTTCCGGGTGAGTTGACGTTTTGAGCCACGCTGCAGAACTCTGCACTGGAGTGATTGAGCGCGG
CATTTATGTCAATCTGGTTTTTCCACGTGTATTCCAGAAGCTTGCCCTGAGAAATACAGATACACTGTCA
CTTTTGAATCGATGTTTTCTGTGTTACGTAACCGCAACATGAGACACGGTCCCTCGATTGGATCGTCATC
ATGTCTTATCTGGCTAGCTGCCGCATTCTTTGTTTCGGCACTTGGCCACGTACAGCAAGGCGCTGGCGTT
GTGCGGCCTCGCCACTGGCAGAACTCGGAAGCCGCTGTTAGTGTCCGGTCGCCGGGAGGCGCGTCCCCTA
GACATTTCCACAGCCCAATTGAGCCAGTAGCATTTATTGATGGGGAGCACGATGAAGACAAGCATGAAGG
CTCATGGTTGGAGCAGGAAGCGGCCGAGGATGTGACCCCTTTACCGGGCAGCCACACAGAGGCCCAGACA
CAGTCCCCCAGTGCTTTTAGAAGGTTAACCAGGCGTTTGCGTTTTTGGCGACGTGGGGTGACAGGCGGAT
CAGATGCTGGAGAAGAGGCGCCTCAGACGCCTCGACCTCCACTACGTACACGAATCCTTCAGTACTTGCG
GCGTGTGGGAACATTTTTCAGACGAGACATTCCAGCGGCAGCACTTCGATTCTTCAGGCGCTTTCGACGA
GTCCGCCAACCTGTATTCCCTCCCGACGAGTTTCCGGAGGATGTCGACACGAACCCTATTTATTTCCGTG
GTACGGATCCTGGAGACGTTGTCATTGAGGAGCTGTTCAATCGTATACCGCAAGCAAACGTACGGACTAC
AAGTGATTACATGCAGTCCGCAGCTGACAGTCTAGTGTCCACATCGTTGTGGAATATTGGACAGCCCTTC
CGCGTAGAGTCGGAGCTTGGCGAGCGTCCAAGGACGCTAGTCAGGGGCACATTGCTCGGCCAGGAAGACC
CTTATGCCTATGTCGAGGCGACCGACCAGGAGACAGGAGAATCATTTGAGGTGCACGTTCCACTTTCCAA
GGAAAAGCCGTCTTCCAACACGATCAAGCAGATGAAGCAGGAGGTGCTGCGCCTACGCTTGCTACGAGGC
ATCAAAAACCAGAAGCAAGCCAAGGTGCATCTCAGATTTATATTCCCCTTCGATTTGGTGAAGGACCCAC
AGAAAAAGAAGATGATCCAGGGTGTCTCAGATGAGGGGGCTGGCTGGATCGTGAACGGATTCTTTCTGTA
TCCCCGAATGCAGACTAACCTTCAGACGCTTGGAGAAGTCCTACTGAGTCATTCCTCAACACACAAGTCC
CTCGTGCACCACGCTCGGTTGCAGCTCACGCTTCAGGTCATAAGGCTGCTTGCGGGTCTCCACCACTATG
GCCTTGTGCATACCTTTTTTAGGGCCGTCGATATCGTCTTGGACCAGCGTGGTGGCGTGTTTTTGACCGG
CTTTGAACATCTGGTGCGAGACGGCGACAGGGTGGTGTCGACCGTCTGTCGAGGATTCGAACCGCCGGAG
CTTGAAGCCAGACGAGCAACCATATCTTACCACAGGGACCGCAGGACGCTGATGACATTTTCGTTTGATG
CATGGGCATTGGGGTTGGTGATCTACTGGATTTGGTGCGCCGATTTGCCCAATACCAAGGACGCGCCGCT
AGGCGGAAGTGACTGGATCTTTCGACGCTGCAAGAATATCCCACAGCCAGTCAGAGCTTTGCTTGCGGGA
TTCTTGCGATACCCGCAAGAGAATCGGCTCCTSCCATTGCAAGCCATGGAGACTCCTGAGTACGAGCAAC
TGCGCACAGAGCTATCAGCCGTTTTGCCCCTGTATCTTTCTGATGGAGAACCGGCATGAGAGGGTGGCGC
GCCACCATCGGGAACATCTCAGCCGGACGAAGCTGGAGTCGCTGAGGCGGTTACGGCAATCTAGAACCTC
GAGGAGGGGCCAGCGATGAGCTTGAATTC
-
Protein Sequence : Show Sequence
>AAC47797.1 ROP8 [Toxoplasma gondii]
MFSVLRNRNMRHGPSIGSSSCLIWLAAAFFVSALGHVQQGAGVVRPRHWQNSEAAVSVRSPGGASPRHFH
SPIEPVAFIDGEHDEDKHEGSWLEQEAAEDVTPLPGSHTEAQTQSPSAFRRLTRRLRFWRRGVTGGSDAG
EEAPQTPRPPLRTRILQYLRRVGTFFRRDIPAAALRFFRRFRRVRQPVFPPDEFPEDVDTNPIYFRGTDP
GDVVIEELFNRIPQANVRTTSDYMQSAADSLVSTSLWNIGQPFRVESELGERPRTLVRGTLLGQEDPYAY
VEATDQETGESFEVHVPLSKEKPSSNTIKQMKQEVLRLRLLRGIKNQKQAKVHLRFIFPFDLVKDPQKKK
MIQGVSDEGAGWIVNGFFLYPRMQTNLQTLGEVLLSHSSTHKSLVHHARLQLTLQVIRLLAGLHHYGLVH
TFFRAVDIVLDQRGGVFLTGFEHLVRDGDRVVSTVCRGFEPPELEARRATISYHRDRRTLMTFSFDAWAL
GLVIYWIWCADLPNTKDAPLGGSDWIFRRCKNIPQPVRALLAGFLRYPQENRLLPLQAMETPEYEQLRTE
LSAVLPLYLSDGEPA
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine encoding multi-epitope ROP8
,
T. gondii DNA vaccine ROP8-pVAX-1
|
|
44. SAG1 |
-
Gene Name :
SAG1
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
VO ID :
VO_0011000
-
NCBI Gene ID :
7900172
-
NCBI Protein GI :
237839159
-
Locus Tag :
TGME49_234370
-
Genbank Accession :
KE138836
-
Protein Accession :
XP_002368877
-
3D structure: PDB ID :
1KZQ
-
Taxonomy ID :
508771
-
Chromosome No :
X
-
Gene Starting Position :
4326607
-
Gene Ending Position :
4329557
-
Gene Strand (Orientation) :
-
-
Protein Name :
surface antigen SAG1
-
Protein pI :
7.13
-
Protein Weight :
18124
-
Protein Length :
174
-
DNA Sequence : Show Sequence
>NC_031478.1:4326607-4329557 Toxoplasma gondii ME49 chromosome X, whole genome shotgun sequence
AGACTGGCATTGCGACCCGACCAGTAGCAAGCTCTGCTCGAGAGGCAATTTGTAGAGATGTTTTGAGCAG
TTTGATGGTGTGTGAGAAGAGGACACGGTTGGGGTCCTCTGTCATTCGAGAACACGATCCAGCCCTTAGA
AAGCATGACTTATGTCGGCGGCGCCCCCTTTCCTCGGGTACCTGTTTTGTCCCCAGGATGAGCAAGCACC
GCTTGTTACACTCGGCAGATTTGAAGTGGGCAGTCACGAGAAAACTGATGTGGCCAGTACGCTCCACCAT
GTTACTGCACTCTCATCACCCGCGATTCTCTGCAAGAACAGATTCAGAGGGTCCCACAATTCCCTATTCC
ACGACACACTCTCGCAGCAGTGCCACAAGCACAAAAGGGTTTGTTTCGACGCATGAAATAGACCGCCCCT
CCAGAGAAAACCTGTATTGGTGCAGCCATTCAAAGCATAGCGGGGCATGATCAACGACTGCCTGCTGCAT
TTTCGGAGTTGGGGCTCTTCAAAACAAACGACGTGAGATGGCTTTGCCACAAGATAGTGCTAAATGCCTG
TTTTTCCATACGAGGTTCGTTACACCGACTTCGGTGTCGCCCTGCAAAATGCTGACCGCTTCCCGCATTG
TCTATGATCCTGCCAGAATGGAGTCACCCTCATGCCCCCACTTCCCCTCGCGAGTGACAGGGCAGCTCGA
GGTTTGACATGAATGGCAGAAGAGTTCACTTTCCGAACGCCCACTCAAGATTACGCCATCCATCTGCCAC
AAAATATTACGCGCCTCCGCTTCCACTGAAGTGCTGCTTGCGGTGTCGCCTAAGCCCTGAAGTTTGCGTT
TTCTGGTGCTTCTTCTGTCACGAGGGTGATGATGTAAGACTGGTCCTTTGCCTTTGAGTCCTCTATCGCC
TCGCATCTGAACGAGAATGTTTTTGAAACAGGGACATTTTCCGGCACGTTGAGTACAGCAGGTTCTTTTA
TGCCGTCACCCCCCGTCCACCATTGGTGCGAGTCCGGCACACCAGGAAAGAGGGCTTGGAGAGTCTTCTT
ACTCGTGCAACTACTGCCTTTTCCCTCACAAACCAGCTTTTTGAAGTCTTCAGGGACCCAGTTCTTGGCA
TTGTTGCATTCGATCGCCACCTTCCATCCAGGATACACATAAGCGATGTTCTCAGTGCCCGTCCCGCGGA
TGGAACTGAACCACACGATGTTGTACTGTCCAAACGGAAACTGCTGCTCCTTTCGTGCATTCTTGAAAAA
CTTTGGGGCGGTAGCTTGGTCTGCGTCCATTGCAGAGGCATAGGCAAATATGGAAAGAAGCATTGCTACC
GAAGCGAGCTTCATTTTGTCAAGCAGAGCCAGGAAGCCTGGAACAATGAGGTTGGCCAGAGAAGACAACC
TACTGACGTTGGTAGAGAGAGCTCAACAACACTACTGCATGCAAGAAAAAGATGCACGTTCCTCCCACTC
AAACATCACTGGAACTTTTGTAATGCCAGGCAGCAGACTCACAAGAATCGATGTTGGTGCCCCGTGCAGG
GAAAGATCAGTCACCCGCGTATGCGGGTAGGTTGGCTACTAAGACAGCGAAGACGAATGCCCATGAGAGT
GGATTTTCCCGGACTCAAGGACAGCGGCTTGTCTGAAACGAGGCACATGAAAGAACAAAATTCGACGGCA
ACTGTGCGTGTCCGGAGAGTCAGCAAAAAGTTCGACTCTCCAGCGTATACCTGCATTACCCTGCGCTCTT
GGTCACCTCGGCTAGCCGCCTTTCTGCTTCGTGTGTGGCTCTCCCCGTTCTTGTGCCGCTGCAGTCGTTG
ATCCAGAGAGGTGTCACCTGTGCTTCAGCGCGGGGGTGTACACTTGGTGTGAGTTTGGAAGCCTTACGTA
AAAGTGGGGTCCAAAGTGCATTGATCCATGGATTACCAAACGAGTCGTAAAACCCCCGTCTTTGCCGTGC
GTTCCCCGTCCGCGCGTTTTAGATTCGATGCTTCTCCGCGGAGTACGGAAACAAAACGAGCTTTACAAAA
CTTTGGGCACTACTCCGGCATCCTTTGCGGCGATTCGTCTCCTTCCACTGAACGCTGCTGTAACTAATGG
CGCGGTTACTGCCTGCAGAGAAATACCAGCGACACACTCCCGTTCGCTTTTGAGGCGCCCTGCGAGTTCA
TTACCTCTACCGGGCGGGCACTATGGTATCGTCACGCGTCACGGTGCAGTCGGCGTGATGTCACCACACG
CTGCCAGTGGATATATCTACGGAAGCTGTAAGTAGGGCAAGCGTTGTCACCTCTGTGCACTTCATCAAGC
ACTCCGAATGAGAGCTTGCACCTAATTCCTCAATACGTAGGCAGAGGCGATGGAACCGTGTGTGTGCATA
TACTGCCCCAGAGGGCGTGCGTGGAAGTCGGCGGTCCACCACGGGGCGGTCAGTCGTGTGCGTCGTGGAT
TCACTTTTGCACAGTTCCGCGAGACTCCTGCAGAAGCAAAAAGTTAATTAAACATTGTTGTTCGTTAATA
ATCTCCGCGCCTGAACAAGGGCATTTAGCGGGCACGACCAGACAAACTGCTCTTTAGCTGCAGTTCTTAG
TGCCACCTTCACATTGCAGGATGGAAAAGAAACTAGACTCCGGGTAAAAGTAGAAGGATACAGGGATTCC
CACAAAAAATTGAACTGTGCAAGGAATTGGTGTTTTATAGATGAAGCACGGACCAGAAAAACAGTTCGCC
TCTCGTTACTCTAAACCGTAGCGTTGCATCGCCAAGCGGGGCGGCACGGTCTGAACTTGTCTACTCCAGT
CGACCTTAGTGCTGCAGAGACATGTTATCTGCGGCTCCGCTGGCGTGCGTTGACATTTGCCAGAAAGTCT
AAAGAGTTACTACACCATACAGCTTCGCAGAAATCCGCAACAGACGGGTGTCTTCGCTCTGGGAATGCAG
GACAGTTGTCC
-
Protein Sequence : Show Sequence
>XP_002368877.1 SAG-related sequence SRS42 [Toxoplasma gondii ME49]
MKLASVAMLLSIFAYASAMDADQATAPKFFKNARKEQQFPFGQYNIVWFSSIRGTGTENIAYVYPGWKVA
IECNNAKNWVPEDFKKLVCEGKGSSCTSKKTLQALFPGVPDSHQWWTGGDGIKEPAVLNVPENVPVSKTF
SFRCEAIEDSKAKDQSYIITLVTEEAPENANFRA
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
Oral immunization of mice with ZJ111/pcDNA3-SAG1 elicited specific humoral responses and stimulated proliferation of splenocytes (P<0.05). Mice immunized with ZJ111/pcDNA3-SAG1 displayed significant protection against an intraperitoneally challenge with 500 tachyzoite forms of T. gondii RH strain. Vaccination at 10(7) and 10(8)CFU per mice provided a 20% and 10% survival rate comparing 100% mortality of the non-immunized mice, exhibiting longer living time and better survival rate (Qu et al., 2008).
- Related Vaccine(s):
T. gondii DNA vaccine pVitro-SAG1-GRA7
|
|
45. SAG2 |
-
Gene Name :
SAG2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Nucleotide GI :
8777958
-
NCBI Protein GI :
8777959
-
Protein Accession :
AAF79156.1
-
Other Database IDs :
CDD:309286
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
surface antigen P22
-
Protein pI :
8.1
-
Protein Weight :
17781.73
-
Protein Length :
242
-
Protein Note :
SRS domain; pfam04092
-
DNA Sequence : Show Sequence
>gi|8777958|gb|AF249698.1| Toxoplasma gondii isolate C56 surface antigen P22 (SAG2) gene, complete cds
AGTGACCCATCTGCGAAGAAAACGAGCGCTGCTTGCGATCCTGTGTGTTGTTTCACGGGTTGCAGTTCTA
GGAACTGAGTTGTGATTGTGCACAATTGCGGTGTGACACCTTCTGTCTCGTTCCAATCTTTGTCTTGTCG
GAACTATGAGTTTCTCAAAGACCACGAGCCTAGCGTCGCTAGCGCTCACGGGCTTGTTTGTTGTGTTCAA
GTTCGCTCTTGCGTCCACCACCGAGACGCCAGCGCCCATTGAGTGCACTGCCGGCGCAACGAAGACTGTT
GATGCACCCTCCAGTGGTTCCGTTGTCTTCCAATGTGGGGATAAACTAACCATCAGTCCCAGTGGCGAAG
GTGATGTCTTTTATGGCAAGGAATGCACAGACTCGAGGAAGTTGACGACTGTCCTTCCAGGTGCGGTCTT
GACAGCTAAGGTCCAGCAGCCCGCGAAAGGTCCTGCTACCTACACACTGTCTTACGACGGTACTCCCGAG
AAACCTCAGGTTCTCTGTTACAAGTGCGTTGCCGAAGCAGGTGCTCCCGCTGGTCGAAATAATGATGGTT
CTAGCGCTCCGACGCCTAAAGACTGCAAACTCATTGTTCGCGTTCCGGGTGCCGATGGCCGTGTCACATC
TGGGTTTGACCCTGTGTCTCTCACGGGCAAGGTTCTTGCTCCCGGTCTCGCAGGTTTGTTGATCACGTTT
GTGTAAAAGAAAGGGCTGATGATTAAGTAGTCAAAAGGTCACACCAAGATATGCACCCCTGAAGAGACGT
CTTTGGGTCAATGGCCTTCTTTCGGAGAAGAGTTGCGAAAGTCGGTGAACGGTGGTCGCCCTCAGGGGTG
CACTTTGTTGTTTTGCTTGAAGATGCTCTTCCTATAAATCTTCCGAAAATGTTTCTCCGCATGACGGGGG
TTGAGCGAAGTTGGTGGTAACGGGAATAATTAAACGGGGATATCATTCCCCGTAGCGGGGTGGATGGGTG
CCTCCGGGGCTGCCGCAGTTCTGTTCTCCGAAGTGACTCCAGGTGGGCCGTGCGGCTTTTGTCTTTTTCG
TGAGAGCGGTCCGACCCTGCAATTCTCATGCCTCCGCTTCGAAATTGTCGTGCAAAGAAAACGTTGTTGA
GGGGTGGGATTGCGATTGTTCTTGGCGTAGATCCTGGGAGGAACGCGAGAAAATGTATTTCCGGATCTGC
GATTATGTGACAGAGGAACTTGTTTGCCCACACACTGCTGCAGTACTGTGCTTTTCCGCCAGACACAACC
AGTGTTCCGGCGGGTGTGCCTTCGTGAAACGTTCTACACATAGAGAC
-
Protein Sequence : Show Sequence
>AAF79156.1 surface antigen P22 [Toxoplasma gondii]
MSFSKTTSLASLALTGLFVVFKFALASTTETPAPIECTAGATKTVDAPSSGSVVFQCGDKLTISPSGEGD
VFYGKECTDSRKLTTVLPGAVLTAKVQQPAKGPATYTLSYDGTPEKPQVLCYKCVAEAGAPAGRNNDGSS
APTPKDCKLIVRVPGADGRVTSGFDPVSLTGKVLAPGLAGLLITFV
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pSAG1-ROP2-SAG2
|
|
46. SAG5B |
-
Gene Name :
SAG5B
-
NCBI Protein GI :
AAB70530.1
-
Other Database IDs :
CDD:240383
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
surface antigen 5B
-
Protein pI :
5.86
-
Protein Weight :
36188.17
-
Protein Length :
425
-
Protein Note :
Surface antigen (SAG) superfamily; Provisional
-
Protein Sequence : Show Sequence
>AAB70530.1 surface antigen 5B [Toxoplasma gondii]
MERTTAISNKFRAAAGLLAAVLFMSSPSGVRGRAAAGNKITPNCMASDNITTCVCEESETPSIRKDGQSD
SATLSESINSVTIQCPTTGDFKFVPSTVTDVCTAEETNITLKTCEGDNNNKNKSPITAFLVDVDGSNAPK
WTVAPPESKTHSLTLPAENFPRVDKKFFAGCLKTSSSRQRNADVECLVKVDVKARTSAVRDGVLICAYGD
KSNTSVPEVTLNAENNSLTIQCGEEGEMQPAPKYLTAYHCTDTNIENCKTVVNLTEVMPSFAKSWWTEDD
KNGKAPKLVIPEGGFPAQEETIVLGCNVRSKVSSKGQKEEANTTATLPTCRVKVTLTAQPAASHAPTLSC
LGLLAVVFTPVVSFGAY
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pSAG5B/SAG5C
|
|
47. SAG5C |
-
Gene Name :
SAG5C
-
NCBI Protein GI :
AAQ63835.1
-
Other Database IDs :
CDD:240383
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
SAG5C
-
Protein pI :
5.94
-
Protein Weight :
36838.83
-
Protein Length :
412
-
Protein Note :
Surface antigen (SAG) superfamily; Provisional
-
Protein Sequence : Show Sequence
>AAQ63835.1 SAG5C [Toxoplasma gondii]
MERTTAISNKFRAAAGLLVAVLFMSSPSGVRGRAAAGNKITPNCMASDNITACVCKESETASLRKDGQSD
SATLSESINSVTIQCPTTGDFKFVPSTLTEVCTAEETNITLKTCEGDNNNKNKSPITAFLVDVDGNNAPK
WTVAPPDSKTHSLTLPAENFPRVDKSFFAGCLKTSSSRQRNADVECLVKVDVKARTSAVRDGVLICAYGD
KSNTSVPEVTLNAENNSLTIQCGEEGEMQPDPKSLTAYHCTDTNIENCKTVVNLTEVMPSFAKSWWTQDD
KNGKAPKLVIPEGGFPAQEETIVLGCNVRRKVSSKGQKEEPNITATLPTCRVKVTLTAQPAASDAPTFSC
LGLLAVVFTPFVSFGAY
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pSAG5B/SAG5C
|
|
48. sdfa |
-
Gene Name :
sdfa
-
Protein Name :
SRS domain-containing protein; SAG
|
|
49. SOD |
-
Gene Name :
SOD
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii
-
NCBI Gene ID :
7900511
-
NCBI Protein GI :
AAC63943
-
Other Database IDs :
CDD:223678
-
Taxonomy ID :
5811
-
Protein Name :
superoxide dismutase
-
Protein pI :
7.07
-
Protein Weight :
21705.88
-
Protein Length :
258
-
Protein Note :
Superoxide dismutase [Inorganic ion transport and metabolism]; COG0605
-
Protein Sequence : Show Sequence
>AAC63943.1 superoxide dismutase [Toxoplasma gondii]
MVFTLPPLPYAHDALAPHISSETLQFHHGKHHAGYVAKLNGFIEGTAFAGKTLEEVIRTSTGAIFNNAAQ
VWNHTFYFSSMKPPMSGGGGEPTGRLLDEIKKEFTSVENFKDEFSKVAAGHFGSGWAWLVWDKQGKKVGI
EQTHDAGTPITEPMKVPLLCCDVWEHAYYLDRKNDRPAYIKAWWNVVNWDFASKNLENALK
-
Molecule Role :
Protective antigen
-
Molecule Role Annotation :
(Liu et al., 2017)
|
|
50. TgADF |
-
Gene Name :
TgADF
-
NCBI Gene ID :
7893682
-
NCBI Protein GI :
AAC47717.1
-
Other Database IDs :
CDD:449582
CDD:200442
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
actin depolymerizing factor
-
Protein pI :
8.2
-
Protein Weight :
12315.08
-
Protein Length :
181
-
Protein Note :
Actin depolymerization factor/cofilin- and gelsolin-like domains; cl15697
-
Protein Sequence : Show Sequence
>AAC47717.1 actin depolymerizing factor [Toxoplasma gondii]
MASGMGVDENCVARFNELKIRKTVKWIVFKIENTKIVVEKDGKGNADEFRGALPANDCRFAVYNCGNKIQ
FVLWCPDNAPVKPRMTYASSKDALLKKLDGATAVALEAHEMGDLAPLA
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
rTgADF
|
|
51. TgCST2 |
-
Gene Name :
TgCST2
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7894302
-
NCBI Protein GI :
237836689
-
Locus Tag :
TGME49_203600
-
Genbank Accession :
CM002041
-
Protein Accession :
XP_002367642
-
Taxonomy ID :
508771
-
Chromosome No :
VIIa
-
Gene Starting Position :
2405172
-
Gene Ending Position :
2411021
-
Gene Strand (Orientation) :
-
-
Protein pI :
8.23
-
Protein Weight :
44237.42
-
Protein Length :
439
-
DNA Sequence : Show Sequence
>NC_031474.1:2405172-2411021 Toxoplasma gondii ME49 chromosome VIIa, whole genome shotgun sequence
AGCACGTGTTACAGTTGTTTCATCGAGTGCTTAAGGGTGGCACCTGTGGGGAAAGCAGTTTTTGCATTCA
GACAAGTCACAGTGCAGCTTACACAAGGCATCAGGAAAACCAGGTGCTTTCACACTGGCATGATCTGTAT
AAGGCTGGAGAAAAGCTCGTGACAATCCCTGATGCTTCGCCAGCTCCACGTTCCGCACATATATCAGTAA
AGGAGCAACTATGTATATGGGGAGGTGTAAGAAGAGCGGGGCATGGTCCCATATATCAGTAAAGGAGCAA
CTATGTATATGGGGAGGTGTAAGAAGAGCGGGGCATGGTCCGACATGCGTTCTTGTCAAAGCACTTGCAA
CAAAGCTATGAGAGCGTGCTTGTAGACGGGTCGCATCTACGGTGTAATGTTTTCAGCAACCCTTCCAGCA
TGGATCACACCGCACGGAAAATGCTCAAGACGTTTCCTTTCCCTATCGTATAGTTTCAAGGCCGTGCAAG
ATATATATAATGTATACATATGATTTCAGTGATTCAGCTAAACGGCAAGCGAGAGACTACGATACTTAAT
CGTGGTCAGCGACAGTCACAGACATGCAATAATTCACAAACGGATCCGAGTCCGGATAGTTCCTCTTACT
CTATGATGTGAATGCGCATTTGTGGAAATCGCAACAGCCAAGCATCACACATCATGTCTTCAGAGACAGT
TCTGCGAGCTCGGCATGTGGCCGCTGACAGGATCGAAGCCACCAGGCTTTCCAAGGTGGCCCATCAAAAC
GCCATCATGGACGGTACCCACGGTATACGAGAGACGCTTTCAGCTACCGCCAGCAACTCTTGTCGCTCTG
CGAGGAAGAACTGATCCTACCTAGCAGCACTGCTAGTGATGCTACGGTATAACCACTGTTTTCCCACATT
TCAGCCGCGGGTTTAAACGCTCTAATCCGTGCCAGTTCCAAGCCTCCGTTTTACAGTTTGGCCTTGACAG
TTTACGCGAGACATGAGAAATACTACTATACAACGCACACAGAGTGACCCGCGCAAGCGGAGCTAATTTG
TTGATTCAGCACGGCATTGGTGGAAACCGGAAGGGAAACTTTTTTCGCGGCAGAAACAAAAACAACGAAC
AGGAGCCTAGTTCCACAATGGTCGCGTAACAACAAAATATGCCACACCGTCACCCACAACGCCGAAATTT
CTATGGTTGACGGAATGCGTTCGGTGTGAGATTGCCTTCCCGCAACTTGTTTACAAGGATGAGAAGCCCG
ACTCACACGATTTGCCACACGTATGACTTCAACCGCCGCGGCGCCACCTTCGAGCACAGGACCCTCAATG
CTCGGCTGTCCCTTGGACAGGCACACTATATGGATGGTAGAAAGGGTATCTGTATAGCCACATCATCGGC
ACCTTCGGCAACTGGTAATAAAATTCACCGTTGCACACAGTGACTGATAACCAACCGCAACCCTTCTTCC
TCTGCCTAGACCGATCCTTCGCAAACGACGTAGTGACACCCAACATCCCCACCAGATAAAACACTCACGA
AGTATCTCGGATCTGTTTATACAAATCTGTCACCTCAGCATTATTAGCATGCCAACAACTAGCCATTCTA
CGACTTAAACACACGACCCACAGTACCCCCCACCGGTCGAGCATGCTTCCACTCGAGTGATAATTTGAGG
CTGTCGTTCGCAACTGAACAGCGGAACCTGCCCCAATGAATCACTCTGGCCACTTCAAAGAAAACAATAT
ACAACGGCATTATGACAACGGAAGGTCCTACAGCATCACATGACCTTACTTCGGAAAATTACAGCATTCA
AGAGCGATGAAGTACAAGCCACTCCTGTCCATGAGCTGAAGAACCCTCAATAACTCGACAGCACTTGTGT
CCGCTTTTCTCATGTTTTGACACGCCACACAGCTCCCTTGAGTTCGCGAAACTTGAATTGCGATCTTGAA
CAGCTATGGCGTCACAAACACGAGTAAAAAGTGAATAGCCGAGGAATTACAGTGAAGGCGGACGCTTCGT
ACAACGGTGGATGGACGGAAATATCGCAGCACCTGATTCTGTTCCACAGTAGGTGCCAATGGCCGACACT
GCCCCGCTACGACCAACAGGTCTACGCTTCCGCAAAAAAACTCAATGACATTCTGTCACAATTGCTTCGG
TGTGAGTGTTCCTGATCAACTTCACCCTTTCTGGCACTATGGCATACAGACGTGACAAATGCAGACAGAC
AGATGGGCGAAAGCATCACCTCAAAAGGACAGGGTCGTACATTGCAACTGTGAGGGGCTCACATCATCTT
TATCTTGGACGATTAGAGGCAAGGGGTGCATGTTTCTTGAGGAGCTAATGCAGCGCACCAGTGAAACGCA
TTTCCGCCATCCGTACGAAGACACCGGACCATGCATCCCAACCAGTATGAGCTGGTTTTCTTGGACGGCC
TACTACCGGACAGAAGTATTGAAAAGCACGCAAATCCTCTCCTCATATGTCACCTTTTTTTCTCAGGGAT
AGCACCCGCGTCGTCGGCACCAGTTACCCTTCCGCAAACGACTCGTACGTCATGTTTCGATTCGTCGTTT
ACTAGATATCTTAGCCTGCCTTCTTCCTTGCAGAGAATCCCCGTTTTTTCTTCTAGATGTCCGTTCGTTT
CCGTTGCTTCGCGGCATTAGCCATCTACTTATCTCATGCCTTATTATCGCAGCAGCAATCCTCTTTTTCT
GACTCTGGTTGTTTCTCGTCCAGTCTTTTCTTCTCCACCGCGATAGCCTCCGCAATTGTGTCGCACAGGT
TGCCTGAGCTGCGTAGCTCCTTCTCAGTTTTCTCCAGGAACTGAGTGAAGACCACTGGACTCATTGTCTC
CTTGGCGGCGGACATGGCAGCAGCAACTGCATCACGTCTCTCGCCGCAGCTCGAATGCTCCATTCCAAGA
GCCGCGGCTTCTCCCCTCACAGCCGCCAGCAGGGTCATTTGATTGAACGACGGAGAAGAGCGCGCACTAG
CGTAGCTGGATCGGACGAGATCTGAGAGAGAATATCCCGATTTTCCCTCTTTTTCTGCCTTCAACTTGTT
GATTTCTTCTTCCACGGTCACACCAGCATTGTTCATTTCAGTCAGCAAAGTGGTACGGAATCTGCGGCAA
CTTTCGCTGGTGTATTTCCCTGCACCCAGCTTAACAAGCCGCGTCTCCACTGCAGAGACATTCACCGAGC
CCTCCTCACCTGCTGCGTTGACAAATGCGGGGTCGGAGTAGACGGCGAAGGGGCACTCGTCCAACTGTAA
AATGGTTTTGAAATTCTTTAGGAGTACCCCAGACCCGTGGGTTGACAGAACCGTGGAATAGAAGAGAGTC
AAAACTGTATACAGGACTTCTTCAACTCTTGAACGGCAGTCTCTGTCACCTACCGCACAAACTGGACTGC
CAGTCTTCGGCCCGCTGCTCTTCCAGACGTTCAAGCTGATCACCTCGAATTTTTCAGCCAGATCATGAAG
CGATGCACCATTAAGCTCCGTTCCTTCCAACGCTTCGCCACTCTTTGTCACACTTGCTGGTTGAACGGCA
CCTGTCAACTGCAGAAGAAGAGCGTGGAGCCAATGTGAGCTGACTCGGGCTGCTGTCGGCTGATCACTCC
CTCGGAACAAACGGCCAAGCCGTTTGCCGACTGCGGATTTCATCAAATTGTAAAGCTTGGTGTAAATGTC
AGAGAAGATGAAATATGACTTGTATCCAAGTTTGATTGGAACTATCACACCAATAGGTGGCGGACCGCCC
CCGCCTTGACCCTCTGCAGCAGGTGCCGCAGCAGATGCTGCTGGTGTTGGATTACGGGAGCCTCCACACG
ATTTCTTGCAGCACCCTTTCGCATTCGCGTACAAGGTGGCATCTTGGCTCCAGAGAAAAAAATAGGAGAG
AGAAACAAGCAACAGGAAAAAAAACGCCCTTCCGCCATTTCGCGAGGCACGATGGCAACCAGGGCGATTC
ATTCTTTCCGTGGAGAGAATCATCCCGGGAAAACGGTGCAAGAGCGTTGAAGTCGTCACGGTTACACGGG
CGAGAGTCGGACGCAGCGATGGTTCGACAGCCTAAAACATTACCACCAATAACGAAACGATCGCTTGGTT
TTACAACTAGAGCATATACGTATGCACAAATGCAGGCAACGAGAGATAACACTCCCGCAGGGCAGTGGCA
AAAGTAGTGGCATACAGGTATCTTCAGGACGGGGACAAACTGTCATGTCCGCGAATGCGGGAGCAAATGC
GTCCCCATTGAAGTCGCCATCATGCTCGCCTTCACCCCCCCCCCTCTCCCTCCCCCCACATGTCAAGGTG
ACGAAGCACACTGCGGTGTCTGGCCCCGCCAACCGCACCACCGACGGCGGATCTATTTTTGGCCGAGGGA
GTGCTTCGCAGACCAGCTTTTCAACGTTGCGTGCCGGTAGGTGAAAAACGCTCGGTTCTGTCGCCTTCGT
CCAAACAACAAAATACGTGAGATGACAGCCAGCCCGTTTAACTTTGTTGACAGGTGCTCAATGACACAGA
AGCAACAATCTTAAGCGGCAGGAACGTCGTTTTGCTCCAGACTCGGGCGCTGATCAACATGTAATCACGG
CATAGGCGAGTCCACAGGGCCTGGTGGACGTGGACTCGATGTGAACAGAAACACTGTGGTGCCCTTCGAT
CGAACATATCTGATTCTTATTTAAACTCAATAATATGATCCGTTCGACCGAGGAGCTGTCTCCTTTTTGA
GTCGCTGGCGGAAAACATGGAAGCGATTGGGGCGCCCCCAGAGCTGAACGGTTTTTCGAAATGCATTCAC
CTTTTCCTTCGCCTTTTTATTTTCACCATAGTGCAATAGCATTTTACGCTTCTGCTTTATTCCTGATACT
GAGGTTGTTTTCGCGTTTGCGGAGAAGGCTGTACAAGGCTCTCGCTGTGTTTGGCTGACGGCTCCACGAA
ACCGCGGCTGCTGCCGCAGATCTTTGCGGCACTGCTCCCGGGATGTCTCTTCCGAGTGTGTTCGTAATTA
GCGAAGCGACCCCGGTCCCTAGTGGTGTACGGAATAACCCACTGGCTCATGCCGCCAGAAGTAATGGAAG
TTCCTGGAAGCAATATCGCAGCCCATATGGAAAACATGACCCGAACCGGCGCACGGTCTGGCGTTCCCGC
GAACTGGACCAGTTTTCGTATTGTTCGTAACGGAAGTGGAACTCACAAAAGGTGGAAATCTCCTGCCTCC
TATTCCAGTGAAAAGGCGTTCTCCCTTACCACGCATGTGTTTCGACAGGCAGGCCAGCAACGAGGTATCC
AGTCTTCTTCCGAAACACGCCAATGTATCTGTCGTTAATGCGTCAATTACGCTGTGTGTGTTCTCTCCTC
TTGATTTTTGTTTGCTTGGCCGATCTTCTAATAGATTCAATATGGTGCAGTGAATGTGGCATACAAGTAG
TCAACTCGTGGGACGCGAGAGGGTGGGTGTTCAGTAGGCTACAGAGCTACAGGACCATTACTCGCTGGAT
ATCTGAGGCACAGTATCACAAGTTGGTGCTGCTGCCTCTGGAAGCACTTACCAACACGAGGGATACCAAG
TCGTTCACTGCTGCACCAGCTAGTGGTAATCCGCATGGTGGGATCCACTGCGTACGTAGAGACGTCCTGC
CTTAAAGTATTGGTCACATCGCCAAGCGGTCGAAACGTCAGTGTTGTGCTTCTACAAGCGTGGGTATGTC
ACTGTTAAAATGTGTTTTTCACAATCAGGTTAGTGTGCCGTGTTCATTGCCATGTTTCGTCTGTCCAAGC
TGAGGAACTTCCGCCCAGCCCTACAGGTAATGTGTTCCTT
-
Protein Sequence : Show Sequence
>XP_002367642.1 hypothetical protein TGME49_203600 [Toxoplasma gondii ME49]
MILSTERMNRPGCHRASRNGGRAFFFLLLVSLSYFFLWSQDATLYANAKGCCKKSCGGSRNPTPAASAAA
PAAEGQGGGGPPPIGVIVPIKLGYKSYFIFSDIYTKLYNLMKSAVGKRLGRLFRGSDQPTAARVSSHWLH
ALLLQLTGAVQPASVTKSGEALEGTELNGASLHDLAEKFEVISLNVWKSSGPKTGSPVCAVGDRDCRSRV
EEVLYTVLTLFYSTVLSTHGSGVLLKNFKTILQLDECPFAVYSDPAFVNAAGEEGSVNVSAVETRLVKLG
AGKYTSESCRRFRTTLLTEMNNAGVTVEEEINKLKAEKEGKSGYSLSDLVRSSYASARSSPSFNQMTLLA
AVRGEAAALGMEHSSCGERRDAVAAAMSAAKETMSPVVFTQFLEKTEKELRSSGNLCDTIAEAIAVEKKR
LDEKQPESEKEDCCCDNKA
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
ISA 201-rTgCST2
|
|
52. TgNTPase-II |
-
Gene Name :
TgNTPase-II
-
NCBI Gene ID :
29769498
-
NCBI Protein GI :
Q27895.1
-
Other Database IDs :
CDD:450142
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
Nucleoside-triphosphatase 2
-
Protein pI :
6.02
-
Protein Weight :
68301.522
-
Protein Length :
842
-
Protein Note :
NTPase-II; Nucleoside triphosphate hydrolase 2; Nucleoside-triphosphatase II
-
Protein Sequence : Show Sequence
>sp|Q27895.1|NTP2_TOXGO RecName: Full=Nucleoside-triphosphatase 2; AltName: Full=NTPase-II; AltName: Full=Nucleoside triphosphate hydrolase 2; AltName: Full=Nucleoside-triphosphatase II; Flags: Precursor
MWLPVYVPLLLVFGVSLSLPHGSLGTDSSSLRGVDADTEKRINVGKTHLQTLRNLETRCHDSLQALVVID
AGSSSTRTNVFLAKTRSCPNKGRSIDPDSIQLIREGKRFTGLRVVLEEWLDTYAGKDWESRPVDARLLFQ
YVPQMHEGAKKLMQLLEEDTVAILDSQLNEEQKVQVKALGIPVMLCSTAGVRDFHEWYRDALFVLLRHLI
NNPSPAHGYKFFTNPFWTRPITGAEEGLFAFITLNHLSRRLGEDPARCMIDEYGVKHCRNDLAGVVEVGG
ASAQIVFPLQEGTVLPSSVRAVNLQRERLLPERYPSADVVSVSFMQLGMASSAGLFLKELCSNDEFLQGG
ICSNPCLFKGFQQSCSAGEVEVRPDGSASVNEDVRKNRLKPLATYCSVHNPEISFKVTNEMQCRENSIDP
TKPLAERMKIENCSIIEGTGNFDKCVSQVESILVAPKLPLPANIEAASSGFESVDQVFRFASSTAPMFIT
GREMLASIDTLKDHRLLRSDFSGDVEELAEAAREFCSSEVIIRTDGPVIQLPNARGEQKLNSLNFDLCKT
MALTVSLLRHMAAGENQPSFIKWEKSIAGPDGKPLADLGWQVGVILHHVLFTEEWGRTAYEAGYSHNL
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
T. gondii DNA vaccine pDREP-TgNTPase-II
|
|
53. TgPF |
-
Gene Name :
TgPF
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7900190
-
NCBI Protein GI :
1084891739
-
Locus Tag :
TGME49_293690
-
Genbank Accession :
CM002034
-
Protein Accession :
XP_018638612
-
Taxonomy ID :
508771
-
Chromosome No :
Ia
-
Gene Starting Position :
510052
-
Gene Ending Position :
513603
-
Gene Strand (Orientation) :
-
-
Protein pI :
4.17
-
Protein Weight :
16550.6
-
Protein Length :
165
-
DNA Sequence : Show Sequence
>NC_031467.1:510052-513603 Toxoplasma gondii ME49 chromosome Ia, whole genome shotgun sequence
ACGTGTATCCTTCAGATTGAGAGTTGACGTTATCTGCCCACATTCACGACCTGAACTGTGGCCTTTTCCT
GCAGCCAAAGATTGCGCACTACGAACATAGGGTATCAGGCGGGTCCCTAGCCTTCTCATAAGCTGGAAAG
TACTCACCTTCAAATGGCCTGCCCAGAGGCATGCAAGACCACGACTGAGCCCTCATCGCATTGTGGCTGT
GTAACATCGCCAATACGCAAATTCGACACGACATATGTCAAAGCGAAGGCGCGCGGCGCTGCCCCCCTAA
CGAGGCATCACGTCTTCTTGCCATTGCGGGAGCACAAAAAACGTTGAGCAATATACTACCCCATTCAAGC
TACGCGGCGCCTGATTCTTGCAAGGAATCATGGTTCGTGGAAAACCCCATGCAAGACGGACACGAGGCGA
GCTAACGTCACGGCGCGGTAGACGAAAGCTCAAAAAAGAGACTGATTGCGTTACACAGGCGACCCCAATC
TAGATCACTGCTGCGATACTCAAGCGTACCACCTACGCTTTTGTGAGATACTTCGACAGAAACACTTTCT
GGAGCTAGGGTCATAACCGGTTGGAAACACGTGATTCGGAGACACACACTTTCTCTCGTCAGGGTAAGAT
CAATCTACCTGCATCGAGTGTCTATCCGTACTACAGCAGCGCTATCCAGTTTGGATCAACATAACCGTTG
GCGGTTAAGGATTCTGAGATTTAAGCATTCTGGAGAGGCACTGATGAGCCGAAGCGACCCATGAGGGGGT
GGACTGACAAAGGCAGAAGCTGCAACCATCGCCAACTCACTTTAACACATGGACCGCCAACGGGGTCATG
AGTGACTAACACCCTTGTATTGGCATACAATTGGACCTAAATCGCCTTTTCACCGCCGGGTGTACTGACT
GATTGGGTTTGCCTCAGAACTAGCACTATAAGCCTAAAAAAACTCGGAACCGTAGTTCGTTTGCCTTCGC
CCTTTTGGATATGTTCTTTGCTGCGTGCCCGAAAAACAAAACGGTGTATGAAACCGAGCCGAGGATGCAT
CCCTAGCACTTGCGTACATCGTTAATAACGAATTCGCTGCTGCACCTAATATGAGTGCCGTGGCACATCT
CACTCAAATGAAGAATCTGCGGTGACCGCGCAAAGAGTTCTGGCACTCTCAGAGGGGATCTGAGCAACGA
CATGCTTACGGAACAGGTCGCAGGCAAAGAGTTGAGCCACCAGGGGCTGAAAGAGATGCTCAACATACGA
AAGCACTTCCGAAGGTCGATAGTGCGTCACCCACAATAGACACGGTCTTCAAAATCGCTAATTCTGGACG
ATTACCACGCTCAAGTTCCGTTACAAACAAAGCAGACAAGTTAGTACCCAGACTGGTGAAGATACTCGGC
AAAGGCCAATGCCGAAGTCCTGCTGTTTCCCTTGTCCTGTTCCTTCTCCTCATCGTAAAGGGCAATGACG
ATAGAGCCATTCGGGGTCTTGATCAAGTGCGCGCCACCCTTGGACCGTGCACACATGGTGATGTCGAAGG
TGCAGTCGTTGTACTCGAATCCTTTCTCCTGCAGAGAAAATAGATAACATTGACAAATGCAACCACTTGG
ATACTGGAGACAAAAAACCGCCTTATCTTTGCATCAACTTTGTTCCCTCGGCGGTAATTTCTGCTAGTAA
GATCGACGTGATAGATACAAAAAAAGAAGAAACAAACAATTTTTGACGGTTGAGGACCAAGCACACGGAG
CACTGTATGTCCTGACAGATCTTCCCGATCCGAGCTGCTTTCTCACGCAGTGCGACCCCTTGCGAGATAT
GATACTTACAGGTCGGACAACCTTGTACTTCTGGCCGCCAATCCAAACACCGTTAGGGGCACTGCCATCG
TCAACTGCAGCTTTGATCGTGGAGGCCTCGTTGATCGACACCTTGCCGCACGCGTTGCCATCCTCTCCGA
TAGTGTCCTCCTCATGATCATCCTTGTACAGCTTGGACCATCCGTCATCATCATCAGCCGCCGCGGCGAA
CACAACACCGTCCTCCGCCTAAGAGTCGAGCGCAACAGAGAGACCAAGTACATTCGCATACAGAGCTGCT
GGCTCGATTACGTGACCATACTATGATCCGGGGACTCCGGAGGGAGTATAACACAGTAGACGCAAGGAAA
TGGTAAAGCACAAAAATCATACGCCGCCGCGCTGAGACACGAACAGCTAATCATGTTTCAGGAGCCTAGT
TATTACCTCTGCGGGAGGGCACTTCTCCCTCAGGCTTCAGAGGCGAGCGACAATTACTACTACCTATTAG
CGGATTCTAACACTGAAAGAATGCAAGGCGTCACAAAGGATTCTCATCCATAGAAGGATGACAGTCAAAC
ATTTGTAGGCACGGCTAGAACCAACAAAGAAAGTAGACGCCGCGGAGCGACACAATCCGCTGTTGAGCAG
CCAAAGGGGATGCGGCATTGATTGAGATGCGCATTAGTACAGCTACGCTGAGACCTCCGACTTTTTCTGC
CGCCTTTCTATAACGATTGGTAACCGGATAGAAACTTTACACGAGCAAACTGTACCGGAACTTCTAAACG
TCTAGCCGGCCTCGTTGTATTTCCCGAAAACTGCGAAGCACGCTTACGTTGGCGATGCCGCCTGCGCAGC
AGTAGCCTGTGTCAACAAGCCACTCCTTGACAACAGGGTCCCAGTCGGACATCTTGGAAAAGAATGGAAA
CAAGCCGCGAAAGAAGCGAAAAAGAATTCTATAAGATGTAGCCGATGACCTGGGAGGAAAGAAAATAATG
CAAGTAACGGCTCACACAACGGGCTACCCACCTTTCTCACACCGAGGCACACACACTGTCGCTGCCGCAT
CACCACCACTCCCGCGATCAGCACGCGCTGGCCAGGAGCAGCATCCAGCGCAAGCGTGCGCATCCCCTGC
CTTAAAACCGTCACGCGTACCGAGGGTCCGATGCAGGGCGCGTTTCGTGAGCCGAGCTTGGTGGCCGAGC
TGGGGAGCTGCTAACCCACTGTTGACAGGGCGTGGAAGAAGAGCGCGCGGCCACCACCAGTAAAAGGAGG
CCGCGGCGTGCCGATCACCGCATGTAGGGAAGGGCGCTGTTGCAGCGCAGCCATTACGGCTGCTTCCATC
GTATCTCCCGGGGGCGAAATTACCGCACCATCTATTTGGGATCCAGGTGGAAAGGTGGAAACACGTATCC
ACCCGCTAAGACGGACGTGCCATACCAGAAGGCTACACAGTAGATGACATGCAGACTTCTCTCCTTTGTT
TCAATCGCAAATGTAGCTTCCTGGTGGACACATTCTACACGCCCTACACGAAGCAACCGAGCTTCAAACA
GTTCCAGCGTAGCCGGCACTCACAGAGCAGAAGCCGCACGCGCCGCGTGCGCGACAGCAACACGGTCTGG
ATGAAGGTAAAACAGAACCCTACTATGACTGTGTCATGGCAGTCACGATTGAGGACAACGAAATGTTGGG
AACAAAACATGATAGATAATGGAGAACGATAGAGAAAATCGTAGTAAGAAGC
-
Protein Sequence : Show Sequence
>XP_018638612.1 profilin PRF [Toxoplasma gondii ME49]
MSDWDPVVKEWLVDTGYCCAGGIANVSAEDGVVFAAAADDDDGWSKLYKDDHEEDTIGEDGNACGKVSIN
EASTIKAAVDDGSAPNGVWIGGQKYKVVRPEKGFEYNDCTFDITMCARSKGGAHLIKTPNGSIVIALYDE
EKEQDKGNSRTSALAFAEYLHQSGY
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
TgPF-OML
|
|
54. TgRACK1 |
-
Gene Name :
TgRACK1
-
NCBI Protein GI :
AAT11121.1
-
Other Database IDs :
CDD:238121
CDD:293791
-
Taxonomy ID :
5811
-
Gene Strand (Orientation) :
?
-
Protein Name :
receptor for activated C kinase 1
-
Protein pI :
6.3
-
Protein Weight :
32518.95
-
Protein Length :
393
-
Protein Note :
WD40 domain, found in a number of eukaryotic proteins that cover a wide variety of functions including adaptor/regulatory modules in signal transduction, pre-mRNA processing and cytoskeleton assembly; typically contains a GH dipeptide 11-24 residues from...; cd00200
-
Protein Sequence : Show Sequence
>AAT11121.1 receptor for activated C kinase 1 [Toxoplasma gondii]
MSGESPLEFKGVLEGHTDCVTAISTPSLKSNTIVSSSRDHKVIVWTLNDNPDDSGSVGYARRALTGHSQC
VQDVVINSDGQFALSGSWDKTLRLWDLNAGVTVRSFQGHTSDVNSVAFSPDNRQIVSGSRDRTIKLWNTL
AECKYTIVDDQHNDWVSCVRFSPSANKPLIVSCGWDKLVKVWNLSNCKLRTNLVGHTSVLYTVTISPDGS
LCASGGKDGVAMLWDVNEGKHLYSLDSNSTINALCFSPCNYWLCAATDKSVKIWDLENKNVLSEITPEKT
NRSGAPWCTSLNWSHDGRTLFVGTFTGAINVYEVSSEQVTA
-
Molecule Role :
Protective antigen
- Related Vaccine(s):
rTgRACK1
|
|
55. UP |
-
Gene Name :
UP
-
Sequence Strain (Species/Organism) :
Toxoplasma gondii ME49
-
NCBI Gene ID :
7900273
-
NCBI Protein GI :
237830025
-
Locus Tag :
TGME49_110640
-
Genbank Accession :
DS984727
-
Protein Accession :
XP_002364310
-
Taxonomy ID :
508771
-
Gene Starting Position :
1252500
-
Gene Ending Position :
1256433
-
Gene Strand (Orientation) :
-
-
Protein pI :
7.12
-
Protein Weight :
31157.07
-
Protein Length :
303
-
DNA Sequence : Show Sequence
>gi|212659389:1252500-1256433 Toxoplasma gondii ME49 scf_1112359874864, whole genome shotgun sequence
GCGTCCCCCGCATTTCGGCAATCCGCGTTTGAACGAAACAATTGCTTGAGCAGCACGGAACTGCGTTGGC
TCTAAAGGCCGCCTGGTTGTACATATACTTTGTGAAAGCCTTCCTTTCCGCCGACCGTCCACTCGAGGCA
AAAACATGGGGGCGGAGAAAACCTGGAGAGGCACGGAAACGTGTGTACGTCGCCCCACTCATCTCCAGAA
TCTCTATCCCACATCTGAAACCCGCTGACGGTGCCTTTGTTGCGTTTTTGTAGGCCGGCCGCAGACGTCA
GTTTCCAGTGCGGCACGTGGACTGCGAAGCGCTCGGCGGTCCAGTGAACATTTCCAAGCAGACAGCCTCT
GTGTGGACTGCTCTGGACCGGGAGGAGAAATTTACGCTCTCTGTGCACGTAACTAATGACGAAGAACCCC
TAAAACGCTCACACGCAGTCTCGCGGTGCTTTTTTCGGGAGCAGCTCTCCTGCGTGGGAATGAAACCCAT
CATTTGAATTCATGACACGAGGGCCCAAGGCAAATATGGAACCCCAGAACCACCGTTCCGTTCTCTCTGG
TAACGTGGTACTGTGTGCATCATCTGGTTACAGTCCTAGAGTGCGCAGCGAGGACGACGTCTGCGCGAGG
GCGCTGGATTTGCTCCGTTCGTCTTTGTGCGCCGCGTATCCACAGTACTTTCATCACCGGCCTTGATGCC
TCCGAAGTTGCTGCTCATGACCTGCTCAGTTGCTTTACGCCGCAGGCTTGATGATGCCTTCGGAAACAAG
TGTCACAAGGGCATCAAAGGCAGCTTCGCCCGCTGCCAAAGTAGCCTTATCTTGGTCTTCCGCCTAAACG
CGACACACACACACAAAAAAAAAACAAGAAAAGTACAGAGTGACACAGCGTGGAAAGTCACTCCATCACC
TAGTTTGCGCTTCGTTTTCGTTGACACAGGCGTCGGCGCCTGTTTGCGGCGGAGTCTGTTTTGTCGTATC
TCCATGACACAACACTGTCTTTTCTTCTCTACCGAGGCAACCCAGAAGGAGAGTGTGACCTCACTCCTTG
ACATTTCTCCCCTCCTCCTGTTTCCGCTCACCGTCACGTGAGCTGTCAAGTTCGGATTGCTCCGGTTCAC
AAGGCCGATCATGAGAGAGGCGGCGTACGACTTGGGTCCGTTTGGGATGCTGTGCTGTCTCTGGTGCATG
AGATGGAAGATTTGGTGCGTCTCCATCTCCAGACTCACGACCCCCAGGTCTGTCATGTCCTTCAGGAGGT
TCGCGTTATTGTCGTTCCACAGCGGCAACTCTCTGCCCTGAATCGCATGCACACAAGAAACACGGCATGA
CCACACATTCACCTTCTCATCCTCTTACCGGCAATCTTTCGAGGTTCCCTTTACCTACGCGTCAAGCGCA
CTGGTGCGATCACGCGTGCGATAGCGCGAAGGAAAACACGAATCCAGCAAGCCTCGACAAGTGGTGAGGT
ATGTGTACCTGCGCCAGGCATCGCCGATGCAAAAGGGATGAGGAGGACCCTCGGGTCCCTCCTCAATCGG
TGTATGTGAAAAGACACTGTCCCTCCCTTTCGGCTAAGGTTCCACGCCTTCGGTGACTAGACTATATGCG
CTATACACACAAGGTCAACAAGTGTCAAAGTTTGGCCATCAACAGCCAGTGCCAAAAGCACATACCCGCG
TACCGCAGGCGGGGCAGCCGGTAGGCGCTGGTCGTTACCGCCCCCCCCTTGTGTGCCACCTTGGTCCCCC
CTTTCGGAGAGCGCACACGAGTCAGTACAGTCTTCGAAATCACCTTATTTGATTAACGTAACAGCGCAGA
CGCCTACGGTGCACCGCATGTAAACTGTACATTGGATACGTTTCAGCACTTCAGGGTTGCGAGAACCTTA
TAAATGAGAGAAGAGATGTTCGGTCTAGTGTTCCGTTATCCTACATAGATGACGTGGCTTGTAGCACGTT
TTTGTATCGTGTTTGTAGAAACGGATTACTGCTCACCTGACAAGCGAAGAAAGTCTCCGCCGAGCAGTTG
AGGCCTCGTTTGACTGCTGCACCCTGCGCATTCAAGTTGGCTTCGATAAGATCGGTCAAACGCTTGTCTG
CCTTGACCGGCGCTGTCAGCAAGTAGGGTCGCGGGTCGCGCCCGCACTCCCGTTTGTTTCCCAAAGCTGC
TTCGCCGTCAAAGTGACAGTAGTTCCTAGAAACACAAGCCGAAGCAAACCACCCCCTAGGTTTGTAGATC
CGCGAGAGAGTGCGTGGATTCGACAGCGCACGGACACTTCCGGAGATGCGTGTGCACAACCCGCCCCGCA
GCAGAGCACATGAACGACCAAGCCGAACCCGCTGCGGGTGCACAACACAGCAACTACACAATCAGTCAAG
AGTTCCCGGCCAAAATGCCCGATCAACAATCTACGGCCACACATCAGCTGGGGGTACTTCGTCGTCGTAC
GAGCAGTACCGTGGACACAGCCCATGTAGGGCTTTCTGCCTCTTTACAACCGTGAAATGCCCTTGTCAGT
GAACCGGGTCGCAACTACGAGGTGACAAAAAAAACAGAACTGCACGCCTTTACCTCTGCCCTCACCTGTA
GCAGTACATGCTCTCGTCGCTGAGCATGAGAGTACCCGGCCGGGTCGCGTAGTCGACGATTCCACAACTG
CCAATGCGAACGACGGCCAAGGGTTCTCCTTCCAAAACAAAAGAGGCTTCACGAATGAAAAAATCTGCCA
TCGGAGCACCCATGCCAATGCAGACGATCGACATGCGCTGTCCGCCTTTGATGTATTTGCCTGAAAACAA
GCAGAGAAAAACGAATACTAGAGAGTTGTGAACGCCAAAAAACAATCCGAAGAAAGCCACCGCCGACCAG
CAGGAGTTGCCACGAGCTGGAGGTCCTCGGGTTTGTCGAAGCACTATCATGCTATGACACCCCGAAGCAC
ACGACTTAAAAGATCGTTCAAAGCTCCCTCACCCTGTTCGGGTGCTCCCCATACACAAGATCTACGTGGG
GGTGCTCACGCGTCCAGTTCGGTCTATCATCAGTCTGTGGGTTTTCTAAACTCCCAAAAACGGTAAAGGC
AACCGATACGCGTTTTTTCAGTCGATTCACTGCCTCTGTGCAGGTGTGGAAAGGGTCTTCCAACTGACGT
CGCCAGGTCATCTGCCACCGTTCGCTCTCCCATGTTGTAGAATGCAAATCGCTACTTACCCGTGAAGGTG
TAGAATTGTCGCGAAGAGGAAACCTCCGTGACATCCGTAAGGAATTTCGCTGCGAGAACCCGCGCGCGCT
GTTCGCAGCCGACCGTCACGATCAGTGATGCCAAGTCTCCCTTCTTGACGCCCAGATGGTACGTGCGACC
ATCCGGGGTAAGGAAGATATTCTTTCCTTTGAGTTCCGACTGTCAGCGACAAACACACAACCACAGGACA
CGTCGTCATGCCCCCGTGCATAAGCTAGAAGTTTAGATAGCTAAATACCAGGTAAGCTCATGTTGAAAAC
AGGCTAGAGGCAGAAAAAAAAGCCGGAAAAAGATGTGATCTGCAACTGGTAAAGATGCCACTCTTGAACT
GGCAGGCACTACGCTCGTGTCCTGCACCACTGTATACGTCGTCATTGCTGCAAGAGAATCAACTACATAC
TAGGCAAATCTACGGCAAAACCCCTCGTCAAGAACTGTGAGGGAATGGGGCGGAAGCGCCCGCCCTTTTA
AATGCGACAAAGCCAGAAAGAGAAGCCCCGCTGCGTCAGACAAGAGGGGGAACGCAGGCGGACGCAGCCC
CCCGTGAATCAACGCAGAGCGTAGATGCGTGCCCTATCTTGCTGAAACTCACCATTGTACGCAAAAACAG
AGGCACTATATACACGACCTAAAGGATGGCGAAACGTTTCTTCACTTTTGTTTGGAAGACAAAAGGGAAT
GTTCAGGCAGCAGC
-
Protein Sequence : Show Sequence
>gi|237830025|ref|XP_002364310.1| uridine phosphorylase, putative [Toxoplasma gondii ME49]
MSELKGKNIFLTPDGRTYHLGVKKGDLASLIVTVGCEQRARVLAAKFLTDVTEVSSSRQFYTFTGKYIKG
GQRMSIVCIGMGAPMADFFIREASFVLEGEPLAVVRIGSCGIVDYATRPGTLMLSDESMYCYRNYCHFDG
EAALGNKRECGRDPRPYLLTAPVKADKRLTDLIEANLNAQGAAVKRGLNCSAETFFACQGRELPLWNDNN
ANLLKDMTDLGVVSLEMETHQIFHLMHQRQHSIPNGPKSYAASLMIGLVNRSNPNLTAHVTAEDQDKATL
AAGEAAFDALVTLVSEGIIKPAA
-
Molecule Role :
Virmugen
-
Molecule Role Annotation :
A UP mutant, in combination with an OMPDC mutation, is attenuated in mice and induces significant protection from wild type T. gondii (Fox and Bzik, 2010).
- Related Vaccine(s):
T. gondii OMPDC/UP mutant vaccine
|
| III. Vaccine Related Host Genes |
|
1. Ccl2 |
-
Gene Name :
Ccl2
-
Sequence Strain (Species/Organism) :
Mus musculus
-
NCBI Gene ID :
20296
-
NCBI Protein GI :
6755430
-
Locus Tag :
RP23-350G1.3
-
Genbank Accession :
AJ238892
-
Protein Accession :
NP_035463
-
Taxonomy ID :
10090
-
Chromosome No :
11
-
Gene Starting Position :
82035576
-
Gene Ending Position :
82037451
-
Gene Strand (Orientation) :
+
-
Protein Name :
chemokine (C-C motif) ligand 2
-
Protein pI :
10.38
-
Protein Weight :
14837.89
-
Protein Length :
148
-
Protein Note :
Also known as JE; HC11; MCAF; MCP1; MCP-1; Scya2; Sigje; SMC-CF; AI323594
-
DNA Sequence : Show Sequence
>gi|372099099:82035576-82037451 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
TGCAGAGAGCCAGACGGGAGGAAGGCCAGCCCAGCACCAGCACCAGCCAACTCTCACTGAAGCCAGCTCT
CTCTTCCTCCACCACCATGCAGGTCCCTGTCATGCTTCTGGGCCTGCTGTTCACAGTTGCCGGCTGGAGC
ATCCACGTGTTGGCTCAGCCAGGTGAGACCCCCCCAGCTCCCTTCCCAGCATATCACCCCATTTTTGAAT
TGTCGTGGATTGTGATAGCATAGTCTCACATGGTCAGGTACTTTTTTTTTTTTCTTTAACCAAGATAAGG
AGCATAAAGAAGGAAGGACAAAGAGCCAACCCAATTACAAGATTGCTTCTGGAAAGCAACTAGAATTTTA
ATTGTTAGATCTAAATTTGGAATCACACCTTCATATAGTTCCTGTTCCAGTTACTTCCCTCAGTATTTGG
GAACCTGGGTGATCAAACAGAGGCTTGGGTTGGTGCCTTTTTCCAGATAGAGGAGAAAGGGGAAGAGATC
CAAGATCCGAGCTGTGTTTCACCCAGCCCTGCTTCCAGAGATAGCAGCTTAGCGGAGGTGGTTGGGATCA
GAGATACTCATGATTTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCCTACAGTAATGTA
CTCAGGTAATCTTCTCAGGTCATAGTAATTTGACTTCTAACTCCCCCAAATGACAGTCCCCAGAGTCACA
TAGTTTTAATGGCATCCCTCTACCCAAGACTGTGAGCCTACTTTAAGCTGCAAATAACTGAGTCTGTTGT
CAAAGATCACATCCCAGATCTGATGTATTGGCATTTATATCCCATCCTGCTGAAACTGCCTTCTCCCCGT
GGTCCTTCTCTTCTCTAAGGTCAGAAGCATCTTTCCTGTCCTAATGTGCTTCTCTTTTACTCTCCAGATG
CAGTTAACGCCCCACTCACCTGCTGCTACTCATTCACCAGCAAGATGATCCCAATGAGTAGGCTGGAGAG
CTACAAGAGGATCACCAGCAGCAGGTGTCCCAAAGAAGCTGTAGTGTGAGTTACATACCCCGGCCCTCCC
TGGTCCAAAGGTTTTTCCTTAAGAACAAGGGATGGTCCTCATATACTTATAGTCAGTCACACACTCAGAT
CCAATGGGGAAACCAAGGCCAAGAAGGCAAAGGCAGTTCTCAACAGCATTGTCTCTATGGCTGCTGTTCA
GGCCCTTTCTACTCCACAAGCTTATCTTAGAAAACCTGCAGGAGAAGCAGGTCACTTTGAGTCCCCTTTT
TCTACCTGCCCTCCCCCGCTGAGCTCTACACAGCCCCTCCATGTATACCAGACTGAACTTCATCTAACAG
TGTCTTTTCTCTTCCCACAGTTTTGTCACCAAGCTCAAGAGAGAGGTCTGTGCTGACCCCAAGAAGGAAT
GGGTCCAGACATACATTAAAAACCTGGATCGGAACCAAATGAGATCAGAACCTACAACTTTATTTAAAAC
TGCATCTGCCCTAAGGTCTTCAGCACCTTTGAATGTGAAGTTGACCCGTAAATCTGAAGCTAATGCATCC
ACTACCTTTTCCACAACCACCTCAAGCACTTCTGTAGGAGTGACCAGTGTGACAGTGAACTAGTGTGACT
CGGACTGTGATGCCTTAATTAATATTAAACTTATTTAACTTATTGATGTTATGGTATTCCCTTTCATGAA
TACTAAAATTTCTTAAATGCAAGGTGTGGATCCATTTTTCCCTCTCTGTGAATCCAGATTCAACACTTTC
AATGTATGAGAGATGAATTTTGTAAAGATGAATGGGTAAACTTTGTGTTTGAGATTCCAAGGTATTGTTT
AAAATATTATTATGGATATTCCTTATTATTAAAAGAAATATATTATTTTTGTACAC
-
Protein Sequence : Show Sequence
>gi|6755430|ref|NP_035463.1| C-C motif chemokine 2 precursor [Mus musculus]
MQVPVMLLGLLFTVAGWSIHVLAQPDAVNAPLTCCYSFTSKMIPMSRLESYKRITSSRCPKEAVVFVTKL
KREVCADPKKEWVQTYIKNLDRNQMRSEPTTLFKTASALRSSAPLNVKLTRKSEANASTTFSTTTSSTSV
GVTSVTVN
-
Molecule Role :
Vaximmutor
- Related Vaccine(s):
T. gondii mic2 mutant vaccine
|
|
2. Ifng (Interferon gamma) |
-
Gene Name :
Ifng (Interferon gamma)
-
Sequence Strain (Species/Organism) :
Mouse
-
NCBI Gene ID :
15978
-
NCBI Protein GI :
33468859
-
Genbank Accession :
NM_008337
-
Protein Accession :
NP_032363.1
-
Other Database IDs :
MGI:107656; UniProt: P01580
-
Taxonomy ID :
10090
-
Gene Strand (Orientation) :
?
-
DNA Sequence : Show Sequence
>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC
-
Protein Sequence : Show Sequence
>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC
-
Molecule Role Annotation :
IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.
-
Additional Molecule Role :
Vaximmutor
-
Additional Molecule Role Annotation :
The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes (Wang et al., 2009).
- Related Vaccine(s):
T. gondii mic2 mutant vaccine
|
|
3. IL-6 |
-
Gene Name :
IL-6
-
Sequence Strain (Species/Organism) :
Mus musculus
-
NCBI Gene ID :
16193
-
NCBI Protein GI :
13624311
-
Genbank Accession :
AC112933
-
Protein Accession :
NP_112445
-
Taxonomy ID :
10090
-
Chromosome No :
5
-
Gene Starting Position :
30013160
-
Gene Ending Position :
30019967
-
Gene Strand (Orientation) :
+
-
Protein Name :
interleukin 6
-
Protein pI :
7.5
-
Protein Weight :
23291.86
-
Protein Length :
211
-
Protein Note :
Also known as Il-6
-
DNA Sequence : Show Sequence
>gi|372099105:30013160-30019967 Mus musculus strain C57BL/6J chromosome 5, GRCm38 C57BL/6J
ACCAAGAACGATAGTCAATTCCAGAAACCGCTATGAAGTTCCTCTCTGCAAGTAAGTGAAGGCAGTTCCT
TGCCCTCTGGCGGAGCTATTGAGACTGTGAGAGAGGAGTGTGAGGCAGAGAGCCAGCATTGTGGGTTGGC
CAGCAGCCATCAGCTAGCAGCAGGCGCCCAACTGTGCTATCTGCTCACTTGCCGGTTTTCCCTTTTCTCC
ACGCAGGAGACTTCCATCCAGTTGCCTTCTTGGGACTGATGCTGGTGACAACCACGGCCTTCCCTACTTC
ACAAGTCCGGAGAGGAGACTTCACAGAGGATACCACTCCCAACAGACCTGTCTATACCACTTCACAAGTC
GGAGGCTTAATTACACATGTTCTCTGGGAAATCGTGGAAATGAGAAAAGAGGTGGGTAGGCTGTGAAACT
GATGAAGACCCAGTGTGGGCGTCCATTCATTCTCTTTGCTCTTGAATTAGAAATTCTCTGCTGGGATCTA
GGGCCCTTAGGATTTGAAGCTAAAGGTCAGACTAGACTGTGTTCTCTCTTTCTCACCTCTTTGCTGGTTT
TGAGTGGAGGTTGGGAAGGGGTTCCTTTCCTGTCTGGAAGATACAGAATGTGACTGCATTTCTAGAAAAT
TCACAGTGGGCCATTCTCTGTTCCAATTTAGCTATTGCTTCTTAGGTGGGGATTCCTTTTCCCTCATTAT
TCCTTTTTCCTTATCTCTTTGCCTTCATTTATCCCTTGAAGTCTACAAGGACCAGAAAGTGCTTTTTGGC
TGAATGTAGTAAGTTCTGTGTGTGTGAAATCAGGATGCTCTAGGGTCAGCCCAGATAAGATGCATATTGT
ATAGAGCCCAATAAAGTGCTAACACACACACACACACACACACACACACACAACCTAGATTAGGCTGGGC
ATGGTGGTGGATGCCTCCCAGCACTTGGGAGGCACACGCAGGAAGATCTCTGTGAGTTAGAGGCCAGCTT
GGTCTACATATTGAGTTCCAGGATATCCAAGACTACATTGAGAGATCCTTTCTCAAAAAAAAAAAAAAAA
AAAAAAAAACAACAACAACAAACAAACAAACAAACAAGAAAAAAAAAACCCAACCAACCCTACCTAGATT
AAAATATCTCCCATCTTTAAATGAAAAGTATTTTGACTCTGCTTGACAGAAAGGAAAAAAAAAATCACAA
ACAAGATTAATAGCCTAGGTCTGGGTGTGTAGAACCAACTTTGTAATCTTGGGAAAATCCTCAACTATTT
AGTACTCTTTATCTGCATAATTATGGAGTTACAGATAATGGCACAGACCCTTCCAGATGGAATATTCTGT
GACTTAAATTTATTTGCCCCAAGATATCATCAAAATTTCTGTCCTTTACCAAGTTCCTACTCTATGCTGG
GCAGTTTTTATCGTTGAATCCTTGAGACAAATGTATAAGAGGGACATCAATAATTCTTTATTGAAACATA
GGAAATACTTAGGAGAGTAACAAGCTTAAAGCCAAGGGACTGAGCCTAAGGGTGCATTTTTATTTATTGG
GCTGCTTAGTAGGGTTCTAAGAAGGTATAGCTTCCCTTTTCTGTGTCCTGGCTATGAAAGAGCATGACTT
GGCCCTCTAGTGGTGCTTGTTGTAAGAGGTGTTTAAGTGATTGCTCTGGTAATCTTTTGCAGTTGTGCAA
TGGCAATTCTGATTGTATGAACAACGATGATGCACTTGCAGAAAACAATCTGAAACTTCCAGAGATACAA
AGAAATGATGGATGCTACCAAACTGGATATAATCAGGTAGAAACTTGTCACGTTTACTTTCAACAATTCT
TCAAGGTTCTCTCTTGCACGTGATACCTGCATTTGTACAGTCCCAGTCAGGCAACAAAGATGGGGGGATA
CATCCAATACCACTTGGATGTAACTGGCCTGCAGTAGCTTGAATACAAAAGGAGATTGAGAGGTACCTCA
GCAGCTGCTAGGGTGAGGGAAAGTTTACCAACCAGTGCTATAAATGTTCACTCAATCTATGTCCATCAGG
AGCTAAATGTTTAAAGTCTCTATTCTCATCTTGGCTTTGAGGTGTTAGATGATTAAAAAAAAAACATTTT
TTTTGTCTAAAAAAGTGGAAGAGTAGATATAAAACATGTTATGTAAACGTCATGAGGAAAGTAACTTACA
GATTTAATTAAAAAGCAGTTTATTTAAACAGGTAAAGGCCCACTATGCTGGGATTCTTCACCACTGTTAA
ATGTTAGAAGTCATAGCAAGTTTAGCTAGTTCATGAGCCATCTCTTCTCTGGCTGCCCCTGGAAGGATCC
AGGCCTACACTCCCTACTGAGAACACTCTTCACACCCCTCTCCTTCCAGCCGGTGAGATAGTCTACATCA
GGTCTCAGGACAAGTCAGACAAGAACAAGAGTACAGGAAGGGCACTGCAGGATAGAAGGGAAGGAGTGAG
GGTCAGAAGTGGATTCCCACTGCCACACTCTGGGGTAGGGGGTGGGGGGATATTAAGTGGTGCCTCTCTC
TACTTGTCCAGATAATTCAGGAGGTCAGCTGATGCTGCCTGTTGTCTAATTCTGTAGAAGATACTGAACA
GCAGGAATCTTTTTTTCAATTTTTTATTAGATATTTTCTTCATTTACATTTCAAATGCTATCCCCACAGT
CCCCTATACCCTCCCCCCCCTCCCCGCTCCCTTACCCACCAACTCCCACTTCTTGGCCCTGGCATTCCCC
TGTACTGGGGCATATAAAGTTTGCAAGACCAAGGGGCCTCTATTCCCAATGATGGCTGACTAGGCCATCT
TCTGCTACATATGCAGCTAGAGATATGAGCTCTGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTAT
AGGGTTGCAGACCCCTTCAGCTCCTTGGGTACTTTCTCTAGCTCCTCCATTGGGGGCCCTGTGTTCCATC
CAATAGAAGACTGTGAGCATCCACTTTTTGCCAGGCATTGGCCTAGCCTCACACGAGACAGCTATATCAG
GGTCCTTTCAGCAAAATCTTGCTGGTATATGCAATACTGTCTGGGTTTGGTGGCTGATTATGGGATGGAT
CCCTAGGTGGGGTAGTCTCTGGATCTTCCATCCTTTTGTCTTAGCTCCAAACTTTGTCTCTGTAACTCCT
TCCATGGGTATTTTGTTCCCCATTCTAAGGAGGAATGAAGTATCCACATGTTGGTCTTCCTTCTTCTTGA
TTTTCTTGTGTTTTGGAAATTGTACCTTGGGTATTCTAAGTTTCTGGGCTAATATCCACTTATCAGTGAG
TGCATATCAAGTGACTTCTTTTGTGATTGGGTTACCTCACTAAGGATCATACTCTCCAGATACATCCATT
TGACCAAGAATTTCATAAATCCATTGTTTTTAATAGCTGAATAGTACTCCATTTGTAAATGTACCACATT
TTCTGTATCCATTCCTCTGTTGAGGGACATCTGGGTTCTTTCCAGCTTCTGGCTATTATGAATAAGGCTG
CTATGAACATAGTGGAGCATATGTCCTTATTACCAGTTGGAACATCTTCTGCGTATATGCCCAGAAGAGG
TATTGCTGGATCTTCCGGTAGTACTATGTCTAATTTTTTGAGGAACAGCCAGACTGATTTCCAGAGTGGT
TATACAAGCTTGCAATCCCAACAGCAATGGAGGAGTGTTCCTCTTTCTCCACATCCTTACCAGCATCTGC
TGTCACCTGAATTTTTGATCTTAGCCATTCTGACTGGTGTGAGGTGGAATCTCAGGGTTGTTTTGATTTG
CATTTCCCTGATGATTAAGGATGTTGAACATTTTTTCAAGTGCTTCTCAGCCATTCAGTATTCCTCAGTT
GAGAATTCTTTGTTTAGCTTTGTACCCCATTTTTAATGGGGTTATTTGAATTTCTGGAGTTCAGCTTCTT
GAGCTCTTTGTATATATTGGATATTAGTCCCCTATCAGATTTAGGATTGGTAAAAATCCTTTCCCAATCT
GTTGGTGGCCTTTTTGTCTTATTGACAGTGTCTTTTCCCTTACAGAAGCTTTGCAATTTTATGAGGTCCC
ATTTGTCGATTCTCGATTTTACTGTACAAGCCATTGCTGTTCTGTTCAGGAATTTTTCCCCTGTTCCCAT
ATCTACGAGGGTTTTTTTCCCACTTTCTCCTCTATAAATTTCAGTGTCTCTGGTTTTATGTGGAGTTCTT
TGATCCACTTAGACTTGAGCTTTGTACAAGGAGATAAGAATGGATCAATTCGGGCTGGAGAGATGGCTCA
GTGGTTAAGAGCACTGACTGCTCTTTCAGAAGTCCTGAGTTCAAATCCCAGCAACCACATGGTGGTTCAT
AACCATCTATAATAAGATCTGATGTCCTTTTCTGGTGTGTCTGAAGACAGCTACAGTGTACTTACATGTA
ATAAATAAATAAAACTAGATTATTTAAAAAAAAAAAAAAAGAATGGATCAATTCACACTCTTCTACATGA
TAACCACCAGTTGAGCCCGCACCAATTGTTGAAAATGCTCTCTTTTTCCCACTGGATGGTTTTAGCTCCC
TTGTCAAAGATCAAGTGACCATAAGTGTGTGGGTTCATTTCTGTGTCTTCAATTGTGTTCCATTGATCTA
CCTGTCTGTTGCTGTATCAATACCATGCAGTTTTTTTTATCACAATTGCTCTGTAGTACAGCTTGAGGTC
AGGCATGGTGAGTCCACCAGAGGTTCTTTTATTGTTGAGAATAGTTTTTGCTATCCTAGTTTTTTTTTTT
TTTTTTTTTTGAACAGCAGGAATCTTATTCTCAAATTGAATCTATTCCTAGAAAGAACTGACTTCCTTTT
CCATTTTACTTATAGGAAATTTGCCTATTGAAAATTTCCTCTGGTCTTCTGGAGTACCATAGCTACCTGG
AGTACATGAAGAACAACTTAAAAGATAACAAGAAAGACAAAGCCAGAGTCCTTCAGAGAGATACAGAAAC
TCTAATTCATATCTTCAACCAAGAGGTGAGTGCTTCCCCATCTCTCATGCAGTGTGGGAAAGAGGACACC
CGGCACCTCAGGGTAGCGGCACTTTTTCCAGACAGCTGCTCAGAAGGGAGAGAGTCTGAACAACAGTTCT
TGATTATAAGGCCTTGCTTTGTTTTACTTTGGGGTTTTGTTTGAGGTTCTCTTTTGCAAAGAACATCAAT
ACCTGCTTTAAACTGTATTAATAGAATGTTACTAATTGCGTAAGAGGTATGAAAACTATGACAGCCATAC
ATAGTCACCCATTATGAGAGCACAGAGACAAAAGTGACTTTAATATTTAATCCTTGGCAAGTGACATTTT
TGTAACCAGAGTTCTAATGCAGAGAAGTAGCCAAAAGCTAAAATGTCAGGGAAGGAAGGGATCAAGGGCT
TCTGGCTACCATTAGCCAGAAGAATGGTAGATATGGAGGATTAATGACTCAGAGTGTGGGCGAACAAAGC
CAGATGCAATAAGAAGGGCCTGGAATGAAACCCTCTTGCTAAGGCTGCTTTTGCCACTTGTAGTTTCTTG
CCTTAAACCAGAGAGTTTCCCAATTTAATGTGCACAGGAACCACTTAGGGTCTTGTTCCAGCAGGGTCTT
ACTTAGGAGGTCTAGGAAGGGAACTAAGATTCATTTTTGTAAACAGCTGCTTGTTTATGACCCTGCTATA
TAGTATTCAGGCTCCTAAGTAGTGGGGCAAGCCTTCCAGTTAGTCTTCCCCATGCCAGTGGGCCCATGGA
AGGGTGTTTCCAGACTTCTTCATGCTACCACACTAAGAGACTCTCAACAGAGTCTGAATGGAAACCACGA
AGGAACACATTTGTTTTAGATTCCTCTGTGCCACCTTTACTGATGGGAGCTTCTGTTTTCCAGTAGAATA
CAGTATGTTAGCATGGATGCTTGGATAACAGACAAATAAGATGGTGGTGCTGACCTCTGGACGCTTACTC
TCTAGTGGCAGACAGAACAGTAAGGTTAGAATTCTGTTGCTATTAAAAAACTAATAATAATCACCTTGAA
AAAGAATGGAGTTGTTAGGCATGGGTCTCTCTCGAGTAAGCTTGGAACAAAAGCATCTCCCCTGGCTTGG
GTGAGTCAAAGCAGATGGACTTAGCTCGTCTCATTCATTCTAAATTAGAACTTCTTCCCACAGCCCAGAA
CACGCCACAAGAAAAAAAAAATGTGCAATATTTAACCAGTCTTTGTTTTTTCCTCCTTTAGGTAAAAGAT
TTACATAAAATAGTCCTTCCTACCCCAATTTCCAATGCTCTCCTAACAGATAAGCTGGAGTCACAGAAGG
AGTGGCTAAGGACCAAGACCATCCAATTCATCTTGAAATCACTTGAAGAATTTCTAAAAGTCACTTTGAG
ATCTACTCGGCAAACCTAGTGCGTTATGCCTAAGCATATCAGTTTGTGGACATTCCTCACTGTGGTCAGA
AAATATATCCTGTTGTCAGGTATCTGACTTATGTTGTTCTCTACGAAGAACTGACAATATGAATGTTGGG
ACACTATTTTAATTATTTTTAATTTATTGATAATTTAAATAAGTAAACTTTAAGTTAATTTATGATTGAT
ATTTATTATTTTTATGAAGTGTCACTTGAAATGTTATATGTTATAGTTTTGAAATGATAACCTAAAAATC
TATTTGATATAAATATTCTGTTACCTAGCCAGATGGTTTCTTGGAATGTATAAGTTTACCTCAATGAATT
GCTAATTTAAATATGTTTTTAAAGAAATCTTTGTGATGTATTTTTATAATGTTTAGACTGTCTTCAAACA
AATAAATTATATTATATT
-
Protein Sequence : Show Sequence
>gi|13624311|ref|NP_112445.1| interleukin-6 precursor [Mus musculus]
MKFLSARDFHPVAFLGLMLVTTTAFPTSQVRRGDFTEDTTPNRPVYTTSQVGGLITHVLWEIVEMRKELC
NGNSDCMNNDDALAENNLKLPEIQRNDGCYQTGYNQEICLLKISSGLLEYHSYLEYMKNNLKDNKKDKAR
VLQRDTETLIHIFNQEVKDLHKIVLPTPISNALLTDKLESQKEWLRTKTIQFILKSLEEFLKVTLRSTRQ
T
-
Molecule Role :
Vaximmutor
- Related Vaccine(s):
T. gondii mic2 mutant vaccine
|
|
4. Il12b |
-
Gene Name :
Il12b
-
Sequence Strain (Species/Organism) :
Mus musculus
-
NCBI Gene ID :
16160
-
NCBI Protein GI :
6680397
-
Locus Tag :
RP23-388G23.1
-
Genbank Accession :
AL607030
-
Protein Accession :
NP_032378
-
Taxonomy ID :
10090
-
Chromosome No :
11
-
Gene Starting Position :
44400062
-
Gene Ending Position :
44414016
-
Gene Strand (Orientation) :
+
-
Protein Name :
interleukin 12b
-
Protein pI :
6.5
-
Protein Weight :
35952.67
-
Protein Length :
335
-
Protein Note :
Also known as p40; Il-12b; Il12p40; Il-12p40
-
DNA Sequence : Show Sequence
>gi|372099099:44400062-44414016 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
CAGAAGGAACAGTGGGTGTCCAGGCACATCAGACCAGGCAGCTCGCAGCAAAGCAAGGTAAGTTCTCTCC
TCTTCCCTGTCGCTAACTCCCTGCATCTAGAGGCTGTCCAGATTCAGACTCCAGGGGACAGGCTACCCCT
GAACCAGGCAGCGTGGGAGTGGGGTAAGTGGATTCTGGGAGCATCTCGGATGGCTTTCCCCGCTGGTGGA
AACCAGGGGCTTTGACGACAGGGGCTTCAAATAGTCATTTAAAAAGTCAGCTAATTACAGATGTGATGGC
GCACACCTGTAATCTCCAAATCTGGGAGGCAGGAAACAGAATGCACAGGAGTTTAAGGCCAGATTCAGCT
GTGTAATGAGTTTGAGAGAGTCTCAAAAAATTGAGCTACTAATAATATGTGCCAAGCATTGTGGACAGAT
GTGTATTTGATAGAAAGGTTTGCTTTGTCTATATAGACACATATACTATGTGCATTTTCTTAAGTATTAA
TGCATATGTGTTAAGGAGTGTTGTTAAAATTCTGTTCTTGCCTTAAGAGTGAAACTTAAAAAAAAAAAAA
GCCTTTCATGTACCCCTTCAAGCCTAAGCTCATCACTGAATGTCCTACCTGTGATGGCCTTTAGAATCAG
CTATGATAATCAAAGTGGAGAGCTGGGTTTGGGGGTTCCTTTGGATTTTAACTAACTTTGCCACCTCTTC
AAAACTGGAAAGCCCAAGGCATGTTCCAAACTATTTCCTAAAGGGTTCTAAAATCTGTGAGAAAGGGAAG
GCTAATCTTCATGGGTTGGCTTCCTCTGCTTGCCCAGGTGAAATCATGAGCACCAGATGGGGCAGGGTGA
TGGGGCAGGGTGACATCTTGCTTTCACCCAGGGATCACTGAGCCTCAGCTGGGGGCTCCGTTTGTTCAAG
CAAGGCATTTCAAGATGAAGTTAGGTCACCCCCAAGAATTCATTTTGCTGAGATCTGAAATACTGTGATT
ATTGCACCAACAATCCATGGACTCTCTCTAGGCTAGATTCTGGATATAAGACTAGACAGATATGACCTCT
GTCACACACCTCGGTATGGGAAAGGGGGGACAGACATTAAAGACGTAATCAAATGATTGTCATTTCAGCG
ATGCTGAAGGGGAAGAGTAGCTATTTGGGGTCCTGTTTTCATTTGGGGCTCAAGCTGGCACTTTCTGTGG
ATCATTTCATGAACTCCTAACCTGACAGAGTTATTTTTAATCTAGGAGTACAGGCTTGACAAAGTCAACA
CAACTTGTCAAGGTCACATAACTAACAAGTGGCAGACTGAGGTCTGTTTGGCTGTAGAACCAAGGCCCTT
TGCCCGTGCCCTCCTTGCCATCCCTGACAGCCACGCCATCTGTACTGTGCATTGTTGTTTCTGGGCATTT
TTATTTTTACATATCATTTCTCTTTTAAATTAAAGAATAACAGAATGAAACTTGCAAAAGGGATGTCCAC
TCAGGCACCCGCTGGCAGCAATGTTTGGAAGCATTTGCATGCTCTAGGGAGCTAGAGTATCCAGCCCAGG
GTTCCTGTGCTCTTTGCACAAGACTTTCAGGACTTAAGAAAACTAATGAAAACAAACAAACAAACAAACA
AACAAAAAAGAATTGTTAAAACATAGCATATGGAAGAATTGTGGAGTGAGAGGGAAACAAAGCCCAGCAT
CTGCCAATCAGCCTGAAAGCCAAAGCCTGGCTACATACTGCACACTTTTTTGCTTGTGCAGATTTGATTA
AGAGGCGACCTGCCATCATCTCCACCCTCTGCTGGTCTTCTATGATCTAAGATGTAGGTGATGCCGAAAT
GAAGATTGTTCCTTGGACCATTGCCAGGGCTCCCTTCAGCCTGAAATATGGTTCACGTGTGATGCTCAAG
TGCATCTGAGGCTGACAGAGGAAATGCTTGGCATGTAGCCAAAGGGGAAATCCCTGTGTTGAGAGCATAT
GAAGAGATCACCAGGAGATGCCAGGAATCTCTGCCTTTTTTCCCTGCCCAGAGTCCTACCATCTGGGTTT
CACAGCCGTGTATAATTGCATCACCTTCTCTGGGCATTTCTCTCTACAGCCTGGCAGATTTTTATTTTTC
AACCCAGTGTGCACAAAACAGAAAGAATTTCAATTTTTTTCCTTAGCTTTTTACTAGTGCAAGGTATTAT
ACAATGTCATCTCACTGCATGCCCAATAGCTCTTGAAGATCACATAAGCCTTATGTCTTTTTATATGAAG
GCAGTCGGGCTCAGAGGAACTAAACCAACACCAAACAGCTACTGAGTAGTAGGGCCAGAATCCAAGTCCA
TGTCTGCTTGACTCCAAGCCTATGAATGTAGCAACCAGCACCATTTCAGCTTGTACTTGTCTTGACTATA
TGATAATTTGGACCTAGACATGTCCTGACTCCTAGTCCTGTCTCTGTCATGAAAAAGAAATCATAGCAGG
GCCCTCAAGAGGTTAGCAGTACTTCTGTTCTCTCAAAGGTCGTGATTTCTGACCAAGGCCTGTTTATTTT
TAAGGCATTTGCCTATAACATTTAAGCCTTAATTCATATGGGTTAGACTGTGGTCTCTCAAATCTTGTTC
CTGACGGGCGGTGGCACCCTCCAGGATAGATGAAAAGTATTTCTGAAGGGAATTAGTAATCTACACTGAT
TATCTCAACCACATTTATGAGTGAGGTATAATCTTTACAGTCTAAAGGTTTGTGTTGCCCTGGTGTTAAT
CTAGACTGGGTTACAATACAGGATGGTTACTGACTTATCTATTTCATGATAGGTTAATCAATATGGTACA
GTCTTCTGCCAAAGAACACCTTGAATTTTAGGAGTTCTGGACTCTCAAACCTAGCTAGCACATTTGCCCT
CACAATGTGTTCAATGGATCATAACATCAGCTTTCAGCACCTCCAAGACATGTTAAGTCAGACACTCTGT
TCTGGGCTGAGACCCAACAGTCTCCGTGAACCCAGGTTATACACACACCCAAGCTTAAGAAATGCTGCAT
TTTGTTGTGAGGGAGAGAATTATTTTAGAATTTGGAGTAATCTCTGCCTAGGTTTAAAAAAACCTAATCC
ACTACAGGTCCTTGTCAGAACTTGAAAGTTTACCCTGTGTCACCTTTCCCACACCTAAGCTGGTCCTCTA
GCCTGGGGCATCCCAGTGCCTACTGCACAGCAGGGTGATTCGGATGCCCAGTGACACTGTTCTCGTCCAT
ACTGGCAGCATGGCAGTACTTTCCCATTCTGTTCAAAGCTCTTTGGGTATTATGTTAATATTACAATCAT
AACTAAGGAAATATCTGATGACTGTGGACCTGGGAAGCCACGGTCATCTCTAAGTTTATGTTTCTGAACC
TTAAAAAAAAATAAATAAGATGGGTGTGGTGGCTCTCGCCTTTAATCCCAGCACTCAGGAAGCAGAGGCA
GGTGGATCCCTGTGAGTTTGGGGTCAGCCTTATCTACATAGAGTTCCAGGACAACGAAGGCTGAAAGTCT
GTCTTAAGAAGAGGGAGGGAGGAGATGATTGTGGATATCAGGAAGACAGTTCAGCAGGTCACATTACTTC
TGCACAAGCCTGGTGACCTGGGTTTGAACCCTGAACCCAGAGTGAAAGGAGACAGTCAACTCCCAAAAGT
TGTCCTCTGACCTCCACACATGCACACATACAATAGTCATACATCAATATATTTTTAAAAAACAAAATGG
TATCAGGTAGCTGGGCCCTATGATTATTTAAGCTCCAGGTAGCCTCTAGTTCTTTATTTGGAGATGTTTT
TACCCAAATCTAGAAGAGACCTCCTATAATCCTGGTCCAACAGTGTGAAAAGAAAGGGGAAAGTGAGTAT
TTGGAAGGCAGATAAGCTGTTGATCGGGTTAATTGGATAACAGTTGACATTCTCTCTCCCATTTCCCCGC
CTTTTCCTTCTCCTCTGCTCCCCTTCTTCCTCCCTCCTGCCCCTCCTCCACACAGATGTGTCCTCAGAAG
CTAACCATCTCCTGGTTTGCCATCGTTTTGCTGGTGTCTCCACTCATGGCCATGTGGGAGCTGGAGAAAG
ACGGTAAGCAGCCTTTTCCCTGTTTTCTTTGGAGCGCCAGCACCTAAACTTGATCTCCAGGCAGCCTGCT
GGGAAGGGATAGTGAAGTCTGAAGTAGGCAACCGTGCATGGGATTGTCTCAGGAAAAATCCTCAGGGAAG
ATGGAGGGTTAGCGTCTCTTCCTCCACCTATCTCTCTCCCTTGTTTGGTTTTCATGTTGGATGACAGGAA
AGGAGTTTCAGGTGAACTATGGTGGTGTGTGGGATATGATCTTGGCCTTAGATACCAGAAAATGACTCTT
CTAAACAATTGAAATTCCCTAATAGAGAATTTGTAACGTAGCAAGATTGTCTTCTACCCTCTCTTGTCTT
GCATATTACAACGTGCTCTCAGTGGGCACCATGATGGTTGTCCTCTGGCTATTTTGGGATTGGCATTCAC
ACTGACTTGGTTTCAGGTCATGGCTCTGCCAGGTATTGATACTGAACCTTTGAGGCTGGGTAGTCTTGTG
ACCTCAGTTTTCTTTCCTTTTTTTTTCCCCCAGACAGGGTTTCTCTATATAGCCTTGACTTGTCCTGAAA
CTCACTCTGTAGACCAGGCTGGCCTTAAACTCAGAAATCTGCCTGCCTCTGCCTCCCGAGTGCTGAGATT
AAAGGAATGCACCACCACTGCCTGGCTGACCTCAGTTTTCTTAATTGGGTGTTCAGTATAGCACAGCCCA
CATGGACTATTGAATATGTTAATAAATACAGAAAATAACATATGGTAGAGTGAGCAAGCACTATTATTTA
AAACAAAAAGTCTCTGAACTTTTCATTATCCCAATGGCAATAAGATTATTAGTAGACAAATAATGAAGGC
ATAGAAGGGGGTGCTCTCTGTCCTCTGTCCTTGTGCCATGTCACAGTTAGCAAATGTCCATCAACTCAGT
CCTCAGATGGTCGTCACAGGATCTCAAATGTTTCATGGAATACAAGGTAATCAAGTCAGGAATTTCTGCT
TTTATAGCTACACTTTAGTAATAATTAATATTTATTTAACACTCAATTTCGCAACAACCATGTAAAGTAG
GAGCTATCTGTATTCCATTTTACAGATAGTAAAAACTGAGGTTCAAGAGGCTAAGTAAGTTTCCCACAAG
GTCCAGAATAGAACTTGATCCCAGTTTAGTCTCACTTCAGAGCCTGTGTGCTTAAATGCTAGATTTTACA
AGTAAGGCGTGAAGCAACTATTTCCTGTGGCCATAAAGAGGAAATGGGTGTAAATTATAAATGAAAAGAT
TTCCCAGCTGCTGATTAGAAATAATCTTCTGAGAATCCAGGAAAAAAAAAAAAGGTGAGCCTTTTTTTCA
TTCTGAAGAATTACAAGAGTTTGAACGATATTCGCAGGTAAAGGTGCTTGCCACCAAGTCCGATGACCTA
GACTTCATCACTGCGATCAGCATGATGGAAGGAGAGGATCGAGTTCTCTAAATTGCCCTCTGCTCTCAAG
ACATGAGCTGTGACACCTGTGCACACACACACACACACACACACACATGAAAGAATTAAATGCAACTTTA
AAAAGAGTAATCTCCAGCCTGGCCACCCACGCCAACAGAATTTTGGATGCTTTCCTAAGTAAAGCCTTTG
CCACAGCCAGATGGACAACTTAGGCCCTGGCAGAGTTAACCCCTTAGTTACTTCTGACCTGATAAACCAC
AGAAATTTCAGAAAAGCAACAGGAGAAACACAGAGAGAGCTTGTGTTGGAGTCACAATGGTGGCCCGAAG
CCCAGCAGATATCTAAGCTCTGATTCCAACGTGTCCAAGAAGTTCTTTCCCTGCCCTGGGGCTAAGGTCT
TCTAGGGTTTCTGAGTTCAGGTTCTAAAAGGAAAATAATAGACAGCCTGTTTCATGGCCTAGGGGACAAA
GGGAAACTGGGAGCCAAAGGGTCCTGTGCACTGGAATCAGCTCAGGCTAACGATTTCTGAAGAGCTTGGC
CTCAAGTGATTTGTACCTCTTATCTTTGCTCCCCATTCAGCAGTGACAAATCCCACTGATGTAAAAGTAA
GAGCTTAGCATTTCACAAGGCTTTAAGCTCCAATGCCAATCACAAAGCCACCATTCACAGGGCACTTAAG
GAAACTGTCTTAAGCTTGCATACAAATTAGTTTAGATGTTACCTTCTAAAGAAAGCACTAATATTTTGCT
TTCTTTTTTCTTTTTTTAAAAGAATGACATCAGACTAGGGCATGGCAGTTCATGCCTGCAATCCCTGAAC
TTGATAGATCAAGACAAGAAGAAAGCCCAATTTTGTGGCCAGCCGGGGCTATAAAGTAAAATTCTAAGTA
GCTGGCTGTCTCTTCCCACCCCCGAGGCCATGGCTCTCTGAAAGCCCTTTGCTGGCTCTGCTCCATAGCC
GTGCTATTCCAAAACCCAGGCTCTTCACCACTATGCCTTCCATATTCAATCAGGCATCAGATGACTGGGG
CCATCCTGATCTGACTCAGCAACCAAGAACAAACCTCACTGATGGGTTTTCAGGTGATGCTGATGATGGA
GGTTGAAAGACGACCCTGCTTTACGGGTCACTGCATTAAGCTAGTCTTTCGATTAATAATTGATATGTAG
GTAACCTTTGAAGCTTTGTCACATGAGGCTTTGGTGTGACCCACTCCAGAATACCTTATGGAGATATTCT
GGAGGCTCCTTCAGAAACTAGCATCAGATATCCATTGCACAACACAGGAGACAAAAGATCCGAAAGACAC
CATTTGTTACCCTTCACACTTGATGGGACCTCACTTAGCCCTTGGCCATCAGCAAAAACAGTTCCTTCAA
AAACTGAGACAATCATCTACTGCTTTGTAAGAGTGTAAAATAGCTTTTAAAAACAAGTAGTTAATGGCAA
TCTCCGTCCACAAATTTCATGCAGAAGAGACTTAAAAAAAAAAAAACCTAAATCTTTCTGGATAATTTTA
AGAGTTTTTCAGTGCATTTGCCTGGCTCTTTGGCCTGTGCATGACAGTGATGATGATGATGGTGGTGGTG
GTGGTGATGATGATGATTTTAAAAAGCTAGCACAGGGTTATCCTGCCGTAACCTTAGCTGTGCTAAGGTG
CATGCTTTTTTACCATCTATCCTCACAGCTAATCCTATTAGCATAGACAATATTGTTCTTACCATTTTGT
GAGGACTCTGGGGCTACTGGTGGTTCAGGACCTTGCTCAAAATCTCCTTTGCAATTAGAGAAGATAGGAT
TTCTGCATCTTTCTTTCTCCACACCTATGCTTTAAGCCACTATGTTATTCTGCTCAATACTCTGCCCTGT
GTATTCCCTGTGAATTACAACTGGAAGCTTACTCCCCCTCATCTCCATTCCCAACACACACACACACACA
CACACACACACACACACACACACACACACTAGTGGCTTCTGACAAGGAATCTTGTGCTGTTTGCATCTTT
TCTTGTTTCAAGGTCTTCCCTTCCTAATCAGAGACCGATTATTACTGGCCACCTGCCAGTTAAATGACTC
GGTGGCAGCTATAGAACTGTTTCTCTGTTCTGTCCCCATGCCCTGAGATCTCTCAGCAAGCACTTGCCAA
ACTCCTGTGAGCTATGACGTTCCAAGGGCCATGGGTGTGTCAAGACACTGAGTGAAACCCAGTTCCCGGG
GTTTGTGAGGCTCCTGGTCCAGGTCCTCACTGCTGGTGCTCTCCAGTTTATGTTGTAGAGGTGGACTGGA
CTCCCGATGCCCCTGGAGAAACAGTGAACCTCACCTGTGACACGCCTGAAGAAGATGACATCACCTGGAC
CTCAGACCAGAGACATGGAGTCATAGGCTCTGGAAAGACCCTGACCATCACTGTCAAAGAGTTTCTAGAT
GCTGGCCAGTACACCTGCCACAAAGGAGGCGAGACTCTGAGCCACTCACATCTGCTGCTCCACAAGAAGG
AAAATGGAATTTGGTCCACTGAAATTTTAAAAAGTAATTCCATCCCCCTTGACAGTATCTTTTCTTCTAC
CCCTCCTTAAAAAGTAATAATTGCAAGTGTGTGTGTGTGTGTGTGTGTGTGCGCGTGCGCGTGCGCGTGC
ACTGAGGCTCAGAAATGTTTCTCATTTCCTTTGAAACAGGAACTCTCATTGGCCCATAGCTTACCAATAA
GCTTTCTTGGTTAGCCAATAACATCCAGAGACCTTGTCTCAAAAAAAAAAAAAAAAAAATCTCACCCTTG
TACCATGTAATGGCCAGTGATCCATCCACAGTAAAAAAGAAATAAATAAATAAAATAAAAATAAAAAATA
ACAAAAACAAATTTCTTTATTAAAAGAAAACTCCTAAATATTTAATTTTTCTTTTCTTTTCAAATGCAGA
TTTCAAAAACAAGACTTTCCTGAAGTGTGAAGCACCAAATTACTCCGGACGGTTCACGTGCTCATGGCTG
GTGCAAAGAAACATGGACTTGAAGTTCAACATCAAGAGCAGTAGCAGGTAAGGGAGCTGCCATGATTTCT
CAAGGTTTTGTGTGATCTACTTCATAACAAAAAGAAGTACAAACTGCCCATGGATTATCAGTGACTGGTA
ATGGAACAGCAAAGTCAATTCTGTATTTTTTTTTTCAACTTCCCTCTGCTCGCCTAAGGAAATAGCATGG
AGCTTTAAGCCAGCCCTCTGAGACTAGTTGGCTGGGTAGTTTGAATTCACTCATCCGAATTGCCTGGCCG
TGCTTCATTAAGGCTCACAGCACCATGGGGAGGAATTAAAAAGAAGCCACAGCTACAAATAACTGGCCAG
AGCTCGACCTTGTGTCAAAAGCAGAATTGAGTGCTCCAGGGCCTTGCTGTTGGAAGCCCTGGAACAGATT
CCAGAACCCTCTGAGGCCTTTCGAGATTTTCCTAGAGCCTTTTCAACTTCTTCCCCCCCCCACCCCCACC
CCCCAACCGTTATTCTGAAGTTCAGTTTCCCCAATGCACTTGGGCTTTTCCTAAAAACATCATCTCCCAG
GGCTGCAGAGCGGGTGTGTCAGACTGCTCTACAGCTGACTTTAGTCAGCAACTAAATCCCTGAGCCACAT
GGAGGGCAGGGAGTGAGCGCCCTGGCTCTCCCACTATTTAAATGAATAAACGGGGGACAGGGGGTGTGGG
GGGGACGACTCCCTTTTCCATCTTTATCATGAATTTGCTATGACTTAACTTAGCTAAGGAAAATAATGGT
TCAGGGTGACATCAGAGTCCTTGTTGCTTCTATGAGAATTTTCTGATCTGGTAAAGGTGGCCCCAAAGGA
GACCAGTGTACAATGCAGATGCTTACATATAGAAACATGCCAGACCTCTATGTGCTTTAAAAAATTAGAC
AAGCACGATACATTTTCCTGCTAGAGAAATCTTGCACGTGTTCCTGAAGAAACTAGTACATGGATAAGGG
TCAGTGGAACATTTTGCATAATTAGCAAAAGCATGCTCAAATGGAACATCAATGTGCATCTATTGAAATA
AATAACTCAACTTTCGTGTTCTGTTTAGAGAACTCCCCCACAATACTTTCAGAGAGGAAAAAGACGTTAC
AAACTCATGCATATATATTTTTCATTTGTCTTTAAAGTTGTGCTACTCTTTGGATAAACTACATATGTAC
ATATATGTCTGTGTGCATGTCTATCTTAAATATTCATTTGGAAAAACTCTAGAAGTAACAAACTGTGAAC
AATGTCTATATGTGGGACTCAGATTTGAGTAAAAAGGAGAATTGTGGCGACACGCATGTTTTCTTTATAA
TCATCTTTGTTGTTATAATTCTTTATAATTCAGCAGTTTCTCTTGCATTACGATATTTTCAGGTTCATTT
AGGCAGAGATGCAACTTTCAGTCTCTTACAGCTAAGCTTCCACTCTGCAAAGGGCAAGGGGGTTTTTGTT
TGGTTTTGGTTTTGGTTGTTTTATTCCACTGGAGAAATCCAACCAGCTGGACAGACTGGCCTCGGACTGT
AGACACCAGGCACTCTATCTCTGATCTATAATACAGAACTCATTCTGTCTTTGCCATCAGTTCCCCTGAC
TCTCGGGCAGTGACATGTGGAATGGCGTCTCTGTCTGCAGAGAAGGTCACACTGGACCAAAGGGACTATG
AGAAGTATTCAGTGTCCTGCCAGGAGGATGTCACCTGCCCAACTGCCGAGGAGACCCTGCCCATTGAACT
GGCGTTGGAAGCACGGCAGCAGAATAAATATGAGAACTACAGCACCAGCTTCTTCATCAGGGACATCAGT
GAGTTTTGCCTGGGAGCAGGTGCTAGGGAAGCAAAGACGATGTCTGCCACGTGTCCATGATACCCTGGGG
CATAGGATTGGCCTGCATTCTTTTCCATTCTCCTAAAAAGCATGATACAGACACTACCCTCTTCATCTTA
CAGATGAGGAAATTAAAGGGTTAAGCTAACCTTTTTCCAGATCTCAAATCTCACAGACAGCAGACCAGAC
CCAGACCTGCCCCAATGGTGGCACCTAATGGATTATGGGTTAACTACATGCTTAGTGTAAAGCAGAAACC
AAGCACAGGGAGGGTTCCCTGATTGCTGAGCCCAGATACGAGACTCTATTAAGCAGAATGACTCAACCAG
TAGGGACTTCCGGTCTGTGCAGTGCAGAAAGGGTTCTAAAATGTAGGATATGGCCAATAATGGTGACTTC
CTCGAGTGGAAAGATCACTCTCAGCAGATCCCTCACAGGTGCTGCCCTGATGCTCAGAGAAGTGAAAGAG
CTATTCCAGAGACTAGAAGGTGGAGGGCTCTGTCAGCCAAGCTCAGGAGCCTAAGTCCTAGCTCCAAAGC
CTGGCCAGGATAATAAAGGATGCTTGTCTTCTTCTGCAGTCAAACCAGACCCGCCCAAGAACTTGCAGAT
GAAGCCTTTGAAGAACTCACAGGTGGAGGTCAGCTGGGAGTACCCTGACTCCTGGAGCACTCCCCATTCC
TACTTCTCCCTCAAGTTCTTTGTTCGAATCCAGCGCAAGAAAGAAAAGATGAAGGAGACAGAGGAGGGGT
GTAACCAGGTAGGATTTATGCAGCCCATGTTGGGGCCATTGGAAAGATCCTGACAACCAGGTGCTTGCCT
CAGGACCAGAACTGTGTTAAGGGCTCTCCATGTGAATCACACACAACCTATACAAAGTCCCAAAGGCAGC
CAGTATTGCTGTCACCTCTCCACAGAGGCCAGGAAAGCTCAGAGAGGCTATGTTTTGCCCACGTTCTTCC
AGCTAGAGCAGTGGCAGAACCAGTACCCAGCAATGGTTTGATGGAGAAAGAGATGGTTAGCTCAACCACT
TCAATTCCTCCAGTATAGTCGATTGTCAATCCTCAACCAAAGTTGTTCATGATATAGAAACCTGGGATCC
AGGAGCCTATAATGATTGTTTAAACTGAGTAAATATAGTAAATGCTAAAACATTGATGCTGGGACCCACC
AAATAAGGATAATCTCTACTTCCTTAATATGAGCAATCATTTCACCTTACAAGATGTCCACCTTTACTGG
GCTAATATGGTGACTTTCTACCTTTCGGGTCCTTAGCACAGTGATCTCTTGCTAGGTTTGAGGAACACTT
TTATGAGCATTTAAGTCACAGAGCAAAGGATTCTTCCAACCTAGCATTGAGAATGTGATAGCAATTCAGC
TCAGAGATTCAACCACTTCCTAAAAGCAGGAGCAAAAAATGGGATTATTTTGAAACAGATTTTAACTGCT
ACCTAAGTTTCATCCCTGTGTGTATGTATTTAATATACCAATCTTAAATAGGTAATGTCTAGTGCTTTCT
ACTTGCTAAAAGCTTTCTACGCATTTTTACATAAATGTTGTATTTAGCTGCTGCAATTCTTAGAGGCAGG
CATCCTGGGACCTACTCATGAATAAGGAGAGACACAGAGAACCAGAGATATTTTCCTGAAGCACCACAGC
TGTTTAGTAGCATTGCCAGGATTTGAAGTCACTTTTGTAAGCTGACAGGCATGGTAATTCTTGATGTCAA
GACAGCTAAAGAAAGCTGGTCTCAGTCCCAACATCAGCTTCATATGGGAGTGGTTACCCATGGGACCTTG
GGGTAATGCTGCTACTTCAAGAGGCAGAAGGGGGAGCAAGCCATTTCTGTTGGAGTTTACTAAATAGAAA
AGTGAGAGTGGGGTGGTGGATGAATCATGCTGGAATATGAAGACCTGAATTTTAACCCCCAGAACCTCTG
TAAAACTGAGTAGTAATGCCTGAACCTGGGCTCTGGAAAGAGGTGGGACACATACACACACACACACACA
CACACACACACACACACACACACACACACACACCTCTGATTATAGCTTCTACCAGCAGGTGGTGCAAGGG
GAGCGCCCATGCCAGCCTGCCTTATATTGCCTAAAGCCCTTACTTAAATTTTCCTCTCCTTTGCAGAAAG
GTGCGTTCCTCGTAGAGAAGACATCTACCGAAGTCCAATGCAAAGGCGGGAATGTCTGCGTGCAAGCTCA
GGATCGCTATTACAATTCCTCATGCAGCAAGTGGGCATGTGTTCCCTGCAGGTGTGTGAGCAGGACCGTG
AAGCCCAACCACACCTGCACATTTAGTGGTCCTGGTGGAGGACAACAGGAGGCTTGTGAGGGAGGTGGGG
GTGGAATTCCTGGCATAGGGATTCCAGTCAGAAACACATTTGTTCATCAGCAGATGTTAACTTGATGTGT
ATGTTAGGTCAGGCACTATGCTAGGCCAAGGATATTACAATAAAGAAAACAAGCATGGGTCCTACCCTTG
TACAGGGAAAGGCAAGAAGGACCAGAGGAGGAGGAAATCAGGAGTCAGAGTATGGAGAACTTGGAAGTAG
ACAGAAGTTGGAACCATATCTTAGGGGTTCTGGGGAACCACTGAAGTCTTTTTAATAAGGAAATATCCCA
ATCAAAGCCCTTTTAAGAAAAATCTCTCAAGAGAGTCCCTGGCAAGCATGAGACCAGCTGAAGTCCAAGC
CCTGTAAGGAAGGGTTGGGCTGTCTCGCACAGAAATCCTCAAGACCCAGTGTCTGGGGATAATAATGTGT
GGTGTGAAATAGGAGGGTATTGAGGCTATACCTCTGACCAATATGGACTTACCTACCCACATTCCTTTAC
AGGGTCCGATCCTAGGATGCAACGTTGGAAAGGAAAGAAAAGTGGAAGACATTAAGGAAGAAAAATTTAA
ACTCAGGATGGAAGAGTCCCCCAAAAGCTGTCTTCTGCTTGGTTGGCTTTTTCCAGTTTTCCTAAGTTCA
TCATGACACCTTTGCTGATTTCTACATGTAAATGTTAAATGCCCGCAGAGCCAGGGAGCTAATGTATGCA
TAGATATTCTAGCATTCCACTTGGCCTTATGCTGTTGAAATATTTAAGTAATTTATGTATTTATTAATTT
ATTTCTGCATTTCACATTTGTATACCAAGATGTATTGAATATTTCATGTGCTCGTGGCCTGATCCACTGG
GACCAGGCCCTATTATGCAAATTGTGAGCTTGTTATCTTCTTCAACAGCTCTTCAATCAGGGCTGCGTAG
GTACATTAGCTTTTGTGACAACCAATAAGAACATAATATTCTGACACAAGCAGTGTTACATATTTGTGAC
CAGTAAAGACATAGGTGGTATTTGGAGACATGAAGAAGCTGTAAAGTTGACTCTGAAGAGTTTAGCACTA
GTTTCAACACCAAGAAAGACTTTTTAGAAGTGATATTGATAAGAAACCAGGGCCTTCTTTAGAAGGGTAC
CTAAATTTAAAAGAATTTTGAAAGGCTGGGTATCGGTGGTATATGCTTTTAATTCCAGCACTCAGGAGAC
CAAGGCAGGCAGATCTCTGTGAGTTTGAGGACAGCCTGGTGTACAGAGGGAGTTCCAGCACAGCCAGTGC
CACACAGAAATTCTGTCTCAAAAAC
-
Protein Sequence : Show Sequence
>gi|6680397|ref|NP_032378.1| interleukin-12 subunit beta precursor [Mus musculus]
MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIG
SGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCS
WLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELAL
EARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEK
MKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRS
-
Molecule Role :
Vaximmutor
- Related Vaccine(s):
T. gondii mic2 mutant vaccine
|
|
5. TNF-alpha |
-
Gene Name :
TNF-alpha
-
Sequence Strain (Species/Organism) :
Mus musculus
-
NCBI Gene ID :
21926
-
NCBI Protein GI :
7305585
-
Genbank Accession :
AB039224
-
Protein Accession :
NP_038721
-
Taxonomy ID :
10090
-
Chromosome No :
17
-
Gene Starting Position :
35199389
-
Gene Ending Position :
35201995
-
Gene Strand (Orientation) :
-
-
Protein Name :
tumor necrosis factor
-
Protein pI :
4.75
-
Protein Weight :
24010.47
-
Protein Length :
235
-
Protein Note :
Also known as DIF; Tnfa; TNFSF2; Tnfsf1a; TNFalpha; TNF-alpha; MGC151434
-
DNA Sequence : Show Sequence
>gi|372099093:35199389-35201995 Mus musculus strain C57BL/6J chromosome 17, GRCm38 C57BL/6J
CTTTATTTCTCTCAATGACCCGTAGGGCGATTACAGTCACGGCTCCCGTGGGGAGCAGAGGTTCAGTGAT
GTAGCGACAGCCTGGTCACCAAATCAGCGTTATTAAGACAATTGGGTTAGATAAATATTTTGTTTTAAAC
ATAAGCAAAAGAGGAGGCAACAAGGTAGAGAGGCCAGGTGGGGACAGCTCAGCTCCGTTTTCACAGAAAA
CATGTCTGTCTGAAGACAGCTTCCCACACTGGGTCCTCCAGGACACCCCGGCCTTCCAAATAAATACATT
CATAAGCAAATAAATAAATAATAAATAAATAATAAATAATAAGTGCAAATATAAATAGAGGGGGGCTGGC
TCTGTGAGGAAGGCTGTGCATTGCACCTCAGGGAAGAATCTGGAAAGGTCTGAAGGTAGGAAGGCCTGAG
ATCTTATCCAGCCTCATTCTGAGACAGAGGCAACCTGACCACTCTCCCTTTGCAGAACTCAGGAATGGAC
ATTCGAGGCTCCAGTGAATTCGGAAAGCCCATTTGAGTCCTTGATGGTGGTGCATGAGAGGCCCACAGTC
CAGGTCACTGTCCCAGCATCTTGTGTTTCTGAGTAGTTGTTGAAAGCTCTGAGCACAGAGTTGGACCCTG
AGCCATAATCCCCTTTCTAAGTTAGAAGGATACAGACTGGGGGCTCTGAGGAGTAGACAATAAAGGGGTC
AGAGTAAAGGGGTCAGAGTGGGGGCTGGGTAGAGAATGGATGAACACCCATTCCCTTCACAGAGCAATGA
CTCCAAAGTAGACCTGCCCGGACTCCGCAAAGTCTAAGTACTTGGGCAGATTGACCTCAGCGCTGAGTTG
GTCCCCCTTCTCCAGCTGGAAGACTCCTCCCAGGTATATGGGCTCATACCAGGGTTTGAGCTCAGCCCCC
TCAGGGGTGTCCTTGGGGCAGGGGCTCTTGACGGCAGAGAGGAGGTTGACTTTCTCCTGGTATGAGATAG
CAAATCGGCTGACGGTGTGGGTGAGGAGCACGTAGTCGGGGCAGCCTTGTCCCTTGAAGAGAACCTGGGA
GTAGACAAGGTACAACCCATCGGCTGGCACCACTAGTTGGTTGTCTTTGAGATCCATGCCGTTGGCCAGG
AGGGCGTTGGCGCGCTGGCTCAGCCACTCCAGCTGCTCCTCCACTTGGTGGTTTGCTGAGGGGGGGGGGG
AGGATTGAGTCAGTGTCACCCTCTTAGTTCACACTCCACATCCTGAGCCTCAGCAGCTACCCACACTTCA
CTTCCGGTTCCTGCACCCTCTGTCTTTCCACATCCCATTGGCTATGAGGTCCCGGGTGGCCCCCTGATGC
CTTGCTTTTGAGTCACTGCTCTGACTCTCACGTGCTGTCTCTAAGAGCTCTGTCTTTTCTCAGCCTGGCT
CGACACCCCTCAACCCGCCCCCCAAAATCATGCCCCTTCATTCTCAAGGCACATGTAAAGAAATCTTACC
TACGACGTGGGCTACAGGCTTGTCACTCGAATTTTGAGAAGATGATCCTGGAGGGGAAGAGACAAAGGCA
AGGATGAGCCTTTTAGGCTTCCCAGCAAGCATCTATGCACTTAGACCCCTTTCCTCCCAAACCAAAGCTT
TAAGTTCTCCCCCCACCCCATCTCATCCCATGCCTAACTGCCCTTCCTCCATCTTAAATTAAGAGAGAGG
TGTGGGAACACTTACTGAGTGTGAGGGTCTGGGCCATAGAACTGATGAGAGGGAGGCCATTTGGGAACTT
CTGTGTAGGAAAAGGAGGTTAGTTAAGACAGACTCACCCCAAAGGAGAAGCCTCCCGGCTGATTGCCCCG
CTTACAGTTCCTCTTTGCCCCACCCCACCCCCCAGCTTTGTGTTTTTCTTCTTCATTCATTCATCTGTCC
AACCCACGGCTTCTTTCTGCGGTGCCCTCTGTGCTTGATCTCCCGTTATCTCCCCTTCATCTTCCTCCTT
ATCTCTCATGCCTCTCTCATTTCTGTCTCTGAGTTTTATCTCTTGCTTATCCCCTCTTCCCCTGGCCACA
TCTTTCCAGATCTCTCCACGTGTGAACACACTTGTTCGTTCATTCATCTCTCTGTGCATCCGACGAAGGA
TGTTTAGTCAGCTGGACGCATGGGTCCGAGGTCCTGACTCTGTCCCCTCCACACTCTCCTCCACCTTGCC
CTGCCCATTAGCCCACTTCTTTCCCTCACACTGTCCTTCTTGCCCTCCTAACCCGTTTTGCTTGTGAGCG
AGAATAAGGGTTGCCCAGACACTCACCTCATCCCTTTGGGGACCGATCACCCCGAAGTTCAGTAGACAGA
AGAGCGTGGTGGCCCCTGCCACAAGCAGGAATGAGAAGAGGCTGAGACATAGGCACCGCCTGGAGTTCTG
GAAGCCCCCCATCTTTTGGGGGAGTGCCTCTTCTGCCAGTTCCACGTCGCGGATCATGCTTTCTGTGCTC
ATGGTGTCTTTTCTGGAGGGAGATGTGGCGCCTTGGGCCAGTGAGTGAAAGGGACAGAACCTGCCTGGTT
GGCTGCTTGCTTTTCTGGGAGCTATTTCCAAGATGTTCTGGAGTTTCTGTTCTCCCTCCTGGCTAGTCCC
TTGCTGTCCTCGCTGAG
-
Protein Sequence : Show Sequence
>gi|7305585|ref|NP_038721.1| tumor necrosis factor [Mus musculus]
MSTESMIRDVELAEEALPQKMGGFQNSRRCLCLSLFSFLLVAGATTLFCLLNFGVIGPQRDEKFPNGLPL
ISSMAQTLTLRSSSQNSSDKPVAHVVANHQVEEQLEWLSQRANALLANGMDLKDNQLVVPADGLYLVYSQ
VLFKGQGCPDYVLLTHTVSRFAISYQEKVNLLSAVKSPCPKDTPEGAELKPWYEPIYLGGVFQLEKGDQL
SAEVNLPKYLDFAESGQVYFGVIAL
-
Molecule Role :
Vaximmutor
- Related Vaccine(s):
T. gondii mic2 mutant vaccine
|
| IV. Vaccine Information |
 |
|
 |
|
|
|
|
1. CAV-2-ROP16 |
| a. Type: |
| Recombinant vector vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Antigen |
| ROP16: Rhoptry protein 16: a specialised kinase released from rhoptries into the host cell during invasion, directly target the host cell nucleus and activate both the signal transducer and activator of transcription 3 and 6 (STAT3 and STAT6) signaling pathways. (Li et al., 2016) |
| f. Gene Engineering of
ROP16 |
- Type:
Recombinant vector construction
- Description:
pPolyII-CAV-â–³E3-ROP16 was constructed. The Kpn I fragment containing the E3 region of CAV-2 from pPolyII-CAV-2 was cloned to pVAX. RPO16 was amplified by PCR using a forward primer introducing Nhe I recognition sites and a reverse primer introducing Bgl II recognition sites. ROP16 was identified, purified, and then cloned to pVAX-E3 vector. The 6.7 kb fragment of Nru I and Sal I double-digested pVAX-ΔE3-ROP16, containing the ROP16 expression cassette flanked by residual E3 sequences, and was cloned back into pPolyII-CAV-2. The recombinant viruses was then generated in MDCK cells. (Li et al., 2016)
- Detailed Gene Information: Click here.
|
| g. Vector: |
| CAV-2 (Li et al., 2016): canine adenovirus type 2: a serotype attenuated strain, induce Infectious tracheobronchitis (ITB) which is characterized by respiratory symptoms. (Zhu et al., 2022) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i. Description |
| Recombinant canine adenovirus expressing the ROP16 gene of the RH strain of T. gondii (Li et al., 2016) |
| j.
Mouse Response |
- Host Strain:
BALB/c mice (Li et al., 2016)
- Vaccination Protocol:
The mice were randomly assigned to four experimental groups (23 mice per group). Group I was intramuscularly inoculated once with 0.1 ml CAV-2-ROP16 (108.0 PFU/ml); group II received 0.1 ml CAV-2 (108.25 PFU/ml) once intramuscularly; group III was inoculated once intramuscularly with 0.1 ml PBS; and group IV was not given any injection. Group 2, 3, and 4 are negative controls. (Li et al., 2016)
- Immune Response:
Humoral: The antibody titres of ROP16 were drastically enhanced in CAV-2-ROP16 group compared to the controls. The ratio of IgG1 to IgG2a in CAV-2-ROP16 group was significantly higher than that of the controls (P < 0.05). (Li et al., 2016)
Cellular: Values of IFN-γ and IL-2 in the CAV-2-ROP16 group were significantly higher than the control groups (P < 0.05). Low concentration of IL-4 showed a weak but obviously proliferative response in CAV-2-ROP16 group compared to the other control groups (P < 0.05). There were no statistically significant differences in the levels of IL-10 in all groups (P > 0.05). There was significant increase in IFN-γ and TNF-α production that was induced by CD4+ and CD8+ T cells, respectively in the mice vaccinated with CAV-2-ROP16 compared to the other three groups (P < 0.05). The percentage of CD3+/CD4+ and CD3+/CD8+ T-cells were significantly increased in mice vaccinated with CAV-2-ROP16 compared to the other three groups (P < 0.05).(Li et al., 2016)
- Challenge Protocol:
Eight weeks after the prime immunisation, 20 mice in all groups were challenged intraperitoneally (i.p.) with 1 × 103 tachyzoites of the virulent T. gondii RH strain. The mice were observed daily for mortality. (Li et al., 2016)
- Efficacy:
The mice vaccinated with a single dose of CAV-2-ROP16 displayed 25% protection 80 days after RH strain infection; the administration of either CAV-2 or PBS did not prevent mortality, that all mice received CAV-2 or PBS died within seven days. (Li et al., 2016)
|
|
|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
2. CAV-2-ROP18 |
| a. Type: |
| Recombinant vector vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| ROP18: Rhoptry protein 18: a polymorphic serine-threonine kinase which is secreted in the host cell during the invasion process, and its catalytic activity is required for the acute virulence phenotype. It is considered one of the key virulence factors in the pathogenesis of the T. gondii infection. (Li et al., 2015) |
| e. Gene Engineering of
ROP18 |
- Type:
Recombinant vector construction
- Description:
Recombinant plasmid pPolyII-CAV-â–³E3-ROP18 was constructed by in vitro ligation. The plasmid includes E3 (the E3 region of CAV-2); CMV (human cytomegalovirus (hCMV) immediate-early gene promoter), ROP18, and polyA (the SV40 early mRNA polyadenylation signal). The plasmid were digested with Asc I and Pme I to release the linear recombinant genome. The recombinant genome was used to transfect MDCK cells. (Li et al., 2015)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| CAV-2 (Li et al., 2015): canine adenovirus type 2: a serotype attenuated strain, induce Infectious tracheobronchitis (ITB) which is characterized by respiratory symptoms. (Zhu et al., 2022) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| Recombinant canine adenovirus expressing the ROP18 gene of the RH strain of T. gondii (Li et al., 2015) |
| i.
Mouse Response |
- Host Strain:
specific-pathogen-free (SPF) grade inbred Kunming mice (Li et al., 2015)
- Vaccination Protocol:
The mice were randomly assigned into four experimental groups (33 mice per group). Group I was intramuscularly inoculated once with 0.1 ml CAV-2-ROP18 (10 8.125 p.f.u. ml−1); group II received 0.1 ml CAV-2 (108.25 p.f.u. ml−1) once as a negative control; group III was inoculated intramuscularly with 0.1 ml PBS as control at weeks 0, 2 and 4; and group IV was not injected with anything as a negative control. (Li et al., 2015)
- Immune Response:
Humoral: Antibody titers significantly increased in the recombinant virus CVA-2-ROP18 group at week 2, 4 and 6 after immunization, compared to CAV-2, PBS and blank control immunized group (P < 0.05). Both IgG1 and IgG2a levels were detected. There was no significant difference in IgG1 and IgG2a levels between the groups immunized CAV-2, PBS, and nothing (P > 0.05). HI antibodies against CAV-2 were detected in all mice vaccinated with CAV-2 and the recombinant CAV-2-ROP18 at 2 weeks post-primary immunization, reaching comparable titers throughout the test period. (Li et al., 2015)
Cellular: Splenocytes from mice immunized with CAV-2-ROP18 showed a significant proliferative response to ROP18 (P < 0.05), which was significantly higher than proliferation by splenocytes from all other controls (P < 0.05). Splenocytes from all groups proliferated to comparable levels in response to the mitogen ConA. Significant CTL activity was tested in mice immunized with CAV-2-ROP18. The percentage of CD3+/CD4+ T cells and CD3+/CD8+ T cells were significantly increased in mice immunized with CAV-2-ROP18 compared to all controls. Similarly, CAV-2-ROP18 significantly altered CD4+ or CD8+ T cell profiles in terms of IFN-γ and TNF-α expression in comparison with all controls. IL-2 and IFN-γ values in CAV-2-ROP18 group are significantly higher than in the controls (P < 0.05). Low levels of IL-4 showed a slight but significantly production from CAV-2-ROP18 groups compared to the controls (P < 0.05). (Li et al., 2015)
- Challenge Protocol:
Eight weeks after the immunization, 20 mice in each group were challenged intraperitoneally (i.p.) with 1 × 103 tachyzoites of the virulent T. gondii RH strain, and 10 other mice were inoculated intragastrically with 5 cysts of the PRU strain. All mice were observed daily for mortality. Two months after the challenge, the surviving mice were euthanized and their brains were removed. Each brain was homogenized in 2 ml of PBS. The mean number of cysts per brain was determined by counting in three samples of 25 μl aliquots of each homogenized brain under an optical microscope. (Li et al., 2015)
- Efficacy:
RH: Mice immunized with only a single dose of CAV-2-ROP18 showed 40% protection until 60 days after challenge, while the administration of either CAV-2 or PBS did not prevent mortality (mice died within 7 days). (Li et al., 2015)
PRU: Mice from the CAV-2-ROP18 group developed a significantly lower (P < 0.05) number of brain cysts (8000 ± 1414 cysts per brain) compared to mice from the other three control control groups (approximately 18000 cysts). (Li et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3. CTLVECNS |
| a. Type: |
| Inactivated or "killed" vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| Toxoplasma lysate: Tachyzoites were collected from previously infected mice and were sedimented by centrifugations and sonications. The supernatant material (the lysated antigen of Toxoplasma) was collected. (El et al., 2016) |
| e. Immunization Route |
| Intraperitoneal injection (i.p.) |
| f. Description |
| Crude Toxoplasma lysate vaccine encapsulated chitosan nanospheres (El et al., 2016) |
| g.
Mouse Response |
- Host Strain:
Swiss strain albino mice (El et al., 2016)
- Vaccination Protocol:
Mice were divided into two main groups, Group I control group (100 mice) which was further subdivided into five equal subgroups (20 mice): Ia: normal non infected; Ib: chitosan delivery control subgroup, received 20 µg of BCNS in 100 µl of PBS/mouse/dose; Ic: FIA control subgroup, received 100 µl of FIA/mouse/dose, Id & Ie: non vaccinated groups for further challenge. Group II experimental vaccinated group (100 mice) was further subdivided into two equal subgroups (50 mice). Subgroup IIa, received CTLVECNS suspended in PBS while subgroup IIb received CTLV + FIA. All vaccinated mice received three doses 2 weeks apart. (El et al., 2016)
- Immune Response:
Higher ratio of IgG2a to IgG1; Higher level of IFN-γ and IL-2 (El et al., 2016)
- Challenge Protocol:
RH: Group Id (20 mice) were infected with 2,500 tachyzoites of RH strain without immunization, serving as RH infected control group. 25 mice from group IIa and 25 mice from group IIb were challenged by 2,500 viable tachyzoites of virulent RH strain. 10 mice out of 25 were sacrificed 5 days post infection and the remaining mice were observed daily to record mortality. (El et al., 2016)
Me49: Group Ie (20 mice) were perorally inoculated by 10 cysts of Me49 strain without immunization, serving as Me49 infected control group. The other 25 mice from group IIa and 25 mice from group IIb were challenged orally by 10 cysts of Me49 strain. 10 mice out of 25 were sacrificed 60 days post infection and the remaining were observed daily to record mortality. (El et al., 2016)
Serum samples were collected from RH and Me49 infected control subgroups mice before being sacrificed simultaneously with their corresponding experimental subgroups. (El et al., 2016)
- Efficacy:
RH: None of the mice of RH infected control subgroup remained alive beyond the seventh day post infection with a mean survival time of 5.9 ± 0.88 days. Mice vaccinated with CTLV either in chitosan nanospheres or in combination with FIA and challenged with RH strain showed significant increase in their survival time. (BCNS: maximum survival time of 80 days with a mean of 35.73 ± 31.82; FIA: 57 days with a mean of 33.67 ± 18.30 days). There was a statistically significant reduction in parasitic count in all studied organs in vaccinated animals. The reduction in the mean tachyzoites count was more evident in the subgroup receiving encapsulated chitosan vaccine in comparison to the subgroup receiving the vaccine in combination with FIA .(El et al., 2016)
Me49: The mean survival time in the control group was 60.7 ± 8.11 days with only one mouse which lived for 120 days post infection. Only mice vaccinated with CTLV in combination with FIA showed a statistically significant increase in the survival time (a mean of 120.53 ± 33.13 days). There was a statistically significant difference between mice vaccinated with CTLV whether in chitosan nanospheres (a mean of 79.20 ± 17.91 days) or in combination with FIA. A statistically significant reduction in the mean cyst count of the brain was found in both experimental subgroups. The difference between vaccinated subgroups was statistically significant with the highest reduction in the subgroup receiving the vaccine in combination with FIA. (El et al., 2016)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4. GRA7(20–28)SAPN |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| None |
| d. Antigen |
| GRA7(20-28) peptide (LPQFATAAT) (El et al., 2014) |
| e. Gene Engineering of
GRA7 |
- Type:
Recombinant protein preparation
- Description:
The GRA7(20–28) peptide sequence was cloned in between the NsiI/BamHI restriction sites of the modified pPEP-T vector to yield the final LP amino acid sequence. The sequence is composed of the his-tag sequence (1-12aa), the CD8+ epitope (13-21aa), the pentameric coiled coil (22-60aa), a glycine-glycine linker (61-62aa), the trimeric coiled coil (63-107aa) and a solubility tag (108-128). The trimeric coiled coil contains a PADRE derivative as a CD4+ epitope (86-98aa). LP monomer was expressed in E. coil, purified, and eventually self-assembled to form nanoparticles (GRA7(20-28)SAPN). (El et al., 2014)
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| subcutaneous injection |
| g. Description |
| Self-assembling nanoparticles displaying the GRA7(20–28) in conjunction with PADRE. (El et al., 2014) |
| h.
Mouse Response |
- Host Strain:
HLA-B*0702 transgenic mice: express a chimeric HLA-B07/H2-Db MHC Class I Molecule and are on a C57BL/6 × Balb/C background backcrossed through many generations (El et al., 2014)
- Vaccination Protocol:
Mice were inoculated subcutaneously with 50 μg GRA7(20–28) SAPN or P4c-RD control SAPN three times at two weeks intervals. (El et al., 2014)
- Immune Response:
Increase of IFN-γ secretion (El et al., 2014)
- Challenge Protocol:
RH: Mice (n = 5 per group) were challenged i.p. with 2000 RH T. gondii expressing stable YFP. Peritoneal fluid was collected 120 h post infection and parasite fluorescence and numbers were measured using a fluorometer and hemocytometer, respectively. (El et al., 2014)
Me49: Mice (n = 6 for PBS(negative control) and GRA7(20–28)SAPN, n = 3 for ΔRPS13(positive control)) were challenged intraperitoneally 14 days post-immunization using 2000 Me49-FLUC tachyzoites and were imaged 21 days post-challenge. Mice were then euthanized, and the number of tissue cysts per brain were counted. (El et al., 2014)
- Efficacy:
RH: Fluorescence from GRA7(20–28)SAPN immunized mice was significantly lower than the control. (El et al., 2014)
Me49: The numbers of luciferase expressing parasites in mice immunized with GRA7(20–28)SAPN were significantly reduced compared to the mice immunized with control SAPN or PBS. This correlates with the reduction of the number of cysts per brain in GRA7(20–28)SAPN immunized mice. (El et al., 2014)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5. ISA 201-rTgCST2 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| recombinant TgCST2 protein (Tian et al., 2022) |
| e. Gene Engineering of
TgCST2 |
- Type:
Recombinant protein preparation
- Description:
TgCST2 95-325aa was amplified and then constructed to the expression vector pET-30a. Escherichia coli strain BL-21 (DE3) system was used for protein expression. The recombinant protein was purified and the endotoxin was removed using His Bind® Resin Chromatography kit (Merck, Darmstadt, Germany) and Detoxi-Gel Affinity Pak Prepacked columns (Pierce, Rockford, USA). (Tian et al., 2022)
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| subcutaneous injection |
| g. Description |
| T. gondii subunit vaccine that uses recombinant TgCST2 protein as antigen and ISA 201 as adjuvant (Tian et al., 2022) |
| h.
Mouse Response |
- Host Strain:
BALB/c mice (Tian et al., 2022)
- Vaccination Protocol:
A total of 60 BALB/c mice were randomized into three groups (20/group), 20 µg of rTgCST2 was immunized subcutaneously each mouse with an equal volume of ISA 201 (Seppic, France) and mice immunized ISA 201 alone or PBS only were enrolled as controls. All mice were vaccinated 3 times at 2-week intervals. (Tian et al., 2022)
- Immune Response:
Humoral: Anti-rTgCST2 titers reached up to 1:104 for vaccinated mice. Serum IgG levels induced by rTgCST2 had a substantial increase compared with control groups (P < 0.001). Both IgG1 and IgG2a levels induced by rTgCST2 showed considerable rise after inoculation (P < 0.001), IgG1 was the predominant subtype. (Tian et al., 2022)
Cellular: On 6 weeks post-vaccination, only the levels of IFN-γ and IL-10 in ISA201-rTgCST2 immunized groups were significantly higher (P < 0.05 and P < 0.001, respectively) than the control groups. (Tian et al., 2022)
- Challenge Protocol:
Two weeks after the last vaccination, 10 immunized mice per group were challenged intraperitoneally with 1 × 102 tachyzoites of RH T. gondii strain and 10 additional mice were challenged intragastrically with 10 cysts of PRU strain. (Tian et al., 2022)
- Efficacy:
Intraperitoneal inoculation of 102 RH strain tachyzoites induced all death of the mice within 9 days after challenge. There was no significant difference in survival time between two control groups (PBS and ISA 201, P > 0.05). The survival time of mice immunized with ISA 201-rTgCST2 was significantly longer than that of PBS group (P < 0.001). (Tian et al., 2022)
After 2 months of observation, 10 of 10 mice infected orally with 10 cysts of PRU strain in ISA 201-rTgCST2 immunized group survived. However, only one animal in the ISA 201 group and two animals in the PBS group died throughout the experiment. Brain cyst burdens in ISA 201-rTgCST2 immunized group had decreased a bit compared with PBS control groups (reduction by 36.4%, P < 0.05). Meanwhile, compared with PBS control groups, there displayed a reduction in brain cyst diameter of ISA 201-rTgCST2 immunized group (P > 0.05, reduction by 16.7%). (Tian et al., 2022)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6. ISP3 VLP |
| a. Type: |
| Other |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| ISP3: IMC sub-compartment protein 3 (Lee et al., 2016) |
| e. Gene Engineering of
ISP3 |
- Type:
Recombinant protein preparation
- Description:
Total RNA of T. gondii tachyzoites was extracted. Complementary DNA (cDNA) was synthesized and Toxoplasma gondii IMC gene was amplified by PCR from cDNA with primers containing EcoRI and XhoI sites. The gene was cloned into pFastBac vector and was transfected and formed recombinant baculovirus (rBV). Sf9 insect cells was co-infected by rBVs expressing T. gondii IMC or influenza M1, and VLPs containing both T. gondii IMC and influenza M1 were released. (Lee et al., 2016)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| VLP (Lee et al., 2016) |
| g. Immunization Route |
| Nasal spray |
| h. Description |
| Virus-like particle (VLP) vaccine consisting of the influenza M1 protein as a core protein together with IMC ISP3 of T. gondii. (Lee et al., 2016) |
| i.
Mouse Response |
- Vaccination Protocol:
Mice (6 per group) were intranasally immunized twice with 100 μg total VLP protein at 4-week intervals. (Lee et al., 2016)
- Immune Response:
Higher levels of IgA and IgG, higher IgG2a than IgG1; higher levels of IFN-γ, IL-6 and IL-11 (Lee et al., 2016)
- Challenge Protocol:
Naïve or immunized mice were infected with T. gondii ME49 intraperitoneally with 20 cysts in 100 μl PBS at 1 month after boosting. Body weight changes and survival were observed daily, and cysts in the brain were counted. (Lee et al., 2016)
- Efficacy:
Significantly decreased cyst counts and cyst sizes in brain were detected in mice upon challenge infections compared to non-immunized mouse controls (Reduction rate of cyst count: 75%, **P < 0.01; Reduction rate of cyst size: 50%, *P < 0.05) Immunized mice gained body weight whereas control mice lost body weight or died upon challenge. All mice immunized survived whereas control mice showed 60% survival. (Lee et al., 2016)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7. Ovilis Toxovax |
| a. Tradename: |
| Ovilis Toxovax |
| b. Manufacturer: |
| Intervet |
| c. Vaccine Ontology ID: |
| VO_0001138 |
| d. Type: |
| Live, attenuated vaccine |
| e. Status: |
| Clinical trial |
| f. Host Species for Licensed Use: |
| Sheep |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| S48 strain with a lost ability to form cysts after passages in mice(Buxton and Innes, 1995) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8. PLG-rROP38-rROP18 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| ROP18(Xu et al., 2015); ROP38 (Xu et al., 2015) |
| e. Gene Engineering of
ROP18 |
- Type:
Recombinant protein preparation
- Description:
TgROP18 complete open reading frame was amplified from the PRU strain RNA by RT-PCR with primers introducing BamHI and SalI sites.The gene was inserted into pET-30a(+) vectors.The recombinant plasmids were transformed into E. coli BL21-codon plus (DE3)-RIL competent cells (Stratagene). The cells were selected, grown, and harvested, releasing the TgROP18 protein. The protein was made into PLG microparticles by water-in-oil-in-water double emulsion solvent evaporation technique. (Xu et al., 2015)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
ROP38 |
- Type:
Recombinant protein preparation
- Description:
TgROP38 complete open reading frame was amplified from the PRU strain genomic DNA with primers introducing BsmBI and BamHI sites. The gene was inserted into pSMK vectors. The recombinant plasmids were transformed into E. coli BL21-codon plus (DE3)-RIL competent cells (Stratagene). The cells were selected, grown, and harvested, releasing the TgROP38 protein.The protein was made into PLG microparticles by water-in-oil-in-water double emulsion solvent evaporation technique. (Xu et al., 2015)
- Detailed Gene Information: Click here.
|
| g. Immunization Route |
| subcutaneous injection |
| h. Description |
| T. gondii subunit vaccine of ROP18 and ROP38 encapsulated in PLG (Xu et al., 2015) |
| i.
Mouse Response |
- Host Strain:
Kunming mice (Xu et al., 2015)
- Vaccination Protocol:
Mice were randomly divided into nine groups (19 mice each) and were injected subcutaneously at five different points at a 2-week interval. Each group were injected of different vaccines (with 10μg proteins): 1) 100μg PBS, 2) 100μg PLG, 3) 100μg rTgROP38, 4) 100μg rTgROP18, 5) 50μg rTgROP38 + 50μg rTgROP18, 6) 100μg PLG-rROP38, 7) 100μg PLG-rROP18, 8) 100μg PLG-rROP38-rROP18 (50μg rROP38 + 50μg rROP18), and 9) blank controls which were not treated until challenged. (Xu et al., 2015)
- Challenge Protocol:
Eight weeks after the second immunization, 10 mice in all groups were challenged orally with 10 cysts of the PRU strain and were used to calculate the mean number of cysts per brain 1 month later. (Xu et al., 2015)
- Efficacy:
Immunization with various protein vaccines significantly decreased the brain cyst formation in mice (P < 0.01), compared with all the control groups. The brain cyst number in the mice immunized with PLG-rROP38-rROP18 was the lowest, with a cyst reduction of 81.3 %. (Xu et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9. rBCGpMV361-TgCyP |
| a. Vaccine Ontology ID: |
| VO_0004656 |
| b. Type: |
| Recombinant vector vaccine |
| c. Status: |
| Research |
| d. Host Species for Licensed Use: |
| None |
| e. Host Species as Laboratory Animal Model: |
| mouse |
| f. Gene Engineering of
CyP |
- Type:
Recombinant vector construction
- Description:
- Detailed Gene Information: Click here.
|
| g. Preparation |
| Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG (Yu et al., 2013). |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i.
Mouse Response |
- Vaccination Protocol:
rBCGpMV261-TgCyP and rBCGpMV361-TgCyP (106 CFU) were used to immunise the mice in two different manners (through an i.v. or oral route) (Yu et al., 2013).
- Vaccine Immune Response Type:
VO_0003057
- Challenge Protocol:
Two weeks after the third vaccination, mice were selected randomly from each group and challenged intraperitoneally (i.p.) with 103 highly virulent T. gondii RH strain tachyzoites (Yu et al., 2013).
- Efficacy:
The levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased following immunisation with the rBCG vaccines via the i.v. or oral route, which indicated that catalytic activity against T. gondii infection was generated in the mice. rBCGpMV361-TgCyP i.v. inoculation resulted in a higher protection efficiency, as demonstrated by the increased survival time and survival rate (17%) of BALB/c mice (Yu et al., 2013).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10. rCDPK6 + rROP18 + PLG |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| None |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Antigen |
| CDPK6 (Zhang et al., 2016); ROP18 (Zhang et al., 2016) |
| f. Gene Engineering of
CDPK6 |
- Type:
Recombinant protein preparation
- Description:
The ORF of TgCDPK6 were amplified with RT–PCR using primers containing Kpn I and Not I restriction sites. The RT–PCR products were inserted into the pET-30a(+) via restriction sites, forming pET-CDPK6. E. coli BL21(DE3) was transformed with pET-CDPK6. rTgCDPK6 was expressed, purified, and encapsulated in 50:50 PLG using the water-in-oil-in-water double emulsion solvent evaporation technique. (Zhang et al., 2016)
- Detailed Gene Information: Click here.
|
| g. Gene Engineering of
ROP18 |
- Type:
Recombinant protein preparation
- Description:
The ORF of TgROP18 were amplified with RT–PCR using primers containing BamH I and Sal I restriction sites. The RT–PCR products were inserted into the pET-30a(+) via restriction sites, forming pET-ROP18. E. coli BL21(DE3) was transformed with pET-ROP18. rTgROP18 was expressed, purified, and encapsulated in 50:50 PLG using the water-in-oil-in-water double emulsion solvent evaporation technique. (Zhang et al., 2016)
- Detailed Gene Information: Click here.
|
| h. Immunization Route |
| subcutaneous injection |
| i. Description |
| T. gondii subunit vaccine of CDPK6 and ROP18 encapsulated in PLG (Zhang et al., 2016) |
| j.
Mouse Response |
- Host Strain:
Specific-pathogen-free Kunming mice (Zhang et al., 2016)
- Vaccination Protocol:
A total of 13 groups of mice were injected subcutaneously with 10 μg of each protein. The vaccinated groups were immunized with rCDPK6, rROP18, rCDPK6 + rROP18, rCDPK6 + Montanide™ ISA 206 VG (206), rROP18 + 206, rCDPK6 + rROP18 + 206, rCDPK6 + PLG, rROP18 + PLG, or rCDPK6 + rROP18 + PLG. The control groups were immunized with PBS alone, PBS + 206, or PBS + PLG, or was not treated. (Zhang et al., 2016)
- Immune Response:
Humoral: Higher levels of IgG in all protein vaccines. The levels of IgG increased sequentially with successive immunizations with the tested antigens, and reached their highest levels in week 8. Six weeks after the last vaccination, the levels of IgG antibodies in the mice immunized with rROP18 + PLG or rCDPK6 + rROP18 + PLG were significantly higher than those in the mice immunized with rROP18 or rCDPK6 + rROP18 (P < 0.01), but were not statistically different from those in the mice immunized with various proteins + 206 adjuvant (P > 0.05). (Zhang et al., 2016)
Cellular: The splenocytes proliferated more strongly in the vaccinated mice than in the controls, and the highest proliferative response was detected in rCDPK6 + rROP18 + PLG mice (P < 0.001). Higher levels of T-cell subtypes were detected in mice immunized with protein vaccines. protein–PLG induced significantly higher levels of CD4+ (P < 0.001) and CD8+ T lymphocytes (P < 0.01) than the controls. rROP18 + 206 and rROP18 + PLG induced significantly higher levels of CD4+ than the controls (P < 0.05). Only mice from rROP18 + 206 group were showed significantly higher level of CD8+ compared to that in controls (P < 0.05). (Zhang et al., 2016)
- Challenge Protocol:
Six weeks after the immunization, 10 mice in each group were challenged intraperitoneally with 103 tachyzoites of the T. gondii RH strain, and their survival was recorded daily until all the mice had died. Six mice in each group were inoculated orally with 10 PRU tissue cysts, and their brain cysts were determined 4 weeks after chronic infection was established. (Zhang et al., 2016)
- Efficacy:
Acute: The average survival time of the mice immunized with the protein vaccines (8.56 days) was slightly longer than that in the controls (8 days). Immunization with rROP18 + PLG (10.9 days ± 2.58), rROP18 (10.1 days ± 1.52), and rCDPK6 + PLG (9.1 days ± 0.24) significantly prolong the average survival time in mice compared with that of the controls (P < 0.05). (Zhang et al., 2016)
Chronic: The tissue cyst loadings in the brains of mice vaccinated with the proteins varied from 47.7 % to 73.6 %, and were significantly lower than those in the control groups (P < 0.001). The protein antigens plus PLG microparticles provided more effective protection to the mice than immunizations only with proteins, but the differences were not statistically significant (P > 0.05). (Zhang et al., 2016)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11. RH-AMA1KO |
| a. Type: |
| Live, attenuated vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| Live, attenuated T. gondii RH strain with AMA1 knockout (Lagal et al., 2015) |
| e. Immunization Route |
| Intraperitoneal injection (i.p.) |
| f. Description |
| T. gondii Live, attenuated vaccine using RH strain with AMA1 knockout (Lagal et al., 2015) |
| g.
Mouse Response |
- Host Strain:
BALB/c, CD-1, or C57BL/6J (Lagal et al., 2015)
- Vaccination Protocol:
Viable parasites (2.5 × 102 to 106) were injected i.p. or subcutaneously into mice in a 100-μl volume of phosphate-buffered saline (PBS). (Lagal et al., 2015)
- Challenge Protocol:
RH: Naive and AMA1KO-injected mice received an i.p. injection of 103 (C57BL/6J) or 105 (BALB/c, CD-1) AMA1+ parasites 6.5 to 15 weeks after the first injection. (Lagal et al., 2015)
Chronic: 103 Me49 tachyzoites were injected in BALB/c mice that had been inoculated with 105 AMA1KO tachyzoites 8 weeks earlier. (Lagal et al., 2015)
- Efficacy:
BALB/c: When challenged with 105 AMA1+ type I parasites, BALB/c naive mice died within 6 days, while mice injected with either 105 or 106 AMA1KO parasites 8 to 10 weeks earlier survived over the assay period of 60 days. The protection went down to 18% when a lower AMA1KO dose (103 AMA1KO parasites) was first injected. Immunity lasting more than 8 months for BALB/c mice immunized with 105 AMA1KO tachyzoites, which resisted the challenge from 105 virulent tachyzoites. 60% of BALB/c mice immunized with 105 AMA1KO parasites and challenged 8 weeks later with 103 type II ME49 tachyzoites gave negative results by qPCR for the presence of parasites in their brain whereas 100% of the nonimmunized mice gave positive results. (Lagal et al., 2015)
C57BL/6J: A rather long-lasting immunity was conferred to C57BL/6J mice immunized with 2.5 × 102 and 1.5 × 103 AMA1KO tachyzoites, which resisted challenge from 103 AMA1+ tachyzoites. (Lagal et al., 2015)
CD-1: CD-1 mice immunized with 104 or 106 AMA1KO parasites survived challenge with 105 AMA1+ tachyzoites. (Lagal et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12. rTgADF |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Antigen |
| TgADF (Liu et al., 2016) |
| f. Gene Engineering of
TgADF |
- Type:
Recombinant protein preparation
- Description:
ORF of TgADF was amplified using PCR from the cDNA template with forward primer introducing BamHI site and reverse primer introducing XhoI site. The PCR products were cloned into the ppET30a(+) vector and transformed into E. coli DH5α competent cells. rTgADF was harvested from E. coil and was purified. (Liu et al., 2016)
- Detailed Gene Information: Click here.
|
| g. Immunization Route |
| Nasal spray |
| h. Description |
| T. gondii subunit vaccine of recombinant TgADF. (Liu et al., 2016) |
| i.
Mouse Response |
- Host Strain:
BALB/c (Liu et al., 2016)
- Vaccination Protocol:
The mice were randomly divided into 5 groups (8 mice per group). Four groups were intranasally administered with 10, 20, 30, or 40 μg of rTgADF that was separately dissolved in 20 μL of phosphate-buffered saline (PBS). The control group was immunized with PBS. On days 0, 14, and 21, the nostrils of the mice were slowly instilled with rTgADF protein solution (10 μL per nostril). (Liu et al., 2016)
- Immune Response:
Mucosal: Significantly higher levels of sIgA titers were observed in the nasal, intestinal, and vesical washes in mice immunized with 20, 30, or 40 μg of rTgADF than in the control groups (P < 0.05). The sIgA levels in three mucosal washes in the 30- and 40-μg groups were prominently higher than that in the 20-μg group. Moreover, an apparent predominance of the 30-μg group over the 40-μg group was observed on the basis of the vesical washes. (Liu et al., 2016)
Humoral: High IgG titers were detected in the serum samples of all immunized mice (P < 0.05). The OD values for IgG were continuously increased following an increase in the immunization dosage, and the 40-μg group showed the highest titer among all the immunized groups (P < 0.01). (Liu et al., 2016)
Cellular: Splenocytes from the 30-μg and 40-μg groups exhibited a significantly greater proliferative response to rTgADF than splenocytes from the control group. Splenocytes from all the immunized groups secreted significantly high levels of IFN-γ and IL-2 when compared with the control group, and the highest levels were elicited by 30 μg of rTgADF. In contrast, IL-4 and IL-10 levels displayed no significant changes between the immunized and control groups (P > 0.05). (Liu et al., 2016)
- Challenge Protocol:
Two groups of BALB/c mice (30 mice per group) were immunized with PBS or 30 μg of rTgADF as mentioned in vaccination protocol. Twenty-two mice from each group were intragastric administrated with a dose of 4 × 104 tachyzoites for the acute assay. Survival times of the infected mice were recorded daily. The other 8 mice per group were challenged with 1 × 104 tachyzoites for the chronic model. Four weeks later, real-time PCR was used to quantify tachyzoite loads in the liver and brain for detecting the SAG1 gene. (Liu et al., 2016)
- Efficacy:
Acute: Most of the mice in the control group were dead within 9 days post-infection, with the last mouse dying on the 23rd day. However, 36.36 % of the mice immunized with 30 μg of rTgADF remained alive 30 days post-infection. (Liu et al., 2016)
Chronic: The tachyzoite load in the livers and brains was significantly lower in the immunized mice {13.89 ± 1.27 (105/g) and 6.33 ± 0.43 (105/g), respectively)} than in the control mice {43.09 ± 3.03 (105/g) and 12.92 ± 3.30 (105/g), respectively}, which showed a reduction in the tachyzoite load by 67.77 % in the liver and 51.01 % in the brain when compared with the control group. (Liu et al., 2016)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13. rTgPGAM 2 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| PGAM2 (Wang et al., 2016) |
| e. Gene Engineering of
PGAM2 |
- Type:
Recombinant protein preparation
- Description:
ORF of the TgPGAM 2 gene was amplified from the RH strain T. gondii tachyzoites and cloned into the pET-30a(+) vector. The rTgPGAM 2 protein was express in BL21 (DE3) cells, purified, and the endotoxin in rTgPGAM2 was removed. (Wang et al., 2016)
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| Nasal spray |
| g. Description |
| T. gondii subunit vaccine of recombinant PGAM2 (Wang et al., 2016) |
| h.
Mouse Response |
- Host Strain:
BALB/c (Wang et al., 2016)
- Vaccination Protocol:
The mice were divided into five groups (10 mice per group) and were intranasally immunised with 10, 20, 30 or 40 μg of rTgPGAM2 suspended in 20 μL of sterile PBS, or PBS only as control. The mice were immunised using the same protocol on days 0, 14 and 21. (Wang et al., 2016)
- Challenge Protocol:
On the 15th day after the last immunisation, eight mice in each group were challenged orally with 1 × 104 T. gondii RH strain tachyzoites for the tachyzoite load assay, and 12 mice in each group were challenged orally with 4 × 104 tachyzoites for the survival assay. The numbers of tachyzoites in the brains and livers of the mice were measured to assess the results of the chronic challenge infection assay. The time to death and survival of the mice were recorded and assessed for one month after parasite challenge. (Wang et al., 2016)
- Efficacy:
Chronic infection: The tachyzoite loads in the brain tissues were (7.64 ± 1.47) × 106/g in the control group and (2.92 ± 0.51) × 106/g in the rTgPGAM 2-vacinated group. The tachyzoite loads in the liver tissues were (10.39 ± 2.17) × 106/g in the control group and (3.85 ± 1.17) × 106/g in the rTgPGAM 2-vacinated group. Compared with the mice in the control group, the average parasite burden was reduced significantly by 56.9% and 69.2% in the brain and liver tissues, respectively. (Wang et al., 2016)
Acute infection: A significant increase in the survival time and survival rate (70%) was observed in the rTgPGAM 2-immunised group compared with the control group. (Wang et al., 2016)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14. rTgRACK1 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Mouse |
| d. Antigen |
| TgRACK1 (Wang et al., 2014) |
| e. Gene Engineering of
TgRACK1 |
- Type:
Recombinant protein preparation
- Description:
First strand cDNA was synthesised from the total RNA extracted from tachyzoites of T. gondii. TgRACK1 was amplified by PCR, which introduced EcoRI and NotI sites. The PCR product was digested and cloned into pGEX-6P-1 vector. The resulting pGEX-6P-1-TgRACK1 plasmid was transformed into E. coli BL21 (DE3) host cells. rTgRACK1 was harvested from E. coil and purified. (Wang et al., 2014)
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| Nasal spray |
| g. Description |
| T. gondii subunit vaccine of recombinant TgRACK1 (Wang et al., 2014) |
| h.
Mouse Response |
- Host Strain:
BALB/c (Wang et al., 2014)
- Vaccination Protocol:
Fifty 6-week-old female BALB/c mice were randomly divided into five groups (10 per group) and were intranasally immunized with 15, 25, 35 or 45 μg of rTgRACK1 dissolved in 20 μl sterile phosphate-buffered saline (PBS) on days 0, 14, and 21. Control mice received PBS alone. (Wang et al., 2014)
- Immune Response:
Mucosal: The sIgA antibody titers in the nasal washes of the rTgRACK1-treated groups were significantly higher than those of the PBS control, with the highest titer of sIgA antibody detected in the 35 μg rTgRACK group (P<0.01). sIgA levels from the intestinal and vesical washes were higher in 25, 35, 45 μg rTgRACK1 groups, and 35 μg rTgRACK1 could also elicit the highest sIgA levels in intestinal and vesical washes (P < 0.01). Enhanced production of both IFN-γ and IL-2 were detected in the 25 μg rTgRACK1 group (P < 0.05) and reached higher levels in the 35 and 45 μg rTgRACK1 groups (P < 0.01). (Wang et al., 2014)
Humoral: Significantly increased levels of total IgG and IgA antibodies were observed in the 25, 35 and 45 μg rTgRACK1 groups compared to the control group (P < 0.05). The maximum IgG antibody response was detected in the 35 μg rTgRACK1-treated group. A mixed IgG1/IgG2a response with predominant IgG2a production was detected. (Wang et al., 2014)
Cellular: Significant productions of IFN-γ, IL-2 and IL-4 were all evident at 25 μg rTgRACK1 treatment and reached a maximum level at 35 μg rTgRACK1. No significant changes in production of IL-10 were seen (P>0.05). (Wang et al., 2014)
- Challenge Protocol:
Mice immunised with 35 μg of rTgRACK1 and PBS control mice (30 mice/group, 10 mice for chronic infection and 20 mice for lethal assay) were orally challenged with either 1 × 104 tachyzoites for the chronic infection or 4 × 104 tachyzoites for an acute infection on the fifteenth day after the last immunisation.The time to death of the challenged mice was monitored for the acute challenge. On the 31st day, the numbers of tachyzoite in the murine brains and livers of the chronic challenge mice were determined by real-time PCR assay. (Wang et al., 2014)
- Efficacy:
Chronic: Significant reductions of tachyzoite were observed in both the brain and liver tissues of rTgRACK1-immunised mice (1.12 ± 0.17 × 106/g and 2.61 ± 0.28 × 106/g respectively) in comparison with those of PBS controls (2.09 ± 0.32 × 106/g and (5.63 ± 0.74) × 106/g, respectively), representing a 57.09% reduction in brain (P < 0.01) and 53.64% reduction in liver (P < 0.01) with rTgRACK1 vaccination. (Wang et al., 2014)
Acute: The death time of mice immunised with 35 μg rTgRACK1 was between 8 and 21 days after the challenge, while all of the mice in the PBS control group died from 6 to 10 days after the challenge, representing significantly increase in the survival rate of vaccinated mice (approximately 45%) (P < 0.01). (Wang et al., 2014)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15. rTgROP17 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Antigen |
| ROP17 (Wang et al., 2014) |
| f. Gene Engineering of
ROP17 |
- Type:
Recombinant protein preparation
- Description:
ORF of the TgROP17 gene was amplified by RT-PCR and was cloned into the pGEX-6P-1 vector. The recombinant plasmid was transferred into E. coli DH5a and were selected. The successful pGEX-6P-1/TgROP17 construct was transformed into E. coli Rosetta (DE3). The rTgROP17 protein was express in E. coli Rosetta (DE3) cells, purified, and the endotoxin in rTgROP17 was removed. (Wang et al., 2014)
- Detailed Gene Information: Click here.
|
| g. Immunization Route |
| Nasal spray |
| h. Description |
| T. gondii subunit vaccine of recombinant ROP17 (Wang et al., 2014) |
| i.
Mouse Response |
- Host Strain:
BALB/c (Wang et al., 2014)
- Vaccination Protocol:
Mice were randomly divided into 5 groups (8 mice per group) and were immunized nasally with 20 µl PBS containing 15, 25, 35 or 45 µg of rTgROP17. The control mice were given PBS solution only. All animals were vaccinated three times on days 0, 14, and 21. (Wang et al., 2014)
- Immune Response:
Humoral: The total IgG antibody productions of the mice immunized with 35 and 45 µg rTgROP17 were significantly higher than those of the control group (P<0.01) but not significantly different from each other (P>0.05). 25 µg but not 15 µg rTgROP17 elicited elevated IgG antibody levels compared to the control groups (P<0.05). Both IgG1 and IgG2a were detected in the sera of all the mice immunized with rTgROP17, and greater levels of IgG2a were detected than IgG1 in general. (Wang et al., 2014)
Cellular: 35 µg and 45µg rTgROP17 significantly stimulated the production of IFN-γ(P<0.01), IL-2(P<0.01), and IL-4 (P<0.05) over the PBS control group. 25 µg rTgROP17 also stimulated the production of IFN-γ and IL-2 (P<0.05) but not IL-4 (P>0.05). 15 µg rTgROP17 did not stimulated the production of IFN-γ, IL-2, or IL-4 (P>0.05). No significant difference was observed for the levels of IL-5 between the rTgROP17-vaccinated and PBS control mice (P>0.05). The splenocyte stimulation indices (SIs) of the mice in 35 and 45 µg rTgROP17 groups were significantly greater than those in 15 µg rTgROP17 group or PBS control (P<0.01). The SI of the 25 µg group was greater than that of the PBS control (P<0.05). No significant difference was found for the SIs of the 15 µg group and PBS controls (P> 0.05). (Wang et al., 2014)
Mucosal: Higher levels of SIgA were detected in the nasal, vaginal and intestinal washes of rTgROP17-immunized mice compared to those of their PBS controls (35 and 45 µg: P<0.01; 25 µg: P<0.05). (Wang et al., 2014)
- Challenge Protocol:
Mice at 6 weeks of age were randomly divided into two groups (20 mice per group) and vaccinated intranasally with 35 µg of rTgROP17 or GST control in 20 µl volumes on days 0, 14, and 21. On day 14 after the final immunization, 8 mice from each group were orally challenged with 1×104 tachyzoites of the RH strain for chronic assay, and the other 12 mice from each group were challenged with 4×104 tachyzoites for acute infection. (Wang et al., 2014)
- Efficacy:
Chronic infection: The tachyzoite loads in the brains and livers of the mice immunized with 35 µg rTgROP17 were significantly reduced to 59.17% (P<0.01) and 49.08% (P<0.05) of the loads found in the GST-treated control mice, respectively (Wang et al., 2014)
Acute infection: The survival rates of the mice in rTgROP17 group were significantly increased (75%) on the 30th day after the challenge when compared to those in GST-treated control group (25%) (P<0.01). Survival of rTgROP17-immunized mice was three times over the GST-treated mice. The death time of the control mice ranged from 5 to 9 days, while the mice immunized with rTgROP17 died between days 10 and 14 after the challenge. (Wang et al., 2014)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16. T. gondii DNA vaccine encoding MIC8 |
| a. Vaccine Ontology ID: |
| VO_0004219 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Antigen |
| MIC8 |
| f. Gene Engineering of
MIC8 |
- Type:
DNA vaccine construction
- Description:
To construct the pVAX-MIC8 expression plasmid, the coding sequence of the T. gondii MIC8 gene was amplified by polymerase chain reaction (PCR) from genomic DNA of T. gondii. The PCR product was cloned in pGEM-T easy vector (Promega, USA) and sequenced in both directions to ensure fidelity and generated pGEM-MIC8. The MIC8 fragment was inserted into the BamH I/Xba I sites of pVAX I by double digestion with BamH I/Xba I restriction enzymes, and ligation was finally done using T4 DNA ligase. The resulting plasmid was named pVAX-MIC8 (Liu et al., 2010).
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pVAX1 (Liu et al., 2010) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i.
Mouse Response |
- Host Strain:
Kunming
- Vaccination Protocol:
Mice (20 per group) received injections of 100 μl of pVAXMIC8 plasmid or empty pVAX I vector into each anterior tibial muscle (final plasmid concentration, 100 μg/100 μl). The injections were repeated using the same protocol 2 and 4 weeks after vaccination. Tail bleeds were performed on vaccinated mice on the day of first vaccination, second vaccination, and third vaccination and pre-challenge to ascertain the presence of specific anti-T. gondii antibodies (Liu et al., 2010).
- Challenge Protocol:
Mice in all groups were intraperitoneally challenged with the virulent T. gondii RH strain (103 tachyzoites per mouse) 2 weeks after the last immunization (Liu et al., 2010).
- Efficacy:
Immunization of mice with pVAXMIC8 dramatically increased the survival time (10.3± 0.9 days) compared with control mice which died within 5 days of challenge (Liu et al., 2010).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17. T. gondii DNA vaccine encoding multi-epitope ROP8 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| ROP8: expressed in tachyzoite and bradyzoite stages. Involved in the pathogenicity of the parasite as well as host cell modulation, critical for acute virulence of T. gondii. (Foroutan et al., 2020) |
| e. Gene Engineering of
ROP8 |
- Type:
DNA vaccine construction
- Description:
The linear B cell epitopes, major histocompatibility complex (MHC) class I and class II molecules for ROP8 protein were predicted using bioinformatic tools. MHC I, MHC II, and linear B-cell epitopes were linked together by the SAPGTP linker, and the Kozak sequence was added at N-terminal. Several physico-chemical parameters, post translational modifications, and the secondary and tertiary structure for the multi-epitope peptide were predicted. The final sequence of the peptide was sent for the construction and cloning into eukaryotic expression vector pcDNA3.1. (Foroutan et al., 2020)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pcDNA3.1 (Foroutan et al., 2020) |
| g. Immunization Route |
| subcutaneous injection |
| h. Description |
| Multi-epitope DNA vaccine encoding the potential B and T-cell epitopes from ROP8 protein using eukaryotic expression vector pcDNA3.1. (Foroutan et al., 2020) |
| i.
Mouse Response |
- Host Strain:
BALB/c mice (Foroutan et al., 2020)
- Vaccination Protocol:
Three groups of BALB/c mice (8 per experimental group) were immunized on days 0, 21, and 42 with 100 μg of plasmid DNA suspended in 100 μl sterile endotoxin free PBS (100 μg/100 μl), including two control groups (PBS and empty pcDNA3.1 vector). (Foroutan et al., 2020)
- Immune Response:
Humoral: Significantly high levels of IgG antibodies were detected post vaccination with multi-epitope ROP8 vaccine compared with PBS and empty pcDNA3.1 vector (P < 0.05). The multi-epitope vaccine elicited both IgG1 and IgG2a production with the predominance of IgG2a compared with control groups (P < 0.05). (Foroutan et al., 2020)
Cellular: Spleen cells from mice vaccinated with multi-epitope ROP8 vaccine generated a significantly higher level of IFN-γ and IL-4 than the mice in the PBS and empty pcDNA3.1 vector groups (P < 0.05). The BALB/c mice vaccinated with multi-epitope vaccine have the greater splenocyte proliferative response compared with control groups (P < 0.05). (Foroutan et al., 2020)
- Challenge Protocol:
Three weeks after the last immunization, five mice per group were intraperitoneally (i.p) challenged with 2 × 103 tachyzoite of virulent T. gondii RH strain. Their survival periods were monitored daily. (Foroutan et al., 2020)
- Efficacy:
The BALB/c mice that received the multi-epitope ROP8 vaccine had prolonged survival time compared with PBS and pcDNA3 control groups (P < 0.05). (Foroutan et al., 2020)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18. T. gondii DNA vaccine pcDNA3-MIC3 |
| a. Vaccine Ontology ID: |
| VO_0011523 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Gene Engineering of
MIC3 |
|
| f. Vector: |
| pcDNA3 (Xiang et al., 2009) |
| g. Immunization Route |
| Footpad injection |
| h.
Mouse Response |
- Host Strain:
Kunming
- Vaccination Protocol:
All studies were done with 6–8 weeks old Kunming mice. For experimental group, 100 μg pcDNA3-MIC3 were injected into mouse hind footpad three times, at week 0, 3 and 6, respectively. The mice of control groups were vaccinated with 100 μg pcDNA3 or normal saline (NS) three times (Xiang et al., 2009).
- Challenge Protocol:
Immunized Kunming mice were challenged intraperitoneally with 500 tachyzoites of RH strain T. gondii 9 weeks after the first immunization (Xiang et al., 2009).
- Efficacy:
The survival time of mice in pcDNA3-MIC3 group was significantly longer than those of in group pcDNA3 and NS (Xiang et al., 2009).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19. T. gondii DNA vaccine pcDNA3.1-HisGRA6 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA6 (Sun et al., 2011) |
| e. Gene Engineering of
GRA6 |
- Type:
Recombinant protein preparation
- Description:
GRA6 ORF was PCR amplified and the PCR product was ligated into the pcDNA3.1 vectors to construct recombinant plasmid pcDNA3.1-HisGRA6. (Sun et al., 2011)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pcDNA3.1 (Sun et al., 2011) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding GRA6 using pcDNA3.1 vector. (Sun et al., 2011) |
| i.
Mouse Response |
- Host Strain:
BALB/c mice carrying H-2Ld gene and Kunming mice without H-2Ld gene. (Sun et al., 2011)
- Vaccination Protocol:
BALB/c mice received three injections of 100 μg of pcDNA3.1-HisGRA6 DNA at 2-week intervals in both tibialis anterior muscles. Kunming mice were immunized with pcDNA3.1-HisGRA6 and BALB/c with empty pcDNA3.1 as controls. One group of BALB/c mice was immunized with pcDNA3.1-HisGRA6 formulated in 1% LMS as the adjuvant. (Sun et al., 2011)
- Challenge Protocol:
The immunized mice were challenged intraperitoneally with 1, 000 tachyzoites of T. gondii RH strain (Type I). One week after the challenge, brain, liver and spleen were removed and fixed in 10% formalin for histological examination. Two weeks after the last immunization, the animals were observed daily for mortality. (Sun et al., 2011)
- Efficacy:
Immunization of BALB/c mice with pcDNA3.1-HisGRA6 significantly increased the survival rate of these mice (40% survival) (P < 0.05) in comparison with BALB/c immunized with the control vector or Kunming mice immunized with pcDNA3.1-HisGRA6 (0% survival) (P < 0.05). Survival was further increased in mice immunized with pcDNA3.1-HisGRA6 plus LMS (53.3% survival cf. 40% without LMS; P < 0.05). Mice alive at week 12 stayed alive for at least 2 months.
No parasite was detected in the brain, liver or spleen of BALB/c mice immunized with pcDNA3.1-HisGRA6 alone or pcDNA3.1-HisGRA6 plus LMS. Parasites were clearly visible in the tissues of the control groups.
(Sun et al., 2011)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20. T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2 |
| a. Vaccine Ontology ID: |
| VO_0004313 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
p30 |
- Type:
DNA vaccine construction
- Description:
Vector pcDNA3.1 expressed SAG1 (Xue et al., 2008).
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
Rop2 |
- Type:
DNA vaccine construction
- Description:
Vector pcDNA3.1 expressed ROP2 (Xue et al., 2008).
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pcDNA3.1 (Xue et al., 2008) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i.
Mouse Response |
- Vaccine Immune Response Type:
VO_0000286
- Efficacy:
When challenged with Toxoplasma gondii RH strain, mice immunized with pIL-12 co-administration had significantly higher survival rates compared to co-administration with pCTA2/B or pcDNA3.1-SAG1-ROP2 alone (control) (Xue et al., 2008).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21. T. gondii DNA vaccine pcDNA3.1/MIC11 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| MIC11 (Tao et al., 2013) |
| e. Gene Engineering of
MIC11 |
- Type:
DNA vaccine construction
- Description:
The α-chain of MIC11 gene was PCR amplified and was ligated into pcDNA3.1 vector forming pcDNA/MIC11 plasmid. The plasmid was cloned in E. coli (DH5α strain) and was confirmed by restriction digestion and sequencing analysis. The large scale plasmid extraction was performed using Endo-Free Plasmid Maxi Kit (OMEGA bio-tek, USA) by following the manufacturer's instructions. (Tao et al., 2013)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pcDNA3.1 (Tao et al., 2013) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding MIC11 as antigen using pcDNA3.1 vector. (Tao et al., 2013) |
| i.
Mouse Response |
- Host Strain:
BALB/c (Tao et al., 2013)
- Vaccination Protocol:
Sixty BALB/c mice were randomly divided into three groups (20 in each group). 100 μg (for each injection) of pcDNA/MIC11 plasmid or the pcDNA3.1 empty vector were suspended in 100 μl sterile PBS and intramuscularly injected into different groups of mice, respectively. The mice injected with 100 μl sterile PBS only were served as the blank control group. All groups of mice were immunized three times at a 2-week interval using same dosages. (Tao et al., 2013)
- Immune Response:
Humoral: higher anti-TLA IgG
Cellular: higher splenocyte proliferation activity, higher levels of IFN-γ, IL-12, and IL-2
(Tao et al., 2013)
- Challenge Protocol:
Ten days after the last immunization, twelve mice from each group were randomly selected and injected intraperitoneally with 1 × 103 tachyzoites of T. gondii RH strain. Tachyzoites were counted with a hemocytometer and adjusted to 5 × 103 parasites/ml with 0.1 M PBS (pH 7.4). The parasite solution (200 μl) was injected into each mouse, and mice survival was subsequently monitored daily for 15 days. (Tao et al., 2013)
- Efficacy:
The mice immunized with pcDNA/MIC11 showed significantly prolonged survival. All mice in the control groups immunized with PBS or pcDNA3.1 died within 8 or 10 days post-infection, respectively. However, 50 % of the mice immunized with pcDNA/MIC11 were alive at day 10, and 17 % of them survived to day 15 after the parasite challenging. (Tao et al., 2013)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22. T. gondii DNA vaccine pDREP-TgNTPase-II |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| TgNTPase-II: Toxoplasma gondii nucleoside triphosphate hydrolase-II: facilitate the parasite to salvage purines from the host cell for survival and replication (Zheng et al., 2017) |
| e. Vector: |
| pDREP: a DNA-based alphaviral RNA replicon vector (suicidal DNA vector). Induce apoptotic cell death of the transfected cells (Zheng et al., 2017). |
| f. Immunization Route |
| Intramuscular injection (i.m.) |
| g. Description |
| T. gondii DNA vaccine encoding TgNTPase using pDREP I vector. (Zheng et al., 2017) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23. T. gondii DNA vaccine pDsRed2-GRA8 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Baboon |
| d. Antigen |
| GRA8 (Chu et al., 2018) |
| e. Vector: |
| pDsRed2-N1 (Chu et al., 2018) |
| f. Immunization Route |
| Intramuscular injection (i.m.) |
| g. Description |
| T. gondii DNA vaccine encoding GRA8 using pDsRed2-N1 vector. (Chu et al., 2018) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24. T. gondii DNA vaccine pEGFP-C1/GRA41 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA41: dense granular protein 41. Induce the interface formation between host cells and parasite. (Zhou et al., 2019) |
| e. Gene Engineering of
GRA41 |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR using a forward primer introducing HindIII recognition sites and a reverse primer introducing BamHI recognition sites. The amplified GRA41 was purified and was inserted into the pEGFP-C1 vector. (Zhou et al., 2019)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pEGFP-C1 (Zhou et al., 2019) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine that encodes GRA41 using pEGFP-C1 vector. Used in PBS. (Zhou et al., 2019) |
| i.
Mouse Response |
- Host Strain:
BALB/c mice (Zhou et al., 2019)
- Vaccination Protocol:
Mice were assigned to three groups where there were 24 mice in each one. All the mice were vaccinated with 100 μL of PBS containing 100 μg pGRA41, 100 μg empty vectors, or 100 μg PBS respectively. There were three injections with 2 week interval. (Zhou et al., 2019)
- Immune Response:
Humoral: The level of IgG in pEGFP-C1/GRA41 group increased continuously after the first injection. There was a reliable difference in the IgG quantity between the test group and the control groups in week 4 and week 6 (P<0.05). The difference was significant between IgG2a and IgG1 in pEGFPC1/GRA41 group (P<0.05). The quantity of the former is approximately two times than that of the latter. (Zhou et al., 2019)
Cellular: For IFN-γ, there was a statistically signifcant difference between the pEGFPC1/GRA41 group and the two controlled groups. However, for IL-4 or IL-10, there was no statistically significant difference between all groups. (Zhou et al., 2019)
- Challenge Protocol:
Two weeks after the fnal immunization, ten mice were challenged intraperitoneally with 1×104 tachyzoites of the high virulence T. gondii RH strain, and another 10 mice were challenged intragastrically with 20 T. gondii PRU strain cysts. (Zhou et al., 2019)
- Efficacy:
RH: All mice in pEGFPC1/GRA41 group died on day 18, with an average survival duration of 13.3±3.37 days, compared to mice in the control groups which all died on day 7. For survival duration, there was remarkable difference between the pEGFPC1/GRA41 group and the control groups (P<0.05). (Zhou et al., 2019)
PRU: The mean number of cysts in control groups (1520±278) was approximately two times higher than that of pEGFP-C1/GRA41 group (618±132), which was statistically signifcant (P<0.05). (Zhou et al., 2019)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25. T. gondii DNA vaccine pIRESneo/MIC6/PLP1 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| MIC6 (Yan et al., 2012); TgPLP1 (Yan et al., 2012) |
| e. Gene Engineering of
MIC6 |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR using a forward primer introducing Sma I recognition sites and a reverse primer introducing Xba I recognition sites. (Yan et al., 2012) The amplified MIC6 was cloned into the pGEM-T Easy vector (Promega) and was sequenced. The ROP18 fragment was cleaved by SmaI/XbaI from pGEM-MIC6, purified, and then cloned into the SmaI/XbaI sites of pIRESneo, generating recombinant plasmid pIRESneo/MIC6. The purified TgPLP1 was cloned into pIRESneo/MIC6 and formed pIRESneo/MIC6/PLP1. (Yan et al., 2012)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
PLP1 |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR using a forward primer introducing Cla I recognition sites and a reverse primer introducing BamH I recognition sites. (Yan et al., 2012) The amplified TgPLP1 was digested, purified, and cloned into pIRESneo/MIC6 and formed pIRESneo/MIC6/PLP1. (Yan et al., 2012)
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pIRESneo (Yan et al., 2012) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i. Description |
| T. gondii DNA vaccine encoding MIC6 and TgPLP1 as antigin using pIRESneo vector. pVAX I plasmids encoding IL-18 are codelivered as adjuvant. (Yan et al., 2012) |
| j.
Mouse Response |
- Host Strain:
Specific-pathogen-free (SPF)-grade inbred Kunming mice (Yan et al., 2012)
- Vaccination Protocol:
Seven groups of mice (25 mice per group) were injected with 100 μg of plasmid DNA suspended in 100 μl sterile PBS. Group I mice were injected with PBS as a blank control; group II to group VI mice were injected with the empty vector pVAX I or pIRESneo, pVAX/IL-18, pVAX/TgPLP1, or pVAX/MIC6, respectively, also as controls; and groups VII and VIII were injected with pIRESneo/MIC6/TgPLP1 or pIRESneo/MIC6/TgPLP1+pVAX/IL-18 (100 μl each) respectively. Two booster injections were administered at 2 week interval. (Yan et al., 2012)
- Immune Response:
Humoral: Mice injected with pIRESneo/MIC6/TgPLP1 or pIRESneo/MIC6/TgPLP1+pVAX/IL-18 had significantly high levels of anti-TgPLP1/MIC6 IgG antibodies, especially after the third immunization. Mice injected with pVAX/PLP1 or pVAX/MIC6 alone also generated anti-TgPLP1/MIC6 antibodies but at significantly lower levels (P < 0.05). Mice injected with PBS, pVAX I, pIRESneo, or pVAX/IL-18 alone did not generate anti-TgPLP1 antibodies, significantly different from the groups mentioned above (P < 0.05). (Yan et al., 2012)
Cellular: Splenocytes from all groups proliferated to comparable levels. The level of splenocyte proliferation increased over those of the other groups when mice were coinjected with pIRESneo/MIC6/TgPLP1 + pVAX/IL-18 (P < 0.05). Mice immunized with pIRESneo/MIC6/TgPLP1 had higher lymphocyte responses than the controls (P < 0.05). Mice immunized with pVAX/TgPLP1, pVAX/MIC6, or pVAX/IL-18 alone had significantly higher lymphocyte responses than the rest of the controls (P < 0.05). Very large amounts of specific IFN-γ, IL-2, and IL-12 were produced in pIRESneo/MIC6/TgPLP1+pVAX/IL-18, pIRESneo/MIC6/TgPLP1, pVAX/IL-18, pVAX/PLP1, or pVAX/MIC6 groups. Specific amounts of IL-4 and IL-10 were synthesized in pIRESneo/MIC6/TgPLP1 or pIRESneo/MIC6/TgPLP1+pVAX/IL-18 groups. (Yan et al., 2012)
- Challenge Protocol:
Five mice were randomly chosen from every group and challenged intragastrically with 80 cysts of strain PRU, and observed daily for mortality. Eight mice of each group were orally infected with 20 cysts of strain PRU at the 14th day after the last immunization. Cysts in the brain were counted 6 weeks after challenge. (Yan et al., 2012)
- Efficacy:
Acute infection: All mice immunized with PBS, pIRESneo, or pVAX I died at day 25. Immunization with pIRESneo/MIC6/TgPLP1 dramatically increased the survival time (42.8 ± 2.9 days) (P < 0.05). Coimmunization with pIRESneo/MIC6/TgPLP1 and pVAX/IL-18 enhanced the survival time even further (45.0 ± 2.9 days), although the difference was not statistically significant (P > 0.05). (Yan et al., 2012)
Chronic infection: The lowest brain cyst burdens were observed in mice immunized with pIRESneo/MIC6/PLP1+pVAX/IL-18 (1,085.67 ± 49.32 cysts per brain) or pIRESneo/MIC6/PLP1 (1,206.00 ± 10.02 cysts per brain) and were significantly lower than those in the PBS group (3,140.33 ± 96.72 cysts per brain) and the other five groups (P < 0.05). Brain cyst burdens were significantly lower (P < 0.05) in mice immunized with pVAX/PLP1 (1,759.00 ± 60.47) or pVAX/MIC6 (1,890.00 ± 46.36) than in the control animals.(Yan et al., 2012)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26. T. gondii DNA vaccine pIRESneo/ROP18/PLP1 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| ROP18 (Chen et al., 2018); TgPLP1 (Chen et al., 2018) |
| e. Gene Engineering of
ROP18 |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR using a forward primer introducing Sma I recognition sites and a reverse primer introducing Xba I recognition sites. (Chen et al., 2018) The amplified ROP18 was cloned into the pGEM-T Easy vector (Promega) and was sequenced. The ROP18 fragment was cleaved by SmaI/XbaI from pGEM-ROP18, purified, and then cloned into the SmaI/XbaI sites of pIRESneo, generating recombinant plasmid pIRESneo/ROP18. The purified TgPLP1 was cloned into pIRESneo/ROP18 and formed pIRESneo/ROP18/PLP1. (Yan et al., 2012)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
PLP1 |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR using a forward primer introducing Cla I recognition sites and a reverse primer introducing BamH I recognition sites. (Chen et al., 2018) The amplified TgPLP1 was digested, purified, and cloned into pIRESneo/ROP18 and formed pIRESneo/ROP18/PLP1. (Yan et al., 2012)
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pIRESneo (Chen et al., 2018) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i. Description |
| T. gondii DNA vaccine encoding ROP18 and TgPLP1 as antigin using pIRESneo vector. pVAX I plasmids encoding IL-18 are codelivered as adjuvant. (Chen et al., 2018) |
| j.
Mouse Response |
- Host Strain:
Specific-pathogen-free (SPF) Kunming mice (Chen et al., 2018)
- Vaccination Protocol:
Eight groups of mice (30 mice/group) were vaccinated intramuscularly with 100 μg of plasmid dissolved in 100 μl of sterile PBS. The experimental groups received pIRESneo/ROP18/PLP1 + pVAX/IL-18, pIRESneo/ROP18/PLP1, pVAX/PLP1, or pVAX/ROP18 respectively. Injection of pVAX/IL-18, PBS, empty pIRESneo vector, or empty pVAX1 vector was performed as controls. All of the mice were boosted twice at 2-week intervals. (Chen et al., 2018)
- Immune Response:
Humoral: Immunization with PBS, pVAXI, pIRESneo, or pVAX/IL-18 alone (four control groups) did not produce an antibody response, which was significantly different (P < 0.05) from the response observed in the four experimental groups. Significant differences were observed between the mice treated with pROP18/PLP1 or pROP18/PLP1 + pVAX/IL-18 and mice treated with pVAX/ROP18 (P < 0.05). (Chen et al., 2018)
Cellular: The lymphocyte proliferative response in mice injected with pROP18/PLP1 or pROP18/PLP1 + pVAX/IL-18 was significantly higher than that in control mice (P < 0.05). Th1-type cytokines (IFN-γ, IL-2 and IL-12) were induced at significantly higher levels by ROP18/PLP1 fusion protein (P < 0.05) than by ROP18 or PLP1 alone. Compared to mice immunized with pROP18/PLP1 + pVAX/IL-18, mice immunized with pROP18/PLP1 had than significantly lower IL-2, IL-12 and IFN-γ levels (P < 0.05) but significantly higher IL-4 and IL-10 levels (P < 0.05). (Chen et al., 2018)
- Challenge Protocol:
Two weeks after the last stimulation, 12 mice per group were randomly chosen for intragastric administration of 80 T. gondii PRU cysts, and survival was monitored daily. Another 8 mice per group were orally infected with 20 PRU tissue cysts, and brain cysts were counted at 6 weeks post-infection. (Chen et al., 2018)
- Efficacy:
Acute infection: the survival time was significantly longer (P < 0.05) in mice vaccinated with pROP18/PLP1 (44 ± 2.9 days) or pROP18/PLP1 + pVAX/IL-18 (47 ± 2.9 days) than in control mice (≤36 days). (Chen et al., 2018)
Chronic infection: brain cyst burden was significantly lower (P < 0.05) in mice immunized with pROP18/PLP1 + pVAX/IL-18 or pROP18/PLP1 than in control mice. (Chen et al., 2018)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27. T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain) |
| a. Vaccine Ontology ID: |
| VO_0004453 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
MIC3 |
|
| f. Vector: |
| pCDNA3 (Ismael et al., 2009) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h.
Mouse Response |
- Vaccine Immune Response Type:
VO_0000286
- Efficacy:
Mice immunized with pMIC3i displayed significant protection against an oral challenge with 76K T. gondii strain cysts, exhibiting fewer brain cysts than the control mice immunized with the empty plasmid pcDNA3. The co-administration of pGM-CSF enhanced this protection (Ismael et al., 2009).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28. T. gondii DNA vaccine pSAG1-ROP2-SAG2 |
| a. Vaccine Ontology ID: |
| VO_0004312 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
p30 |
- Type:
DNA vaccine construction
- Description:
Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
SAG2 |
- Type:
DNA vaccine construction
- Description:
Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
- Detailed Gene Information: Click here.
|
| g. Gene Engineering of
ROP2 |
- Type:
DNA vaccine construction
- Description:
Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
- Detailed Gene Information: Click here.
|
| h. Vector: |
| pcDNA3.1 (Cui et al., 2008) |
| i. Immunization Route |
| Intramuscular injection (i.m.) |
| j.
Mouse Response |
- Vaccination Protocol:
Six groups (14 per group) of mice were injected intramuscularly (50 µL in each thigh skeletal muscle) with 100 µg of plasmid DNA suspended in 100 µL sterile PBS. Group I was injected with PBS as control, group II with pcDNA3·1 vector alone as control, group III with pSAG2, group IV with pSAG1-ROP2, group V with pSAG1-ROP2-SAG2 and group VI with pSAG1-ROP2-SAG2 + pIL-12 (100 µg each). The mice were immunized on days 0, 14 and 28 with the same protocol. (Cui et al., 2008)
- Vaccine Immune Response Type:
VO_0000286
- Challenge Protocol:
On day 56, seven immunized mice per group were challenged with 104 tachyzoites of the T. gondii RH strain. The survival days of the mice was recorded. (Cui et al., 2008)
- Efficacy:
Higher survival rates after lethal challenge were obtained in mice immunized with pSAG1-ROP2-SAG2 as compared to the mice immunized with PBS, expression vector alone or pSAG2, or pSAG1-ROP2. In addition, the protection induced by pSAG1-ROP2-SAG2 was remarkably enhanced by pIL-12 co-administration (Cui et al., 2008).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29. T. gondii DNA vaccine pSAG5B/SAG5C |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| SAG5B and SAG5C: sequence branches of surface antigen protein 5, transcribed in T. gondii tachyzoites and bradyzoites, play an important role in cyst persistence in the host. (Lu et al., 2017) |
| e. Gene Engineering of
SAG5B |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR. The PCR products from SAG5B and SAG5C genes were cloned into the pEASY-T1 vector and digested with restriction enzymes. The SAG5B and SAG5C fragments were purified and inserted into the mammalian expression vector pBudCE4.1 to produce pSAG5B and pSAG5C. The NotI/KpnI fragment encoding SAG5B was excised and cloned into the HindIII/XbaI sites of the pSAG5C to produce pSAG5B/SAG5C. (Lu et al., 2017)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
SAG5C |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR. The PCR products from SAG5B and SAG5C genes were cloned into the pEASY-T1 vector and digested with restriction enzymes. The SAG5B and SAG5C fragments were purified and inserted into the mammalian expression vector pBudCE4.1 to produce pSAG5B and pSAG5C. The NotI/KpnI fragment encoding SAG5B was excised and cloned into the HindIII/XbaI sites of the pSAG5C to produce pSAG5B/SAG5C. (Lu et al., 2017)
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pBudCE4.1 (Lu et al., 2017) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i. Description |
| Multi-antigenic DNA vaccine that express SAG5B and SAG5C using mammalian expression vector pBudCE4.1. (Lu et al., 2017) |
| j.
Mouse Response |
- Host Strain:
BALB/c mice (Lu et al., 2017)
- Vaccination Protocol:
Mice were divided randomly into five groups (28 in each group) and were immunized four times on weeks 0, 2, 4, and 6. Three experimental groups were immunized with 100 μL of PBS containing 100 μg pSAG5B, 100 μg pSAG5C, or 100 μg pSAG5B/SAG5C . The other two mouse groups (the controls) were injected with the empty vector or with PBS. (Lu et al., 2017)
- Immune Response:
Humoral: The IgG levels for the experimental mice increased gradually over time. Significant differences were found in the sera of mice vaccinated using pSAG5B, pSAG5C, or pSAG5B/SAG5C compared with the mice injected with PBS or pBudCE4.1 (P < 0.05). Moreover, IgG levels in the pSAG5B/SAG5C-immunized mice were significantly higher compared with the mice immunized with the single-gene (P < 0.05). A predominance of IgG2a over IgG1 was observed. (Lu et al., 2017)
Cellular: The IFN-γ levels in mice immunized with pSAG5B, pSAG5C, or pSAG5B/SAG5C were significantly higher than those of the mice immunized with PBS or pBudCE4.1 (P < 0.05). The pSAG5B/SAG5C-immunized mice generated the highest IFN-γ level. The pSAG5C-immunized mice generated a higher level of IFN-γ than the pSAG5B-immunized mice, but no significant difference was found between these two groups (P > 0.05). The splenocyte supernatant IL-4 levels of all groups were similar (P > 0.05). (Lu et al., 2017)
- Challenge Protocol:
Two weeks after the final inoculation (day 56), 12 mice from each group were challenged intraperitoneally with 1 × 104 tachyzoites of the highly virulent T. gondii RH strain, while another 12 mice from each group were infected intragastrically with 20 cysts of the T. gondii PRU strain. The mice challenged with the RH strain were observed and those that showed signs of illness were sacrificed immediately using CO2 gas. (Lu et al., 2017)
- Efficacy:
RH: The survival time of the mice immunized with pSAG5B (8.5 ± 0.53), pSAG5C (7 ± 0.56) or pSAG5B/SAG5C (12.3 ± 0.68) was longer than that of the PBS-immunized mice (3.8 ± 0.24) or the pBudCE4.1-immunized mice (3.9 ± 0.26) (P < 0.05). Mice in the pSAG5B/SAG5C immunization group survived longer (17 days) than the mice immunized with the single gene (P < 0.05), while the number of survival days for the single gene groups were similar (P > 0.05). (Lu et al., 2017)
PRU: Mice in the pSAG5B, pSAG5C, and pSAG5B/SAG5C groups showed significantly fewer brain cysts than the PBS- or pBudCE4.1-immunized mice (P < 0.05). Brain cyst numbers in the mice vaccinated with pSAG5B/SAG5C were much lower than those of the other mouse groups (P < 0.05). (Lu et al., 2017)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30. T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL21-IL15 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| CDPK1: calcium-dependent protein kinase 1: involved in the regulation of the parasite’s life cycle at stages dependent on microneme secretion, the key regulator of calcium dependent exocytosis, acts in calcium-dependent secretion of specialized organelles called micronemes, which play a critical role in direct parasite motility, host-cell invasion, and egress (Chen et al., 2014) |
| e. Gene Engineering of
CDPK1 |
- Type:
DNA vaccine construction
- Description:
CDPK1 was amplified by RT-PCR using a forward primer introducing Kpn I recognition sites and a reverse primer introducing Xba I recognition sites. The amplified CDPK1 was purified and was inserted into the pVAX I vector and generated plasmid pVAX-CDPK1. (Chen et al., 2014)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX I (Chen et al., 2014) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding CDPK1 as antigen and IL-21 and IL-15 as adjuvants using pVAX I vector. (Chen et al., 2014) |
| i.
Mouse Response |
- Host Strain:
Kunming mice (Chen et al., 2014)
- Vaccination Protocol:
Six groups (35 mice in each group) were intramuscularly injected twice at 2-week intervals in three immunizations (at weeks 0, 2 and 4) with 100 μg pVAX-CDPK1 DNA in 100 μl sterile PBS, 100 μg pVAX-CDPK1 + pVAX-IL-21-IL-15 DNA in 100 μl sterile PBS, 100 μg pVAX/IL-21/IL-15 DNA in 100 μl sterile PBS, 100 μg the empty vector pVAX, PBS (100 μl/each), respectively, and one group of mice was not inoculated to constitute blank control. (Chen et al., 2014)
- Immune Response:
Humoral: A significant antibody responses corresponding to total antibodies including IgG, IgG1and IgG2a (P < 0.05) were induced in pVAX-CDPK1, pVAX-IL-21-IL-15 and pVAX-CDPK1 plus pVAX-IL-21-IL-15 groups compared to the controls. The highest antibody levels were observed in pVAX-IL-21-IL-15 and pVAX-CDPK1 co-injection group. There was a predominance of IgG2a over IgG1, and co-injection of pVAX-IL-21-IL-15 with pVAX-CDPK1 significantly increased the ratio (P < 0.05). (Chen et al., 2014)
Cellular: Stimulation index in spleen cells from mice immunized with pVAX-CDPK1 or pVAX-IL-21-IL-15 alone was significantly higher compared to the controls, and the level of splenocyte proliferation was further increased (P < 0.05) in mice co-injected pVAX-IL-21-IL-15 and pVAX-CDPK1. The percentage of CD3 + CD8 + CD4-T cells and CD3 + CD4 + CD8-T cells were significantly increased in all immunized mice compared with the controls, and the most increase presented in pVAX-CDPK1 plus pVAX-IL-21-IL-15 co-injection group. IFN-γ and IL-2 significantly increased in all immunized mice, and the largest amounts of both two cytokines were produced in pVAX-CDPK1 and pVAX-IL-21-IL-15 co-injection group compared to the controls (P < 0.05). Small amounts of IL-4 and IL-10 were secreted from splenocytes stimulated by TLA in vitro in all immunized mice compared to the control groups (P < 0.05). (Chen et al., 2014)
- Challenge Protocol:
Two weeks after the last immunization, 15 mice per group were challenged intraperitoneally (IP) with 1 × 103 tachyzoites of the RH strain. The survival time for each mouse and the percentages of mice survived were recorded until a fatal outcome for all animals. In addition, 10 mice per group were inoculated orally with 20 cysts of the PRU strain at day 14th after the third immunization, and observed mice daily for mortality. Four weeks after the PRU strain challenge, surviving mice were sacrificed. The mean number of cysts per brain was determined by counting three samples of 10 μl aliquots of each homogenized brain under an optical microscope. (Chen et al., 2014)
- Efficacy:
RH: Mice immunized with pVAX-CDPK1 (17.3 ± 4.3 days) or pVAX/IL-21/IL-15 (12.0 ± 2.0 days) significantly prolonged survival time after challenge in comparison to mice in control groups. There was significant difference of survival time between the two groups (P < 0.05). Co-injection with pVAX-CDPK1 and pVAX/IL-21/IL-15 enhanced the survival time of the immunized mice (19.2 ± 5.1 days) in contrast to the group of pVAX-CDPK1 or pVAX/IL-21/IL-15 (P < 0.05). (Chen et al., 2014)
PRU: The immunized groups challenged with PRU strain cysts showed a significant reduction in the number of cysts in the brain (P < 0.05) (Chen et al., 2014)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31. T. gondii DNA vaccine pVAX-CDPK1 with pVAX-IL7-IL15 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| CDPK1 (Chen et al., 2016): calcium-dependent protein kinase 1: involved in the regulation of the parasite’s life cycle at stages dependent on microneme secretion, the key regulator of calcium dependent exocytosis, acts in calcium-dependent secretion of specialized organelles called micronemes, which play a critical role in direct parasite motility, host-cell invasion, and egress (Chen et al., 2014) |
| e. Gene Engineering of
CDPK1 |
- Type:
DNA vaccine construction
- Description:
CDPK1 was amplified by RT-PCR using a forward primer introducing Kpn I recognition sites and a reverse primer introducing Xba I recognition sites. The amplified CDPK1 was purified and was inserted into the pVAX I vector and generated plasmid pVAX-CDPK1.(Chen et al., 2014)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX I (Chen et al., 2016) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding CDPK1 as antigin and IL-7 and IL-15 as adjuvants using pVAX I vector. (Chen et al., 2016) |
| i.
Mouse Response |
- Host Strain:
Specific-pathogen-free (SPF) grade Kunming mice (Chen et al., 2016)
- Vaccination Protocol:
Mice were randomly divided into six groups (30 mice each). Three vaccination groups were immunized three times at 2-week intervals with 100 μg plasmid dissolved in 100 μl sterile PBS (pVAX-CDPK1, pVAX-IL-7-IL-15, or pVAX-CDPK1 + pVAX-IL-7-IL-15). Another two groups of mice were injected with empty pVAX I vector or PBS respectively as negative control, and one group of mice was not inoculated to constitute blank control. (Chen et al., 2016)
- Immune Response:
Humoral: Specific total IgG antibodies were detected in the experimental group, with the highest antibody levels in the group of pVAX-CDPK1 + pVAX-IL-7-IL-15 (CDPK1.7.15) in contrast to PBS, pVAX I or blank control (p < 0.05), and the antibody levels increased with successive DNA immunizations. Immunization with pVAX-CDPK1 induced a higher IgG2a/IgG1 ratio compared to the pVAX-IL-7-IL-15 alone immunized animals, and co-injection of pVAX-CDPK1 with pVAX-IL-7-IL-15 induced the highest IgG2a/IgG1 ratio. (Chen et al., 2016)
Cellular: Mice immunized with pVAX-CDPK1 + pVAX-IL-7-IL-15 generated significantly higher lymphocytes proliferative response (SI) and levels of IFN-γ and IL-2 compared with mice immunized with pVAX-CDPK1 or pVAX-IL-7-IL-15 alone (p < 0.05). IL-4 and IL-10 levels increased in pVAX-CDPK1, pVAX-IL-7-IL-15 and pVAX-CDPK1 + pVAX-IL-7-IL-15 groups compared to the control groups (p < 0.05). The percentages of CD3+CD8+CD4- T cells and CD3+CD4+CD8– T cells in pVAX-CDPK1, pVAX-IL-7-IL-15 and pVAX-CDPK1 + pVAX-IL-7-IL-15 groups were significantly increased compared to the controls. CD8+ and CD4+ T cell profiles were also significantly altered in theses groups in terms of IFN-γ expression compared to all controls (p < 0.05). There were no difference between changes in CD8+ and CD4+ T cell profiles in terms of IFN-γ secretion (p > 0.05). (Chen et al., 2016)
- Challenge Protocol:
10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of virulent T. gondii (RH strain). The survival periods were recorded until a fatal outcome for all animals. The other 10 mice per group were inoculated orally with 10 cysts of cyst T. gondii (PRU strain) 14 days after the last immunization. The cysts in their brains were counted 30 days post challenge. (Chen et al., 2016)
- Efficacy:
RH: immunized mice showed a prolonged survival time compared to mice receiving the controls (all these mice died within 9 days, p > 0.05), with 14.13 ± 3.85 days in the group of pVAX-CDPK1, 11.73 ± 1.83 days in the group of pVAX-IL-7-IL-15 and 18.07 ± 5.43 days in the group of pVAX-CDPK1 + pVAX-IL-7-IL-15 (p < 0.05). (Chen et al., 2016)
PRU:Immunization with pVAX-CDPK1, pVAX-IL-7-IL-15 and pVAX-CDPK1 + pVAX-IL-7-IL-15 induced reduction in average parasite burden significantly by 46.0%, 45.0% and 73.5% respectively (p < 0.05) in comparison with the control groups (p < 0.05). (Chen et al., 2016)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32. T. gondii DNA vaccine pVAX-GRA16 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA16 (Hu et al., 2017) |
| e. Gene Engineering of
GRA16 |
- Type:
DNA vaccine construction
- Description:
TgGRA16 gene was PCR amplified, and the PCR products were subcloned into the pVAX I and generated recombinant plasmid pVAX-GRA16. The recombinant plasmids pVAX-GRA16 were purified from transformed E. coli DH5α cells by anion exchange chromatography. (Hu et al., 2017)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX I (Hu et al., 2017) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding GRA16 as antigen using pVAX I vector. (Hu et al., 2017) |
| i.
Mouse Response |
- Vaccination Protocol:
A total of 4 groups were performed (28 mice per group). Mice in different groups were intramuscularly injected with pVAX-GRA16 plasmids, empty pVAX I, and PBS (100 μl/each) 3 times at a 2-week interval. The mice that received nothing were used as negative control. (Hu et al., 2017)
- Challenge Protocol:
10 mice in each group were intraperitoneally (IP) challenged with 103 tachyzoites of the virulent T. gondii RH strain 2 weeks after the last immunization. The survival time for each mouse and the percentages of mice survived were recorded until a fatal outcome for all animals. Meanwhile, 6 mice in all groups were inoculated orally with 10 tissue cysts as experimental chronic toxoplasmosis. One month after infection, brains of mice from each group were homogenized in 1 ml PBS. The number of cysts per brain was determined. (Hu et al., 2017)
- Efficacy:
The average survival time of immunized mice (8.4 ± 0.78 days) showed an extension tendency compared to that of the control groups (7.1 ± 0.30 days), but the differences were not significant (p > 0.05).
Compared to pVAX I, PBS, and negative control groups, immunization with pVAX-GRA16 significantly reduced brain cyst numbers in the immunized mice (p < 0.001), with a cyst reduction of 43.89%.
(Hu et al., 2017)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33. T. gondii DNA vaccine pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA24(Xu et al., 2019), GRA25(Xu et al., 2019), MIC6 (Xu et al., 2019) |
| e. Gene Engineering of
MIC6 |
- Type:
DNA vaccine construction
- Description:
MIC6 was PCR amplified and was cloned in pGEM-T easy vector, generated pGEM-MIC6. The MIC6 fragment was cleaved by BamHI/XhoI from pGEM-MIC6 and cloned into the BamHI/XhoI sites of pVAXI. (Xu et al., 2019)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
GRA24 |
- Type:
DNA vaccine construction
- Description:
GRA24 was PCR amplified and was cloned in pMD-18 T vector, generated pMD-GRA24. The GRA24 fragment was cleaved by KpnI/XbaI from pMD-GRA24 and cloned into the KpnI/XbaI sites of pVAXI. (Xu et al., 2019)
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pVAX (Xu et al., 2019) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i. Description |
| T. gondii DNA vaccine using three pVAX I plasmids encoding GRA24, GRA25, and MIC6 respectively(Xu et al., 2019) |
| j.
Mouse Response |
- Host Strain:
Kunming mice (Xu et al., 2019)
- Vaccination Protocol:
Eight groups (30 Kunming mice per group) were used for this study, consisting of five experimental and three control groups. Mice in the experimental groups were immunized three times (2-week intervals) with 100 μL (1 μg/μL) of pVAX-GRA24, pVAX-GRA25, pVAX-MIC6, pVAX-GRA24 + pVAX-GRA25 or pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 plasmids by intramuscular injection into the quadriceps, respectively. Control groups included mice injected with 100 μL empty pVAX I vector (1 μg/μL), 1× PBS or blank control, respectively. (Xu et al., 2019)
- Immune Response:
Humoral: Highest antibodies titer was observed in pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 group. Also, boosting with pVAX-GRA24 and pVAX-GRA25 increased the IgG titer induced by pVAX-GRA24 or pVAX-GRA25. The levels of IgG titer in the pVAX-GRA24, pVAX-GRA25 or pVAX-MIC6 groups were significantly higher (p < 0.05) than those in the three control groups. Higher IgG2a to IgG1 ratio.
Cellular: Highest levels of IL-2, IFN-γ, IL-12 and IL-23 in co-injected mice. The percentages of CD3+CD4+CD8− and CD3+CD8+CD4− T lymphocytes were significantly increased in all experimental groups. pVAX-GRA24 + pVAX-GRA25 showed higher percentage than single plasmid group, whereas pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 group showed the highest percentage. Higher SI in all experimental groups.
(Xu et al., 2019)
- Challenge Protocol:
Two weeks after the third booster vaccine dose, 10 mice from all groups were challenged intraperitoneally with 1 × 103 tachyzoites of the virulent RH strain, and the survival periods were recorded daily until all mice were dead. Meanwhile, another 10 mice per group were challenged with a non-lethal dose of 20 cysts of the Pru strain. Then, 4 weeks after the challenge, the surviving mice were sacrificed via cervical dislocation, and the mean number of cysts per brain was determined by counting three samples of 10 μL aliquots of each homogenized brain under an optical microscope. (Xu et al., 2019)
- Efficacy:
Mice immunized with pVAX-GRA24 (8.1 ± 0.5 days), pVAX-GRA25 (9.4 ± 0.7 days), pVAX-MIC6 (11.5 ± 0.8 days), pVAX-GRA24 + pVAX-GRA25 (13.8 ± 0.9 days) and with pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 (18.7 ± 1.3 days) had a significantly longer survival time compared to the three control groups. The mice in the three control groups died within 6 days after challenge. (Xu et al., 2019)
The number of cysts in the mouse brain was reduced significantly in the pVAX-GRA24 (29.03%), pVAX-GRA25 (40.88%), pVAX-MIC6 (37.70%), pVAX-GRA24 + pVAX-GRA25 (48.06%) and pVAX-GRA24 + pVAX-GRA25 + pVAX-MIC6 (55.37%) groups, compared to the control group (p < 0.05). There was no apparent reduction of brain cysts among the three control groups. (Xu et al., 2019)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34. T. gondii DNA vaccine pVAX-ROP38 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| ROP38: Rhoptry protein 38: an active rhoptry protein kinase (ROPK) that could have an inhibitory effect on host cell transcription by down-regulating the MAPK signaling track, observed inside rhoptries. (Xu et al., 2014) |
| e. Gene Engineering of
ROP38 |
- Type:
DNA vaccine construction
- Description:
Amplified by PCR using a forward primer introducing Kpn I recognition sites and a reverse primer introducing Xba I recognition sites. The amplified ROP38 was purified and was inserted into the pVAX I vector. (Xu et al., 2014)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX I (Xu et al., 2014) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding ROP38 using pVAX I vector. (Xu et al., 2014) |
| i.
Mouse Response |
- Host Strain:
Specific-pathogen-free (SPF) grade Kunming mice (Xu et al., 2014)
- Vaccination Protocol:
Three groups of mice (28 per group) were injected with 100 μl diluted pVAX-ROP38 DNA vaccine, PBS or empty pVAX I plasmid, respectively. Another group of 28 mice were kept as blank control without injection. Mice in the pVAX-ROP38 DNA vaccine, PBS and pVAX I groups were vaccinated three times with a two-week interval. (Xu et al., 2014)
- Immune Response:
Humoral: Compared with the three control groups, a statistically significantly higher level of IgG antibody was detected in the sera of mice immunized with pVAX-ROP38 (P < 0.01), and the OD values of IgG were continuously increased with successive DNA immunization. The levels of IgG1 and IgG2a in the experimental group (immunized with TgROP38) were also the highest (P < 0.01). A significantly higher IgG2a value than IgG1 was detected. (Xu et al., 2014)
Cellular: The percentage of CD3+ CD4+ CD8- and CD3+ CD8+ CD4- T lymphocytes in the pVAX-ROP38 group were significantly higher than those in the control groups, respectively (P < 0.01). There were no significantly differences in the ratio of CD8+/CD4+ between mice immunized with pVAX-ROP38 and in controls (P > 0.05). A significantly high level of both IFN-γ and IL-2 in the pVAX-ROP38 group was detected in pVAX-ROP38 group compared with that in the three control groups (P < 0.05). (Xu et al., 2014)
- Challenge Protocol:
Two weeks after the last immunization, 10 mice in each group were challenged intraperitoneally with 1000 tachyzoites of the virulent T. gondii RH strain, and other 6 mice were inoculated with 10 cysts of the attenuated virulent PRU strain orally. Mice injected with RH strain were observed twice a day for mortality until a fatal outcome for all animals. The brain cysts were determined one month after the challenge infection. Each brain was homogenized in 2 ml PBS, and the mean number of cysts per brain was calculated. (Xu et al., 2014)
- Efficacy:
RH: The average survival time of mice in the pVAX-ROP38 group was slightly longer than that of the three control groups, but the difference was not statistically significant (P > 0.05). (Xu et al., 2014)
PRU: The number of brain cysts in mice from the pVAX-ROP38 group was significantly decreased (76.6%) compared to that of the three control groups (P <0.01). (Xu et al., 2014)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35. T. gondii DNA vaccine pVAX-TgGRA17 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA17 (Zhu et al., 2017) |
| e. Gene Engineering of
GRA17 |
- Type:
DNA vaccine construction
- Description:
The coding sequences of GRA17 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA17 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA17. (Zhu et al., 2017)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX I (Zhu et al., 2017) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding GRA17 using pVAX I vector. (Zhu et al., 2017) |
| i.
Mouse Response |
- Host Strain:
BALB/c (Zhu et al., 2017)
- Vaccination Protocol:
A total of 78 mice were randomly divided into six groups (13 mice per group). For the experimental groups, mice were immunized with 100 μl (100 μg) of pVAX-TgGRA17, pVAX-TgGRA23, and pVAX-TgGRA17 + pVAX-TgGRA23, respectively, by intramuscular injections and given booster immunizations 2 and 4 weeks later. Mice injected with empty pVAX I vector or PBS were served as negative control groups, and the blank control group received nothing. (Zhu et al., 2017)
- Challenge Protocol:
Two weeks after the last immunization, 10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of the highly virulent T. gondii RH strain and the survival time of mice was monitored daily. (Zhu et al., 2017)
- Efficacy:
The average survival time of mice immunized with pVAX-TgGRA17 (9.1 ± 0.32 days) was significantly longer than that of the three control groups (blank control, 7.11 ± 0.33 days; PBS control, 7.22 ± 0.44 days; pVAX I control, 7.11 ± 0.33 days) (P < 0.05). The difference in the average survival time of mice among the three control groups was not statistically significant, which all died within 8 days after challenge. (Zhu et al., 2017)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36. T. gondii DNA vaccine pVAX-TgGRA17 + pVAX-TgGRA23 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA17 and GRA23 (Zhu et al., 2017) |
| e. Gene Engineering of
GRA17 |
- Type:
DNA vaccine construction
- Description:
The coding sequences of GRA17 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA17 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA17. (Zhu et al., 2017)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
GRA23 |
- Type:
DNA vaccine construction
- Description:
The coding sequences of GRA23 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA23 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA23. (Zhu et al., 2017)
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pVAX I (Zhu et al., 2017) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i. Description |
| T. gondii DNA vaccine encoding GRA17 and GRA23 using pVAX I vector. (Zhu et al., 2017) |
| j.
Mouse Response |
- Host Strain:
BALB/c (Zhu et al., 2017)
- Vaccination Protocol:
A total of 78 mice were randomly divided into six groups (13 mice per group). For the experimental groups, mice were immunized with 100 μl (100 μg) of pVAX-TgGRA17, pVAX-TgGRA23, and pVAX-TgGRA17 + pVAX-TgGRA23, respectively, by intramuscular injections and given booster immunizations 2 and 4 weeks later. Mice injected with empty pVAX I vector or PBS were served as negative control groups, and the blank control group received nothing. (Zhu et al., 2017)
- Challenge Protocol:
Two weeks after the last immunization, 10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of the highly virulent T. gondii RH strain and the survival time of mice was monitored daily. (Zhu et al., 2017)
- Efficacy:
The average survival time of mice immunized with pVAX-TgGRA17 + pVAX-TgGRA23 (12.6 ± 2.55 days) was significantly longer than that of the three control groups (blank control, 7.11 ± 0.33 days; PBS control, 7.22 ± 0.44 days; pVAX I control, 7.11 ± 0.33 days) (P < 0.05). The difference in the average survival time of mice among the three control groups was not statistically significant, which all died within 8 days after challenge. (Zhu et al., 2017)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37. T. gondii DNA vaccine pVAX-TgGRA23 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA23 (Zhu et al., 2017) |
| e. Gene Engineering of
GRA23 |
- Type:
DNA vaccine construction
- Description:
The coding sequences of GRA23 was amplified by RT-PCR from total RNA, and then were inserted into pMD18-T. The GRA1 fragment was cleaved from pMD-TgGRA23 and was sub-cloned into the corresponding sites of pVAX I, eventually formed pVAX-TgGRA23. (Zhu et al., 2017)
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX I (Zhu et al., 2017) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h. Description |
| T. gondii DNA vaccine encoding GRA23 using pVAX I vector. (Zhu et al., 2017) |
| i.
Mouse Response |
- Host Strain:
BALB/c (Zhu et al., 2017)
- Vaccination Protocol:
A total of 78 mice were randomly divided into six groups (13 mice per group). For the experimental groups, mice were immunized with 100 μl (100 μg) of pVAX-TgGRA17, pVAX-TgGRA23, and pVAX-TgGRA17 + pVAX-TgGRA23, respectively, by intramuscular injections and given booster immunizations 2 and 4 weeks later. Mice injected with empty pVAX I vector or PBS were served as negative control groups, and the blank control group received nothing. (Zhu et al., 2017)
- Challenge Protocol:
Two weeks after the last immunization, 10 mice per group were challenged intraperitoneally with 1 × 103 tachyzoites of the highly virulent T. gondii RH strain and the survival time of mice was monitored daily. (Zhu et al., 2017)
- Efficacy:
The average survival time of mice immunized with pVAX-TgGRA23 (10.8 ± 0.79 days) was significantly longer than that of the three control groups (blank control, 7.11 ± 0.33 days; PBS control, 7.22 ± 0.44 days; pVAX I control, 7.11 ± 0.33 days) (P < 0.05). The difference in the average survival time of mice among the three control groups was not statistically significant, which all died within 8 days after challenge. (Zhu et al., 2017)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38. T. gondii DNA vaccine pVAX-TgMIC13 |
| a. Vaccine Ontology ID: |
| VO_0004528 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
MIC13 |
- Type:
DNA vaccine construction
- Description:
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX I (Yuan et al., 2013) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h.
Mouse Response |
- Vaccine Immune Response Type:
VO_0000286
- Immune Response:
Immunization with pVAX-TgMIC13 induced a strong immune responses demonstrated by significant lymphocyte proliferation, cytokine production and antibody responses (Yuan et al., 2013).
- Challenge Protocol:
Acute: Subgroup A were challenged intraperitoneally with 1 x 103 tachyzoites of virulent T. gondii (RH strain) 14 day after the final immunization. The time of the death was recorded.
Chronic: Subgroup B were challenged intragastrically with 10 cysts of cyst T. gondii (PRU strain) 14 day after the final immunization. The cysts in their brain were counted 30 days post challenge. (Yuan et al., 2013)
- Efficacy:
Immunized mice showed increased survival time (21.3±11.3 days) and reduced number of cysts in brain of mice (57.14%) after challenge with tachyzoites of the virulent T. gondii RH strain and cysts of the T. gondii PRU strain, respectively (Yuan et al., 2013).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39. T. gondii DNA vaccine pVitro-SAG1-GRA7 |
| a. Type: |
| DNA vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| SAG1 (Mavi et al., 2019); GRA7 (Mavi et al., 2019) |
| e. Gene Engineering of
SAG1 |
- Type:
DNA vaccine construction
- Description:
Full-length coding region of SAG1 were PCR amplified and were cloned into pTZ57R/T vectors. The recombinant construct pTZ-SAG1 was digested with BglII and NheI, and the ligations were subcloned into empty pVitro2-neo-mcs vectors, previously digested by corresponding restriction enzymes. (Mavi et al., 2019)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
GRA7 |
- Type:
DNA vaccine construction
- Description:
Full-length coding region of GRA7 were PCR amplified and were cloned into pTZ57R/T vectors. The recombinant construct pTZ-GRA7 was digested with BamHI and ClaI, and the ligations were subcloned into empty pVitro2-neo-mcs vectors, previously digested by corresponding restriction enzymes. (Mavi et al., 2019)
- Detailed Gene Information: Click here.
|
| g. Vector: |
| pVitro2-neo-mcs (Mavi et al., 2019) |
| h. Immunization Route |
| Intramuscular injection (i.m.) |
| i. Description |
| T. gondii DNA vaccine encoding SAG1 and GRA7 as antigens using pVitro2-neo-mcs vector (Mavi et al., 2019) |
| j.
Mouse Response |
- Host Strain:
BALB/c (Mavi et al., 2019)
- Vaccination Protocol:
84 BALB/c mice were divided randomly into seven groups of 12 mice. Negative control groups, including Groups I to III, received 100 µL of PBS, 100 µg of empty pVitro2-neo-mcs vector in 100 µL of PBS and 30 µg of CpG-ODN in 100 µL of PBS, respectively. Experimental groups of IV to VII were injected with 100 µg of pVitro-SAG1 plasmid in 100 µL of PBS, 100 µg of pVitro-GRA7 plasmid in 100 µL of PBS, 100 µg of pVitro-SAG1-GRA7 plasmid in 100 µL of PBS and 100 µg of pVitro-SAG1-GRA7 plasmid with 30 µg of CpG-ODN in 100 µL of PBS, respectively. Mice were immunized intramuscularly (IM) thrice on days 1, 21 and 42. (Mavi et al., 2019)
- Immune Response:
Humoral: higher IgG levels in pVitro-SAG1-GRA7 and pVitro-SAG1-GRA7 with CpG-ODN groups, higher IgG levels in pVitro-SAG1 group than in pVitro-GRA7 group. IgG2a levels significantly increased in all experimental groups.
Cellular: higher lymphocyte proliferation and IFN-γ levels in pVitro-SAG1-GRA7 and pVitro-SAG1-GRA7 with CpG-ODN groups. Difference of SI was statistically significant in mice immunized with pVitro-SAG1-GRA7 with CpG-ODN, compared to that in mice received pVitro-SAG1-GRA7 alone (P<0.001).
(Mavi et al., 2019)
- Challenge Protocol:
Four weeks after the last immunization, nine immunized BALB/c mice from each group were randomly selected and involved in infection experiments. Each mouse was inoculated intraperitoneally (IP) with a single dose of 1×103 tachyzoites of the virulent T. gondii, RH strain. Mice were monitored twice daily and the time of death was recorded until all mice were dead. (Mavi et al., 2019)
- Efficacy:
All mice in control groups died within 5–8 days after confronting lethal challenge. The survival time in experimental groups was significantly (P<0.05) longer than that in control groups. Mice immunized with pVitro-SAG1–GRA7 vaccine alone and pVitro-SAG1-GRA7 with CpG-ODN vaccine, respectively, survived 9–15 days (13.25±1.85) and 11–18 days (15.0±2.29) after lethal challenges which were significantly longer than that mice immunized with pVitro-SAG1 or pVitro-GRA7 groups did, including 8–14 (10.87±2.02) and 8–12 (10.0±1.41) days after lethal challenges, respectively. Furthermore, in pVitro-SAG1-GRA7 with CpG-ODN group, a longer survival time was observed, compared to that in pVitro-SAG1-GRA7 group. (Mavi et al., 2019)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40. T. gondii DNA vaccine pVR1020-GRA1 |
| a. Vaccine Ontology ID: |
| VO_0004454 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
GRA1 |
- Type:
DNA vaccine construction
- Description:
Vector VR1020 expressed T. gondii excreted-secreted dense granule proteins GRA1 (Scorza et al., 2003).
- Detailed Gene Information: Click here.
|
| f. Vector: |
| VR1020 (Scorza et al., 2003) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h.
Mouse Response |
- Vaccine Immune Response Type:
VO_0000286
- Efficacy:
All control pVR1020-vaccinated mice succumbed to infection after challenge, while 75% of the mice vaccinated with pVR1020-GRA1 were protected against infection with strain IPB-G. In the second experiment, all mice vaccinated with GRA1 DNA survived, while 75% of the mice vaccinated with control DNA succumbed to infection (P < 0.05) (Scorza et al., 2003).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41. T. gondii DNA vaccine ROP8-pVAX-1 |
| a. Vaccine Ontology ID: |
| VO_0004531 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
ROP8 |
- Type:
DNA vaccine construction
- Description:
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pVAX1 (Parthasarathy et al., 2013) |
| g. Immunization Route |
| Intramuscular injection (i.m.) |
| h.
Mouse Response |
- Vaccine Immune Response Type:
VO_0000286
- Immune Response:
splenocytes from mice immunized with ROP8-pVAX-1 secreted significantly high levels of IFN-γ (816 ± 26.3 pg/mL) compared with spleen cells cultured from mice immunized with pVAX-1 (48 ± 10.8) or PBS (45 ± 6.6). Only a low level of IL-4 was detected in the culture supernatant of splenocytes from mice immunized with ROP8-pVAX-1 (148 ± 18.3) but was significantly higher compared with mice immunized with pVAX-1 (50 ± 13.6) or PBS (47 ± 6.1) (Parthasarathy et al., 2013).
- Efficacy:
Mice immunized with ROP8-pVAX-1 DNA had a 100% survival rate until Day 9, whereas all the control mice died. On top of that, mice immunized with ROP8-pVAX-1 DNA showed a significant increase in the survival time (29 days, P < 0.05) (Parthasarathy et al., 2013).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42. T. gondii DNA vaccine T.g.HSP70 |
| a. Vaccine Ontology ID: |
| VO_0004455 |
| b. Type: |
| DNA vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
hsp70 |
- Type:
DNA vaccine construction
- Description:
- Detailed Gene Information: Click here.
|
| f. Vector: |
| pME18100 (Kikumura et al., 2010) |
| g. Immunization Route |
| Gene gun |
| h.
Mouse Response |
- Vaccine Immune Response Type:
VO_0000286
- Efficacy:
The T.g.HSP70 gene vaccination induced protective immunity against T.g.HSP70-induced anaphylactic reaction not only at the acute phase but also at acute exacerbation of the chronic phase of infection, although the protective effect was partial (Kikumura et al., 2010).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43. T. gondii GRA17 mutant vaccine |
| a. Type: |
| Live, attenuated vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| GRA17 (Wang et al., 2017) |
| e. Gene Engineering of
GRA17 |
- Type:
DNA vaccine construction
- Description:
Deleted gene
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| Intraperitoneal injection (i.p.) |
| g. Description |
| T. gondii attenuated vaccine: used CRISPR-Cas9 method to delete GRA17 gene in T. gondii RH strain (Wang et al., 2017) |
| h.
Mouse Response |
- Host Strain:
Kunming mice (Wang et al., 2017)
- Vaccination Protocol:
Mice were immunized with 5 × 104 ΔGRA17 tachyzoites or mock-immunized in a volume of 200 µl PBS intraperitoneally (i.p.) (Wang et al., 2017)
- Immune Response:
Humoral: Higher IgG and IgG2a levels at day 28 postimmunization. Increased IgG1 level at 70 days postimmunization. (Wang et al., 2017)
Cellular: Significantly higher levels of Th1-type cytokines (IFN-γ, IL-2, and IL-12) and significant increase in the level of Th2-type cytokine (IL-10) (Wang et al., 2017)
- Challenge Protocol:
The efficacy of ΔGRA17 was tested against acute, latent, and congenital infections in mice 70 days after vaccination.
Acute: mice were challenged with 1 × 103 RH tachyzoites of T. gondii RH, ToxoDB#9 PYS, or ToxoDB#9 TgC7 strain.
Chronic mice werechallenged with 20 Pru cysts.
Congenital: female mice were mated to males on a 2:1 ratio 70 days post vaccination. Compared between five groups: (A) ΔGRA17-immunized and orally gavaged with 10 tissue cysts of Pru on day 12 of gestation, (B) ΔGRA17-immunized and i.p. inoculated with 200 RH tachyzoites on day 18 of gestation, (C) non-immunized, and orally gavaged with 10 tissue cysts of Pru on day 12 of gestation, (D) non-immunized and i.p. inoculated with 200 RH tachyzoites on day 18 of gestation, and (E) non-immunized and uninfected.
(Wang et al., 2017)
- Efficacy:
Acute: All immunized mice survived the challenge, whereas all challenged naïve mice died within 10 dpi. Significantly higher levels of IFN-γ and IL-12 in the sera and peritoneal washes in non-immunized and infected mice than in the immunized and infected, and non-immunized and uninfected mice.
Chronic: All ΔGRA17-immunized mice survived compared to 40% survival of non-immunized and infected mice. Immunized mice had significantly less cyst burden (53 ± 15 cysts/brain compared to 4,296 ± 687 cysts/brain) (P < 0.05). Brain cysts were not found in 4 out of 10 (40%) immunized mice.
Congenital: The mean sizes of viable pups born to immunized and infected mice were similar to pups born to non-immunized and uninfected mice and in both groups, and no abortions were observed. The mean litter sizes of viable neonates born to non-immunized and infected mice were significantly reduced, and abortions were observed. Five days after birth, the survival rate and mean BW of pups born to non-immunized and uninfected, and immunized and infected mice were significantly higher than that from non-immunized and infected mice. Non-immunized and infected dams showed clinical signs of toxoplasmosis, whereas immunized and infected, and non-immunized and uninfected dams did not show any clinical signs. T. gondii DNA was found in all examined non-immunized and infected dams, but not in any of the 10 examined pups. However, parasites DNA was detected in some aborted fetuses. The pups from the immunized and infected mice had equivalent mean BW and survival rate to that from non-immunized and uninfected dams on day 35 of age.
(Wang et al., 2017)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
44. T. gondii irradiated sterilised tachyzoites |
| a. Type: |
| Live, attenuated vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Immunization Route |
| Intraperitoneal injection (i.p.) or oral gavage (v.o.) |
| e. Description |
| Viable irradiated tachyzoites of T. gondii, maintains morphology and physiology but abolishes reproduction (Zorgi et al., 2016) |
| f.
Mouse Response |
- Host Strain:
BALB/c (Zorgi et al., 2016)
- Vaccination Protocol:
Groups of five BALB/c mice received three doses of 107 irradiated T. gondii tachyzoites (ME-49 or VEG strain) biweekly; the parasites were administered either by i.p. injection or via oral gavage (v.o.) of 107 irradiated tachyzoites suspended 1:1 (v/v) in 6 % aluminum hydroxide. The unimmunized mice served as negative controls, and mice chronically infected by ME-49 or VEG strain served as positive control. (Zorgi et al., 2016)
- Immune Response:
Humoral: Significant increase in the total IgG and IgM levels in i.p. immunized groups. Higher IgA levels in oral immunized groups. (Zorgi et al., 2016)
Cellular: Higher levels of IL-10, TNF-α, IFN-ɤ, IL-4, IL-2, and IL-6 in i.p. immunized groups (Zorgi et al., 2016)
- Challenge Protocol:
The immunized or control mice were challenged with ten cysts of the respective strain (ME49 or VEG) administered by oral gavage 90 days after the last immunizing dose; the mice were observed for daily survival determination. After 30 days, the surviving animals were killed and the brains were macerated in sterile saline solution. The solution containing the brain was subjected to DNA extraction to analyze the absolute number of parasites. (Zorgi et al., 2016)
- Efficacy:
The challenge with both the ME-49 strain and the VEG strain in the intraperitoneally and orally immunized animals showed a significant decrease in the number of parasites in the brain tissue compared with the infected mice without immunization. (Zorgi et al., 2016)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45. T. gondii LDH1 and LDH2 mutant vaccine |
| a. Type: |
| Live, attenuated vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Immunization Route |
| Intraperitoneal injection (i.p.) |
| e. Description |
| T. gondii attenuated vaccine: deleted LDH1 and LDH2 gene in T. gondii PruΔKu80::hxgprt strain (Abdelbaset et al., 2017) |
| f.
Mouse Response |
- Host Strain:
BALB/c (Abdelbaset et al., 2017)
- Vaccination Protocol:
Mice were vaccinated with a low-dose with 103 tachyzoites of the parental PruΔKu80::hxgprt strain or LDH knockout strains (ΔLDH1, ΔLDH2, or ΔLDH1ΔLDH2). A group of non-vaccinated mice was kept as control. (Abdelbaset et al., 2017)
- Side Effects:
Infection study:
Infection with 106 tachyzoites: parental or Δldh2 strain infected mice demonstrated a 10 and 0% survival rate, respectively. On the other hand, mice challenged with Δldh1 and Δldh1Δldh2 strains demonstrated a 60 and 30% survival rate, respectively. Average number of cysts in each group was 680 (parental, n = 1), 177 ± 62 (Δldh1, n = 6), no data (Δldh2, n=0) and 60 ± 40 (Δldh1Δldh2, n = 3).
Infection with 104 tachyzoites: parental and Δldh2 strain infected mice demonstrated a 60 and 40% survival rate, respectively. On the other hand, Δldh1 and Δldh1Δldh2 strain infected mice showed 100% survival. Average number of cysts in each group was 231 ± 116 (parental, n = 6), 27 ± 7 (Δldh1, n = 10), 52 ± 11 (Δldh2, n = 4), and 1 ± 1 (Δldh1Δldh2, n = 10)
Infection with 103 tachyzoites: parental, Δldh1 and Δldh1Δldh2 strain infected mice showed 100% survival. Δldh2 infected mice showed low (10%) mortality. Average number of cysts in each group was 640 ± 72 (parental, n = 4), 56 ± 5 (Δldh1, n = 5), 330 ± 34 (Δldh2, n = 5), and 0 (Δldh1Δldh2, n = 5)
(Abdelbaset et al., 2017)
- Challenge Protocol:
30 days after vaccination, mice were challenged with 100 highly virulent (LD100) RH strain parasites. (Abdelbaset et al., 2017)
- Efficacy:
All mice in the naïve group died within 11 days after challenge, one mouse died in parental strain infected group, and all mice survived in the other vaccinated groups. (Abdelbaset et al., 2017)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46. T. gondii mic2 mutant vaccine |
| a. Vaccine Ontology ID: |
| VO_0003012 |
| b. Type: |
| Live, attenuated vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
mic2 |
|
| f. Immunization Route |
| Intraperitoneal injection (i.p.) |
| g.
Mouse Response |
- Persistence:
A mic2 mutant is attenuated in mice (Huynh and Carruthers, 2006).
- Efficacy:
A mic2 mutant induces protection in mice from challenge with wild type T. gondii (Huynh and Carruthers, 2006).
- Host Gene Response of
Ccl2
- Gene Response:
Levels of serum MCP-1 (Ccl2) were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post infection (Huynh and Carruthers, 2006).
- Detailed Gene Information: Click here.
- Host Gene Response of
Ifng (Interferon gamma)
- Gene Response:
Levels of serum IFN-gamma were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post-infection (Huynh and Carruthers, 2006).
- Detailed Gene Information: Click here.
- Host Gene Response of
IL-6
- Gene Response:
Levels of serum IL-6 were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post infection (Huynh and Carruthers, 2006).
- Detailed Gene Information: Click here.
- Host Gene Response of
Il12b
- Gene Response:
Levels of serum IL-12p40 (IL-12b) were higher than those of uninfected mice on days 4, 6 and 8 post-infection (Huynh and Carruthers, 2006).
- Detailed Gene Information: Click here.
- Host Gene Response of
TNF-alpha
- Gene Response:
Levels of serum TNF-alpha were higher in mice infected with MIC2 deletion mutants than in uninfected mice on days 4, 6 and 8 post infection (Huynh and Carruthers, 2006).
- Detailed Gene Information: Click here.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47. T. gondii OMPDC mutant vaccine |
| a. Vaccine Ontology ID: |
| VO_0003013 |
| b. Type: |
| Live, attenuated vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Gene Engineering of
OMPDC |
|
| f. Immunization Route |
| Intraperitoneal injection (i.p.) |
| g.
Mouse Response |
- Persistence:
An OMPDC mutant is attenuated in mice (Fox and Bzik, 2010).
- Efficacy:
An OMPDC mutant induces significant protection in mice from challenge with wild type T. gondii (Fox and Bzik, 2010).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
48. T. gondii OMPDC/UP mutant vaccine |
| a. Type: |
| Live, attenuated vaccine |
| b. Status: |
| Research |
| c. Host Species as Laboratory Animal Model: |
| Mouse |
| d. Gene Engineering of
OMPDC |
- Type:
Recombinant protein preparation
- Description:
This OMPDC/UP mutant is from Toxoplasma gondii (Fox and Bzik, 2010).
- Detailed Gene Information: Click here.
|
| e. Gene Engineering of
UP |
- Type:
Gene mutation
- Description:
This OMPDC/UP mutant is from Toxoplasma gondii (Fox and Bzik, 2010).
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| Intraperitoneal injection (i.p.) |
| g.
Mouse Response |
- Persistence:
An OMPDC/UP mutant is attenuated in mice (Fox and Bzik, 2010).
- Efficacy:
An OMPDC/UP mutant induces significant protection in mice from challenge with wild type T. gondii (Fox and Bzik, 2010).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49. T. gondii Pru strain cdpk2 mutant vaccine |
| a. Type: |
| Live, attenuated vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Immunization Route |
| Intraperitoneal injection (i.p.) |
| e. Description |
| T. gondii attenuated vaccine: used CRISPR-Cas9 method to delete cdpk2 gene in T. gondii Pru strain (Wang et al., 2018) |
| f.
Mouse Response |
- Host Strain:
Kunming mice (Wang et al., 2018)
- Vaccination Protocol:
Mice were either vaccinated once with 500 freshly harvested Pru:Δcdpk2 tachyzoites or mock-vaccinated in a total of 200 µL phosphate-buffered saline (PBS) ip. (Wang et al., 2018)
- Immune Response:
Humoral: Higher levels of IgG and IgG2a antibodies 28 dpv, increased level of IgG1 at 70 dpv (Wang et al., 2018)
Cellular: Significantly higher levels of Th1-type cytokines (IFN-γ, IL-2, and IL-12) and Th2-type cytokine (IL-10) at 70 dpv. (Wang et al., 2018)
- Challenge Protocol:
At 70 dpv, both vaccinated and age-matched naive mice were challenged.
Acute: mice were challenged ip with 200 μL PBS containing 1000 tachyzoites of RH, or ToxoDB#9 (PYS or TgC7) strain
Chronic: mice were inoculated orally with 20 Pru cysts.
Congenital: female mice were mated to males on a 2:1 ratio 70 days post vaccination. Compared between three groups: (A) Δcdpk2-immunized and orally gavaged with 10 Pru cysts on day 12 of gestation, (B) non-immunized, and orally gavaged with 10 Pru cysts on day 12 of gestation, and (C) non-immunized and uninfected.
(Wang et al., 2018)
- Efficacy:
Acute: All nonvaccinated and infected mice died within 10 dpi, whereas all mice vaccinated survived. Significantly elevated levels of IL-12 and IFN-γ were found in the nonvaccinated + RH-infected mice, whereas only modestly elevated levels of the same cytokines was observed in Pru:Δcdpk2 vaccinated + RH-infected mice.
Chronic: All vaccinated mice survived, whereas only 40% of nonvaccinated infected mice survived. Pru:Δcdpk2-vaccinated mice had significantly less brain cyst burden(78 ± 48 cysts/brain compared to 4296 ± 687 cysts/brain) (P < .001).
Congenital: Body weight of neonates born to Pru:Δcdpk2-vaccinated dams was similar to neonates born to nonvaccinated uninfected dams. In contrast, the litter size and body weight of pups of nonvaccinated + infected mice were significantly lower. The average brain cyst number in all neonates (n = 19) born to nonvaccinated + infected dams was 919 ± 339. In contrast, 41.4% (24/58) of neonates born to vaccinated dams had an average brain cyst number of (60 ± 33). The brain of 58.6% (34/58) of neonates born to vaccinated + infected dams revealed no cysts. The average brain cyst number was significantly higher in nonvaccinated + infected dams (3287 ± 569 cysts/brain) than in that of vaccinated dams (77 ± 58 cysts/ brain).
(Wang et al., 2018)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50. T. gondii recombinant vaccine vector rBCGpMV361-TgCyP |
| a. Vaccine Ontology ID: |
| VO_0004602 |
| b. Type: |
| Recombinant vector vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| Mouse |
| e. Antigen |
| TgCyP(Yu et al., 2013) |
| f. Vector: |
| BCG |
| g. Immunization Route |
| Intravenous injection (i.v.) |
| h.
Mouse Response |
- Host Strain:
BALB/c mice
- Vaccine Immune Response Type:
VO_0003057
- Immune Response:
Greater proliferation of CD4+ and CD8+ T cells; levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased (Yu et al., 2013)
- Efficacy:
rBCGpMV361-TgCyP i.v. inoculation protected the BALB/c mice, as shown by the 17% increased survival rate compared to those mice not inoculated (Yu et al., 2013)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
51. T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine |
| a. Vaccine Ontology ID: |
| VO_0011521 |
| b. Type: |
| Subunit vaccine |
| c. Status: |
| Research |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Gene Engineering of
Rop2 |
- Type:
Recombinant protein preparation
- Description:
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| Footpad Injection |
| g.
Mouse Response |
- Host Strain:
Balb/c, C57BL/6 and C3H
- Vaccination Protocol:
The immunization doses and boosters of each antigen were the following: Rop2 (44 kDa, 2 μg), LiHsp83 (86 kDa, 6 μg), Rop2-LiHsp83 (not, vert, similar120 kDa, 9 μg) and the mixture of Rop2 and LiHsp83 (2 + 6 μg, respectively). Balb/c, C57BL/6 and C3H mice were immunized by footpad injections on days 0, 21, 35 and 45 with PBS (control) or recombinant proteins (Echeverria et al., 2006).
- Challenge Protocol:
To analyze protection against virulent T. gondii strain (lethal challenge) immunized mice were challenged intraperitoneally with 105 T. gondii RH tachyzoites 2 weeks after the last immunization. To analyze protection against non-lethal challenge, immunized mice were orally infected with 20 cysts of the ME49 T. gondii strain 2 weeks after the last booster. The brain parasite load was evaluated 1 month after infection (Echeverria et al., 2006).
- Efficacy:
Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups (Echeverria et al., 2006).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52. TgMIC1 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Antigen |
| MIC1 (Pinzan et al., 2015) |
| f. Gene Engineering of
MIC1 |
- Type:
Recombinant protein preparation
- Description:
MIC1 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC1. Inserts from pENTR-TgMIC1 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC1. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC1. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| g. Immunization Route |
| subcutaneous injection |
| h. Description |
| T. gondii subunit vaccine expressing MIC1 (Pinzan et al., 2015) |
| i.
Mouse Response |
- Host Strain:
C57BL/6 (Pinzan et al., 2015)
- Vaccination Protocol:
Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
- Challenge Protocol:
One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
- Efficacy:
Mice immunized with TgMIC1, compared with non-immunized mice, showed reductions in brain cysts by 52%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Immunization with TgMIC1 was associated with a survival rate of about 50%, indicating that these vaccines confer partial protection against T. gondii infection. (Pinzan et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53. TgMIC1-4 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| MIC1 and MIC4 (Pinzan et al., 2015) |
| e. Gene Engineering of
MIC1 |
- Type:
Recombinant protein preparation
- Description:
MIC1 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC1. Inserts from pENTR-TgMIC1 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC1. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC1. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
MIC4 |
- Type:
Recombinant protein preparation
- Description:
MIC4 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC4. Inserts from pENTR-TgMIC4 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC4. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC4. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| g. Immunization Route |
| subcutaneous injection |
| h. Description |
| T. gondii subunit vaccine expressing MIC1 and MIC4 (Pinzan et al., 2015) |
| i.
Mouse Response |
- Host Strain:
C57BL/6 (Pinzan et al., 2015)
- Vaccination Protocol:
Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
- Challenge Protocol:
One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
- Efficacy:
Mice immunized with TgMIC1-4, compared with non-immunized mice, showed reductions in brain cysts by 59%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Effective and highly significant protection was demonstrated in mice immunized with TgMIC1-4, since 70% of the mice survived to the acute phase of infection. (Pinzan et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
54. TgMIC1-4-6 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| MIC1, MIC4, and MIC6 (Pinzan et al., 2015) |
| e. Gene Engineering of
MIC6 |
- Type:
Recombinant protein preparation
- Description:
The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pET21b-MIC6. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| f. Gene Engineering of
MIC1 |
- Type:
Recombinant protein preparation
- Description:
MIC1 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC1. Inserts from pENTR-TgMIC1 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC1. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC1. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| g. Gene Engineering of
MIC4 |
- Type:
Recombinant protein preparation
- Description:
MIC4 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC4. Inserts from pENTR-TgMIC4 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC4. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC4. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| h. Immunization Route |
| subcutaneous injection |
| i. Description |
| T. gondii subunit vaccine expressing MIC1, MIC4, and MIC6 (Pinzan et al., 2015) |
| j.
Mouse Response |
- Host Strain:
C57BL/6 (Pinzan et al., 2015)
- Vaccination Protocol:
Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
- Challenge Protocol:
One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
- Efficacy:
Mice immunized with TgMIC1-4-6, compared with non-immunized mice, showed reductions in brain cysts by 67.8%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Effective and highly significant protection was demonstrated in mice immunized with TgMIC1-4-6, since 80% of the mice survived to the acute phase of infection. (Pinzan et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
55. TgMIC4 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Antigen |
| MIC4 (Pinzan et al., 2015) |
| e. Gene Engineering of
MIC4 |
- Type:
Recombinant protein preparation
- Description:
MIC4 was PCR amplified and was cloned into pDONR201 vector and yielded pENTR-TgMIC4. Inserts from pENTR-TgMIC4 were transferred into pDEST17 vectors and yielded pEXP17-TgMIC4. The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pDEST17-MIC4. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| subcutaneous injection |
| g. Description |
| T. gondii subunit vaccine expressing MIC4 (Pinzan et al., 2015) |
| h.
Mouse Response |
- Host Strain:
C57BL/6 (Pinzan et al., 2015)
- Vaccination Protocol:
Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
- Challenge Protocol:
One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
- Efficacy:
Mice immunized with TgMIC4, compared with non-immunized mice, showed reductions in brain cysts by 46.9%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Immunization with TgMIC4 was associated with a survival rate of about 50%, indicating that these vaccines confer partial protection against T. gondii infection. (Pinzan et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56. TgMIC6 |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Baboon |
| d. Antigen |
| MIC6 (Pinzan et al., 2015) |
| e. Gene Engineering of
MIC6 |
- Type:
Recombinant protein preparation
- Description:
The proteins were expressed by E. coli BL21 (DE3) (Novagen) cells transformed with pET21b-MIC6. (Pinzan et al., 2015)
- Detailed Gene Information: Click here.
|
| f. Immunization Route |
| subcutaneous injection |
| g. Description |
| T. gondii subunit vaccine expressing MIC6 (Pinzan et al., 2015) |
| h.
Mouse Response |
- Host Strain:
C57BL/6 (Pinzan et al., 2015)
- Vaccination Protocol:
Mice were subcutaneously (s.c.) injected with TgMIC1 (10 μg), TgMIC4 (10μg), TgMIC6 (10μg), TgMIC1-4 (5 μg of each protein), TgMIC1-4-6 (3.3μg of each protein), or lactose-binding proteins (Lac+, 10 μg) emulsified in Freund’s complete adjuvant. Animals were boosted at the same dose and regimen on day 15 and 30 after first injection, now emulsified in Freund’s incomplete adjuvant. A control group was injected at the same regimen with PBS emulsified in Freund’s adjuvant (vehicle). (Pinzan et al., 2015)
- Challenge Protocol:
One month after the last immunization procedure, the mice were orally infected with 80 cysts of the ME49 strain and were monitored and recorded for 30 days to compute the survival rates. The brain of the mice infected with 40 cysts was removed 1 month after the challenge and the mean number of cysts per brain was determined. (Pinzan et al., 2015)
- Efficacy:
Mice immunized with TgMIC6, compared with non-immunized mice, showed reductions in brain cysts by 27.2%. Non-immunized control mice started dying 6 days after T. gondii infection, and they were all dead by day 11 post infection. Immunization with TgMIC6 was associated with a survival rate of about 40%, indicating that these vaccines confer partial protection against T. gondii infection. (Pinzan et al., 2015)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57. TgPF-OML |
| a. Type: |
| Subunit vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Host Species as Laboratory Animal Model: |
| mouse |
| e. Antigen |
| TgPF (Tanaka et al., 2014) |
| f. Gene Engineering of
TgPF |
- Type:
Recombinant protein preparation
- Description:
TgPF gene was amplified by PCR using a forward primer introducing EcoRI site and a reverse primer introducing XhoI site. The amplified TgPF was digested and purified and was inserted into the pGEX-4T1 vector. Recombinant TgPF was expressed as a glutathione-S-transferase (GST) fusion protein in the E. coli DH5α strain. Endotoxins were removed from the purified protein fraction. TgPF was encapsulated in OMLs. (Tanaka et al., 2014)
- Detailed Gene Information: Click here.
|
| g. Immunization Route |
| subcutaneous injection |
| h. Description |
| T. gondii subunit vaccine of recombinant TgPF encapsulated in OMLs. (Tanaka et al., 2014) |
| i.
Mouse Response |
- Host Strain:
C57BL/6 mice (Tanaka et al., 2014)
- Vaccination Protocol:
Mice were inoculated subcutaneously with 40 pmol of TgPF encapsulated in OMLs (TgPF-OML), OMLs, 40 pmol of TgPF in PBS (TgPF), or PBS alone (each 100 μl). Booster immunizations were administered 14 and 28 days after the first immunization. (Tanaka et al., 2014)
- Immune Response:
Significantly higher levels of total IgG and IgG2c antibodies, but not IgG1 antibodies, were detected in the sera of mice immunized with TgPF-OML. (Tanaka et al., 2014)
- Challenge Protocol:
Fourteen days after the third immunization, the mice were challenged with the 1 × 103 tachyzoites of PLK strain. DNA was isolated from the brain samples 30 days after infection, and parasite numbers were analyzed with PCR. (Tanaka et al., 2014)
- Efficacy:
The survival rate of the mice immunized with TgPF-OML (66.7%) was significantly higher than that of mice treated with PBS (25.0%), OML (25.0%), or TgPF (16.7%). The parasite burden in the brains of the surviving mice in the TgPF-OML-immunized group (386 ± 336 parasites/50 ng of DNA) was significantly lower than that in the group injected with TgPF (2707 ± 929 parasites/50 ng of DNA) or PBS (2521 ± 1540 parasites/50 ng of DNA). (Tanaka et al., 2014)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58. UV-attenuated Toxoplasma gondii with DSCG adjuvant |
| a. Type: |
| Live, attenuated vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| Human |
| d. Immunization Route |
| Intraperitoneal injection (i.p.) |
| e. Description |
| UV-attenuated RH strain T. gondii tachyzoites. DSCG was used as the adjuvant (Li et al., 2018) |
| f.
Mouse Response |
- Host Strain:
Kunming mice (Li et al., 2018)
- Vaccination Protocol:
Mice were randomly divided into 7 groups (10 mice per group) and received immunization of 105 UV-irradiated T. gondii tachyzoites alone or 105 UV-irradiated T. gondii tachyzoites co-administrated with DSCG (Sigma-Aldrich, 25 mg/kg). Each mouse received three times of immunization at 10-day interval. 1) naive mice without vaccination or infection, 2) mice injected with DSCG without vaccination or infection, and 3) mice immunized with 105 UV-Tg without challenge. 4) mice immunized with UV-Tg without DSCG and then challenged, 5) mice immunized with UV-Tg with DSCG and then challenged, 6) naive mice challenged (without DSCG), and 7) mice injected with DSCG without vaccination and then challenged. (Li et al., 2018)
- Immune Response:
Higher level of TNF-α, IFN-ɤ, IL-2, IL-4, IL-10, IL-17 (Li et al., 2018)
- Challenge Protocol:
Group (4) - (7) were i.p. challenged with 102 RH tachyzoites after the final immunization (Li et al., 2018)
- Efficacy:
All mice infected alone (Tg) died at 5–7 days post-infection (p.i.). Tg + DSCG group had survival times ranged from 7 to 16 days and UV-Tg + Tg group had survival times ranged from 6 to 17 days, significantly longer (P < 0.01) compared to Tg group but no significant difference between these two groups (P > 0.05). UV-Tg + DSCG + Tg group had survival times ranged from 7 to 27 days, significantly longer compared to Tg group (P < 0.0001), Tg + DSCG group (P < 0.01), and UV-Tg + Tg group (P < 0.01).
Compared to that of Tg group 5-7 days p.i., parasite burdens were significantly decreased in the livers of Tg + DSCG group (P < 0.01), and UV-Tg + Tg group (P < 0.01) and UV-Tg + DSCG + Tg group (P < 0.001) at 7–9 days p.i.. Compared to UV-Tg + Tg group, the parasite burden in UV-Tg + DSCG + Tg group was significantly decreased (P < 0.05) at 7–9 days post-challenge.
(Li et al., 2018)
|
|
|
|
|
|
|
|
|
| V. References |
1. Bhopale, 2003: Bhopale GM. Pathogenesis of toxoplasmosis. Comparative immunology, microbiology and infectious diseases. 2003; 26(4); 213-222. [PubMed: 12676122].
2. Buxton and Innes, 1995: Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology. 1995; 110 Suppl; S11-16. [PubMed: 7784124].
3. Ching et al., 2017: Ching XT, Fong MY, Lau YL. Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice. The American journal of tropical medicine and hygiene. 2017; 96(6); 1441-1447. [PubMed: 28719288].
4. Cong et al., 2008: Cong H, Gu QM, Yin HE, Wang JW, Zhao QL, Zhou HY, Li Y, Zhang JQ. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii. Vaccine. 2008; 26(31); 3913-3921. [PubMed: 18555564].
5. Cui et al., 2008: Cui YL, He SY, Xue MF, Zhang J, Wang HX, Yao Y. Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice. Parasite immunology. 2008; 30(5); 309-313. [PubMed: 18331395].
6. Czarnewski et al., 2017: Czarnewski P, Araújo ECB, Oliveira MC, Mineo TWP, Silva NM. Recombinant <i>Tg</i>HSP70 Immunization Protects against <i>Toxoplasma gondii</i> Brain Cyst Formation by Enhancing Inducible Nitric Oxide Expression. Frontiers in cellular and infection microbiology. 2017; 7; 142. [PubMed: 28487847].
7. Echeverria et al., 2006: Echeverria PC, de Miguel N, Costas M, Angel SO. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine. 2006; 24(19); 4102-4110. [PubMed: 16545504].
8. Fox and Bzik, 2010: Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infection and immunity. 2010; 78(9); 3744-3752. [PubMed: 20605980].
9. Huynh and Carruthers, 2006: Huynh MH, Carruthers VB. Toxoplasma MIC2 is a major determinant of invasion and virulence. PLoS pathogens. 2006; 2(8); e84. [PubMed: 16933991].
10. Ismael et al., 2009: Ismael AB, Hedhli D, Cérède O, Lebrun M, Dimier-Poisson I, Mévélec MN. Further analysis of protection induced by the MIC3 DNA vaccine against T. gondii: CD4 and CD8 T cells are the major effectors of the MIC3 DNA vaccine-induced protection, both Lectin-like and EGF-like domains of MIC3 conferred protection. Vaccine. 2009; 27(22); 2959-2966. [PubMed: 19428907].
11. Kikumura et al., 2010: Kikumura A, Fang H, Mun HS, Uemura N, Makino M, Sayama Y, Norose K, Aosai F. Protective immunity against lethal anaphylactic reaction in Toxoplasma gondii-infected mice by DNA vaccination with T. gondii-derived heat shock protein 70 gene. Parasitology international. 2010; 59(2); 105-111. [PubMed: 20346412].
12. Liu et al., 2010: Liu MM, Yuan ZG, Peng GH, Zhou DH, He XH, Yan C, Yin CC, He Y, Lin RQ, Song HQ, Zhu XQ. Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis. Parasitology research. 2010; 106(5); 1079-1084. [PubMed: 20177910].
13. Liu et al., 2017: Liu Y, Cao A, Li Y, Li X, Cong H, He S, Zhou H. Immunization with a DNA vaccine encoding Toxoplasma gondii Superoxide dismutase (TgSOD) induces partial immune protection against acute toxoplasmosis in BALB/c mice. BMC infectious diseases. 2017; 17(1); 403. [PubMed: 28592247].
14. Parthasarathy et al., 2013: Parthasarathy S, Fong MY, Ramaswamy K, Lau YL. Protective Immune Response in BALB/c Mice Induced by DNA Vaccine of the ROP8 gene of Toxoplasma gondii. The American journal of tropical medicine and hygiene. 2013; 88(5); 883-887. [PubMed: 23509124].
15. Picchio et al., 2018: Picchio MS, Sánchez VR, Arcon N, Soto AS, Perrone Sibilia M, Aldirico MLA, Urrutia M, Moretta R, Fenoy IM, Goldman A, Martin V. Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice. Experimental parasitology. 2018; 185; 62-70. [PubMed: 29309783].
16. Qu et al., 2008: Qu D, Wang S, Cai W, Du A. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice. Vaccine. 2008; 26(35); 4541-4548. [PubMed: 18590785].
17. Scorza et al., 2003: Scorza T, D'Souza S, Laloup M, Dewit J, De Braekeleer J, Verschueren H, Vercammen M, Huygen K, Jongert E. A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection. Infection and immunity. 2003; 71(1); 309-316. [PubMed: 12496180].
18. Wiki: T. gondii: Wiki: T. gondii [http://en.wikipedia.org/wiki/T._gondii]
19. Xiang et al., 2009: Xiang W, Qiong Z, Li-peng L, Kui T, Jian-wu G, Heng-ping S. The location of invasion-related protein MIC3 of Toxoplasma gondii and protective effect of its DNA vaccine in mice. Veterinary parasitology. 2009; 166(1-2); 1-7. [PubMed: 19800170].
20. Xue et al., 2008: Xue M, He S, Zhang J, Cui Y, Yao Y, Wang H. Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine. Experimental parasitology. 2008; 119(3); 352-357. [PubMed: 18442818].
21. Yu et al., 2013: Yu Q, Huang X, Gong P, Zhang Q, Li J, Zhang G, Yang J, Li H, Wang N, Zhang X. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Vaccine. 2013; ; . [PubMed: 24176493].
22. Yuan et al., 2013: Yuan ZG, Ren D, Zhou DH, Zhang XX, Petersen E, Li XZ, Zhou Y, Yang GL, Zhu XQ. Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic Toxoplasma gondii infection in a murine model. Vaccine. 2013; ; . [PubMed: 23707448].
|
|
